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Abstract
Investigating the effects of tau mutations in induced pluripotent stem cell-derived
neurons
By Janine Louise Ostick
Microtubule-associated protein tau (MAPT) is a neuronal protein which promotes micro-
tubule assembly and stabilisation. The MAPT gene is alternatively spliced to give six tau
isoforms: three with 3 microtubule-binding repeats (3R, excluding exon 10) and three with 4
microtubule-binding repeats (4R, including exon 10). MAPT mutations cause the progressive,
degenerative disorder fronto-temporal dementia with Parkinsonism linked to chromosome 17
(FTDP-17T), in which tau becomes abnormally phosphorylated and aggregates. FTDP-17T
related MAPT mutations can either alter exon 10 splicing and the 3R:4R tau isoform ratio
(such as N279K), or affect tau’s biochemical properties (such as P301L and V337M).
In this project, I differentiated induced pluripotent stem cells (iPSCs) derived from control
subjects and people with the N279K or V337M MAPT mutations to monolayer neurons.
There was an increase in the proportion of neurons containing tau phosphorylated at the
AT8 epitope in N279K cultures after 50 days, and more 4R tau was detected earlier in
the N279K cultures than in controls, confirming the action of the N279K mutation. All
monolayer neural cultures matured at similar rates in terms of synapse formation, neuronal
marker expression and astrocyte production, and I did not detect other FTDP-17T-relevant
phenotypes in MAPT-mutant cultures, perhaps due to the time points (50 and 80-100 days)
at which I examined them.
To investigate the effects of the N279K mutation independent of iPSC line genetic
background, I attempted to create isogenic iPSC lines using CRISPR. This was not successful,
but I obtained isogenic control and P301L iPSCs from Axol Bioscience, from which, along
with the patient-derived P301L MAPT-mutant iPSCs, I made cerebral organoids (COs).
Similar amounts of neuronal, astrocyte, and synaptic proteins were detected in the control
and MAPT-mutant COs, as were cortical layer markers indicating a forebrain-like fate.
xPhosphorylation at the AT8 epitope was detected in the control and MAPT-mutant COs, as
was tau misfolding, detected using the MC-1 antibody.
In conclusion, some alterations similar to those observed in FTDP-17T brains can be
observed in monolayer iPSC-derived neurons and perhaps in iPSC-derived COs. However,
some phenotypes may be masked by experimental variability which needs to be addressed in
the future.
Table of contents
List of figures xix
List of tables xxiii
Abbreviations xxiv
1 Introduction 1
1.1 Tau in a normal brain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 Isoforms and alternative splicing . . . . . . . . . . . . . . . . . . . 1
1.1.2 Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.3 Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.1.4 Functions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.2 Tau in disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.2.1 FTDP-17T: fronto-temporal dementia with Parkinsonism linked to
chromosome 17 and MAPT mutations . . . . . . . . . . . . . . . . 7
1.2.2 Classification of FTDP-17T and other fronto-temporal dementias . 7
1.2.3 Symptoms of FTDP-17T . . . . . . . . . . . . . . . . . . . . . . . 9
1.2.4 Neuropathology of FTDP-17T . . . . . . . . . . . . . . . . . . . . 9
1.2.5 MAPT mutations in FTDP-17T . . . . . . . . . . . . . . . . . . . 14
1.2.6 Toxic gain-of-function . . . . . . . . . . . . . . . . . . . . . . . . 14
1.2.7 Toxic partial loss-of-function . . . . . . . . . . . . . . . . . . . . . 15
1.2.8 Mutations altering the 3R:4R tau ratio . . . . . . . . . . . . . . . . 17
1.2.9 Mutations altering tau’s physical properties . . . . . . . . . . . . . 20
1.3 Tau dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
1.3.1 Tau aggregation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
1.3.2 Toxic tau species . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
1.3.3 Spreading of tau pathology . . . . . . . . . . . . . . . . . . . . . . 26
xii Table of contents
1.4 iPSC-derived neural cells . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
1.4.1 iPSC origins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
1.4.2 Reprogramming somatic cells to pluripotent cells . . . . . . . . . . 29
1.4.3 Monolayer or 2D culture of iPSC-derived neural cells . . . . . . . . 31
1.4.4 Organoids and 3D culture of iPSC-derived neural cells . . . . . . . 34
1.4.5 Advantages and disadvantages of iPSC-derived neuronal cultures for
modelling the human brain . . . . . . . . . . . . . . . . . . . . . . 35
1.4.6 iPSC-derived neurons as models of tauopathy . . . . . . . . . . . . 39
1.5 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
2 Materials and Methods 41
2.1 General Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.2 iPSC culture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.2.1 Media and solutions for iPSC maintenance . . . . . . . . . . . . . 41
2.2.2 Induced pluripotent stem cell (iPSC) culture conditions . . . . . . . 43
2.2.3 iPSC cryopreservation . . . . . . . . . . . . . . . . . . . . . . . . 44
2.2.4 iPSC thawing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
2.2.5 Karyotyping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
2.3 Differentiation of iPSCs to monolayer neurons . . . . . . . . . . . . . . . . 46
2.3.1 Media recipes and growth factors for monolayer neurons . . . . . . 46
2.3.2 Protocol for differentiation to monolayer neurons . . . . . . . . . . 47
2.4 iPSC differentiation to cerebral organoids . . . . . . . . . . . . . . . . . . 50
2.4.1 Media for cerebral organoids . . . . . . . . . . . . . . . . . . . . . 50
2.4.2 Protocol for forebrain-specific cerebral organoids . . . . . . . . . . 52
2.5 Immunocytochemistry . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
2.5.1 Preparation of cells for immunocytochemistry . . . . . . . . . . . . 52
2.5.2 Immunofluorescence protocol . . . . . . . . . . . . . . . . . . . . 53
2.5.3 Tau antibodies and signal amplification . . . . . . . . . . . . . . . 53
2.5.4 Use of the dye pFTAA . . . . . . . . . . . . . . . . . . . . . . . . 54
2.5.5 Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
2.6 Western blotting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
2.6.1 Reagents and solutions for Western Blotting . . . . . . . . . . . . . 56
2.6.2 Sample preparation . . . . . . . . . . . . . . . . . . . . . . . . . . 56
2.6.3 Protein extraction . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
2.6.4 Determination of protein concentration . . . . . . . . . . . . . . . 57
Table of contents xiii
2.6.5 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
2.6.6 Stripping and re-probing membranes . . . . . . . . . . . . . . . . . 58
2.6.7 Western blotting for tau isoforms . . . . . . . . . . . . . . . . . . 58
2.7 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3 Characterisation of iPSC-derived neurons with MAPT mutations 61
3.1 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.2.1 Tau isoform expression in iPSC-derived neurons . . . . . . . . . . 62
3.2.2 Synapses in FTDP-17T and in iPSC-derived neurons . . . . . . . . 64
3.2.3 Astrocytes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.3 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
3.3.1 iPSC culture and differentiation . . . . . . . . . . . . . . . . . . . 68
3.3.2 Immunostaining, Western blotting and statistical analysis . . . . . . 68
3.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
3.4.1 Suitability of iPSC lines for differentiation to neurons . . . . . . . 69
3.4.2 Regional specificity of neural precursors . . . . . . . . . . . . . . . 69
3.4.3 Proliferative capacity of neural precursors . . . . . . . . . . . . . . 75
3.4.4 β III-tubulin in iPSC-derived neuronal cultures over time . . . . . . 75
3.4.5 Synaptophysin in iPSC-derived neuronal cultures over time . . . . 80
3.4.6 Expression of tau isoforms . . . . . . . . . . . . . . . . . . . . . . 82
3.4.7 Appearance of astrocytes in aged cultures . . . . . . . . . . . . . . 89
3.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
3.5.1 Differentiation of iPSCs to NPCs . . . . . . . . . . . . . . . . . . 92
3.5.2 Differentiation of NPCs to neurons . . . . . . . . . . . . . . . . . 94
3.5.3 Tau isoforms detected . . . . . . . . . . . . . . . . . . . . . . . . 97
3.5.4 Advancing the maturity of iPSC-derived neurons . . . . . . . . . . 100
3.5.5 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
4 Pilot search for morphological and phenotypic changes in MAPT-mutant iPSC-
derived neurons 103
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
4.2 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
4.2.1 Tau phosphorylation and misfolding . . . . . . . . . . . . . . . . . 104
4.2.2 Sodium channels . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
xiv Table of contents
4.2.3 Balloon neurons . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
4.2.4 Cell death . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
4.3 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
4.3.1 iPSC culture and differentiation . . . . . . . . . . . . . . . . . . . 111
4.3.2 Immunostaining, Western blotting and statistical analysis . . . . . . 111
4.3.3 LDH assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
4.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
4.4.1 Tau phosphorylation at Ser202 and Thr205; the AT8 epitope . . . . 112
4.4.2 Conformational changes in tau . . . . . . . . . . . . . . . . . . . . 118
4.4.3 Preliminary results: probing for filamentous tau . . . . . . . . . . . 118
4.4.4 Balloon neurons . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
4.4.5 Markers of the AIS . . . . . . . . . . . . . . . . . . . . . . . . . . 122
4.4.6 Cell death . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
4.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
4.5.1 Tau phosphorylation at the AT8 epitope . . . . . . . . . . . . . . . 128
4.5.2 Conformational changes in tau . . . . . . . . . . . . . . . . . . . . 130
4.5.3 αB-crystallin-positive balloon-type neurons . . . . . . . . . . . . . 131
4.5.4 Sodium channel expression and the lack of an AIS . . . . . . . . . 133
4.5.5 Spontaneous cell death measured by LDH release . . . . . . . . . . 134
4.5.6 Experiments on iPSC-derived neural cultures at day 80-100 . . . . 136
4.5.7 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
5 Gene editing by CRISPR to make isogenic iPSC lines 139
5.1 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
5.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
5.2.1 The origins of CRISPR . . . . . . . . . . . . . . . . . . . . . . . . 139
5.2.2 CRISPR for gene editing . . . . . . . . . . . . . . . . . . . . . . . 140
5.2.3 Mechanisms of DNA repair by homologous recombination . . . . . 142
5.2.4 Off-target editing with CRISPR . . . . . . . . . . . . . . . . . . . 142
5.2.5 Minimising unwanted CRISPR activity . . . . . . . . . . . . . . . 144
5.2.6 Maximising on-target editing . . . . . . . . . . . . . . . . . . . . . 148
5.2.7 Advantages of CRISPR for gene editing . . . . . . . . . . . . . . . 149
5.2.8 Using CRISPR to make isogenic iPSC lines . . . . . . . . . . . . . 150
5.3 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
5.3.1 Design and assembly of Cas9 nickase and Cas9 wild-type plasmids 152
Table of contents xv
5.3.2 Homology directed repair templates . . . . . . . . . . . . . . . . . 154
5.3.3 iPSC transfection by electroporation . . . . . . . . . . . . . . . . . 155
5.3.4 PCR for mutation screening . . . . . . . . . . . . . . . . . . . . . 156
5.3.5 Mutation screening by restriction digest . . . . . . . . . . . . . . . 158
5.3.6 Mutation screening by Sanger Sequencing . . . . . . . . . . . . . . 158
5.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
5.4.1 CRISPR nickase strategy 1 . . . . . . . . . . . . . . . . . . . . . . 159
5.4.2 CRISPR nickase strategy 2 . . . . . . . . . . . . . . . . . . . . . . 163
5.4.3 Transfection of iPSCs with CRISPR 2 nickase components . . . . . 167
5.4.4 Wild-type CRISPR strategy design . . . . . . . . . . . . . . . . . . 170
5.4.5 Transfection of iPSCs with CRISPR 3 components . . . . . . . . . 175
5.4.6 The effect of silent mutations in isogenic P301L iPSC lines . . . . . 176
5.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
5.5.1 Improvements to CRISPR 2 . . . . . . . . . . . . . . . . . . . . . 179
5.5.2 Improvements to CRISPR 3 . . . . . . . . . . . . . . . . . . . . . 181
5.5.3 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
6 Cerebral organoids 185
6.1 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
6.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
6.2.1 Cerebral cortex development . . . . . . . . . . . . . . . . . . . . . 187
6.2.2 Cerebral organoids as models of the brain . . . . . . . . . . . . . . 188
6.2.3 Advantages of 3D neural cultures over 2D cultures . . . . . . . . . 189
6.2.4 Tau dysfunction in 3D PSC-derived cultures . . . . . . . . . . . . . 191
6.3 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192
6.3.1 iPSC culture and differentiation . . . . . . . . . . . . . . . . . . . 192
6.3.2 Immunostaining, Western blotting and statistical analysis . . . . . . 193
6.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
6.4.1 Cell types present in cerebral organoids . . . . . . . . . . . . . . . 193
6.4.2 Layer markers . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197
6.4.3 Tau isoform expression in cerebral organoids . . . . . . . . . . . . 201
6.4.4 Tau phosphorylation at Ser202 and Thr205 (the AT8 epitope) . . . . 206
6.4.5 Conformational changes in tau . . . . . . . . . . . . . . . . . . . . 209
6.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213
6.5.1 Cell types detected . . . . . . . . . . . . . . . . . . . . . . . . . . 213
xvi Table of contents
6.5.2 Layer markers detected . . . . . . . . . . . . . . . . . . . . . . . . 214
6.5.3 Tau isoform expression in cerebral organoids . . . . . . . . . . . . 215
6.5.4 Tau phosphorylation . . . . . . . . . . . . . . . . . . . . . . . . . 216
6.5.5 Tau misfolding . . . . . . . . . . . . . . . . . . . . . . . . . . . . 217
6.5.6 Limitations and improvements . . . . . . . . . . . . . . . . . . . . 217
6.5.7 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218
7 Discussion 221
7.1 Characterisation of control and MAPT-mutant iPSC-derived cultures . . . . 221
7.1.1 Monolayer cultures . . . . . . . . . . . . . . . . . . . . . . . . . . 221
7.1.2 COs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222
7.2 FTDP-17T-relevant phenotypes detected . . . . . . . . . . . . . . . . . . . 222
7.2.1 Comparison of my work with other findings . . . . . . . . . . . . . 222
7.2.2 Tau splicing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222
7.2.3 Tau phosphorylation . . . . . . . . . . . . . . . . . . . . . . . . . 225
7.2.4 Tau misfolding . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226
7.2.5 Other phenotypes in monolayer cultures . . . . . . . . . . . . . . . 227
7.2.6 Protective factors . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
7.3 Generation of isogenic N279K iPSC lines . . . . . . . . . . . . . . . . . . 227
7.4 Limitations and improvements . . . . . . . . . . . . . . . . . . . . . . . . 228
7.4.1 Choice of control and sample size . . . . . . . . . . . . . . . . . . 228
7.4.2 Variability between iPSC lines . . . . . . . . . . . . . . . . . . . . 229
7.4.3 Variability between cultures . . . . . . . . . . . . . . . . . . . . . 230
7.4.4 Specificity of brain areas modelled . . . . . . . . . . . . . . . . . . 231
7.5 Future directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232
7.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233
References 235
Appendix A Off-target matches with CRISPR 3 281
Appendix B NPC-derived monolayer neurons from IsoCon and P301Lhet iPSCs 283
B.1 Confirmation of genotype in IsoCon and P301Lhet neurons . . . . . . . . . 283
B.2 Cytoskeleton proteins in IsoCon and P301Lhet neurons . . . . . . . . . . . 286
B.3 Tau isoforms in IsoCon and P301Lhet neurons . . . . . . . . . . . . . . . . 286
Table of contents xvii
B.4 Tau phosphorylation at Ser202 and Thr205 (AT8) in IsoCon and P301Lhet
neurons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 286
B.5 Tau phosphorylation at Thr212 and Ser214 (AT100) in IsoCon and P301Lhet
neurons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 290
B.6 α-synuclein and β III-tubulin positive puncta and loops in neuronal processes
of IsoCon and P301Lhet neurons . . . . . . . . . . . . . . . . . . . . . . . 291

List of figures
1.1 Tau gene expression and alternative splicing . . . . . . . . . . . . . . . . . 3
1.2 Pathology and atrophy in FTDP-17T brains . . . . . . . . . . . . . . . . . 11
1.3 Mutations in the MAPT gene linked to FTDP-17T . . . . . . . . . . . . . . 15
2.1 Pluripotent and differentiated iPSC colonies . . . . . . . . . . . . . . . . . 45
2.2 Neuronal differentiation of iPSCs . . . . . . . . . . . . . . . . . . . . . . . 48
2.3 Differentiation of iPSCs to cerebral organoids . . . . . . . . . . . . . . . . 51
3.1 Comparison of two protocols for iPSC differentiation to neurons . . . . . . 67
3.2 Pluripotent iPSCs with a normal karyotype . . . . . . . . . . . . . . . . . . 70
3.3 Sanger sequencing to show the N279K mutation in the N279K1 and N279K2
iPSC lines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
3.4 Neural precursors express forebrain markers Pax6, Nestin and Otx2 at day 16 72
3.5 Neural precursors express forebrain markers FoxG1 and Nestin at day 16 . 73
3.6 There is no significant difference in the proportion of proliferating neural
precursor cells made from CTRL1, CTRL2, N279K1, N279K2 and V337M
iPSC lines at day 16 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
3.7 The amount of β III-tubulin in iPSC-derived neuronal cultures decreased
from day 50 to day 80-100, as measured by Western blot . . . . . . . . . . 77
3.8 Representative Western blots of synaptophysin, β III-tubulin, and βactin in
iPSC-derived neuronal cultures at day 50 and day 80-100 . . . . . . . . . . 78
3.9 The amount of synaptophysin in iPSC-derived neuronal cultures increased
relative to the amount of β III-tubulin from day 50 to day 80-100, as measured
by Western blot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
3.10 Representative images of synaptophysin positive puncta associated with β III-
tubulin positive neurons in iPSC-derived neuronal cultures at day 50 and day
80-100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
xx List of figures
3.11 Western blots for tau show expression of 0N3R tau and some 0N4R tau at
day 50 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
3.12 Western blots for tau show expression of 0N3R tau, some 0N4R tau, and
occasional 1N3R tau at day 80-100 . . . . . . . . . . . . . . . . . . . . . . 84
3.13 3R tau is expressed in iPSC-derived neurons at day 50 and 80-100 . . . . . 87
3.14 4R tau is expressed in iPSC-derived neurons at day 50 and 80-100 . . . . . 88
3.15 The proportion of S100β positive astrocytes in neuronal cultures increases
from day 50 to day 80-100 . . . . . . . . . . . . . . . . . . . . . . . . . . 90
4.1 Tau phosphorylated at Ser202 and Thr205 (detected with the AT8 antibody)
is present in some neurons at day 50 and day 80-100 . . . . . . . . . . . . 113
4.2 The proportion of AT8 positive neurons is significantly higher at day 80-100
than at day 50, and there is a significantly higher proportion of AT8 positive
N279K neurons as compared to control neurons at day 50 . . . . . . . . . . 114
4.3 MC-1 positive misfolded tau is not detectable in day 80-100 neural cultures 117
4.4 Filamentous tau was not detected in day 100 neural cultures using the dye
pFTAA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
4.5 αB-crystallin positive neurons, resembling balloon neurons, were detected
at day 80-100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
4.6 The number of αB-crystallin positive balloon neuron-like neurons was not
significantly different between control and MAPT mutant cultures at day
80-100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
4.7 αB-crystallin positive balloon neuron-like neurons in cultures at day 80-100
were 4R tau positive, but most were not AT8 positive . . . . . . . . . . . . 123
4.8 αB-crystallin positive balloon-neuron-like neurons at day 80-100 compared
to αB-crystallin positive balloon neurons in human FTDP-17T brain . . . . 124
4.9 Sodium channel staining in day 50 cultures was not specific for the AIS . . 125
4.10 There was no significant change in cell death over time as measured by
spontaneous LDH release into the media . . . . . . . . . . . . . . . . . . . 127
5.1 The S. pyogenes CRISPR system in immunity and in gene editing . . . . . 141
5.2 Mechanisms of DNA repair by homologous recombination. . . . . . . . . . 143
5.3 Workflow for gene editing in iPSCs using CRISPR. . . . . . . . . . . . . . 157
5.4 gRNA sequences for CRISPR 1. . . . . . . . . . . . . . . . . . . . . . . . 160
5.5 Cis regulatory sequences in tau exon 10. . . . . . . . . . . . . . . . . . . . 161
5.6 gRNA sequences for CRISPR 2. . . . . . . . . . . . . . . . . . . . . . . . 164
List of figures xxi
5.7 Potential changes in tau exon 10 splicing caused by a PAM mutation in intron 9.165
5.8 Screening for CRISPR-corrected iPSC colonies by restriction digest follow-
ing CRISPR 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
5.9 Immunostaining with the FLAG-M2 antibody was not specific enough to
detect FLAG-tagged Cas9 in transfected iPSCs . . . . . . . . . . . . . . . 169
5.10 gRNA sequences for CRISPR 3 . . . . . . . . . . . . . . . . . . . . . . . 172
5.11 Screening for CRISPR-corrected iPSC colonies by restriction digest follow-
ing CRISPR 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
5.12 Screening by Sanger sequencing following CRISPR 3 . . . . . . . . . . . . 174
5.13 The position of silent blocking mutations and the P301L mutation in tau
exon 10 DNA from P301L heterozygous and homozygous iPSCs created
using CRISPR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176
6.1 Western blots for GFAP, synaptophysin, β III-tubulin, and GAPDH in iPSC-
derived COs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194
6.2 There is no significant difference in the amount of β III-tubulin positive
neurons, in the amount of GFAP-expressing astrocytes, or in the amount of
the synaptic protein synaptophysin between IsoCon, P301Lhet, P301Lhom
and P301Lpat iPSC-derived COs at day 84-100 . . . . . . . . . . . . . . . 195
6.3 IsoCon, P301Lhet, P301Lhom, and P301Lpat iPSC-derived COs all express
GFAP and β III-tubulin at day 84-100 . . . . . . . . . . . . . . . . . . . . 196
6.4 Tbr2 positive intermediate progenitor cells were detected in IsoCon, P301Lhom,
and P301Lpat (but not P301Lhet) iPSC-derived COs at day 84-100 . . . . . 198
6.5 Tbr1 positive layer 6 neurons were detected in IsoCon, P301Lhet, P301Lhom,
and P301Lpat iPSC-derived COs at day 84-100 . . . . . . . . . . . . . . . 199
6.6 Cux1/2 positive layer 2-4 neurons were detected in IsoCon, P301Lhom, and
P301Lpat (but not P301Lhet) iPSC-derived COs at day 84-100 . . . . . . . 200
6.7 Western blots for tau isoforms show expression of 0N3R, 0N4R and some
1N3R tau in IsoCon, P301Lhet, P301Lhom and P301Lpat iPSC-derived COs
at day 84-100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
6.8 3R tau expression was detected in IsoCon, P301Lhet, P301Lhom, and
P301Lpat iPSC-derived COs at day 84-100 . . . . . . . . . . . . . . . . . 203
6.9 4R tau expression detected in IsoCon, P301Lhet, P301Lhom, and P301Lpat
iPSC-derived COs at day 84-100 . . . . . . . . . . . . . . . . . . . . . . . 204
xxii List of figures
6.10 Positive control for 4R tau immunostaining: dRG from a 5 month-old P301S
mouse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205
6.11 Tau phosphorylated at Ser202 and Thr205 (detected with the AT8 antibody)
is found in IsoCon, P301Lhet, P301Lhom, and P301Lpat COs at day 84-100 207
6.12 Positive control for AT8 immunostaining: dRG from a 5 month-old P301S
mouse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208
6.13 There is no significant difference in AT8 immunofluorescence intensity
between IsoCon, P301Lhet, P301Lhom, and P301Lpat iPSC-derived COs at
day 84-100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208
6.14 Possible background staining with the MC-1 antibody against mis-folded tau
is detected in IsoCon, P301Lhet, P301Lhom, and P301Lpat COs at day 84-100211
6.15 Positive control for MC1 immunostaining: dRG from a 5 month-old P301S
mouse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212
6.16 There is no significant difference in MC-1 immunofluorescence intensity
between IsoCon, P301Lhet, P301Lhom, and P301Lpat iPSC-derived COs at
day 84-100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212
A.1 Top 20 predicted off-target sites for CRISPR 3 gRNA . . . . . . . . . . . . 282
B.1 Sanger sequencing and restriction digest to assess the P301L mutation locus
in IsoCon, P301Lhet and Con6 neurons . . . . . . . . . . . . . . . . . . . 284
B.2 The cytoskeletal proteins neurofilament-M and β III-tubulin in 41 day-old
IsoCon and P301Lhet NPC-derived neurons . . . . . . . . . . . . . . . . . 285
B.3 3R and 4R tau in day 41 IsoCon and P301Lhet neurons . . . . . . . . . . . 287
B.4 Tau isoforms in 41 day-old IsoCon and P301Lhet neurons detected by West-
ern blot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 288
B.5 Tau phosphorylation at the AT8 epitope in IsoCon and P301Lhet neurons . 289
B.6 No tau phosphorylation at the AT100 epitope in IsoCon and P301Lhet neurons290
B.7 α-synuclein positive, β IIItubulin positive puncta and loops in processes . . 292
List of tables
1.1 Tau phosphorylation in development and FTDP-17T . . . . . . . . . . . . 13
1.2 Summary of findings from tau knock-out mouse lines . . . . . . . . . . . . 18
1.3 Effects of MAPT mutations N279K, P301L and V337M . . . . . . . . . . 22
1.4 Published studies using iPSC-derived neurons with the N279K MAPT mutation 36
1.5 Published studies using iPSC-derived neurons with the P301L or V337M
MAPT mutations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.1 Materials used and where purchased . . . . . . . . . . . . . . . . . . . . . 42
2.2 iPSC lines used . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
2.3 Reagent for iPSC maintenance and neuronal differentiation . . . . . . . . . 47
2.4 Primary antibodies for Immunofluorescence and Western Blot . . . . . . . 55
3.1 Comparison of the protocols developed by Shi et al. (2012a) and Kirkeby
et al. (2012)/Santiváñez Pérez (2017) for iPSC differentiation to neurons . . 68
3.2 Tau isoforms in day 50 and day 80-100 iPSC-derived neurons detected by
Western blotting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
4.1 Proteins detected in balloon neurons found in the brains of people with
neurodegenerative diseases . . . . . . . . . . . . . . . . . . . . . . . . . . 108
5.1 iPSC lines and iPSC-derived cells with MAPT mutations induced by gene
editing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
5.2 Oligomer sequences for incorporation into Cas9 plasmids . . . . . . . . . . 153
5.3 Primers used for PCR and sequencing . . . . . . . . . . . . . . . . . . . . 154
6.1 Differentiation of iPSCs to COs . . . . . . . . . . . . . . . . . . . . . . . 193
6.2 COs expressing the layer markers Tbr2, Tbr1, and Cux1/2 . . . . . . . . . 197
6.3 Tau isoforms in day 84-100 IsoCon, P301Lhet, P301Lhom, and P301Lpat
COs detected by Western blotting . . . . . . . . . . . . . . . . . . . . . . 205
xxiv List of tables
7.1 Comparison of results from control, N279K and V337M iPSC-derived neu-
rons from my work in monolayer neurons with Iovino et al.’s results in
control and N279K monolayer neurons made from the same iPSC lines using
a different method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223
7.2 Comparison of results from control and P301L iPSC-derived neurons from
my work in monolayer neurons, Iovino et al.’s work in monolayer neurons,
and my work in cerebral organoids . . . . . . . . . . . . . . . . . . . . . . 224
List of tables xxv
Abbreviations
2D 2 dimensional
3D 3 dimensional
0N No N-terminal inserts
1N 1 N-terminal insert
2N 2 N-terminal inserts
3R 3 repeat tau
4R 4 repeat tau
AA Ascorbic acid
ACE A/C rich splice enhancer
AD Alzheimer’s disease
AGD Argyrophilic grain disease
AIS Axon initial segment
ANOVA Analysis of variance
AP Action potential
ASCL1 Achaete-scute homolog 1
ATP Adenosine triphosphate
BCA Bicinchoninic acid
BDNF Brain-derived neurotrophic factor
BiP Binding immunoglobulin protein
BMP Bone morphogenic protein
bp Base pairs
xxvi List of tables
BPS Branch-point sequence
BSA Bovine serum albumin
C9ORF72 Chromosome 9, open reading frame 72
Cas9 CRISPR-associated protein 9
Cas9n Cas9 nickase
Cas9wt Cas9 wild-type
CBD Cortico-basal degeneration
CC Corpus callosum
CCK Cell culture kitchen
Cdk5 Cyclin-dependent kinase 5
ChAT Choline acetyltransferase
CHMP2B Charged mulitvesicular body protein 2b
CJD Creutzfeldt-Jakob disease
CNS Central nervous system
CO Cerebral organoid
Con6 non-isogenic control 6
CP Caudate putamen
CRISPR Clustered regularly-interspaced short palindromic repeats
crRNA CRISPR RNA
CTRL control
DAPI 4’,6-diamidino-2-phenylindole
DAPT N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester
db-cAMP Dibutyl-cyclic adenosine monophosphate
List of tables xxvii
dd Double-distilled
DM-1 Differentiation medium 1
DM-2 Differentiation medium 2
DM-3 Differentiation medium 3
DMEM Dulbecco’s modified Eagle’s medium
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid
DSB Double-stranded break
DSBR Double-stranded break repair
E8 Essential 8 medium
EB Embryoid body
EDTA Ethylenediaminetetraacetic acid
EEA1 Early Endosome Antigen 1
EGFP Enhanced green fluorescent protein
EPSC Excitatory post-synaptic current
ERK2 Extracellular signal-regulated kinase 2
ESE Exon splicing enhancer
(h) (m) ESC (human) (mouse) embryonic stem cell
ESS Exon splicing silencer
FACS Fluorescence-activated cell sorting
FBS Fetal bovine serum
FGF Fibroblast growth factor
FoxG1 Forkhead box protein G1
xxviii List of tables
FTD Frontotemporal dementia
FTDP-17T Frontotemporal dementia with parkinsonism, linked to chromosome 17 and tau
mutations
FTLD Frontotemporal lobar degeneration
FTLD-ni Frontotemporal lobar degeneration, no inclusions
FUS Fused in sarcoma
G3BP Ras GTPase-activating protein-binding protein 1
GABA Gamma-aminobutyric acid
GDNF Glial derived neurotrophic factor
GFAP Glial fibrillary acidic protein
GFP Green fluorescent protein
GGT Global glial tauopathy
GL Granule layer
gRNA guide RNA
GSK-3β Glycogen synthase kinase 3β
HC Hippocampus
HDR Homology-directed repair
HEK293 Human embryonic kidney cells
HR Homologous recombination
HRP Horseradish peroxidase
HSF Human splicing finder
IF Immunofluorescence
iN Induced neuron
List of tables xxix
Indel Insertion-deletion mutation
iPSC Induced pluripotent stem cell
ISM Intron splicing modulator
IsoCon isogenic control
ISS Intron splicing silencer
KANSL1 KAT8 regulatory NSL complex subunit 1
kDa kilodaltons
Klf4 Kruppel-like factor 4
KO Knock-out
KSR Knock-out serum replacement
LAMP-1 Lysosomal-associated membrane protein 1
LD Lysogeny broth
LDH Lactate dehydrogenase
LRM Laboratory of Regenerative Medicine
LTD Long-term depression
LTP Long-term potentiation
LVA Lateral ventricular area
MAP Microtubule associated protein
MAPT Microtubule associated protein tau
MEF Mouse embryonic fibroblast
mRNA messenger RNA
MSA Multi-system atrophy
MT Microtubule
xxx List of tables
NDM Neuronal differentiation medium
NEAA Non-essential amino acids
NEC Neuroepithelial cell
NeuroD1 Neurogenic differentiation 1
NF-M Neurofilament-medium
NFT Neurofibrillary tangle
Ngn2 Neurogenin 2
NHEJ Non-homologous end-joining
NI Neural induction medium
NIM Neuronal induction medium
NMR Nuclear magnetic resonance
NPC Neural precursor cell
NPM Neuronal proliferation medium
OCT Optimum cutting temperature
Oct4 Octamer-binding transcription factor 4
P301Lhet P301L heterozygous
P301Lhom P301L homozygous
P301Lpat P301L heterozygous, patient derived
PAM Protospacer-adjacent motif
Pax6 Paired box 6
PBS Phosphate buffer saline
PCR Polymerase chain reaction
PD Parkinson’s disease
List of tables xxxi
pen-strep Penicillin and streptomycin
PFA Paraformaldehyde
pFTAA Pentameric formyl thiophene acetic acid
PGRN Progranulin
PiD Pick’s disease
P/L Poly-L-ornithine and laminin
PP1, PP2A, PP2B, PP5 Protein phosphatase 1, 2A, 2B, 5
PPE Polypurine enhancer
p-PERK Phosphorylated protein kinase RNA-like ER kinase
PPT Polypurine tract
PSC Pluripotent stem cell
PSD-95 Post-synaptic density protein 95
PSP Progressive supranuclear palsy
PUMA P53-upregulated modulator of apoptosis
RD Repeat domain
RIPA Radioimmunoprecipitation assay
RNA Ribonucleic acid
rpm Revolutions per minute
ROCK Rho-associated coiled-coil containing protein kinase
SatB2 Special AT-rich sequence-binding protein 2
SC35 SC35-like binding sequence
SD Standard deviation
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
xxxii List of tables
SDSA Synthesis-dependent strand annealing
Ser Serine
SFEBq Serum-free floating culture of embryoid body-like aggregates with quick reaggrega-
tion
Shh Sonic hedgehog
shRNA Short hairpin RNA
SN Substantia nigra
SNP Single-nucleotide polymorphism
Sox2 Sex determining region Y box 2
SRp Serine/arginine-rich protein
ssDI Single-strand DNA incorporation
SSEA-4 Stage-specific embryonic antigen-4
ssODN Single-stranded DNA oligomer
STP Short-term plasticity
TALENs Transcription activator-like effector nuclease
Tbr1 T-box brain 1
Tbr2 T-box brain 2
TBS Tris-buffered saline
TBST Tris-buffered saline with Tween
TDP-43 TAR DNA binding protein 43
TGFβ1 Transforming growth factor β
Th Tyrosine hydroxylase
Thr Threonine
List of tables xxxiii
TIA-1 T-cell intracytoplasmic antigen 1
tracrRNA Transactivating CRISPR RNA
TRS Tandem repeat sequence
UPR Unfolded protein response
UPS Ubiquitin proteasome system
VCP Valosin containing protein
VTA Ventral tegmental area
VTN-N Truncated recombinant human vitronectin
WB Western blot
WT Wild-type
ZFN Zinc-finger nuclease

Chapter 1
Introduction
1.1 Tau in a normal brain
1.1.1 Isoforms and alternative splicing
Microtubule-Associated Protein Tau (MAPT) is encoded by the MAPT gene on chromosome
17q21 (Neve et al., 1986). Due to a 970kB inversion encompassing MAPT, there are two
tau haplotypes (H1 and H2), in which MAPT lies in opposite orientations (Baker et al.,
1999, Figure 1.1). MAPT encodes 16 exons: eight are constitutively expressed (1, 4, 5, 7,
9, 11, 12, 13) and three are alternatively spliced (2, 3 and 10). In the peripheral nervous
system, inclusion of exons 4a, 2, 3 and 10 generates big tau, a 110 kDa protein expressed in
peripheral neurons (Georgieff et al., 1993; Goedert et al., 1992).
In the central nervous system, alternative splicing of exons 2 and 3 results in the inclusion
or exclusion of a 29 amino acid (exon 2) or 58 amino acid (exons 2 and 3) insert towards tau’s
N-terminus (Goedert et al., 1989a). Exon 10 inclusion adds a microtubule-binding repeat in
addition to the three encoded by the constitutively expressed exons 9, 11 and 12 (Goedert
et al., 1989b). The three tau isoforms lacking exon 10 have three microtubule-binding repeats
and are known as 3 repeat (3R) tau, whilst the three isoforms including exon 10 have four
microtubule-binding repeats and are known as 4 repeat (4R) tau. Alternative splicing of
exons 2, 3 and 10 gives six tau isoforms: 0N3R, 0N4R, 1N3R, 1N4R, 2N3R and 2N4R
(Goedert and Jakes, 1990a; Figure 1.1).
Tau isoform expression is developmentally regulated: only the shortest isoform (0N3R)
is present in fetal brains, whereas all six isoforms are expressed post-natally (Goedert and
Jakes, 1990; Goedert et al., 1989a,b). In a healthy adult human brain 3R and 4R tau are
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present in a 1:1 ratio (Goedert and Jakes, 1990). 0N, 1N and 2N tau make up approximately
37%, 54% and 9% of total tau, respectively (Hong, 1998).
1.1.2 Structure
In a healthy brain, tau is a soluble protein with an unfolded structure (Mukrasch et al.,
2009). The addition of N-terminal inserts encoded by exons 2 and 3 makes the N-terminal
more acidic and negatively charged, whereas the proline-rich region, microtubule binding
repeats and C-terminal regions have more basic residues and a net positive charge (Goedert
et al., 1989a). The N-terminal is referred to as the projection domain (Steiner et al., 1990),
because it projects away from microtubules when tau is bound to them (Hirokawa et al., 1988;
Figure 1.1). The proline rich region, the microtubule binding repeats, and 10 downstream
residues bind with negatively charged microtubules, so this region is known as the assembly
domain (Sillen et al., 2007; Steiner et al., 1990).
Post-translational modifications
Tau is subject to many post-translational modifications, including acetylation, cleavage or
truncation, glycation, glycosylation, nitration, oxidation, phosphorylation, polyamination,
prolyl-isomerisation, sumoylation and ubiquitination (reviewed by Martin et al., 2011). Of
these, phosphorylation is the most frequently occurring, and is discussed below.
The roles of these modifications in diseased and normal states are many and varied: some
affect tau-microtubule interactions, and many have been implicated in tau accumulation
during disease. For example, ubiquitination targets tau for degradation under normal condi-
tions, but in disease states, tau filaments are thought to be ubiquitinated after they have been
phosphorylated and glycated. Glycation is an age-related modification that may make tau
more resistant to degradation, leading to tau accumulation, whereas phosphorylation alters
tau’s binding to microtubules (reviewed by Mietelska-Porowska et al., 2014).
Tau phosphorylation
Tau has 85 serine, threonine and tyrosine residues which are potential phosphorylation sites,
although not all of them are phosphorylated: up to 16 phosphorylated residues have been
found in control brains and 45 have been identified in brains from people with Alzheimer’s
disease (AD; reviewed by Hanger and Noble, 2011). However, Matsuo et al. (1994) report
that adult human tau from rapidly analysed brain biopsy tissue is more highly phosphorylated
1.1 Tau in a normal brain 3
H2 orientation H1 orientation
N-terminal region C-terminal
region
Microtubule
binding
repeats
Proline-rich
region
Assembly domainProjection domain
Fetal tau
3R:4R
1:1
Fig. 1.1 Tau gene expression and alternative splicing. The position of microtubule-associated
protein tau (MAPT) on chromosome 17 is shown in red and the orientations of a chromosomal region
including tau are shown by arrows (H1 and H2). Green boxes represent constitutively expressed exons
and green shaded boxes represent exons -1 and 14 which are transcribed but not translated. White
boxes represent exons which are not included in tau central nervous system transcripts: exon 4a is
expressed in the peripheral nervous system in big tau but exons 6 and 8 are not expressed in human tau
proteins. Exons 2 (yellow), 3 (orange) and 10 (red) are alternatively spliced to give six tau isoforms.
Exon 3 is not included in tau mRNA without exon 2. Inclusion of exon 10 gives three tau isoforms
with 4 microtubule-binding repeats (4 repeat or 4R tau) and exclusion of exon 10 three tau isoforms
with 3 microtubule-binding repeats (3 repeat or 3R tau). Alternative splicing of exons 2 and 3 adds
N-terminal inserts (0N, 1N or 2N). Tau without exon 2, 3 or 10 is the fetal isoform, 0N3R, which
also persists in the adult brain. The microtubule binding repeats interact with microtubules and (along
with part of the proline-rich region) promote microtubule assembly (Sillen et al., 2007; Steiner et al.,
1990). The N-terminal part of tau projects out when tau is bound to microtubules and is therefore
named the projection domain. Diagram altered from Warren and Burn (2007).
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than tau from post-mortem brain tissue, indicating that tau is dephosphorylated after death,
which may make estimates of tau phosphorylation in the normal living brain inaccurate.
Tau phosphorylation is developmentally regulated: fetal 0N3R tau is heavily phosphory-
lated (Goedert and Jakes, 1990) at epitopes including AT8 (Brion et al., 1993; Matsuo et al.,
1994; Milenkovic et al., 2018) and PHF-1 (Bramblett et al., 1993; Kenessey and Yen, 1993;
Matsuo et al., 1994), which are also detected in brains from people with tauopathies (Table
1.1).
Tau phosphorylation and dephosphorylation are mediated by a balance of kinase and
phosphatase activity. At least 24 kinases which phosphorylate tau have been identified
(reviewed by Wang et al., 2012), including serine/threonine kinases, such as GSK-3β (Hanger
et al., 1992) and tyrosine kinases, such as Fyn (Lee et al., 2004). At least four phosphatases
which dephosphorylated tau have been identified, including the serine/threonine protein
phosphatases PP1, PP2A, PP2B and PP5 (Wang et al., 2017). Kinases and phosphatases
are implicated in tau phosphorylation in normal and disease states, and their activity can
be altered by other post-translational modifications of tau, indicating a complex and highly
regulated system (Wang et al., 2012).
1.1.3 Distribution
Tau is predominantly expressed in neuronal axons, where it binds to microtubules (Binder
et al., 1985) and other cytoskeletal proteins including actin (Griffith and Pollard, 1982) and
spectrin (Carlier et al., 1984), as well as motor proteins such as dynactin (Magnani et al.,
2007) and kinesin, whose motility is modulated by competition with tau to bind microtubules
(Dixit et al., 2008). Neuronal tau has also been detected bound to the plasma membrane via
its N-terminus (Brandt et al., 1995), bound to ribosomes (Papasozomenos and Binder, 1987)
and in nuclei (Loomis et al., 1990; Thurston et al., 1996).
Low levels of phosphorylated tau have been found in dendrites (Papasozomenos and
Binder, 1987; Tashiro et al., 1997), where tau targets the tyrosine kinase Fyn to the post-
synaptic density (Ittner et al., 2010). Both isoform-specific sorting and dendritic translation
of tau mRNA have been shown to contribute to dendritic tau in mouse models (Kobayashi
et al., 2017; Zempel et al., 2017), although it is not clear whether tau’s presence in dendrites
is linked to overexpression and disease (Ashe and Zahs, 2010).
In addition, tau has been detected in non-neuronal cells: at low levels in astrocytes (Pa-
pasozomenos and Binder, 1987) and in oligodendrocytes in some species (LoPresti et al.,
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1995), where tau interacts with Fyn and may have a functional role in myelination (Klein
et al., 2002). However, this is still debated (Ossola et al., 2016).
Area specific variations in tau expression across the brain have been reported. For
example, a study of tau expression in five brain regions from 12 control brains found the most
tau protein in the frontal cortex, with lower tau protein levels in the white matter, occipital
cortex, putamen and cerebellum. Protein levels were correlated with total tau mRNA levels
in these regions (Trabzuni et al., 2012). The same study found that tau isoform expression
did not differ between the frontal cortex, white matter, occipital cortex or putamen, but found
significantly less 0N3R tau in the cerebellum.
Other studies have found different patterns in tau isoform expression. For example,
Majounie et al. (2013) examined brain samples from control and PSP subjects with H1/H1 or
H1/H2 haplotypes and found higher 4R tau mRNA levels in the pons and cerebellum than the
temporal and frontal cortices, regardless of haplotype and disease status. Tau protein levels
in these brain areas were not quantified. In another study, Caffrey et al. (2006) measured the
ratio of 4R to 3R tau mRNA transcripts in 14 control brains and found 1.3 to 3.5 times more
4R tau mRNA in the globus pallidus than the frontal cortex in 13 of the brains. However,
whether the difference in mRNA transcript levels resulted in different protein expression
levels was not assessed.
Differences in tau isoform distribution have also been detected at the cellular level.
Goedert et al. (1989b) found both 3R and 4R mRNA in cerebral cortex pyramidal cells, but
in the hippocampus 3R mRNA was present in both pyramidal and granule cells, whereas
4R mRNA was detected in most, though not all, pyramidal cells and not in granule cells.
Since adult neurogenesis may occur in the dentate gyrus of the hippocampus where granule
cells are located, the expression of 3R but not 4R tau may indicate the relative immaturity
of newly-born neurons (Bullmann et al., 2007). Alternatively, this could indicate that tau
mRNA (and possibly tau protein) is expressed in a cell-specific manner.
Tau is also released into the extracellular space and is detectable in cerebrospinal fluid
from healthy individuals (reviewed by Blennow and Hampel, 2003). However, the release
mechanism and role of extracellular tau is unclear (reviewed by Wang and Mandelkow,
2015).
Finally, tau expression has been reported in peripheral tissues including the heart, skeletal
muscle, lung, kidney, and testis in rat (Ashman et al., 1992; Gu et al., 1996) and in the nuclei
of cells including fibroblasts and lymphocytes (Loomis et al., 1990; Thurston et al., 1996).
6 Introduction
1.1.4 Functions
Tau has many binding partners including microtubules, motor proteins, kinases, phosphatases,
chaperones, and membrane proteins (reviewed by Wang and Mandelkow, 2015).
As a microtubule-associated protein (MAP), tau promotes the assembly of tubulin into
microtubules (Weingarten et al., 1975) and decreases the rate of tubulin depolymerisa-
tion, thereby stabilising microtubules (Drubin and Kirschner, 1986) which form part of
the cytoskeleton. Tau’s microtubule binding is isoform- and phosphorylation-dependent,
with phosphorylation decreasing tau’s microtubule binding ability and as a consequence
decreasing microtubule stability (Drechsel et al., 1992). Tau isoforms with three microtubule
binding repeats have a lower affinity for microtubules than tau isoforms with four repeats
(Dayanandan et al., 1999; Goedert and Jakes, 1990). The N-terminal inserts (which are part
of tau’s projection domain that does not bind to microtubules) may regulate the spacing of
microtubules (Chen et al., 1992), or bind to the plasma membrane (Brandt et al., 1995).
The switch from highly phosphorylated 0N3R tau in fetal human brains to a 50:50 mix
of less phosphorylated 3R and 4R isoforms in adult human brains suggests that modulating
tau’s function has an important developmental role. The low microtubule binding ability of
phosphorylated fetal 0N3R tau may increase microtubule dynamics and allow the plasticity
needed for the outgrowth and synaptic connection of neurons (Goode and Feinstein, 1994).
As part of the cytoskeleton, tau is involved in neurite and axon outgrowth (Black et al.,
1996; Dawson et al., 2001; Liu et al., 1999) and neurite polarisation (Caceres and Kosik,
1990), as well as in axonal transport, in which motor proteins move cellular cargo along mi-
crotubules. Tau interacts with the motor protein dynein (Magnani et al., 2007) and modulates
the motility of both dynein and kinesin by competing with them to bind microtubules (Dixit
et al., 2008). In addition, tau binds to proteins with SH3 domains, such as Fyn (Lee et al.,
2004), suggesting that tau may have a role in neuronal signalling (reviewed by Wang and
Liu, 2008).
Tau has also been reported in the nucleus, where it may have a role in chromosome
stability (Granic et al., 2010; Rossi et al., 2008) and DNA protection, since tau increases
DNA melting temperatures in vitro (Hua and He, 2000) and protects against heat-induced
DNA damage in vivo (Sultan et al., 2011).
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1.2 Tau in disease
Tau aggregates in diseases known as tauopathies which include AD, corticobasal degeneration
(CBD), chronic traumatic encephalopathy, Pick’s disease (PiD), progressive supranuclear
palsy (PSP), fronto-temporal dementia with Parkinsonism linked to chromosome 17 and
tau mutations (FTDP-17T), and many others (Ghetti et al., 2015). Although tau pathology
varies between tauopathies, there are some unifying features: in diseased brains, tau becomes
hyperphosphorylated, insoluble and aggregated (reviewed by Spillantini and Goedert, 2013).
The mechanism by which tau dysfunction results in tauopathies is still unknown.
1.2.1 FTDP-17T: fronto-temporal dementia with Parkinsonism linked
to chromosome 17 and MAPT mutations
Mutations in MAPT cause the progressive, degenerative disorder FTDP-17T. FTDP-17
was defined at an international conference which discussed 13 familial dementias linked to
chromosome 17q21-22 that shared symptoms, genetic linkage and some neuropathology
(Foster et al., 1997). At the time, tau pathology had been described in brains from four of
the families, but tau mutations were later discovered in nine of the 13 families, showing that
MAPT mutations are sufficient to cause neurodegeneration (Hutton et al., 1998; Poorkaj et al.,
1998; Spillantini et al., 1998b). The remaining four families had mutations in progranulin
(PGRN) (Baker et al., 2006; Cruts et al., 2006), sub-dividing FTDP-17 into FTDP-17T
(linked to MAPT mutations) and FTDP-17 GRN (linked to PGRN mutations).
1.2.2 Classification of FTDP-17T and other fronto-temporal demen-
tias
FTDP-17T is defined by the presence of MAPT mutations, and is part of the wider group
of fronto-temporal lobar degeneration (FTLD), which encompasses the clinical diagnoses
of fronto-temporal dementia (FTD), progressive non-fluent aphasia, and semantic dementia
(Neary et al., 1998).
FTLD can be divided into subtypes based on the protein aggregates present. Subtypes
include FTLD-tau (tau positive inclusions), FTLD-TDP (TAR DNA binding protein-43
(TDP-43) and ubiquitin positive inclusions), FTLD-UPS (inclusions of ubiquitin proteasome
system (UPS) proteins, which are TDP-43 negative), FTLD-FUS (fused in sarcoma (FUS)
inclusions), and FTLD-ni (no inclusions) (Mackenzie et al., 2011, 2009).
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Most occurrences of FTD are sporadic: only about 10-25% of cases have evidence
of a dominantly inherited mutation (Rohrer et al., 2009; Seelaar et al., 2008). To date,
mutations linked to FTLD have been found in PGRN (Baker et al., 2006; Cruts et al., 2006),
valosin-containing protein (VCP) (Watts et al., 2004), charged multivesicular body protein
2b (CHMP2B) (Skibinski et al., 2005), FUS (Broustal et al., 2010), TDP-43 (Synofzik et al.,
2014), a hexanucleotide repeat in the intronic region of chromosome 9, open reading frame
72 (C9ORF72) (DeJesus-Hernandez et al., 2011; Renton et al., 2011) and MAPT (Hutton
et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998c).
FTLD-tau
The FTLD-tau subtype includes PiD, CBD, PSP, argyrophilic grain disease (AGD), globular
glial tauopathy (GGT) and neurofibrillary tangle predominant dementia (NFTPD) (Forrest
et al., 2018; Mackenzie et al., 2009). FTLD-tau (sporadic, without MAPT mutations) and
FTDP-17T (familial, with MAPT mutations) are often classified separately, even though
FTLD-tau and FTDP-17T cases have similar disease durations, similar neuropathology, and
can be classified into the FTLD-tau subtypes (Forrest et al., 2018). For example, MAPT
mutations have been identified in people suffering from PSP, CBD and AGD (reviewed by
Sieben et al., 2012). MAPT mutations account for 30-40% of FTLD-tau cases (Zempel and
Mandelkow, 2014), and about 5% of FTD cases (Goedert, 2016).
Tau haplotype as a tauopathy risk factor
Although many tauopathy cases are sporadic, tau haplotype (the orientation of MAPT, Baker
et al., 1999) is a genetic risk factor: being homozygous for the H1 haplotype is associated
with sporadic PSP (Baker et al., 1999), CBD (Houlden et al., 2001), and Parkinson’s disease
(PD) (Pastor et al., 2000). The latter association is surprising since PD brains do not contain
much tau (reviewed by Irwin et al., 2013). Association with the H1 haplotype could implicate
genes other than MAPT which characterise the H1 and H2 haplotypes, including those for
corticotropin releasing hormone receptor 1 and N-ethylmaleimide-sensitive factor (Stefansson
et al., 2005). However, the presence of tau aggregates in PSP and CBD brains (Arai et al.,
2001) suggests that tau may be the culprit.
The increased risk may be due to an increase in 4R tau mRNA from the H1 relative to the
H2 haplotype, which has been shown in human brain (Caffrey et al., 2006) and human induced
pluripotent stem cell (iPSC)-derived neurons (Beevers et al., 2017). However, Trabzuni
et al. (2012) contend that observed differences in H1- and H2-specific tau mRNA expression
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are artefacts, caused by qPCR problems. Specifically, these are preferential probe binding
to H1 mRNA (from whose sequence the probes were designed) and decreased binding
to H2 mRNA, due to H2-specific single-nucleotide polymorphisms and insertion-deletion
mutations.
An alternative explanation is a protective effect of the H2 haplotype, which may increase
tau exon 3 expression (Caffrey et al., 2008; Trabzuni et al., 2012). Inclusion of exon 3 in
tau protein increases the minimal concentration needed to cause aggregation in vitro by
1.5-fold and decreases the extension rate of filaments (Zhong et al., 2012). By comparison,
inclusion of exons 2 or 10 increase the filament extension rate and decrease the minimal tau
concentration required for aggregation.
1.2.3 Symptoms of FTDP-17T
FTDP-17T symptoms vary between people with different mutations and even between
individuals with the same mutation, suggesting the existence of other genetic or environmental
influences (Foster et al., 1997). Most FTDP-17T patients exhibit at least two of the three
main symptom groups, which are behaviour and personality changes, motor dysfunction, and
cognitive impairment (reviewed by Ghetti et al., 2015). However, memory and visuospatial
skills are usually somewhat preserved until very late stages of the disease (Neary et al., 1998).
1.2.4 Neuropathology of FTDP-17T
In FTDP-17T, the frontal and temporal lobes atrophy, and other brain areas can also be
affected. These include the parietal cortex, caudate nucleus, entorhinal cortex, amygdala and
hippocampus in the cerebrum; the substantia nigra and basal ganglia in the midbrain; parts
of the pons, medulla and cerebellum; and the anterior horn of the spinal cord (reviewed by
Ghetti et al., 2015; Figure 1.2). Neuronal loss in the substantia nigra and basal ganglia is
consistently observed in N279K cases (Slowinski et al., 2007), which may contribute to the
early parkinsonism reported in patients with this MAPT mutation (reviewed by van Swieten
et al., 1999).
Cellular neuropathology
At autopsy, brains from people with FTDP-17T contain insoluble aggregates of abnormally
phosphorylated tau in neurons and sometimes in glia, alongside neuronal loss and gliosis
(Foster et al., 1997; Spillantini et al., 1998a) (Figure 1.2).
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Both tau inclusion morphology and isoform composition vary between individuals with
different MAPT mutations (Section 1.2.5). Mutations which increase exon 10 inclusion, such
as N279K (Hong, 1998), lead to 4R tau inclusions (Ogaki et al., 2013), whereas mutations
which alter tau’s properties (such as P301L and V337M) result in inclusions containing 3R
and 4R tau (Spillantini et al., 1996a, 1998b).
Inclusions in neurons can be intraneuronal (in the cell body) or neuropil threads (in
neuronal processes). Intraneuronal tau deposits can appear dot-like, resembling the pre-
tangles of AD, or can be neurofibrillary tangles (NFTs) which may leave ghost tangles when
a neuron dies. Inclusions can also resemble Pick bodies found in PiD, or the intraneuronal
inclusions (known as cortico-basal bodies) found in CBD (reviewed by Reed, 2001).
Glial inclusions are sometimes present: mutations in exons 9, 11, 12 and 13 are associated
with mainly neuronal tau deposition, whereas mutations in exon 1 and 10 or introns 9 and 10
are associated with neuronal and glial tau aggregates (Ghetti et al., 2015). Individuals with
the P301L mutation can have oligodendrocytic inclusions which are globular, or inclusions
known as coiled bodies (Forrest et al., 2018), which have also been observed in the presence
of the N279K mutation (Arvanitakis et al., 2007; Slowinski et al., 2007). Tau aggregates in
astrocytes can be dot-like, thread-like or globular inclusions, all of which have been observed
in the presence of the P301L mutation (Forrest et al., 2018; Tacik et al., 2017). Tau deposits in
astrocytes also include astrocytic plaques, found in CBD, and tufted astrocytes, characteristic
of PSP (Forrest et al., 2018).
Astrogliosis occurs in cortical and sub-cortical areas in FTDP-17T, including in people
with the N279K (Arvanitakis et al., 2007; Slowinski et al., 2007), P301L (Miyasaka et al.,
2001), and V337M mutations (Spina et al., 2017). Astrogliosis is a response to a brain
injury or insult, and can range from astrocyte hypertrophy to astrocyte overgrowth and
astrocytic scar formation. Reactive astrocytes release molecules including neurotrophic and
inflammatory factors, which can have neuroprotective or neurotoxic effects (reviewed by
Phatnani and Maniatis, 2015).
Balloon neurons have been reported in FTDP-17T (Foster et al., 1997), including in
P301L (Forrest et al., 2018) and N279K cases (Arvanitakis et al., 2007; Delisle et al., 1999;
Wren et al., 2015), Figure 1.2. Balloon neurons are recognisable by their swollen cell
bodies and displaced nuclei, and are usually positive for αB-crystallin and phosphorylated
neurofilament (reviewed by Aoki et al., 2003). Balloon neurons are observed in various
neurodegenerative diseases including PiD, CBD, PSP, AGT and Wernicke’s encephalopathy
(Freiesleben et al., 1997; López-González et al., 2014) but their role in neurodegeneration is
unclear.
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Fig. 1.2 Pathology and atrophy in FTDP-17T brains. A Tau-positive neurons in the temporal
cortex of a FTDP-17T patient with the P301L mutation, detected with the AT8 antibody which detects
tau phosphorylated at Ser202 and Thr205. Scale bar = 66 µM (Spillantini et al., 1998b). B Tau-positive
astrocytes with granular inclusions in a FTDP-17T patient with the P301L mutation, detected by the
AT8 antibody. Scale bar = 25µM (Ferrer et al., 2014). C 3D renderings of grey matter loss (shown
in red) in FTDP-17T patients with the N279K (n=3), P301L (n=4) and V337M (n=3) mutations, in
relation to controls (Whitwell et al., 2009). D, E, F αB-crystallin positive balloon neurons in the
frontal (D) and temporal (E) cortex and αB-crystallin positive glia (F) in the brain of a FTDP-17T
patient with the N279K mutation. Scale bar = 25µM (Wren et al., 2015).
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Molecular neuropathology
Tau inclusions contain tau filaments, which can be paired helical filaments, like those found in
AD (Goedert et al., 1988; Grundke-Iqbal et al., 1986; Wischik et al., 1988), straight filaments,
or twisted ribbon-like filaments (reviewed by Ghetti et al., 2015).
Tau is a phosphoprotein and 85 potential phosphorylation sites have been described
(reviewed by Hanger and Noble, 2011). Tau is abnormally phosphorylated in FTDP-17T and
in other tauopathies (Goedert et al., 1992; Spillantini et al., 1996b) and several antibodies
have been developed against epitopes phosphorylated in AD or FTDP-17T brains (Table
1.1). However, there is some overlap between tau phosphorylation in disease and tau
phosphorylation during development: phosphorylated tau has been detected with the AT8,
AT270, AT180, PHF-1 and 12E8 antibodies in both human fetal brain and brains from
tauopathy sufferers (Table 1.1). Tau phosphorylation during development may have a
functional role, by decreasing tau binding to microtubules (Drechsel et al., 1992) and
potentially increasing plasticity (Goode and Feinstein, 1994), but the significance of fetal-like
phosphorylation in tauopathies is unknown. Epitopes of other antibodies, such as AT100 or
AP422, have not been detected in fetal brains and may be more specific for pathological tau
(Hasegawa et al., 1996; Ksiezak-reding et al., 2000; Matsuo et al., 1994; Milenkovic et al.,
2018; Morishima-Kawashima et al., 1995).
There is also overlap between tau phosphorylation in disease and tau phosphorylation
under physiological circumstances. For example, Preuss and Mandelkow (1998) detected tau
phosphorylation with the AT8, AT180, and PHF-1 antibodies during mitosis, but not in the
parent or daughter cells. Phosphorylated tau has also been detected with the AT8, AT180,
and 12E8 antibodies in the brains of hibernating ground squirrels, although phosphorylation
is reversed after hibernation (Arendt et al., 2003).
The abnormal nature of tau phosphorylation in tauopathies may be the degree of phospho-
rylation, as well as the epitopes phosphorylated. In Western blotting experiments, autopsy-
derived aggregated tau from AD brains has been found to be more highly phosphorylated at
epitopes including AT8, PHF-1, AT270 and AT180 as compared to fetal tau, brain biopsy-
derived adult tau and autopsy-derived adult tau (Matsuo et al., 1994). Fetal and biopsy-derived
adult tau were phosphorylated to similar levels, whereas autopsy-derived adult tau was mostly
dephosphorylated at the epitopes measured, suggesting that rapid post-mortem dephosphory-
lation may explain the differences in phosphorylation observed between fetal brains, control
adult brains and tauopathy brains found in other studies.
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Table 1.1 Tau phosphorylation in development and FTDP-17T
Antibody Epitope In human fetal brain In FTDP-17T brain
AT8 [1] pSer202+pThr205 [2] Y [3,4,5,20] Y [6,7,8,9,10,18]
AT270 [11] pThr181 Y [4,20,]; low [5] Y [6,8]
AT180 [11] pThr231+pSer235 Y [4,20,]; low [5] Y [6,8,18]
PHF-1 pSer396+pSer404 [12] Y [4,13,14,] Y [6,8,18]
12E8 [15] pSer262 and/or pSer356 [15] Y [15] Y [6,18]
AT100 [1] pThr212+pSer214 [19] N [4,16]; low [5] Y [6,8,18]
MC-1 [17] 7-9, 312-342 [17] No data Y [6]
AP422 [21] pSer422 [21] N [22]; low [21] Y [23]
Tau antibodies which bind to phosphorylated or conformational epitopes found in developing brains,
or in brains of people with FTDP-17T. The symbol  indicates that phosphorylation at this epitope was
detected in brain biopsy-derived adult human tau but not in post-mortem human tau by Matsuo et al.
(1994). The MC-1 antibody is conformational; the AT100 antibody requires both phosphorylation
and a conformation change. References: [1]: Mercken et al. (1992); [2]: Goedert et al. (1995); [3]:
Brion et al. (1993); [4]: Matsuo et al. (1994); [5]: Milenkovic et al. (2018); [6]: Spillantini et al.
(1996a); [7]: Spillantini et al. (1998b); [8]: Rizzini et al. (2000); [9]: de Silva et al. (2006); [10]:
Arvanitakis et al. (2007); [11]: Goedert et al. (1994); [12]: Lang et al. (1992); [13]: Bramblett et al.
(1993); [14]: Kenessey and Yen (1993); [15]: Seubert et al. (1995); [16]: Ksiezak-reding et al. (2000);
[17]: Jicha et al. (1996); [18]: van Swieten et al. (1999); [19]: Zheng-Fischhöfer et al. (1998); [20]:
Goedert and Jakes (1990); [21]: Hasegawa et al. (1996); [21]: Morishima-Kawashima et al. (1995);
[23]: Miyasaka et al. (2001).
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1.2.5 MAPT mutations in FTDP-17T
More than 60 MAPT mutations have been linked to FTDP-17T (Goedert, 2016; Figure 1.3).
My project focuses on three of them: N279K and P301L in exon 10, and V337M in exon 12.
These mutations are described in detail in this section and in Table 1.3.
The main evidence for a causative role of MAPT mutations in FTDP-17T is the co-
segregation of mutations with the disease, and their absence in unaffected family members
and control subjects (Poorkaj et al., 1998; Hutton et al., 1998; Spillantini et al., 1998; Clark
et al., 1998; Malkani et al., 2006; McCarthy et al., 2015; and many others). In addition,
expression of wild-type or mutant human tau in mouse models can lead to tau pathology,
neurofibrillary tangles, neuronal loss, behavioural phenotypes, and sometimes premature
death (reviewed by Götz and Ittner, 2008).
Tau mutations can be divided into two types: those altering exon 10 splicing and the
3R:4R tau ratio, and those affecting tau’s biochemical and physiological properties (although
some mutations may do both). Tau mutations are thought to cause tau dysfunction by two
main mechanisms: a toxic gain-of-function model and a toxic partial loss-of-function.
1.2.6 Toxic gain-of-function
Several lines of evidence support the idea that tau mutations result in a toxic gain of function:
almost all known MAPT mutations are autosomal dominant (Ghetti et al., 2015) (apart
from S352L: Nicholl et al., 2003); tau knock-out in mice does not cause neurodegeneration
(Dawson et al., 2001; Fujio et al., 2007; Harada et al., 1994; Tucker et al., 2001); and
microduplication of 17q21.31 (including MAPT) in humans increases MAPT RNA 1.6-1.9
fold and results in a tauopathy (Le Guennec et al., 2017). In addition, it has been speculated
that a loss-of-function affecting only 25% of total tau (caused by heterozygous tau mutations
in exon 10) is unlikely to cause the neurodegeneration seen in FTDP-17T (Goedert, 2016).
The toxic function gained may be aggregation, which might damage cells (Mandelkow
et al., 2003). Aggregation could occur due to mutations increasing tau’s propensity for aggre-
gation (Alonso et al., 2004; Combs and Gamblin, 2012; Hasegawa et al., 1998; Nacharaju
et al., 1999). An increase in tau phosphorylation, or mutations increasing tau’s propensity for
phosphorylation (Alonso et al., 2004; Han et al., 2009), may also contribute to the toxic gain
of function aggregation, since phosphorylation at some sites can enhance tau aggregation
(Despres et al., 2017; Haase et al., 2004). Phosphorylation itself may also be a toxic gain of
function: tau phosphorylation may enhance the spreading of tau pathology (Hu et al., 2016),
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Fig. 1.3 Mutations in the MAPT gene linked to FTDP-17T. The N279K, P301L and V337M
mutations which this project focuses on are highlighted in red. Adapted from Ghetti et al. (2015).
and it can contribute to tau toxicity in mouse (Le Corre et al., 2006; Shahani et al., 2006) and
Drosophila models of tau dysfunction (Steinhilb et al., 2007) (Section 1.3.2).
A tau isoform imbalance favouring 4R tau may also lead to tau aggregation, since 4R
isoforms are more aggregation-prone (Adams et al., 2010). In addition, a tau isoform
imbalance may itself be a toxic gain of function, since increasing the amount of 4R to 3R tau
in mice expressing human tau increased tau phosphorylation at epitopes including Ser202
and Thr205, decreased tau solubility, and increased the severity of induced seizures (Schoch
et al., 2016).
1.2.7 Toxic partial loss-of-function
Tau mutations may also cause dysfunction due to a partial loss of physiological function. One
deletion affecting just MAPT in humans has been reported: a heterozygous deletion of exons
6-9 (including the Saitohin gene in MAPT intron 9) in a person with FTD (Rovelet-Lecrux
et al., 2009). The deletion would remove a microtubule binding repeat, and recombinant tau
with the same deletion was less able to bind microtubules than wild-type tau in vitro, with no
effect on tau aggregation. These results suggest that a loss of microtubule binding function
could also be involved in causing FTD. However, abnormal binding of the deletion mutant
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tau to MAP-1B was also reported, suggesting a possible alternative toxic gain of function
(Rovelet-Lecrux et al., 2009). This remains speculation, since brain tissue from the FTD
patient with the deletion was not available for analysis, so tau pathology in the brain of this
individual could not be confirmed.
Other evidence suggests that heterozygous deletion of tau does not cause problems in
humans. Heterozygous tau deletion has been reported in 17q21.31 microdeletion syndrome
(Shaw-Smith et al., 2006), in which a region encompassing MAPT, four flanking genes
and two putative genes was absent in individuals with developmental delay and intellectual
disability. Although this could suggest a crucial role for tau in brain development, Zollino
et al. (2012) and Koolen et al. (2012) reported two individuals with 17q21.31 microdeletion
syndrome but with heterozygous loss-of-function mutations in KANSL1, indicating that
KANSL1 loss-of-function is sufficient to cause 17q21.31 microdeletion syndrome, and
indicating that tau does not play a role.
Tau knock-out mice offer some evidence of a tau loss-of-function phenotype. Five knock-
out lines have been created, and their phenotypes are summarised in Table 1.2. Young mice
are viable and reportedly appear normal, but adult mice develop deficits in muscle strength,
balance, movement and behaviour from three (Ikegami et al., 2000) or 12 months of age
onwards (Lei et al., 2012; Ma et al., 2014; Morris et al., 2013). Quantification of MAP
proteins indicates that elevated MAP1A levels may compensate for tau’s absence in young
mice, and to a lesser extent in mice older than three months (Dawson et al., 2001; Fujio et al.,
2007; Harada et al., 1994; Ma et al., 2014). These results suggest that tau is required for
normal neuronal function, although its absence can be compensated for during early life.
The tau knock-out mice show limited evidence of a neurodegenerative phenotype. Al-
though Lei et al. (2012) reported decreased brain weight, neuronal loss and iron accumulation
in 12 month-old mice, Van Hummel et al. (2016) found no change in brain volume and
no neuron loss in 16 month-old mice from a different line. Similarly, Ma et al. (2014)
reported decreased levels of the post-synaptic proteins PSD-95 and drebrin, but no change
in levels of the pre-synaptic synaptophysin in 19-20 month-old mice from one line, but
PSD-95 and drebrin levels were unchanged in 22 month-old mice from a different line (Van
Hummel et al., 2016). These results suggest that tau knock-out may not be sufficient to cause
neurodegeneration, although further investigation may be warranted.
The toxic gains-of-function aggregation and phosphorylation could lead to toxic losses
of normal physiological function, since both aggregated and phosphorylated tau are less
able to bind and stabilise microtubules (Drechsel et al., 1992). This loss of function could
be enhanced by mutations which decrease tau’s affinity for microtubules. Loss of tau’s
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microtubule binding function could create a pool of unbound tau, which may be necessary
for aggregation (Goedert and Spillantini, 2001). Alternatively, loss of function could be
caused by aggregation depleting soluble tau, and by phosphorylation decreasing microtubule
binding.
Decreased binding of tau to microtubules may decrease microtubule stability, since
tau stabilises microtubules (Drubin and Kirschner, 1986). This could lead to cytoskeletal
disruptions, disrupting cellular functions such as axonal transport, leading to retrograde
degeneration and synaptic loss, and even cell death (reviewed by Rossi and Tagliavini,
2015, Rovelet-Lecrux et al., 2009). Loss of tau’s normal physiological function could also
contribute to DNA damage, since tau may have a role in genome stability in the nucleus
(Rossi and Tagliavini, 2015), and to post-synaptic dysfunction, since dendritic tau may have
a role at the post synaptic density (Ittner et al., 2010).
Another potential toxic loss of function is unbalancing of the 1:1 3R:4R ratio. Changes
in the 3R:4R tau ratio can alter and impair axonal transport in PSC-derived neurons (Iovino
et al., 2015; Lacovich et al., 2017) and in mice (Dawson et al., 2007). Correspondingly, in a
mouse expressing all six isoforms of human tau, but preferentially expressing 3R isoforms,
restoring a 1:1 3R:4R tau ratio decreased cognitive impairment and decreased the amount of
tau phosphorylated at Ser202 and Thr231/Ser235 (Espíndola et al., 2018).
1.2.8 Mutations altering the 3R:4R tau ratio
Tau mutations disrupting the 1:1 3R:4R tau ratio to favour 3R (Anfossi et al., 2011; Stanford
et al., 2003) or 4R (Hong, 1998) tau production can both lead to neurodegenerative disease,
suggesting that upsetting the 3R:4R tau balance is sufficient to cause neurodegeneration in
humans.
The 3R to 4R tau ratio may vary from the 1:1 ratio in some areas of the human brain.
For example, Majounie et al. (2013) measured tau mRNA levels in different brain regions in
control subjects, and found that 4R tau mRNA was approximately 35-65% of total tau mRNA,
depending on the brain area. However, the tau ratio across the whole brain was not measured.
In addition, the 3R to 4R tau ratio varies across species. Mice, for example, express the three
4R tau isoforms in adulthood, and express 0N3R tau only early in development (Takuma
et al., 2003), indicating that changes in the 3R:4R isoform ratio without neurodegenerative
disease are possible.
The idea that upsetting the 3R:4R tau balance can cause neurodegeneration is supported
by in vivo evidence. For example, Espíndola et al. (2018) used trans-splicing to correct
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the over-production of 3R tau in mice transgenic for all six tau isoforms. Aged transgenic
mice developed tau phosphorylation and cognitive deficits, which were reduced when trans-
splicing equalised the 3R:4R human tau ratio.
Since recombinant 3R tau promotes microtubule assembly at a lower rate than 4R tau
(Goedert and Jakes, 1990) and 3R tau is less able to stabilise microtubules than 4R tau
(Panda et al., 2003), an 3R:4R imbalance may alter microtubule assembly and stabilisation.
Additionally, since 4R tau is more aggregation-prone than a 3R and 4R tau mixture (Adams
et al., 2010), an isoform imbalance towards 4R tau may favour tau aggregation.
N279K
The N279K mutation is a T→G mutation in exon 10 which results in an asparagine instead of
a lysine residue (Clark et al., 1998). Although the mutation causes an amino acid change, it
has its main effect at the mRNA level where it alters a polypurine enhancer (PPE) sequence,
one of several splice enhancers in exon 10 (D’Souza et al., 1999). The T→G base change
increases splicing factor binding (D’Souza and Schellenberg, 2006), either by increasing the
number of GA-purine repeats, or by increasing the number of AAG repeats (D’Souza and
Schellenberg, 2002). This increases exon 10 inclusion in RNA by approximately 80% in
splicing assays (D’Souza et al., 1999). In soluble tau from the frontal cortex of individuals
with the N279K mutation, there is a two-fold increase in the 4R:3R ratio relative to control
(Hong, 1998), and tau inclusions contain 4R (but not 3R) tau protein (Clark et al., 1998).
Most evidence indicates that the N279K mutation leads to increased expression of
functionally normal 4R tau, but there is limited evidence that the mutation also alters tau’s
properties (Table 1.3). For example, the N279K mutation may also decrease tau aggregation
over a period of minutes (Yao, 2003) but increase aggregation over a period of days (Barghorn
et al., 2000). In addition, N279K tau is reported to be less able to promote microtubule
assembly than wild-type tau, and to be less able to bind microtubules than wild-type tau at
low tau concentrations, but more able at high concentrations (Barghorn et al., 2000). This
is in direct contrast to several other studies, which found that N279K tau does not alter
microtubule binding or assembly (D’Souza et al., 1999; Hasegawa et al., 1999; Hong, 1998).
The discrepancy between these results may be due to the different amounts of tau used:
Barghorn et al. (2000) used a maximum of 50µM of tau, compared to a maximum of 3µM
used in the other studies.
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1.2.9 Mutations altering tau’s physical properties
Mutations which alter tau’s physical properties can increase tau’s aggregation rate (Alonso
et al., 2004; Combs and Gamblin, 2012; Nacharaju et al., 1999), increase the size of tau
filaments (Combs and Gamblin, 2012), decrease (Hong, 1998) or increase (Pickering-Brown
et al., 2004) microtubule binding, decrease microtubule assembly (Hasegawa et al., 1998;
Hong, 1998), and alter the rate and extent of tau phosphorylation (Alonso et al., 2004; Han
et al., 2009).
P301L
P301L is a missense C→T mutation in exon 10. Multiple studies have shown that it decreases
microtubule assembly (Barghorn et al., 2000; Hasegawa et al., 1998, 1999; Hong, 1998),
increases tau’s propensity to aggregate (Aoyagi et al., 2007; Barghorn et al., 2000; Hong,
1998; Nacharaju et al., 1999), and increases tau’s propensity for phosphorylation (Alonso
et al., 2004; Han et al., 2009), but does not alter the 3R:4R tau ratio (Hasegawa et al., 1999;
Hong, 1998; Hutton et al., 1998) (Table 1.3). Some studies report a decreased ability to bind
microtubules (Hong, 1998), decreased chaperone-assisted stabilisation of tau (Gunawardana
et al., 2015), and increased elongation rate and length of tau filaments (Combs and Gamblin,
2012).
Since the P301L mutation is heterozygous and is only present in 4R tau, only 25% of
total tau carries the mutation. In the brains of FTDP-17T sufferers with this mutation, P301L
mutant tau is sequestered into insoluble inclusions, which contain mostly 4R P301L tau
and some 3R tau (Miyasaka et al., 2001; Rizzu et al., 2000; Spillantini et al., 1998b). This
depletes soluble P301L tau but the ratio of 3R:4R soluble tau is unchanged, suggesting that
4R tau synthesis is upregulated to maintain a 1:1 3R:4R ratio (Rizzu et al., 2000). In addition,
P301L and wild-type 4R tau mRNA levels remain equal, indicating that the lack of soluble
P301L tau is not caused by decreased stability or increased degradation of P301L tau mRNA
(Miyasaka et al., 2001).
V337M
V337M is a missense G→A mutation in the constitutively expressed exon 12, meaning that
it affects all 6 tau isoforms (Poorkaj et al., 1998). Since the mutation is heterozygous, 50%
of total tau in people with this mutation is mutant. Several studies have demonstrated that
the mutation decreases microtubule assembly (Barghorn et al., 2000; Hasegawa et al., 1998;
Hong, 1998; Pickering-Brown et al., 2004), increases tau’s propensity to aggregate (Barghorn
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et al., 2000; Nacharaju et al., 1999), and increases tau’s propensity for phosphorylation
(Alonso et al., 2004; Han et al., 2009) (Table 1.3). Individual studies indicate that the V337M
mutation decreases tau’s microtubule binding (Hong, 1998), has no effect on exon 10 splicing
(Hong, 1998) and does not affect tau filament formation dynamics (Combs and Gamblin,
2012).
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1.3 Tau dysfunction
In the brains of FTDP-17T sufferers, tau becomes abnormally phosphorylated and forms
aggregates (Goedert and Spillantini, 2001). However, the toxic form of tau is not definitively
known, and neither is the mechanism by which tau leads to cell death.
1.3.1 Tau aggregation
Tau aggregation is dependent on two motifs in the second and third microtubule binding
repeats, which have a high propensity to form β -sheets (von Bergen et al., 2000). In the tau
filaments found in AD, the filament core consists of two protofilaments which are arranged
differently to give either straight or paired helical filaments. Each protofilament consists of
tau residues 306-378, which form a C-shape due to the interaction of 8 β -sheets (Fitzpatrick
et al., 2017). Tau fibrils made in cell-free experiments follow a pattern of nucleation and
elongation, suggesting that they are constructed by addition of monomers to a growing fibril
after a "nucleus" of aggregation has formed (reviewed by Goedert, 2016). In the brains of
people with AD, tau monomers have been found assembled into oligomers (Lasagna-Reeves
et al., 2012), but it is not clear if these soluble oligomers are the precursors to insoluble
filamentous tau (Mudher et al., 2017).
The trigger for tau aggregation in the brain is unknown, but aggregation can be promoted
by factors including truncation, some tau mutations, polyanions, and aggregated tau acting
as seeds (reviewed by Cowan and Mudher, 2013), and requires a critical tau concentration
(Goedert et al., 1996).
Tau phosphorylation in aggregation
Tau hyperphosphorylation is thought to occur before aggregation, but there is little evidence
that phosphorylation causes aggregation (Goedert and Spillantini, 2001). Recombinant
tau isoforms, hyperphosphorylated with brain extract-derived kinases, can assemble into
filaments in vitro (Alonso et al., 2004, 2001), but this may be caused by factors other
than kinases in the brain extract, since filament formation in vitro has been shown to be
independent of phosphorylation, but dependent on polyanions (Goedert et al., 1996; Pérez
et al., 1996).
Although phosphorylation is not sufficient to cause aggregation, it has been shown to
influence the degree of aggregation in vitro (in the presence of polyanions). For example,
phosphorylation or pseudo-phosphorylation at some epitopes (including Ser214, Ser262,
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Ser324, Ser356, and Ser320) prevents aggregation in vitro (Haase et al., 2004; Schneider et al.,
1999), although Ser214, Ser262 and Ser356 can also be phosphorylated after in vitro filaments
have formed, indicating that the timing of phosphorylation is crucial (Schneider et al., 1999).
Phosphorylation or pseudo-phosphorylation at other epitopes promotes aggregation. These
epitopes include Ser422 and other residues in tau’s C-terminus (Haase et al., 2004), as well
as the combination of Ser202, Thr205 and Ser208 (Despres et al., 2017).
1.3.2 Toxic tau species
Tau species include monomers, dimers and trimers, various oligomers, filaments and aggre-
gates, which may be interconverted in in vitro or in vivo models (Cowan and Mudher, 2013).
Evidence from several animal models suggests that the toxic tau species is either a small
soluble, or small insoluble tau species.
The core of a tau filament is composed of two protofilaments, each consisting of tau
residues 306-378, which form a C-shape due to the interaction of 8 β -sheets (Fitzpatrick et al.,
2017). Formation of β -sheets may be necessary for neurodegeneration, since Drosophila
expressing β -sheet incompetent tau (tau without a hexapeptide repeat encoded by nucleotides
306-311) did not develop an age-related rough-eye phenotype, and had lifespans approaching
those of Drosophila not expressing any exogenous tau. In comparison, Drosophila expressing
wild-type tau which was β -sheet competent developed an age-related rough-eye phenotype
and had a significantly reduced lifespan relative to that of Drosophila expressing β -sheet
incompetent tau (Passarella and Goedert, 2018).
In some mouse models, such as in one expressing human tau but not mouse tau, cell death
and dysfunction precede the detection of sarkosyl-insoluble tau filaments and thioflavin-S
positive tau inclusions, implicating soluble tau species (Andorfer et al., 2005). Similarly,
Drosophila expressing wild-type or mutant human tau have cell death and a reduced lifespan,
but tau filaments are not detectable in sarkosyl-insoluble tau preparations, suggesting that
soluble tau species are toxic (Wittmann, 2001).
However, in another model, a mouse over-expressing 0N3R human tau, a decrease in
tau solubility was detected at the same time as neurodegeneration-like changes, such as
silver-positive tau inclusions and axon degeneration (Ishihara et al., 1999), suggesting that
less soluble tau species may be to blame.
Other studies support a protective role for tau aggregation. For example, in mice over-
expressing 2N4R P301L tau under an inducible promotor, Santacruz et al. (2005) showed
that tau-mediated behavioural deficits could be reversed and neuron loss could be halted by
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reducing tau over-expression. When tau expression was decreased, tau aggregates continued
to accumulate whilst tau-related behavioural deficits were reversed, suggesting that toxic tau
species were being sequestered into harmless aggregates.
In support of this idea, Andorfer et al. (2005) reported that in aged mice expressing
human tau but no mouse tau, most dying cells identified by electron microscopy did not
contain large tau inclusions, whereas some apparently healthy neurons with tau inclusions
aggregates were visible. This is supported by findings in AD. For example, mathematical
modelling of hippocampal neuron loss in AD patients suggests that NFT-containing neurons
can live for approximately 20 years, indicating that NFTs alone may not be sufficient to
cause cell death (Morsch et al., 1999). In addition, the number of hippocampal neurons lost
in AD far exceeds the number of NFTs, indicating that NFT formation might not be required
for cell death and suggesting that smaller tau aggregates may be to blame (Kril et al., 2002).
However, AD is not a pure tauopathy since amyloid-β is also involved, meaning that results
in AD may not generalise to FTDP-17T.
Nevertheless, Gallyas silver-positive, aggregated tau has been reported in the brains of
young, apparently healthy individuals (Braak and Del Tredici, 2011), and in non-demented
older people (Lagui et al., 1995), suggesting that a small number of NFTs can exist without
disease, although it is possible that all of these people would have gone on to develop a
tauopathy had they lived longer.
Toxic phosphorylated tau species
Although some mutations increase tau’s propensity for phosphorylation (Alonso et al.,
2004; Han et al., 2009), no mutations create new phosphorylation sites (with the possible
exception of P301S), suggesting that phosphorylation is unlikely to be the primary driver
of tauopathies (Ghetti et al., 2015). However, tau phosphorylation may have deleterious
effects, as many other post-translational modifications, including acetylation, glycosylation,
glycation, deamidation and isomerisation, which are not covered here (reviewed by Wang
and Mandelkow, 2015).
For example, in mice expressing human P301L tau, Le Corre et al. (2006) found that
treatment of pre-symptomatic animals with an inhibitor of the tau kinase ERK2 decreased
tau phosphorylation, which correlated with a decrease in motor impairments, although the
number of tau inclusions was not affected. This suggests that abnormally phosphorylated tau
contributes to motor impairments, but other tau species were not considered in the study and
cannot be excluded. In addition, inhibition of ERK2 may also affect other pathways.
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Evidence for the toxicity of phosphorylated tau has also been found in Drosophila. For
example, expression of human wild-type tau in Drosophila retina causes a "rough-eye"
phenotype (disorganised eye cells), but this phenotype is decreased in Drosophila expressing
pseudo-dephosphorylated tau (where 14 serine/proline and threonine/proline sites were
replaced with alanine and therefore could not be phosphorylated). Correspondingly, the
rough-eye phenotype is increased in Drosophila expressing tau pseudo-phosphorylated at the
same 14 sites (Steinhilb et al., 2007).
In another study, pseudo-phosphorylated wild-type tau (but not normal wild-type tau)
expressed in mouse hippocampal slice cultures was reported to increase cell death, as
measured by LDH release and live imaging (Shahani et al., 2006). Pseudo-phosphorylated
tau was also less soluble than normal wild-type tau, suggesting that phosphorylated insoluble
tau species may be toxic.
Phosphorylation may also influence the spreading of tau pathology. Hu et al. (2016) found
that injecting phosphorylated tau extracted from AD brains into the brains of mice expressing
all six human wild-type tau isoforms induced phosphorylated tau inclusions after six months.
However, when the AD brain extracts were (incompletely) dephosphorylated before injection,
fewer tau inclusions were found in injected mouse brains, and some inclusions had a different
morphology. This suggests that tau phosphorylation may have roles in seeding, and in the
morphology of the resulting inclusions.
1.3.3 Spreading of tau pathology
Spreading of tau pathology between cells has been shown in both in vitro and in vivo
models. For example, Clavaguera et al. (2009) took brain homogenate from aged mice which
expressed human P301S-mutant 0N4R tau and had developed argyrophilic filamentous tau
inclusions, and injected the brain homogenate into the brains of mice expressing human
wild-type 2N4R tau. The injected mice developed filamentous tau inclusions which contained
wild-type human tau, and the inclusions seemed to spread from the injection site to more
distal brain regions in a time-dependent manner. Mice expressing wild-type human 2N4R
tau did not develop tau aggregates without a brain homogenate injection, nor when the brain
homogenates were depleted of tau before injection, indicating that aggregated tau can act as
a seed for further aggregation.
Similar induction and spreading of tau pathology has been shown using recombinant tau
fibrils injected into the brains of pre-symptomatic mice expressing human P301S tau (Iba
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et al., 2013), and using filamentous tau extracted from the brains of AD patients injected into
the brains of mice expressing mouse tau but not human tau (Guo et al., 2016).
Spreading of tau pathology may also take place in the human brain. Braak and Braak
(1991) proposed "staging" of AD tau pathology: spreading between synaptically connected
parts of the brain, starting in the entorhinal cortex and eventually progressing to the neocortex.
However, since staging is based on post-mortem brain tissue it is only circumstantial evi-
dence; another explanation of tau’s apparent spreading could be that tau pathology develops
autonomously within vulnerable cells over time (Mudher et al., 2017). This seems unlikely,
since tau extracted from different regions of AD brains seeded aggregation in a cell-based
assay in a manner positively correlated with Braak stage (Furman et al., 2017). Moreover,
in transgenic mice expressing the tau transgene specifically in the entorhinal cortex, tau
aggregates can be found in the hippocampal formation of 22 month-old mice (de Calignon
et al., 2012; Liu et al., 2012), supporting the idea that tau pathology may spread.
Tau seeds
Spreading of tau pathology necessitates a tau seed, which might not be the same as the
toxic tau species. Neuronal loss after injecting tau fibrils into a mouse brain has only been
reported in one study (Peeraer et al., 2015); other studies report the appearance and apparent
spreading of tau inclusions, but do not report detectable cell death (Clavaguera et al., 2009,
2014; Dujardin et al., 2014; Iba et al., 2013), suggesting that the toxic and seed species may
be different.
Possible tau seeds have been identified in some models. For example, using symptomatic
mice expressing human P301S-mutant tau, Jackson et al. (2016) found that short tau fila-
ments, which were nitrated, phosphorylated at the AT8 epitope, and made up of at least
10 tau monomers, were able to induce tau aggregation when injected into the brains of
pre-symptomatic mice. Smaller tau species, including monomers and smaller aggregates
were not sufficient to induce aggregation. Other studies have reported that AD brain-derived
or recombinant tau species of at least three, but up to 20, tau monomers can be taken up by
cells and seed tau aggregation (Mirbaha et al., 2015). In contrast, tau monomers did not
cause seeding (Mirbaha et al., 2015).
Tau uptake and release
As well as a tau seed, spreading of tau pathology between brain regions requires tau to be
taken up from the extracellular space, cause aggregation intracellularly, and be released and
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taken up by other cells (reviewed by Goedert, 2016). Potential mechanisms for tau uptake
and release have been identified, which may have a role in the spreading of tau pathology.
In cultured cells, tau fibrils can be taken up by macropinocytosis (Falcon et al., 2015;
Holmes et al., 2013) or endocytosis (Wu et al., 2013). Uptake in vitro and in vivo has been
reported to be dependent on heparan sulphate proteoglycans: cell surface receptors with
multiple known ligands (Holmes et al., 2013). However, it is not known how tau taken up by
these mechanisms escapes endosomes (Mudher et al., 2017).
Tau release has also been demonstrated in culture. For example, control iPSC-derived
neurons release tau into the media under normal conditions (Chai et al., 2012), although the
mechanism behind tau release remains unclear (reviewed by Wang and Mandelkow, 2015).
Tau is also present in cerebrospinal fluid from both AD patients and control subjects, mostly
as free tau but also in exosomes (Blennow and Hampel, 2003; Wang et al., 2017).
Some studies have shown that aggregated tau can be transferred from cell to cell. For
example, Wang et al. (2017) showed that RFP-labelled exosomes containing GFP-labelled tau
were taken up by neurons in one side of a microfluidic device, and transferred to neurons in
the other side of the device. Uptake of labelled endosomes containing tau was only observed
when the neurons made synaptic connections (detected by immunofluorescence) and not
before, suggesting that the transfer of these endosomes was trans-synaptic rather than through
release into the media and subsequent uptake. Furthermore, Polanco et al. (2016) have shown
that exosomes isolated from cells containing aggregated tau (which was seeded using brain
lysates from mice expressing human P301L-mutant tau) but not exosomes from cells without
aggregated tau (seeded with brain lysates from control mice) could cause aggregation in cells
from the same line (all of which expressed tau’s repeat domain fused to CFP or YFP for
detection of aggregation by FRET).
1.4 iPSC-derived neural cells
Human induced pluripotent stem cell (iPSC)-derived neurons provide a way to study tau
toxicity in a human system.
iPSCs are made by reprogramming somatic cells to a pluripotent state from which they
can be differentiated to multiple cell types. iPSCs are donor-specific, with the same DNA as
the tissue donor but without age-associated markers and most epigenetic markers (Rouhani
et al., 2014). This specificity means that iPSCs derived from a donor with a neurological
disease can be differentiated into cell types such as neurons and astrocytes, which are usually
inaccessible in a living patient, to study disease-related processes. iPSCs can also be modified
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using gene-editing technologies such as CRISPR (clustered, regularly interspaced, short
palindromic repeats, Chapter 4) to correct or introduce genetic aberrations linked to a disorder,
so that a specific genetic change can be studied without confounding genetic background
effects.
iPSC-derived neurons have been used to model numerous diseases and disorders of the
brain including AD, amyotrophic lateral sclerosis, Dravet Syndrome, PD, Rett Syndrome,
schizophrenia and Huntington’s Disease (reviewed by Ichida and Kiskinis, 2015). They may
provide a particular advantage over mouse-derived neurons for studying the effects of tau
mutations, since adult human brains express six tau isoforms (three 3R and three 4R; Goedert
and Jakes, 1990), whereas adult mice express only 4R tau (Götz et al., 1995).
1.4.1 iPSC origins
Gurdon (1962) first demonstrated reprogramming of differentiated cells to a totipotent state
when he put Xenopus somatic cell nuclei into enucleated Xenopus oocytes, which developed
into tadpoles. Later, Campbell et al. (1996) repeated this feat in mammalian cells, using
somatic nuclear transfer to clone Dolly the sheep. These results showed that the nuclei of
differentiated cells still contain the genetic information required for developmental programs
and this concept, along with the discovery of master transcription factors like MyoD in mice
(Davis et al., 1987), and the first embryonic stem cells (ESCs) made from human blastocysts
(Thomson et al., 1998), led to attempts to make mammalian somatic cells into pluripotent
cells using transcription factors.
The first iPSCs were made by Takahashi and Yamanaka (2006), who transduced mouse
fibroblasts with 24 factors necessary for ESC pluripotency. Takahashi and Yamanaka identi-
fied the factors Oct3/4, Sox2, c-Myc and Klf4 (now known as Yamanaka factors) as sufficient
to reprogram fibroblasts to iPSCs, which had ESC-like morphology, expressed ESC markers,
and were pluripotent - able to differentiate into the three germ layers: mesoderm, endoderm
and ectoderm. Within a year, Takahashi et al. (2007) and Yu et al. (2007) reported the
reprogramming of human fibroblasts to iPSCs. Since 2007, other methods of making iPSCs
have been developed.
1.4.2 Reprogramming somatic cells to pluripotent cells
iPSCs have been made from cells including fibroblasts, lymphocytes, keratinocytes, neural
cells and melanocytes (Hochedlinger and Jaenisch, 2015) and can be generated using several
reprogramming methods. The necessary transcription factors were first expressed using
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retroviruses, which integrate their DNA into the host cell’s genome. However, this can lead
to incomplete reprogramming in which the cell’s endogenous pluripotency programs are
not sufficiently activated and the cells remain dependent on the continued high expression
of the added transcription factors (Takahashi and Yamanaka, 2006). Continued expression
of one factor in particular (c-Myc) would be a barrier to transplant of iPSC-derived cells,
since c-Myc is an oncogene whose over-expression can cause cancer (Miller et al., 2012). To
counteract this, non-integrating vectors for transcription factor expression have been used,
such as non-integrating adenovirus, plasmids, or RNA viruses. Alternatively, transcription
factors can be delivered to cells as RNA or recombinant proteins, or can be replaced by small
molecules to make iPSCs free from reprogramming factors (reviewed by (Hochedlinger and
Jaenisch, 2015).
Reprogramming does not completely remove epigenetic modifications: several studies
have shown that certain epigenetic modifications in somatic cells are retained by their iPSC
progeny (reviewed by Brix et al., 2015). For example, Hargus et al. (2014) made iPSCs
from different somatic cell types, differentiated them to NPCs, then compared their gene
expression to that of fetal NPCs. Hargus et al. found a separation in gene expression
between NPCs whose parent iPSCs were mesoderm-derived and those whose parent iPSCs
were neuroectoderm-derived. The neuroectoderm-derived iPSCs produced NPCs with gene
expression profiles more similar to those from fetal NPCs, suggesting that neuroectoderm
and mesoderm programs were not fully removed during reprogramming.
In addition, reprogramming itself can introduce mutations, at an estimated density of six
protein coding mutations per exome, which could decrease the genetic similarity between an
iPSC model and the individual from whom the iPSCs were derived (Gore et al., 2011).
iPSCs and ESCs
Despite coming from different sources, iPSCs are similar to ESCs. Both cell types have
similar morphology, express pluripotency markers, can differentiate into all three germ
layers (Takahashi and Yamanaka, 2006; Yu et al., 2007) and, when used to form tetraploid
blastocysts, mouse iPSCs can contribute to the birth of live mice (Kang et al., 2009). iPSC and
ESC lines have different gene expression profiles, but the differences between iPSC and ESC
lines is no bigger than the difference between different ESC lines, suggesting that iPSC and
ESC lines are overlapping populations (Bock et al., 2011). There is also epigenetic variation
between iPSC and ESC lines, but the relevance of this, and of the genetic differences, is
unknown (Colman and Dreesen, 2009). However, there may be some functional differences
between iPSCs and ESCs: Hu et al. (2010) have reported that ESCs and iPSCs differentiated
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to neurons using the same protocol develop over the same time course and express the same
neural markers, but iPSCs differentiated with lower efficiency and with considerable variation
between lines.
1.4.3 Monolayer or 2D culture of iPSC-derived neural cells
Neurons can be produced from iPSCs in 2D cultures by either directed differentiation or
transdifferentiation. Directed differentiation uses the timed application of morphogens to
recreate aspects of development, producing neurons via NPCs. The addition of different
morphogens or morphogen-mimicking small molecules recapitulates the morphogen environ-
ment in different parts of the rostral-caudal and dorsal-ventral axes, to give region-specific
cells. Alternatively, transdifferentiation uses over-expression of transcription factors to take
cells from their current state (somatic or iPSCs) straight to neurons, without passing through
intermediate states such as NPCs.
Morphogen-directed neuron differentiation in vivo
Body axes in the developing embryo are determined by morphogen gradients. In the de-
veloping vertebrate CNS rostral-caudal identity is determined first, and other axes are
determined later by factors such as Wnt and retinoic acid (rostral-caudal), as well as by
bone morphogenetic protein (BMPs), Wnt and Shh (dorsal-ventral) (reviewed by Astick and
Vanderhaeghen, 2018). Initial rostral-caudal identity is thought to be established according
to the neural-default model, in which ectodermal cells develop towards a rostral (forebrain)
identity if they receive no signals to the contrary (Wilson and Houart, 2004). The intrinsic
rostral fate is inhibited by BMP signalling, and BMP signalling itself is inhibited in the
nascent forebrain by ligands such as Noggin, follistatin and chordin, which bind BMPs
(Bachiller et al., 2000; Muñoz-Sanjuán and Brivanlou, 2002).
PSC-derived neurons via directed differentiation
Differentiation of pluripotent stem cells (PSCs, either iPSCs or ESCs) in vitro also follows
the neural default model: culturing ESCs without caudalising factors results in NPCs with a
forebrain fate (Tropepe et al., 2001; Watanabe et al., 2005). Morphogens such as Wnt and
Nodal can be produced in culture, where they can cause caudalisation and promote ectoderm
differentiation (Eiraku and Sasai, 2012), so inhibitors of these morphogens are often added
to increase the induction of a forebrain fate (Watanabe et al., 2005).
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The developmental signals to produce NPCs from PSCs can be recreated in culture
in a method known as dual SMAD inhibition. BMPs are bound by the artificial ligand
Dorsomorphin, or by the natural ligand Noggin, preventing binding to receptors ALK1, 2, 3
and 6. This prevents phosphorylation of the SMAD proteins 1, 5, 8 and 9. Small molecules,
such as SB431542, fulfil the role of Lefty in vivo and inhibit the Activin/Nodal/TGFβ
signalling pathway via the receptors ALK4, 5 and 7, which prevents phosphorylation of
SMAD2 and 3. Blocking SMAD signalling via both the BMP and Activin/Nodal/TGFβ
pathways gives the method the name dual SMAD inhibition, and prevents the activation of
transcription factors which lead to mesodermal and epidermal fates (reviewed by Muñoz-
Sanjuán and Brivanlou, 2002).
PSC-derived NPCs form neural rosettes, which are self-organising radial structures around
a central ventricle-like cavity, like a 2D-recreation of the neural tube. Rosette-forming NPCs
have a default rostral identity after dual SMAD inhibition (Chambers et al., 2009; Elkabetz
et al., 2008), but this can be altered by the addition of morphogens such as Shh (which induces
ventralisation), and retinoic acid, Wnts, or FGFs (inducing caudalisation) (Chambers et al.,
2009; Kirkeby et al., 2012). Rosette-forming PSCs with a forebrain fate left to spontaneously
differentiate produce temporally restricted neuronal populations expressing cortical layer
markers, and also astrocytes, according to the inside-out model of cerebral cortex formation
in vivo (Elkabetz et al., 2008; Gaspard et al., 2008; Shi et al., 2012a) (Section 6.2.1 in Chapter
6). As an alternative to spontaneous differentiation, PSC-derived NPCs can be driven out of
the cell cycle by inhibiting Notch signalling (using small molecules such as DAPT), which
results in differentiation of NPCs to neurons (Lowell et al., 2006; Pierfelice et al., 2011).
Neurons from transdifferentiation
Neurons can also be produced from somatic cells or iPSCs by transdifferentiation (also called
lineage reprogramming or direct conversion) which is similar to the method used to generate
iPSCs from somatic cells. In transdifferentiation, forced expression of transcription factors
activates existing pathways and redirects cell fate to produce neurons (called induced neurons,
iNs) without passing through precursor intermediates.
Single transcription factors, including Neurogenin 2 (Thoma et al., 2012), NeuroD1
(Zhang et al., 2013), and ASCL1 (Chanda et al., 2014) can be expressed in human or mouse
fibroblasts or ESCs to drive differentiation to iNs. iNs produced by these methods are
excitatory, electrophysiologically active, express neuronal and synaptic markers, and are
present in homogenous cultures (Chanda et al., 2014; Thoma et al., 2012; Zhang et al., 2013).
Expression of other transcription factors, alone or in combination, can produce a wide range
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of neuronal subtypes, including dopaminergic, GABAergic, cholinergic, hypothalamic, and
striatal medium spiny neurons, as well as astrocytes and oligodendrocytes (reviewed by
Ichida and Kiskinis, 2015).
Comparing transdifferentiation and directed differentiation
Transdifferentiation allows some cell types to be produced more quickly than directed dif-
ferentiation. For example, Caiazzo et al. (2015) made induced astrocytes (which showed
similar gene expression and function to primary astrocytes) from fibroblasts in 21 days, as
compared to 100-180 days for directed differentiation. Since transdifferentiation bypasses
the developmental stages mimicked in directed differentiation, transdifferentiation can be
used to produce cell types whose developmental origins are unclear. This is because transdif-
ferentiation uses the forced expression of transcription factors which are active in the target
cell type, making it (theoretically) easier to identify and express the relevant transcription
factors to identify each of the developmental stages and develop a directed differentiation
method (Ichida and Kiskinis, 2015).
However, there are distinct advantages to mimicking developmental conditions in culture.
Directed differentiation produces neurons via NPCs, which can be expanded in culture,
whereas transdifferentiation does not give proliferative intermediates, and therefore produces
fewer neurons (Ichida and Kiskinis, 2015). Directed differentiation also produces related cell
types (for example, forebrain neurons and astrocytes), whereas transdifferentiation produces
pure cultures of a particular cell type (for example, forebrain neurons). Producing astrocytes
alongside neurons can be advantageous, since they support neuron survival and function
(Johnson et al., 2007). Indeed, pure iN cultures produced by transdifferentiation often have
primary astrocytes added to them (Zhang et al., 2013).
Neurons made by transdifferentiation of cells from aged people maintain some features
of aged cells. For example, Mertens et al. (2015) found that fibroblasts transdifferentiated
to neurons by Ascl1 and Ngn2 expression had transcriptome signatures which depended
on the donor’s age. However, reprogramming these fibroblasts to iPSCs before directed
differentiation to neurons removed the age-related signatures from the transcriptomic profiles.
Retaining age-related transcriptomes may be important for modelling age-related disease
with iNs. Hu et al. (2015) produced iNs by transdifferentiation of fibroblasts from AD
sufferers and found that iNs from three out of four AD-affected donors had higher expression
of Aβ40 or Aβ42 than iNs from non-affected donors.
Despite this, cells produced by directed differentiation may more closely resemble the
target cells than those produced by transdifferentiation, according to gene expression studies
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(Cahan et al., 2014). Transdifferentiation does not completely silence gene expression
patterns of the initial cell population, but this thought to be because some non-converted cells
remain in otherwise lineage-converted cultures (Li et al., 2014c). Therefore, Cahan et al.’s
findings may be due to heterogeneous cultures rather than individual mixed-property cells.
Non-converted cells can remain in culture because transdifferentiation is not completely
efficient. Different transgene expression levels can contribute to this: Treutlein et al. (2016)
suggest that, in MEFs transdifferentiated to neurons using Ascl1 alone, some cells are not
differentiated because Ascl1 expression is reduced and remains low, whereas in cells which
become neurons, Ascl1 expression is higher. Heterogeneity in the starting cells may also
impact transdifferentiation efficiency: Francesconi et al. (2019) report that differences in
Myc expression in pre-B cells predicts their capacity to be transdifferentiated to macrophages.
In addition, fibroblasts which have been grown in culture for longer are converted to neurons
with lower efficiency (Sun et al., 2014), meaning that the number of neurons which can be
produced from one batch of human cells may be limited.
Methods to produce neurons by either directed differentiation or transdifferentiation
can both suffer from variability. Different PSC lines vary in their response to directed
differentiation protocols (Bock et al., 2011; Hu et al., 2010; Wu et al., 2007) and different
fibroblast lines can be converted to neurons by transdifferentiation with different efficiencies
(McCoy et al., 2018). These differences may be due to the genetic background of the cell
lines.
1.4.4 Organoids and 3D culture of iPSC-derived neural cells
Monolayer or 2D neuronal cultures obtained by directed differentiation have a degree of
self-organisation, since NPCs form neural rosettes, although these are lost with extended time
in culture (Chambers et al., 2009). The 3D cerebral organoid (CO) cultures, described below,
have a higher degree of self-organisation: 3D rosette-like structures are maintained, and
produce neurons and glia in a manner similar to that in vivo (discussed in detail in Section
6.2 in Chapter 6). Some culture techniques are reported as 3D, but lack the self-organising
component of COs, making them more akin to thick monolayers. These cultures involve
embedding NPCs in thick layers of matrigel or hydrogel, and allowing them to differentiate
into neurons (Choi et al., 2014; Zhang et al., 2016).
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Self-organising 3D culture of iPSC-derived neural cells: cerebral organoids
Organoids are organ-like tissues, made from PSCs or organ-specific progenitors, which
produce multiple organ-specific cell types that self-organise into organ-like structures and
recapitulate (to some degree) organ-specific function (Lancaster and Knoblich, 2014b). COs
hold great potential, and their future uses may be as platforms for drug testing in a more
physiologically relevant environment than 2D cultures, modelling patient-specific diseases,
or even as replacement tissues (Lancaster and Knoblich, 2014b). Although many organoid
types have been generated, this section focuses on COs, which provide a model of the brain.
COs can be divided into two main types: those grown without patterning factors, which
produce a variety of brain areas within the same structure (Lancaster et al., 2013), and those
grown with patterning factors, which restrict cell fate to give brain area-specific organoids.
Patterning factors have been used to produce COs specific to various brain areas including
the forebrain (Lancaster et al., 2017; Mariani et al., 2015), which is of most interest in
FTDP-17T.
As a model of the developing human brain, COs have been used to investigate devel-
opmental diseases and disorders, including Zika virus infection (Qian et al., 2016, and
others), microcephaly (Lancaster et al., 2013), and autism spectrum disorders (Mariani
et al., 2015). COs have also been used to model diseases and disorders of the adult brain,
including AD (Raja et al., 2016, and others), but only one study to date has used COs to
study FTDP-17T-relevant MAPT mutations (Seo et al., 2017).
Self-organising 3D iPSC-derived neuronal cultures may be more physiologically relevant
than their 2D counterparts, since the microenvironment for each cell is more like that in the
brain (reviewed by Ranjan et al., 2018). In addition, 3D culture may increase neuron maturity
with respect to tau splicing (Choi et al., 2014), electrophysiological activity (Zhang et al.,
2016), and glial cell differentiation (Choi et al., 2014), although this has not yet been studied
in self-organising COs. The potential advantages of 3D COs over 2D monolayer cultures are
further discussed in Section 6.2 in Chapter 6.
1.4.5 Advantages and disadvantages of iPSC-derived neuronal cultures
for modelling the human brain
iPSCs allow human-specific brain diseases and disorders to be modelled using human-derived
cells, and these models hold great promise for determining disease mechanisms, for drug
discovery and even for transplant. However, as discussed in this section, iPSC-derived neural
cultures do not recapitulate all aspects of the brain: they lack certain cells types, are relatively
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immature, and different differentiation methodologies make comparisons between studies
difficult (reviewed by Ranjan et al., 2018). iPSC lines themselves are highly variable due
to the genetic variability between the many and diverse somatic cell donors from whom the
lines originate. Therefore, it is important that phenotypes revealed using iPSC-derived neural
cells are corroborated by multiple studies, and that sufficient controls lines are used.
Immaturity of iPSC-derived neural cultures
Several studies indicate that iPSC-derived neurons are more representative of the fetal than
the adult brain. For example, 72 day-old iPSC-derived cortical neurons had similar RNA
expression profiles to primary human fetal neurons cultured for 28 days, but less similarity to
fresh fetal neurons or adult neurons (Handel et al., 2016). Likewise, 56 day-old hESC-derived
midbrain-like neurons were more similar to fetal brain than adult substantia nigra in terms of
gene expression (Patani et al., 2012). Transdifferentiated neurons are also immature: motor
iNs had similar gene expression profiles to their primary fetal counterparts (Son et al., 2011).
Even COs are more similar to the fetal than adult brain, as demonstrated by several gene
expression studies which found similarities between COs and the 8-9-week-old (Dang et al.,
2016), 12-13-week-old (Camp et al., 2015), or 19-24-week-old (Qian et al., 2016) fetal brain.
Immaturity with respect to tau expression
Six tau isoforms are expressed in the adult human brain, as compared to one in the fetal brain
(Goedert and Jakes, 1990). However, iPSC-derived neurons express mostly the fetal 0N3R
tau isoform until around day 50 in culture (Iovino et al., 2015; Sposito et al., 2015), with
expression of up to six tau isoforms being reported at day 150 (Iovino et al., 2015), day 190
(Beevers et al., 2017), and day 365 (Sposito et al., 2015). In addition, 0N3R tau predominates
in younger cultures (Iovino et al., 2015), indicating high numbers of immature neurons. The
extended culture times necessary to recapitulate adult-like tau splicing is a limit to modelling
the full effects of MAPT mutations.
Genetic background effects in experimental models
In FTDP-17T, variation in symptoms and neuropathology between people with the same
mutation suggests the presence of as yet unknown genetic or environmental modifiers (Foster
et al., 1997). Similar effects are also seen in animal studies. For example, the expression of
truncated human tau in two rat strains led to significantly different NFT loads (measured by
AT8 staining) and microglial responses, although astrogliosis was similar between the rat
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strains (Stozicka et al., 2010). Although this study used truncated, not mutated, human tau
and although immune cells would not be present in iPSC-derived neuron models of tauopathy,
it still suggests that differences in tau phosphorylation at the AT8 epitope could be attributed
to genetic variation.
As well as disease-related neuropathology, the genetic background of iPSCs has been
shown to influence their gene expression, DNA methylation profiles, and capacity for dif-
ferentiation to other cells types (Bock et al., 2011; Boulting et al., 2011). These results
demonstrate the importance of controlling for genetic background, particular in experiments
using iPSC-derived neurons which typically only have iPSC lines from a small number of
donors. CRISPR is a powerful tool to do this: it can be used to rescue or introduce specific
mutations, creating a pair of iPSC lines sharing a genetic background and differing at the
chosen mutation locus (Chapter 4).
1.4.6 iPSC-derived neurons as models of tauopathy
iPSC-derived neurons have been used to model the effects of several MAPT mutations, and
findings from published studies on iPSC-derived neurons with the N279K, P301L or V337M
tau mutations are summarised in Tables 1.4 and 1.5. The extent to which FTDP-17T-relevant
phenotypes are recapitulated in iPSC-derived neural cultures is discussed in detail in Section
4.1 in Chapter 4.
The experiments using iPSC-derived neurons described in Tables 1.4 and 1.5 did not
use isogenic controls, which can minimise the contribution of genetic background effects to
subtle phenotypes (Section 1.4.5). This project aims to fill that gap, by making iPSC lines
isogenic for the N279K mutation and using them to investigate tau splicing, phosphorylation
and aggregation.
In addition, the experiments described in Tables 1.4 and 1.5 were all conducted in
monolayer culture (except for that of Seo et al., 2017). Since 3D culture may increase
neuronal maturity (Choi et al., 2014) and would provide neurons with a more brain-like
environment, this project will also use cerebral organoid cultures with the aim of increasing
neuronal maturity with respect to tau splicing.
1.5 Aims
The aim of my PhD project was to investigate the extent to which FTDP-17T-relevant
phenotypes caused by the MAPT mutations N279K, P301L and V337M can be recapitulated
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in forebrain-specific monolayer neurons and COs derived from FTDP-17T patient and control
subject iPSCs. The overall aim is sub-divided as follows:
1. Differentiate forebrain-specific monolayer neuronal cultures from control subject
iPSCs and FTDP-17T patient-derived iPSCs with the MAPT mutations N279K and
V337M. The neuronal cultures will be maintained for up to 100 days to allow the
neurons to mature and:
• Determine the proportion of neuronal and glia cells in each culture, as a measure
of the cultures’ maturity and to check for FTDP-17T-relevant astrogliosis
• Determine which tau isoforms are present, to establish the cultures’ maturity with
respect to tau expression, and to observe the previously established effect of the
N279K mutation: an increase in 4R tau relative to 3R tau
• Investigate if and at what time point FTDP-17T-relevant tau phosphorylation or
misfolding is detectable. Tau misfolding has not previously been detected in
iPSC-derived neural cultures without the addition of exogenous tau
• Investigate whether other FTDP-17T-relevant phenotypes are present in neurons
with MAPT mutations.
2. Decrease variability between iPSC lines by using CRISPR to produce isogenic iPSC
lines. This will be done by correcting the N279K mutation in FTDP-17T patient-
derived iPSCs, or inducing the N279K mutation in control subject-derived iPSCs
• Ensure that gene-edited iPSC lines express the desired mutations and establish if
off-target mutations or karyotypic defects are present.
3. Differentiate isogenic iPSC lines to 3D COs, to investigate the effects of MAPT
mutations in a more brain-like environment by:
• Examine which tau isoforms are present, to determine maturity with respect to
tau expression, and to investigate whether 3D culture can accelerate neuronal
maturation with respect to tau expression
• Investigate if and at what time point FTDP-17T-relevant tau phosphorylation or
misfolding is detectable, or if it is enhanced by 3D culture, as observed by Choi
et al. (2014) using AD-relevant cells
• Compare my findings in monolayer neurons with those in COs, to determine
if CO culture is advantageous in terms of tau expression or the appearance of
FTDP-17T-relevant changes.
Chapter 2
Materials and Methods
2.1 General Materials
Materials and reagents used in culture and differentiation of induced pluripotent stem cells
(iPSCs), where they were purchased from, and their stock concentrations (if appropriate) are
listed in Table 2.1.
2.2 iPSC culture
2.2.1 Media and solutions for iPSC maintenance
Indicated recipes are for 50ml of each solution. All media and solutions were filtered under
sterile conditions with a 0.22µm filter and stored at 4°C.
MEF media: 44ml DMEM/F12, 5ml FBS, 500µl pen-strep (10,000 U/ml stock solution),
500µl L-glutamine (200mM stock solution).
Knockout Serum Replacement (KSR) Medium: 39ml Advanced DMEM/F12, 10ml
Knockout Serum Replacement, 500µl L-glutamine (200mM stock solution), 500µl pen-
strep (10,000 U/ml stock solution), 3.5µl β -mercaptoethanol (50mM stock solution). KSR
medium was purchased from the CCK.
Essential 8 (E8) Medium: 49ml DMEM/F12, 1ml Insulin-Transferrin-Selenium (100x
stock solution), 360µl sodium bicarbonate (7.5% stock solution), 500µl L-ascorbic acid
(200mM stock solution in ddH2O), 500µl pen-strep (10,000 U/ml stock solution). E8
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Table 2.1 Materials used and where purchased
Material or reagent Supplier Stock concentration
β -mercaptoethanol Life Technologies 50mM
γ-irradiated mouse embryonic feeder cells (MEFs) Globalstem -
Accutase Innovative Cell Technologies 1x
Advanced DMEM/F12 Invitrogen -
B27 supplement without vitamin A Invitrogen 50x
B27 supplement with vitamin A Invitrogen 50x
Bovine serum albumin (BSA) Europa Bioproducts -
Dispase powder Life Technologies -
DMEM/F12 Invitrogen -
Dulbecco’s phosphate buffered saline (DPBS) Gibco -
EDTA in H2O Invitrogen 0.5M
ES Cell Qualified Fetal Bovine Serum (FBS) Gibco -
FBS Fisher Scientific -
Fibroblast growth factor 2 (FGF2) CCK 4mg/ml
Gelatine in sterile H2O CCK 0.1%
GlutaMAX Gibco 100x
Heparin Sigma 100mg/ml
Karyomax Colcemid solution Gibco 10µg/ml
Knockout Serum Replacement Invitrogen -
Insulin Sigma 10mg/ml
Insulin-Transferrin-Selenium Gibco 100x
L-ascorbic acid powder Sigma 200mM (diluted in ddH2O)
L-glutamine Gibco 200mM
Laminin Invitrogen 1mg/ml
N2 supplement Invitrogen 100x
Neurobasal Invitrogen -
Non-Essential Amino Acids (MEM-NEAA) Sigma 100x
Penicillin and streptomycin (pen-strep) Gibco 10,000 U/ml
Poly-L-ornithine Sigma 0.1mg/ml
Sodium bicarbonate Gibco 7.5%
Transforming growth factor beta 1 (TGFβ -1) powder R&D 2mg/ml (diluted in ddH2O)
Trypsin/EDTA solution Invitrogen 0.05%
Trypsin inhibitor Sigma 1x
Vitronectin Gibco 500µg/ml
CoolCell freezing container BioCision -
Coverslips: tissue culture treated plastic Thermo Fisher -
Cryovials Thermo Scientific Nunc -
Plates: low-attachment 24-well Costar -
Plates: low-attachment 96-well round-bottomed Costar -
Vicryl polyglactin 910 surgical sutures Ethicon -
.
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Table 2.2 iPSC lines used
Line name Diagnosis Source References
CTRL1 none LRM BBHX in [1]
CTRL2 none LRM [3] CRL in [1,2]
N279K1 FTDP-17T Coriell [1]
N279K2 FTDP-17T Coriell [1]
V337M FTDP-17T Coriell -
P301Lpat FTDP-17T [4] [1]
IsoCon none Axol -
P301Lhet n/a: heterozygous knock-in Axol -
P301Lhom n/a: homozygous knock-in Axol -
All iPSC lines were derived from fibroblasts. “Coriell” indicates that the NINDS Coriell Repository
provided fibroblasts with MAPT mutations, which were re-programmed to iPSCs at the Laboratory
for Regenerative Medicine (LRM). The P301Lhet (P301L heterozygous knock-in) and P301Lhom
(P301L homozygous knock-in) lines were generated from the IsoCon (isogenic control) line using
CRISPR by Horizon Discovery Group and obtained as part of a collaboration with Axol Bioscience.
Abbreviations used in this table: FTDP-17T: frontotemporal dementia with Parkinsonism, linked to
chromosome 17 and tau mutations. References: [1]: Iovino et al. (2015); [2]: Shi et al. (2012b); [3]:
Vallier et al. (2009); [4]: Alberici et al. (2004).
medium was purchased from the MRC Laboratory of Regenerative Medicine Cell Culture
Kitchen facility (CCK).
1mg/ml collagenase IV: 40ml Advanced DMEM/F12, 10ml Knockout Serum Replace-
ment, 500µl L-glutamine (200mM stock solution), 0.35µl β -mercaptoethanol (50mM stock
solution), 50mg collagenase IV powder. Collagenase solution was purchased from the CCK.
Collagenase-dispase mix: Dispase powder was dissolved in DPBS to make a 10mg/ml
stock, which was diluted to 1mg/ml in Advanced DMEM. Equal volumes of 1mg/ml collage-
nase solution and 1mg/ml dispase solutions were mixed to make a 0.5mg/ml solution of both
enzymes.
2.2.2 Induced pluripotent stem cell (iPSC) culture conditions
Nine iPSC lines were used (Table 2.2). The feeder-dependent iPSC lines CTRL1, CTRL2,
N279K1, N279K2, V337M and P301L-patient (P301Lpat) were cultured on γ-irradiated
mouse embryonic feeder cells (MEFs). Six-well plates were coated with 0.1% gelatine in
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sterile H2O for at least 1 hour before MEFs were seeded. MEFs were maintained in MEF
media (Section 2.2.1) overnight before thawing or passaging iPSCs. iPSCs were maintained
in KSR medium (Section 2.2.1) with 4ng/ml FGF2 (4mg/ml stock solution). Differentiated
colonies (Figure 2.1) were marked under the microscope and removed by aspiration. iPSCs
were passaged when they reached approximately 70% confluency, using collagenase-dispase
(Section 2.2.1). If the iPSCs did not reach sufficient confluency for splitting within 1 week,
more MEFs in KSR media were added to support iPSC growth. iPSCs were kept in a
humidified incubator at 37°C with 5% CO2.
Some iPSCs were grown in feeder-free conditions. These were the P301L-heterozygous
knock-in (P301Lhet), P301L-homozygous knock-in (P301Lhom), and isogenic control
(IsoCon) iPSC lines. They were cultured on 6-well plates coated with 5µg/ml vitronectin
(500µg/ml stock solution) in DPBS for at least 1 hour at room temperature. iPSCs were
maintained in E8 medium (Section 2.2.1) with 25ng/ml FGF2 (4mg/ml stock solution)
and 2ng/ml TGFβ -1 (2mg/ml stock solution). Differentiated colonies (Figure 2.1) were
marked under the microscope and removed by aspiration. Cells were passaged at about 70%
confluency with 0.5mM EDTA in DPBS (0.5M stock solution) and kept in a humidified
incubator at 37°C with 5% CO2.
2.2.3 iPSC cryopreservation
iPSCs were cryopreserved both at low passage numbers and after karyotyping showed a
normal complement of chromosomes and no genetic re-arrangements. Confluent iPSCs
were lifted from the culture plate with either EDTA or collagenase-dispase, depending on
the culture system (Section 2.2.2). Colonies were then added to 10ml of culture medium
and centrifuged for 3 minutes at 300g in a Sorvall ST-16 centrifuge. The medium was
removed and a mixture of 20% DMSO and 80% culture medium (KSR or E8) was added
dropwise to the iPSC colonies. The colonies were transferred to a sterile, labelled cryovial
and immediately frozen at -80◦C in a CoolCell freezing container. The following day, vials
were moved to liquid nitrogen for long term storage.
2.2.4 iPSC thawing
Vials containing cryopreserved iPSCs were thawed in a 37◦C water bath until a ball of ice
approximately 0.75cm in diameter remained. One ml of media (KSR or E8) was added
dropwise to the vial, then the colonies were added to 10ml of culture medium and centrifuged
for 3 minutes at 300g in a Sorvall ST-16 centrifuge. One ml of culture medium supplemented
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A- B-
C- D-
Fig. 2.1 Pluripotent and differentiated iPSC colonies. Pluripotent (A) and differentiating (B) iPSC
colonies cultured on MEFs with KSR media supplemented with 4ng/ml FGF2. Pluripotent (C) and
differentiating (D) iPSC colonies cultured on vitronectin with E8 supplemented with 25ng/ml FGF2
and 2ng/ml TGFβ -1. Scale bar = 10µm.
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with 10µm ROCK inhibitor (10mM stock) to reduce cell death was added to the iPSC
colonies, and colonies were gently plated on MEFs or vitronectin-coated plates. The medium
was changed to KSR or E8 media without ROCK inhibitor 24 hours after plating.
2.2.5 Karyotyping
Karyomax Colcemid solution was diluted to 0.1µg/ml (from the 10µg/ml stock solution) in
KSR and added to a non-confluent well of iPSCs. The plate was incubated at 37◦C for 3
hours, then the colcemid solution was removed and the iPSCs were washed with DPBS. iPSC
colonies were lifted from the culture plate with collagenase-dispase and added to 10ml of
culture medium. The cell pellet was collected by centrifugation at 1200rpm for 7 minutes in a
Sorvall ST-16 centrifuge, the supernatant was removed and a hypotonic 0.055M KCl solution
was gently mixed with the iPSC colonies, to obtain chromosome spreading by swelling the
cells without lysing them. The cell pellet was collected by centrifugation at 1200rpm for 7
minutes in a Sorvall ST-16 centrifuge, then fixed with 100% methanol and acetic acid in a
3:1 ratio. The fixed cell suspension was sent for karyotypic analysis.
2.3 Differentiation of iPSCs to monolayer neurons
Differentiation of iPSCs to neural precursor cells (NPCs) followed a protocol developed
for human embryonic stem cells by Kirkeby et al. (2012), which was modified for iPSCs
by a previous lab member (Santiváñez Pérez, 2017). Santiváñez Pérez made NPCs and
plated them for terminal differentiation to neurons in 3D droplets, whereas I plated NPCs
for terminal differentiation as a 2D monolayer. The method is summarised in Figure 2.2.
CTRL1, CTRL2, N279K1, N279K2 and V337M iPSCs were differentiated to monolayer
neurons in three independent differentiations.
2.3.1 Media recipes and growth factors for monolayer neurons
Neuronal Induction Medium (NIM): 25ml DMEM/F12, 25ml Neurobasal, 500µl N2 sup-
plement (100x stock solution), 1ml B27 supplement without vitamin A (50x stock solution),
500µl L-glutamine (200mM stock solution), 100µl pen-strep (10,000 U/ml stock solution).
Neuronal Proliferation Medium (NPM): 25ml DMEM/F12, 25ml Neurobasal, 250µl N2
supplement (100x stock solution), 500µl B27 supplement without vitamin A (50x stock
solution), 500µl L-glutamine (200mM stock solution), 100µl pen-strep (10,000 U/ml stock
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solution).
Neuronal Differentiation Medium (NDM): 50ml Neurobasal, 1ml B27 supplement with
vitamin A (50x stock solution), 500µl L-glutamine (200mM stock solution), 100µl pen-strep
(10,000 U/ml stock solution).
Table 2.3 Reagent for iPSC maintenance and neuronal differentiation
Reagent Supplier Stock concentration Dilutant
ROCK inhibitor (Y-27632) Tocris 10mM ddH2O
Noggin R&D 100µg/ml 0.1% BSA in DPBS
SB431542 Tocris 10mM DMSO
Ascorbic acid Sigma 200mM ddH2O
BDNF R&D 20µg/ml 0.1% BSA in DPBS
GDNF R&D 20µg/ml 0.1% BSA in DPBS
db-cAMP Sigma 50mM ddH2O
DAPT Sigma 40mM DMSO
CHIR (CT99021) Axon 10mM DMSO
Factors were aliquoted and stored at -20°C. Abbreviations used in this table: BDNF: brain-derived
neurotrophic factor; BSA: bovine serum albumin; DAPT: N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester; db-cAMP: dibutyl-cyclic adenosine monophosphate; DPBS: Dulbecco’s
Phosphate Buffered Saline; GDNF: glial cell-derived neurotrophic factor; ROCK: p160-rho-associated
coiled kinase.
2.3.2 Protocol for differentiation to monolayer neurons
On day 0, confluent iPSC colonies were released from the MEFs with collagenase-dispase,
added to 10ml of a 50-50 mixture of DMEM/F12 and Neurobasal media and allowed to fall by
gravity for approximately 2 minutes. The medium was removed neuronal induction medium
(NIM) was added, with 100ng/ml Noggin and 10µM SB431524 for neuronal differentiation
by dual Smad inhibition, and 10µM ROCK inhibitor for the first 2 days to reduce cell
death. The cells were cultured in low-attachment 24-well plates (coated with a hydrogel that
decreases cell attachment to the plate surface) for embryoid body (EB) formation. Large
clumps of cells were separated by gentle pipetting with a P1000 Gilson pipette.
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Fig. 2.2 Neuronal differentiation of iPSCs. Images show the stages of differentiation at high
(first row) and low (second row) magnification. Scale bar = 10µm. Left to right: floating embryoid
bodies (EBs) at day 1; attached EBs with circular neuronal rosettes at day 8; neuronal precursors
(NPCs) from dissociated neuronal rosettes at day 12; neurons at day 31. The black bar indicates
the day of differentiation, starting from iPSCs at day 0. Text above the black bars indicates the
cell culture surface: low-attachment plates were used for EBs, poly-L-ornithine and laminin coated
plates were used for attached cells. Pink bars indicate the medium in which differentiating cells
were maintained: neuronal induction medium (NIM), neuronal proliferation medium (NPM) or
neuronal differentiation medium (NDM). Blue bars show factors added to the differentiation media,
and grey sideways ”T” shapes show inhibition by added factors. Cells were maintained in media
containing BDNF and GDNF to induce terminal neuronal maturation, as described by Kirkeby et al.
(2012). BDNF: brain-derived neurotrophic factor; BMP: bone morphogenic protein; DAPT: N-[N-
(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; GDNF: glial-derived neurotrophic
factor; db-cAMP: dibutyl-cyclic adenosine monophosphate; ROCK: rho-associated protein kinase.
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Prior to day 4, a poly-L-ornithine and laminin (P/L) coated 24-well plate was prepared, to
culture the EBs as attached cells. Poly-L-ornithine (50µg/ml, from a 0.1mg/ml stock solution)
was added to each well and incubated overnight at 37°C. The poly-L-ornithine was removed,
replaced with laminin diluted in DPBS (5µg/ml, from a 1mg/ml stock solution) and incubated
overnight at 37°C. On day 4, the laminin was removed and the EBs were re-plated in P/L
coated wells in neuronal proliferation medium (NPM) with 100ng/ml Noggin and 10µM
SB431524. On day 9, the medium was changed to NPM without SB431524 or Noggin.
Prior to day 11, P/L coated 24-well plates were prepared as described above. On day
11, laminin was removed from the P/L coated plates and each well was dried thoroughly
by aspiration. The cells were incubated with 1x Accutase for 10 minutes, triturated to a
single-cell suspension and transferred to a falcon tube containing 10ml Neurobasal medium.
The cell pellet was collected by centrifugation at 300g in a Sorvall ST-16 centrifuge for
three minutes, then the medium was removed and the cells were re-suspended in neuronal
differentiation medium (NDM) at a concentration of 15000 cells/µl and plated on the dried
P/L coated plates in 10µl droplets. The plates were placed in the incubator for one hour
to allow the cells to attach, then NDM with 20ng/ml BDNF, 10ng/ml GDNF and 0.2mM
ascorbic acid was added to each well. By day 16, neuronal precursors (NPCs) were visible
as radially arranged rosette-like formations.
Prior to day 20, P/L coated plates were prepared. To grow neurons for immunofluores-
cence, tissue culture treated plastic coverslips were placed in 24-well plates and P/L coated
as described above. To grow neurons for protein extraction, 24-well plates without coverslips
were P/L coated and to collect conditioned media, 96-well plates were P/L coated. On day 20,
NPCs were incubated with 1x Accutase for 10 minutes, triturated to a single-cell suspension
and transferred to a falcon tube containing 10ml Neurobasal medium. The cell pellet was
collected by centrifugation at 300g for three minutes, then the medium was removed and the
cells were re-suspended in NDM at a concentration of 15000 cells/µl. Immediately before
plating, laminin was removed from the coated plates and a minimal volume of NDM was
added to each well. The cells were plated at 80000 cells/cm2 and the plates were gently
shaken to ensure an even coverage of cells over each well.
On day 22, the medium was changed to NDM with 20ng/ml BDNF, 10ng/ml GDNF,
0.2mM ascorbic acid, 500µM db-cAMP and the γ-secretase inhibitor DAPT (1µM), which
inhibits Notch signalling and promotes neuronal differentiation. The medium was replaced
every two days. From day 32 onward, DAPT was removed and the neurons were maintained
in NDM with 20ng/ml BDNF, 10ng/ml GDNF, 0.2mM ascorbic acid and 500µM db-cAMP
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until day 50, 80-100. To prevent the neurons peeling off the coverslips, laminin (1µg/ml) was
added to NDM every 10 days, starting at day 30.
2.4 iPSC differentiation to cerebral organoids
Differentiation of iPSCs to forebrain-specific cerebral organoids (COs) followed the method
described by (Lancaster et al., 2017) (Figure 2.3).
2.4.1 Media for cerebral organoids
Low FGF medium: 40ml DMEM/F12, 10ml Knockout Serum Replacement, 1.5ml ES Cell
Qualified FBS, 500µl GlutaMAX (100x stock solution), 500µl MEM-NEAA (100x stock
solution). Non-scaffold method: 0.35µl β -mercaptoethanol (50mM stock solution). Scaffold
method: 100µl β -mercaptoethanol (50mM stock solution). 50µM ROCK inhibitor (10mM
stock solution) and 4ng/ml FGF2 (4mg/ml stock solution) were added immediately before
use.
Neural Induction Medium (NI): 50ml DMEM/F12, 500µl N2 supplement (100x stock
solution), 500µl GlutaMAX (100x stock solution), 500µl MEM-NEAA (100x stock solution),
50µl heparin (100mg/ml stock solution).
Differentiation Medium Without Vitamin A, scaffold method (DM-1): 25ml DMEM/F12,
25ml Neurobasal, 250µl N2 supplement (100x stock solution), 1ml B27 supplement without
vitamin A (50x stock solution), 500µl GlutaMAX (100x stock solution), 250µl MEM-NEAA
(100x stock solution), 12.5µl insulin (10mg/ml stock solution), 50µl β -mercaptoethanol
(50mM stock solution), 500µl pen-strep (10,000 U/ml stock solution).
Differentiation Medium With Vitamin A, scaffold method (DM-2): 25ml DMEM/F12,
25ml Neurobasal, 250µl N2 supplement (100x stock solution), 1ml B27 supplement with
vitamin A (50x stock solution), 500µl GlutaMAX (100x stock solution), 250µl MEM-NEAA
(100x stock solution), 12.5µl insulin (10mg/ml stock solution), 50µl β -mercaptoethanol
solution (50mM stock solution), 667µl sodium bicarbonate solution (7.5%), 100µl ascorbic
acid solution (200mM stock solution), 500µl pen-strep (10,000 U/ml stock solution).
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Fig. 2.3 Differentiation of iPSCs to cerebral organoids. Images show the stages of differentiation.
Left to right: an EB formed around a fibre scaffold; an EB with brightening edges, indicating
neuroectoderm tissue; a CO with growing neuroepithelial buds after embedding in matrigel. Scale bar
= 10µm. The day of differentiation was counted from iPSCs at day 0. Pink bars indicate the culture
medium: low FGF medium, neuronal induction medium (NI) or neuronal differentiation medium
(DM-1 or 2; Section 2.2.1). Blue bars show factors added to the media; vitamin A was added as
part of the B27 supplement. FGF2: fibroblast growth factor 2; GSK-3: glycogen synthase kinase
3; ROCK: rho-associated protein kinase. ”M” indicates addition matrigel, dissolved in cold DM-2
medium, at day 40.
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2.4.2 Protocol for forebrain-specific cerebral organoids
Vicryl polyglactin 910 surgical sutures were untwisted to fray the end of the suture. Fibres
of approximately 1mm were shaved from the frayed suture with a sterile razor blade and
collected in low FGF medium with a cut P1000 pipette tip. The concentration of fibres was
estimated by counting with a haemocytometer.
On day 0, confluent feeder-free iPSC colonies were washed with DPBS and lifted from
the culture surface with EDTA as described in Section 2.2.2. Confluent feeder-dependent
iPSC colonies were lifted from the feeder layer with collagenase-dispase as described in
Section 2.2.2. iPSC colonies were then incubated with 1ml 1x Accutase for 4 minutes at
37◦C. The iPSCs were triturated to a single-cell suspension, added to 9ml of E8 medium
and centrifuged at 300g for 3 minutes in a Sorvall ST-16 centrifuge to collect the cell pellet.
The medium was removed, then the cells were re-suspended in low FGF medium containing
fibres to make a cell suspension of 9000 cells/150µl, with approximately 2 fibres/150µl.
Fifty µM ROCK inhibitor and 4ng/ml FGF2 were added, then 150µl of cell suspension was
pipetted with a cut P200 tip into each well of a 96-well round-bottomed low-attachment
plate. On day 4, the medium was changed to low FGF medium without ROCK inhibitor or
FGF2. On day 6, when EBs were brightening and had smooth edges, EBs were transferred
to neural induction (NI) medium in a low-attachment 24-well plate, or cultured in the same
round-bottomed plate in NI medium. NI medium was replaced every other day until day
10, when translucent neuroepithelial buds became visible. EBs were embedded in 10-20µl
matrigel droplets and incubated NI medium until day 13, when 3µM CHIR was added (Table
2.3). On day 16, the medium was changed to differentiation medium 2 without vitamin A
(DM-1, Section 2.4.1) and the EBs were transferred to an orbital shaker moving at 60rpm
on day 18. On day 20, the medium was changed to differentiation medium 3 with vitamin
A (DM-2, Section 2.4.1). The medium was replaced every 7-10 days until day 40, when
the medium was replaced with cold DM-2 containing Matrigel diluted 1:50. Subsequently,
DM-2 medium without matrigel was replaced every 7-10 days until day 100.
2.5 Immunocytochemistry
2.5.1 Preparation of cells for immunocytochemistry
Monolayer neurons were washed with DPBS, fixed with 4% paraformaldehyde in DPBS for
20 minutes at 4°C and washed twice with DPBS, before storage at 4°C in DPBS with 0.1%
sodium azide.
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COs were washed with DPBS, fixed with 4% paraformaldehyde in DPBS for one hour at
4°C, then washed once with DPBS and incubated with fresh DPBS at 4°C for 1 hour. COs
were cryoprotected by incubation in 30% sucrose with 0.01% sodium azide in DPBS at 4°C
overnight. The next day, COs were embedded in OCT (Thermo Scientific) and frozen in
isopropanol cooled with dry ice. Embedded COs were stored at -80°C until cryosectioning
into 15µm sections using a Bright OFT5000 cryostat. Sections were collected on SuperFrost
Plus slides (VWR International) and stored at -20°C until immunostaining was performed.
2.5.2 Immunofluorescence protocol
For both monolayer neurons and COs, blocking of non-specific sites and cell permeabilisation
was performed with 5% normal goat serum or normal donkey serum (Vector Labs) in DPBS
with 0.3% Triton X-100 (Sigma) for one hour at room temperature. Primary antibodies
and their dilutions are listed in Table 2.4. Primary antibodies were diluted in DPBS with
0.3% Triton X-100 (Sigma) and incubated at 4°C overnight. The next day, the samples
were washed three times (for five minutes each time) with DPBS and incubated with the
appropriate Alexa Fluor secondary antibodies (1:500, Invitrogen) at room temperature for
two hours.
Samples were then incubated with 1µg/ml DAPI (Roche) in DPBS for 20 minutes and
washed three times (for five minutes each time) with DPBS. A drop (approximately 100 µl)
of Fluoromount-G (Southern Biotech) was placed on each sample and a coverslip was placed
on top. After drying, the slides were stored at 4°C.
2.5.3 Tau antibodies and signal amplification
Blocking was not performed when using tau antibodies and incubation with additional
primary antibodies (such as β III tubulin) was performed sequentially over the following
night. Signal amplification was required for 4R tau and AT8 antibodies: after incubation
with the primary antibody, samples were washed three times with DPBS and incubated
with biotinylated anti-mouse IgG (Vector Laboratories) diluted 1:250 in DPBS at room
temperature for two hours. Samples were washed three times (for five minutes each time)
with DPBS, then incubated with streptavidin Alexa Fluor conjugate (Invitrogen) diluted
1:500 in DPBS at room temperature for one hour.
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2.5.4 Use of the dye pFTAA
The dye pentameric formyl thiophene acetic acid (pFTAA), which recognises filamentous
β -sheet tau aggregates, was diluted to 3µM in ddH2O and incubated on the samples for 30
minutes at room temperature prior to incubation with DAPI. Samples were then washed three
times (for five minutes each time) with DPBS and incubated with DAPI as described above.
2.5.5 Imaging
Images were taken with a Leica DMI4000 B inverted microscope, or a Leica TCS SP8
laser-scanning confocal microscope. Where possible, the same microscope settings were
used for each antibody across all differentiation rounds. Images were analysed with LAS AF
software and ImageJ (from the National Institues of Health).
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2.6 Western blotting
2.6.1 Reagents and solutions for Western Blotting
10% Running Gel: 4ml ddH2O, 3.3ml 30% acrylamide (Sigma), 2.5ml 1.5M pH 8.8 Tris
HCl (Sigma), 100µl 10% SDS in H2O, 100µl 10% APS (ammonium persulphate) in H2O,
4µl TEMED (tetramethylethylenediamine).
Stacking Gel: 2.1ml ddH2O, 500µl acrylamide; 350µl M Tris HCl, 30µl SDS in H2O,
30µl 10% APS in H2O, 3µl TEMED.
Running Buffer (10x) : 10g SDS, 30g Trizma Base, 144g glycine (all Sigma), dissolved in
1L H2O.
Transfer Buffer (3x): 9.09g Trizma Base, 43.23g glycine, 300ml methanol (Sigma), dis-
solved in 1L H2O.
Stripping Buffer (1x): 50mM Tris HCl pH 7.4, 2% SDS, 100mM β -mercaptoethanol.
2.6.2 Sample preparation
Monolayer neurons were collected at day 50 or 80-100 by incubation with 500µl 1x Accutase
for 2 minutes at 37◦C. The sheets of cells were collected in falcon tubes containing 15ml
of DPBS to dilute the Accutase and centrifuged at 300g for 3 minutes in a Sorvall ST-16
centrifuge. The cell pellets were washed with DPBS and frozen at -80◦C.
At least 6 COs were collected at day 100. COs were transferred to falcon tubes containing
15ml of DPBS with a cut P1000 pipette tip and centrifuged at 300g for 3 minutes in a Sorvall
ST-16 centrifuge. The cell pellets were washed with DPBS and frozen at -80◦C.
2.6.3 Protein extraction
Cell pellets were thawed on ice, then centrifuged for 3 minutes at 300g in a Heraeus
Megafuge centrifuge. Remaining DPBS was removed and each pellet was re-suspended in
50µl (monolayer neurons) or 100µl (COs) of ice-cold Pierce RIPA buffer (Thermo Scientific),
containing 1x complete EDTA-free protease inhibitor cocktail (Roche) and phosphatase
inhibitor (1mM sodium orthovanadate, Sigma). The cells were lysed for 20 minutes on
2.6 Western blotting 57
ice, vortexing every 2 minutes. The cells were then sonicated (4 x 30 second cycles) in a
Diagenode Bioruptor sonicator and the cell lysate was cleared by centrifugation at 14000g
for 15 minutes at 4◦C in a Heraeus Megafuge centrifuge. The supernatant was removed to a
clean Eppendorf tube and both the pellet and supernatant were stored at -20◦C.
2.6.4 Determination of protein concentration
A bicinchoninic acid (BCA) assay was performed to quantify the protein concentration in
the cell lysate, and is described here. Two mg/ml bovine serum albumin (BSA, Europa
Bioproducts) was serially diluted 1:2 in DPBS as a protein concentration standard. Cell
lysate samples were diluted 1:5 in DPBS and added to a 96-well plate in triplicate. BCA
buffer solution was prepared by mixing BCA solution with 4% cupric sulphate (1:50, both
from BCA protein assay kit, Novagen). 200µl of BCA buffer solution was added to each
well and the plate was incubated at 37◦C for 30 minutes, protected from light. Absorbance
was read at 562nm with an Infinite M200 Pro Tecan plate reader. The BSA protein standards
were used to make a standard curve in Excel, from which the concentration of the samples
was calculated.
2.6.5 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE)
Ten µg of protein was diluted in ice cold RIPA buffer containing protease and phosphatase
inhibitors, such that all samples were the same volume. Four x NuPAGE LDS Sample
Buffer and 10x NuPAGE Sample Reducing Agent (both Invitrogen) were added to the
samples, which were incubated at 95◦C for 5 minutes. Samples were loaded into the wells
of a NuPAGE Novex Bis-Tris 4-12% 1.5mm gel (Invitrogen) alongside SeeBlue Plus2 Pre-
Stained Protein Standard (Life Technologies). Loaded samples were run in NuPAGE MES
buffer at 120mV. Proteins were transferred to 0.2µm nitrocellulose membrane (Bio-Rad) at
0.3A for 3 hours at 4◦C, in 1x Transfer Buffer (Section 2.6.1). Non-specific binding of the
primary antibody to the membrane was blocked by incubating the membrane with 5% BSA
in TBS-Tween (TBST, 0.05%) for 1 hour at room temperature before incubation with the
primary antibody overnight at 4◦C (Table 2.4). The next day, the membrane was washed
with TBST (3 x 5 minutes) and incubated with the appropriate HRP-conjugated secondary
antibody (DAKO, GE Healthcare) diluted 1:5000 in 5% BSA in TBST for 2 hours at room
temperature. The membrane was washed again with TBST (3 x 5 minutes) and primary
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antibody binding was visualised using SuperSignal West Dura Extended Duration Substrate
(Thermo Scientific) on a Biorad ChemiDoc. Band intensity was quantified using ImageJ.
2.6.6 Stripping and re-probing membranes
When membranes were probed with more than one antibody, bound primary and secondary
antibodies were removed from the membrane by incubation with Stripping Buffer (Sec-
tion 2.6.1) for 45 minutes at 55◦C. The membrane was then washed with ddH2O (20 x 5
minutes). Non-specific binding of the primary antibody to the membrane was blocked as
described in Section 2.6.5, and the membrane was incubated with a second primary antibody
as described in Section 2.6.5.
2.6.7 Western blotting for tau isoforms
To visualise tau isoforms, dephosphorylated samples were run next to their phosphorylated
counterparts. To dephosphorylate samples, 15µg of protein was dephosphorylated by incuba-
tion with 16 units of alkaline phosphatase from E. coli (Sigma), in 50mM pH 7.4 Trizma HCl
(Sigma), and 5mM MgCl2 at 65◦C for 4 hours. For the phosphorylated samples, 5µg of pro-
tein was diluted with ddH2O, such that all samples were the same volume. Four x NuPAGE
LDS Sample Buffer and 10x NuPAGE Sample Reducing Agent were added to the samples,
which were incubated at 70◦C for 10 minutes. Samples were then loaded into the wells of a
10% 1.5mm polyacrylamide gel (Section 2.6.1), alongside SeeBlue Plus2 Pre-Stained Protein
Standard. Protein extract from control human cortex was included as a positive control for
all six tau isoforms (one lane contained phosphorylated protein, one lane dephosphorylated
protein). Recombinant tau protein (all 6 isoforms, rPeptide) was diluted 1:800 and included
as a molecular weight marker for human tau isoforms. SDS-PAGE was performed in 1x
Running Buffer (Section 2.6.1) at 90mV until the 36kDa marker ran off the gel. Transfer of
proteins onto a membrane, blocking of non-specific background and incubation with primary
and secondary antibodies were performed as described in Section 2.6.5.
2.7 Statistical analysis
Statistical analysis was performed with GraphPad Prism 7. To determine whether the data
was normally distributed, a D’Agostino-Pearson K2 omnibus test or a Shapiro-Wilk test was
performed. Equality of variance was assessed with Bartlett’s test or the Brown-Forsythe
test. For normally distributed data, a one-way or two-way repeated measures ANOVA
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was used to compare means with one or two variables, followed by a Bonferroni post-hoc
correction. Repeated measures ANOVAs were used because cultures were made from each
iPSC line three times in non-concomitant differentiation rounds. This is a "randomised
block" experiment, in which the blocking factor is the differentiation round. Matching the
data by differentiation round (using a repeated measures ANOVA) decreases the contribution
of variation by differentiation round. When data did not follow a normal distribution, a
Friedman test was used to compare the means with one variable, followed by Dunn’s post test.
Mean values were calculated from three independent differentiations. When two groups were
compared, a paired, two-tailed Student’s t-test was used, or non-parametric Mann-Whitney
tests if the data was not normally distributed.

Chapter 3
Characterisation of iPSC-derived
neurons with MAPT mutations
3.1 Aims
FTDP-17T predominantly affects the frontal and temporal lobes of the brain. In FTDP-17T,
neurons and sometimes astrocytes contain abnormally phosphorylated tau, which forms
insoluble aggregates. Cultures containing both neurons and astrocytes can be made by
directed differentiation of iPSCs by applying development-mimicking cues. Patterning
factors can also be applied to direct the neurons towards a forebrain-like fate, making the
neuronal cultures a relevant model in which to examine FTDP-17T-like changes.
Although the control and N279K iPSC lines described in this Chapter have been used
to make monolayers of forebrain-specific neurons by Iovino et al. (2015), I used a different
differentiation method. Therefore, characterisation of the iPSC-derived neurons was repeated.
The aim of the work described in this Chapter is to make forebrain-specific neurons from
control and MAPT-mutant iPSCs, and then to characterise them, examining the maturation
of the cultures over time in terms of tau isoform expression, synapse formation and the
appearance of astrocytes. This aim will be fulfilled by:
1. Differentiating iPSCs to NPCs, then confirming their forebrain fate and proliferative
capacity
2. Differentiating NPCs to neurons, then determining the proportion of astrocytes and
neurons in the cultures, to examine maturation with respect to the appearance of
astrocytes, and to check for FTDP-17T-relevant astrocyte overgrowth
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3. Examining synaptic protein expression as a proxy for synapse formation, to determine
whether neurons are forming synaptic connections and if there is FTDP-17T relevant
synapse loss
4. Assessing tau isoform expression as a measure of neuronal maturity and to confirm
that the effect of the N279K mutation (an increase in 4R tau relative to 3R tau) can be
seen in these cultures.
3.2 Introduction
Directed differentiation of iPSCs to forebrain neurons provides neural cultures which mature
over time, and in which neurons and glial cells are generated in a manner similar to cerebral
cortex development (Angevine and Sidman (1961); Shi et al. (2012c), Chapter 1). In this
Chapter I will describe the characterisation of control and MAPT-mutant iPSC-derived neural
cultures over three timepoints, during which NPCs are generated, differentiate into neurons
with synaptic connections, and eventually produce astrocytes.
3.2.1 Tau isoform expression in iPSC-derived neurons
Tau protein expression is developmentally regulated: of the six tau isoforms, the shortest
0N3R isoform is expressed during development, and the remaining five isoforms are co-
expressed with the 0N3R isoform in the adult brain (Goedert and Jakes, 1990; Goedert and
Spillantini, 1990). Tau isoform expression can therefore be used as a measure of a neuronal
culture’s maturity relative to the adult human brain. However, some of the MAPT mutations
which cause FTDP-17T alter tau isoform ratios by either increasing or decreasing exon 10
splicing (Hutton et al. (1998); Spillantini et al. (1998b); and many others).
Maturation of tau isoform expression in control iPSC-derived neuronal cultures over
time
In control iPSC-derived neural cultures, 0N3R tau expression usually predominates (Beevers
et al., 2017; Iovino et al., 2015; Sposito et al., 2015), suggesting a large proportion of
immature neurons in culture. 4R tau mRNA has been reported in control cultures from day
30 (Iovino et al., 2015) or day 40 (Ehrlich et al., 2015) onwards. At day 50, 0N3R tau protein
is strongly expressed, and 0N4R tau is starting to become visible in Western blots for tau
isoforms using control cells (Iovino et al., 2015; Sposito et al., 2015). Extended time in
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culture increases the number of tau isoforms visible. Sposito et al. (2015) have demonstrated
the presence of 0N3R, 0N4R and at least two higher molecular weight tau isoforms by
Western blot in 365 day-old cultures, whereas Iovino et al. (2015) have shown 0N3R, 0N4R,
1N3R and 1N4R tau isoforms, and very weak 2N3R and 2N4R tau isoforms in control 150
day-old forebrain iPSC-derived neural cultures. Similarly, Beevers et al. (2017) report the
expression of all six tau isoforms in control midbrain-like iPSC-derived neural cultures after
190 days in culture, as detected by antibodies against all six tau isoforms, against 4R tau
isoforms, and against isoforms with two N-terminal inserts.
Splicing mutations and tau isoforms ratios
In addition to adult-like tau splicing in aged cultures, the effects of MAPT mutations which
alter tau splicing are recapitulated in iPSC-derived models. Cultures with mutations such as
N279K have been shown to escape the developmental regulation of tau splicing, resulting in
the earlier expression of 4R tau (Iovino et al., 2015). Neural cultures with MAPT mutations
which do not alter tau isoform ratios in vitro or in the human brain (such as V337M or
P301L), express tau isoforms in a pattern similar to control neuronal cultures (Ehrlich et al.,
2015; Iovino et al., 2015).
In iPSC-derived cultures with the N279K mutation, 4R tau mRNA has been detected
from day 1 of differentiation onwards, whereas it was absent in control cultures until day
30 (Iovino et al., 2015). Four repeat tau mRNA has also been detected in N279K NPCs, at
higher levels than in control NPCs (Wren et al., 2015). In 40 day-old neurons, 4R tau mRNA
has been detected in N279K iPSC-derived neural cultures, but was not detected in control
cultures (Ehrlich et al., 2015). This alteration in the ratio of 3R:4R tau mRNA has also been
observed in cultures of iPSC-derived neurons with the intron 10+16 (Sposito et al., 2015)
and intron 10+14 mutations (Imamura et al., 2016), both of which increase exon 10 inclusion
in tau mRNA.
As would be expected given the early appearance of 4R tau mRNA, 0N4R tau protein is
expressed earlier in iPSC-derived neurons with the N279K mutation than in controls (Iovino
et al., 2015). In addition, iPSC-derived neurons with the N279K, 10+16, or 10+14 mutation
show lower 0N3R tau protein expression than controls, indicating a change in the 4R:3R
ratio, such that relatively more 4R tau is expressed (Imamura et al., 2016; Iovino et al., 2015;
Sposito et al., 2015).
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3.2.2 Synapses in FTDP-17T and in iPSC-derived neurons
Synapse loss in FTDP17-T
Several studies have found that synapse number declines in the brains of people with
tauopathies. For example, Bigio et al. (2001) found lower synaptophysin levels in the frontal
and temporal lobes of brains from people with PSP and AD, Masliah et al. (1989) found
fewer synaptophysin puncta in Pick’s disease and AD brains, and Callahan and Coleman
(1995) found decreased synaptophysin levels in neurons containing tau inclusions, compared
neurons without tau inclusions in AD brains. Synapse loss has also been shown to correlate
with cognitive decline in AD (Koffie et al., 2011; Terry et al., 1991), indicating the relevance
of synapse loss to AD symptoms.
Synapses are also lost in animal models of tauopathy. In the ventral striatum of aged
mice expressing human V337M tau, Warmus et al. (2014) found decreased post-synaptic
density area and thickness, lower PSD-95 protein levels, and decreased synapse function.
Lower synaptophysin and PSD-95 levels have been observed from 1.3 months onwards
in mice expressing 0N4R human tau lacking 20 C-terminal amino acids to mimic caspase
cleaved tau (Kim et al., 2016), and in mice expressing R406W mutant tau with several
pseudo-phosphorylated residues (Di et al., 2016).
In some mouse models, synapse loss is an early sign of disease. For example, in a mouse
transgenic for human P301S tau, Yoshiyama et al. (2007) reported decreased hippocampal
synaptophysin levels in three month-old mice, before tau phosphorylation and tau filaments
were observed at six months, and before neuronal loss at nine months. Xu et al. (2014)
observed a similar pattern in another P301S mouse, which had decreased dendritic spine
density and length in the hippocampus at 2.5 months, before phosphorylated and filamentous
tau was detected at five months, and before cell death at six months. Synaptic loss has also
been observed in other mouse lines expressing mutant tau, including in mice expressing the
P301L MAPT mutation (Kopeikina et al., 2013).
These results indicate that synaptic loss is a feature present alongside tau pathology, but
it has only been investigated in a few studies of iPSC-derived neurons with MAPT mutations.
Silva et al. (2016) measured the levels of PSD-95, synapsin-I and synaptophysin by Western
blot in 35 day-old iPSC-derived control and A152T tau neurons, and found no differences in
expression level. The other studies investigating synapse density in relation to tau have added
exogenous tau. For example, Usenovic et al. (2015) found fewer synaptophysin and synapsin
I positive puncta in control iPSC-derived neurons which were exposed to fibrils made of
recombinant full-length human tau for two weeks. Similarly, Reilly et al. (2017) expressed
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the tau repeat domain with the P301L and V337M mutations in control iPSC-derived neurons,
and found a decrease in synapsin I puncta density.
The presence of synapses in iPSC-derived neurons
iPSC-derived neurons express synaptic proteins, which have been detected from as early as
day 21 (Birnbaum et al., 2018). Synapse number, measured by PSD-95 and synaptophysin
immunofluorescence, continues to increase over time: from day 60 to day 90 (Bergström
et al., 2016), and from day 112 to 300 (Odawara et al., 2016). At least some of these synapses
are also functional, which has been demonstrated by electrophysiological recordings from
day 28 onwards (Iovino et al., 2015; Shi et al., 2012c).
The expression of synaptic proteins can therefore serve as a marker of a culture’s maturity,
but synapse number has been shown to decrease in both human and animal brains in the
presence of mutant tau. iPSC-derived neural cultures of MAPT-mutant and control neurons
will be used to investigate whether MAPT mutations affect synapse formation and number.
3.2.3 Astrocytes
In iPSC-derived neural cultures and the developing brain, astrocytes begin to appear after
neurons, starting at approximately day 45 in iPSC-derived neural cultures (Shi et al., 2012a),
and making the appearance of astrocytes another indication of a culture’s maturity.
In the brain astrocytes secrete gliotransmitters, neurotrophic factors and synaptogenic
factors, as well as maintaining the extracellular environment by controlling potassium ion
concentration and removing excess glutamate, amongst other roles (reviewed by Kettenmann
and Verkhratsky, 2016). The extent to which astrocytes fulfil all of these roles in iPSC-
derived neural culture is not known, but there is some evidence that astrocytes are beneficial
to neurons in culture, and support synapse formation as part of a tri-partite synapse (reviewed
by Chung et al., 2015).
ESC-derived neurons co-cultured with embryonic mouse astrocytes have been shown
to express synaptic proteins sooner, and to form electrophysiologically active synapses
before cultures without astrocytes (Johnson et al., 2007). ESC-derived neurons cultured with
astrocyte-conditioned media (but without astrocytes) also expressed higher synaptic protein
levels than neurons in non-conditioned media, but Johnson et al. only detected an increase in
electrophysiological activity in co-cultured neurons, suggesting that cell-to-cell contact is
important for functional maturity.
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The relative immaturity of the astrocytes themselves may also be for their role in synapse
formation, since Christopherson et al. (2005) have demonstrated that immature (but not
mature) astrocytes release synaptogenic factors, such as thrombospondin.
The abundance and appearance of astrocytes in iPSC-derived neuronal cultures with tau
mutations has not yet been studied in published papers. It is of interest because it reflects
not only maturation of the culture, but could also reflect astrogliosis, which is observed in
cortical and sub-cortical areas in the brains of patients with the N279K (Arvanitakis et al.,
2007; Slowinski et al., 2007), P301L (Miyasaka et al., 2001), and V337M mutations (Spina
et al., 2017). Features of astrogliosis include astrocyte hypertrophy, overgrowth, and release
of factors which can have neuroprotective or neurotoxic effects (reviewed by Phatnani and
Maniatis, 2015). NPC-derived astrocytes from N279K mutant and control iPSC lines have
been studied in the absence of neurons (Hallmann et al., 2017): the N279K astrocytes were
found to be larger, and to express more 4R tau mRNA than control astrocytes. Although
the larger size of N279K astrocytes indicates they may be hypertrophic, their tau expression
raises questions about their astrocytic identity, since astrocytes do not express tau in the
human brain, nor in the mouse brain (Forman, 2005).
3.3 Materials and Methods
I was unable to differentiate iPSCs to neurons following the protocol published by Shi et al.
(2012a), which was previously modified by Iovino et al. (2015) to differentiate the CTRL
and N279K iPSC lines used in this thesis. Instead, I used a protocol developed for ESC
differentiation by Kirkeby et al. (2012) and adapted for iPSC differentiation by a Spillantini
lab member (Santiváñez Pérez, 2017). The protocols differ substantially (Figure 3.1 and
Table 3.1). Therefore, I repeated the previously published characterisation of tau isoforms (in
this Chapter) and investigated tau phosphorylation using the anti phospho-tau antibody AT8
(in Chapter 4) in neurons obtained using the Kirkeby et al. (2012)/Santiváñez Pérez (2017)
protocol.
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Fig. 3.1 Comparison of the protocols developed by 1) Shi et al. (2012a) and 2) Kirkeby et al.
(2012)/Santiváñez Pérez (2017) for iPSC differentiation to neurons. Black bars indicate the day
of differentiation, starting from dual Smad inhibition at day 0. Text above the black bars indicate
the cell culture surface: low attachment plates were used for embryoid bodies, CellStart or poly-L-
ornithine and laminin coated plates were used for attached cells. Orange (1) or pink (2) bars indicate
the medium in which differentiating cells were maintained: neuronal induction medium (NIM),
neuronal proliferation medium (NPM) neuronal differentiation medium (NDM), mouse embryonic
fibroblast-conditioned KSR medium (MEF-KSR), or N2B27 medium. Green (1) or blue (2) bars
show factors added to the differentiation media. Protocol 1 has a step before the induction of Smad
inhibition: on day -2, iPSCs were dissociated to a single-cell suspension with Accutase and plated as
a monolayer. iPSCs were maintained with MEF-conditioned KSR-medium and 20ng/ml FGF until
they reached confluency on day 0, when SMAD inhibition began. No factors to block proliferation
were added to neuronal cultures. Abbreviations: BDNF: brain-derived neurotrophic factor; BMP:
bone morphogenic protein; DAPT: N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl
ester; db-cAMP: dibutyl-cyclic adenosine monophosphate; GDNF: glial-derived neurotrophic factor;
NPCs: neural precursor cells; RI: ROCK (rho-associated protein kinase) inhibitor.
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Table 3.1 Comparison of the protocols developed by Shi et al. (2012a) and Kirkeby et al.
(2012)/Santiváñez Pérez (2017) for iPSC differentiation to neurons
Differences between the two methods
Differentiation step Shi et al. (2012a) Kirkeby et al. (2012)/Santiváñez Pérez (2017)
Initial iPSC plating Single-cell monolayer Embryoid bodies
Smad inhibitor exposure 12 days 9 days
Smad inhibitors SB, Noggin (protein) SB, Dorsomorphin (small molecule)
NPC expansion Up to 4 passages None
DAPT exposure 4 days 10 days
Factors in neural media N2, B27 N27, B27, AA, BDNF, GDNF, db-cAMP
Comparison of the protocols developed by Shi et al. (2012a) and Kirkeby et al. (2012)/San-
tiváñez Pérez (2017) for iPSC differentiation to neurons. Abbreviations: AA: ascorbic acid;
BDNF: brain-derived neurotrophic factor; DAPT: N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester; db-cAMP: dibutyl-cyclic adenosine monophosphate; GDNF: glial-derived
neurotrophic factor; iPSC: induced pluripotent stem cell; NPC: neural precursor cell; SB: small
molecule SB431542.
3.3.1 iPSC culture and differentiation
iPSCs were thawed, cultured, prepared for karyotyping and differentiated to neurons as
described in Chapter 2.
3.3.2 Immunostaining, Western blotting and statistical analysis
Immunostaining was performed as described in Section 2.5.1 and Western blots were per-
formed as described in Section 2.6. Statistical analysis was performed as described in
Section 2.7.
Quantification of immunostaining
Quantification was carried out using ImageJ (image analysis software developed at the
National Institutes of Health). DAPI-positive nuclei were counted, then an appropriate
threshold was applied to the images showing the cells with the marker of interest (Ki67 or
S100β ), to minimise background staining. The cells of interest were counted in the same
way as the DAPI-positive nuclei. Cells were counted in three technical replicates from each
of three independent differentiation rounds.
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3.4.1 Suitability of iPSC lines for differentiation to neurons
To determine that the iPSC lines were pluripotent before differentiation, I immunostained for
the nuclear pluripotency markers Oct4 and Sox2, and the cytoplasmic pluripotency markers
Tra-1-60 and SSEA4 (Figure 3.2). Oct4 and Sox2 are both transcription factors needed for
pluripotency (Niwa et al., 2000; Pierfelice et al., 2011), and Sox2 is a marker for both iPSCs
and NPCs (Ellis et al., 2004). SSEA4 is a glycolipid and Tra-1-60 is a keratan sulfate, both
of which are expressed on the surface of human iPSCs and ESCs, and whose expression
decreases during differentiation (The International Stem Cell Initiative, 2007).
All lines were positive for the pluripotency markers, which were expressed in the appro-
priate cellular compartment: Sox2 and Oct4 staining were co-localised with DAPI staining,
indicating their presence in the nucleus, and both Tra-1-60 and SSEA4 staining were visible
outside the DAPI staining in the merged image, suggesting their presence on the cell surface.
All lines also exhibited iPSC-like morphology: iPSCs formed uniform colonies with clean
edges, which lacked differentiating cells and were not overgrown (Figure 3.2). Based on
immunostaining and morphology, the iPSCs were pluripotent and suitable for differentiation
to neurons.
To ensure that the iPSC lines had a normal karyotype, karyotyping was performed on
fixed cell suspensions by members of the Spillantini lab or Axol Bioscience. A late passage
of the CTRL2 line had a deletion (-15) and a translocation t(15;18)(q21;q21) (Figure 3.2).
This likely occurred because multiple passages over extended time in culture can result in the
accumulation of karyotypic abnormalities (Lund et al., 2012). These iPSCs were discarded.
CTRL2 iPSCs from an earlier passage were thawed and karyotyped, which revealed a normal
karyotype (Figure 3.2).
In addition, the presence of the N279K mutation in the N279K1 and N279K2 iPSC lines
was confirmed by Sanger sequencing (Figure 3.3).
3.4.2 Regional specificity of neural precursors
The iPSC lines CTRL1, CTRL2, N279K1, N279K2 and V337M were differentiated to NPCs
as described in Section 2.3. Pluripotent stem cells (PSCs - either ESCs or iPSCs) differentiate
towards a forebrain fate in minimal media (Tropepe et al., 2001; Watanabe et al., 2005).
Since neither caudalising factors nor ventralising factors were used, iPSC-derived NPCs
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Fig. 3.2 Pluripotent iPSCs with a normal karyotype. Normal morphology in A) V337M iPSCs
on MEFs and B) IsoCon iPSCs in feeder-free culture. C) Representative immunostaining of N279K2
iPSCs (on MEFs) for Oct4 and Tra-1-60. MEF nuclei are visible alongside iPSC nuclei in the DAPI
image. D) Representative immunostaining of IsoCon iPSCs (feeder-free) for Sox2 and SSEA4. Scale
bar = 10µm. E) Representative normal karyotype from CTRL2 iPSCs. F) The abnormal karyotype in
CTRL2 iPSCs found at high passage number. Red boxes indicate the deleted chromosome 15 and
the translocation on chromosome 18. These CTRL2 iPSCs were discarded, and an earlier passage of
CTRL2 iPSCs with a normal karyotype was used instead.
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N279K1
N279K2
CTRL2
Heterozygous T to G
iPSC line Mutation detected
Heterozygous T to G
No mutation
Sanger sequencing trace
Fig. 3.3 Sanger sequencing to show the N279K mutation in the N279K1 and N279K2 iPSC
lines. Sanger sequencing traces showing the 5’ end of tau exon 10. The heterozygous N279K
mutation (a base change from T to G) is visible as a double peak, outlined in red, in the N279K1 and
N279K2 lines, but not in the control CTRL2 line.
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Fig. 3.4 Neural precursors express forebrain markers Pax6, Nestin and Otx2 at day 16. Im-
munostaining for the forebrain markers Pax6, Nestin and Otx2 and at day 16 in NPCs derived from
CTRL1, CTRL2, N279K1, N279K2 and V337M iPSCs. The expected staining pattern was observed
with Pax6, Nestin and Otx2 antibodies, indicating that the NPCs had a telencephalic or diencephalic
fate. Representative images were taken to show that neural rosettes were positive for forebrain
markers, but were not quantified. Scale bar = 10µm.
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Fig. 3.5 Neural precursors express forebrain markers FoxG1 and Nestin at day 16. Immunos-
taining for the forebrain markers FoxG1 and Nestin at day 16 in NPCs derived from CTRL1, CTRL2,
N279K1, N279K2 and V337M iPSCs. The expected staining pattern was observed with the Nestin
antibody. FoxG1 staining was expected to be nuclear, since FoxG1 is a transcription factor, but
cytoplasmic staining was observed. Cytoplasmic FoxG1 staining may indicate that the NPCs are
already differentiating towards neurons, or it may be caused by non-specific antibody staining. Scale
bar = 10µm.
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generated via the Kirkeby et al./Santiváñez Pérez protocol are expected to have a forebrain
fate.
To determine the fate of the NPCs, I immunostained for the transcription factors Pax6,
Otx2 and FoxG1, and the intermediate filament Nestin at day 16, when neural rosettes were
visible (Figure 3.4 and Figure 2.2). Nestin is expressed in NPCs throughout the developing
human brain (Hockfield and McKay, 1985; Takano et al., 1996). Pax6 is expressed in
NPCs and radial glia in the ventricular zone of the diencephalon (which becomes the
thalamus, hypothalamus, epithalamus and subthalamus) and telencephalon (which becomes
the cerebral cortex, basal ganglia, hippocampus, amygdala, and hypothalamus), as well as
in the developing medulla oblongata, spinal cord and eye of 6-week old human embryos
(Terzic´ and Saraga-Babic´, 1999). Otx2 is expressed in the telencephalon, diencephalon,
mesencephalon (which becomes the midbrain) and choroid plexus in 7-14 week-old human
embryos (Larsen et al., 2010). FoxG1 is expressed in NPCs of the telencephalon, but not the
diencephalon in embryonic day (E) 11.5 rats, as well as in the olfactory placode, auditory
vesicle and pharyngeal pouches (Tao and Lai, 1992). Together, expression of these markers
would indicate NPCs with a forebrain fate.
In all five lines, Pax6 and Otx2 staining overlap with DAPI, indicating their nuclear
expression. Nestin is distributed outside DAPI-positive nuclei, suggesting its presence in the
cytoplasm (Figure 3.4). FoxG1 staining does not overlap with DAPI, even though FoxG1 is
a transcription factor and therefore expected to be expressed in nuclei. This suggests that
FoxG1 expression is mostly cytoplasmic. FoxG1 staining still appeared to be nuclear in
day 14 NPCs, and after antigen retrieval methods recommended for other FoxG1 antibodies
(data not shown). A search of the literature revealed that FoxG1 is able to alternate between
the nucleus and cytoplasm (Pancrazi et al., 2015), and that cytoplasmic FoxG1 has been
observed in NPCs which are starting to differentiate towards neurons (Regad et al., 2007).
Some β III-tubulin positive neurons were visible in cultures by day 16, which may explain
the cytoplasmic localisation of FoxG1 in these cultures.
NPCs from all lines formed neural rosettes, which is a stage of differentiation analogous
to formation of the neural tube (Elkabetz et al., 2008). These are visible in Figure 3.4, but less
clearly visible in Figure 3.5, since images in the latter were obtained with an epifluorescent
microscope, whereas images in the former are from a confocal microscope, which can take
a picture of a single slice from the NPC 3D culture, as compared to the epifluorescent
microscope, which does not. The rosettes in Figure 3.4 are similar to those visible with live
microscopy in Figure 2.2.
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The expression of Pax6, Otx2, FoxG1 and Nestin, and the formation of neural rosettes,
suggests that the iPSC-derived neurons have a forebrain fate. Since FTDP-17T is charac-
terised by neuronal loss in the frontal and temporal lobes of the cortex (Foster et al., 1997),
the neurons produced from these NPCs should provide a relevant model for observing MAPT
mutation related changes.
3.4.3 Proliferative capacity of neural precursors
To investigate whether the MAPT mutations N279K and V337M influenced NPC proliferation
or differentiation to neurons, I immunostained for the proliferation marker Ki67 (Figure 3.6),
which is detectable during cell division but not in non-dividing cells (Gerdes et al., 1984).
As can be seen in Figure 3.6, Ki67 staining overlaps with DAPI, indicating the presence
of Ki67 in the nucleus. Individual cells are differently labelled with the Ki67 antibody: some
nuclei are completely labelled, whereas others contain puncta. This is because Ki67 can be
detected at all stages of cell division and is localised to the surface of chromosomes (Cuylen
et al., 2016), whose arrangement in the nucleus changes during the cell cycle. The various
chromosomal arrangements are detected by Ki67 staining, which appears as different staining
patterns. For example: during interphase Ki67 positive puncta are visible in the nucleus;
during metaphase the chromosomes are visible as one Ki67 positive central mass; and during
anaphase the Ki67 positive chromosomes are form two distinct masses (Gerdes et al., 1984;
Scholzen and Gerdes, 2000).
DAPI stained nuclei and Ki67-positive nuclei were counted using Fiji, and the proportion
of proliferating cells was calculated and compared between lines using a one-way ANOVA.
There was no significant difference in the mean proportion of proliferative NPCs between
iPSC lines (F(4, 8)=2.049, p=0.1800). This suggests that the NPCs derived from control
or MAPT-mutant iPSC have a similar proliferative capacity, and are not spontaneously
differentiating to neurons at different rates at day 16.
3.4.4 β III-tubulin in iPSC-derived neuronal cultures over time
β III-tubulin positive neurons were first visible at day 16, although these cultures contained
mostly proliferative NPCs (Figure 3.6). β III-tubulin positive neurons were also visible at
day 50 and day 80-100, as can be seen in Figure 3.10. I assessed the proportion of neurons in
day 50 and day 80-100 cultures by Western blotting, using an antibody against β III-tubulin
(Figure 3.8).
76 Characterisation of iPSC-derived neurons with MAPT mutations
CTRL1 CTRL2 N279K1 N279K2 V337M
0.0
0.2
0.4
0.6
0.8
1.0
iPSC line
P
ro
p
o
rt
io
n
 o
f 
K
i6
7
p
o
s
it
iv
e
 c
e
ll
s
A
B
V337M
Ki67
DAPI
Merge
Ki67
DAPI
Merge
Ki67
DAPI
Merge
Ki67
DAPI
Merge
Ki67
DAPI
Merge
N279K2N279K1CTRL2CTRL1
C DAPI Ki67 βIIItub
n/s
Fig. 3.6 There is no significant difference in the proportion of proliferating neural precursor
cells made from CTRL1, CTRL2, N279K1, N279K2 and V337M iPSC lines at day 16. A) Day
16 CTRL1, CTRL2, N279K1, N279K2 and V337M NPCs immunostained for Ki67. Neural rosettes
are highlighted by white dotted lines in the DAPI images. Scale bar = 10µm. B) The proportion of
Ki67-positive NPCs was not significantly different between NPCs from the CTRL1, CTRL2, N279K1,
N279K2 or V337M iPSC lines, which was an expected result. The proportion of Ki67 positive cells
was determined by quantification of immunofluorescence images. For every iPSC line, each point
represents the mean of one of three independent differentiations. Values represent mean±SD. C)
Rosette-like formations of Ki67 positive NPCs and β III-tubulin positive young neurons.
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Fig. 3.7 The amount of β III-tubulin in iPSC-derived neuronal cultures decreased from day 50
to day 80-100, as measured by Western blot. A) The fold change in the amount of β III-tubulin
between day 50 and day 80-100 in CTRL1, CTRL2, N279K1, N279K2 and V337M cultures. A
decrease in the amount of β III-tubulin over time was not the expected result, and may be due to
neuronal loss or an increase in the proportion of non-neuronal cells. The amount of β III-tubulin at
day 80-100 has been normalised to the amount of β III-tubulin at day 50 in the same cell line, which is
set to 1. Data is from the quantification of three Western blots, using protein from cultures generated
in three independent differentiations. Error bars show the SD and mean; significance bars show the
results of a two-way ANOVA: there was a significant main effect of time, *** = p≤0.001 . B) The
data shown in A) is presented as the amount of β III-tubulin normalised to the amount of β -actin at day
50 and day 80-100 in CTRL1, CTRL2, N279K1, N279K2 and V337M cultures. Again, a decrease in
the amount of β III-tubulin over time can be seen. All results are relative to the amount of β III-tubulin
in CTRL1 cultures at day 50, which was set to 1. Each point shows β III-tubulin normalised to β -actin
from one of three independent differentiations; error bars show the SD and mean.
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Fig. 3.8 Representative Western blots of synaptophysin, β III-tubulin, and βactin in iPSC-
derived neuronal cultures at day 50 and day 80-100. Representative blots showing cultures from
one differentiation of CTRL1, CTRL2, N279K1, N279K2 and V337M cultures, at day 50 and day
80-100. Protein weight in kDa is indicated. The amount of protein run in each lane was determined
by measuring protein extract concentration using a BCA assay, then calculating the volume needed
for 10µg of protein. Volumes were equalised using ice cold RIPA buffer containing protease and
phosphatase inhibitors. Despite this, differing amounts of protein were detected in each lane
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To visualise the change in the amount of β III-tubulin in each iPSC line over time, I
normalised the day 80-100 levels to those at day 50 (Figure 3.7A). Figure 3.7A shows a
decrease in β III-tubulin levels between day 50 and day 80-100 in all but two cases. The same
decrease in β III-tubulin levels between day 50 and day 80-100 can be seen when the data
is shown relative to the amount of in β -actin, in Figure 3.7B. The data in Figure 3.7A was
analysed by a two-way ANOVA. This found a significant main effect of time, meaning that
the amount of β III-tubulin was significantly different between all cultures at day 50 and all
cultures at day 80-100 (F(1,10)=22.45, p=0.0008, Figure 3.7). There was no significant main
effect of iPSC line (the amount of β III-tubulin did not vary significantly between the cultures
derived from the five iPSC lines: F(4,10)=2.069, p=0.1601), and there was no significant
interaction effect (time has the same effect on the amount of β III-tubulin in cultures derived
from all five iPSC lines: F(4,10)=2.069, p=0.1601). I analysed the decrease in the amount of
β III-tubulin in cultures from each iPSC line (for example: CTRL1 at day 50 versus CTRL1
at day 80-100; CTRL2 at day 50 versus CTRL2 at day 80-100, and so on) using two-tailed
t-tests. These found no significant difference in the amount of β III-tubulin between day 50
and day 80-100 in CTRL2, N279K1, N279K2 or V337M cultures, but there was a significant
decrease in CTRL1 cultures (p=0.0264).
These results suggest that the number of β III-tubulin positive neurons decreased over
time, although the effect was not big enough to be statistically significant in all cultures when
comparing day 50 and day 80-100 cultures from the same iPSC line. β III-tubulin staining
in some day 80-100 cultures derived from each of the five iPSC lines appeared broken and
blobby rather than smooth and continuous, which can be seen to a small extent in Figure
3.10. This may have contributed to the decrease in the relative amount of β III-tubulin at day
80-100 relative to day 50.
However, a decrease in the amount of β III-tubulin protein does not necessarily reflect
a decrease in the absolute number of neurons over time. An alternative or concurrent
factor could be the proliferation of non-neuronal cells in culture, which would decrease the
proportion of cells which were neurons and thereby decrease the contribution of β III-tubulin
protein to total protein in older cultures. The proliferation of one non-neuronal cell type
(astrocytes) is further explored in Section 3.4.7.
In summary, these results suggest that the amount of β III-tubulin positive neurons in
each culture was variable, and that there was an overall decrease in the amount or proportion
of β III-tubulin positive neurons over time.
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Fig. 3.9 The amount of synaptophysin in iPSC-derived neuronal cultures increased relative to
the amount of β III-tubulin from day 50 to day 80-100, as measured by Western blot. A) The
amounts of synaptophysin in CTRL1, CTRL2, N279K1, N279K2 and V337M cultures at day 50 and
day 80-100, normalised to the amount of β III-tubulin in the cultures. The amount of synaptophysin
increased over time, which was an expected result, and may reflect synapse formation in the cultures.
All results are relative to the amount of synaptophysin (normalised to β III-tubulin) in an external
control (mouse brain, not shown) which was set to 1 for normalisation between blots. Each point
shows synaptophysin normalised to β III-tubulin from one of three independent differentiations;
protein from each differentiation was run on a separate Western blot. Bars mean±SD. Significance
bars show the results of a two-way ANOVA: there was a significant main effect of time, * = p<0.05 .
B) The fold change in synaptophysin between day 50 and day 80-100. The amount of synaptophysin
at day 80-100 has been normalised to the amount of synaptophysin at day 50 in the same cell line,
which is set to 1. No synaptophysin was detected in one differentiation round in cultures from CTRL1,
N279K1 and V337M at day 50, and N279K2 at day 100. Since no ratio can be taken for these cultures,
the graph has two, instead of three, points.
3.4.5 Synaptophysin in iPSC-derived neuronal cultures over time
To establish if MAPT mutations influenced synapse number, I used the amount of the pre-
synaptic vesicle protein synaptophysin as a proxy measure for the number of synapses. I
chose synaptophysin because it is the most abundant synaptic protein (Takamori et al., 2006),
has been used to estimate synapse number in both mouse and human brain, and is reported to
be an accurate marker for synapse number (Bigio et al., 2001).
I assessed the amount of synaptophysin in day 50 and day 80-100 cultures by Western
blotting, using antibodies against synaptophysin and β III-tubulin (Figure 3.8). To quantify
the Western blots, the synaptophysin band in each lane was normalised to the β III-tubulin
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Fig. 3.10 Representative images of synaptophysin positive puncta associated with β III-tubulin
positive neurons in iPSC-derived neuronal cultures at day 50 and day 80-100. CTRL1, CTRL2,
N279K1, N279K2 and V337M iPSC-derived neural cultures at day 50 and day 80-100 stained for the
pre-synaptic marker synaptophysin and the neuronal marker β III-tubulin. Synaptophysin positive
puncta (in white) overlap with β III-tubulin positive neurons (in red) in the merged images, suggesting
that the puncta are synapses. Representative images were taken, but the amount of synaptophysin
present was quantified by Western blot, since definitively assigning synaptophysin puncta to a neuronal
process and counting individual puncta was difficult. Although the amount of synaptophysin relative
to β III-tubulin increased over time when measured by Western blot, this increase is not clear by eye.
Scale bar = 10µm.
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band in the same lane. In Figure 3.9A, the amount of synaptophysin is shown relative
to the amount in an external control (mouse brain, not shown), which was set to one for
normalisation between the blots. Figure 3.9A shows that the amount of synaptophysin is
highly variable between differentiation rounds at day 80-100, but less variable at day 50.
To visualise the change in the amount of synaptophysin in each iPSC line over time, I
normalised the day 80-100 levels to those at day 50 for each differentiation round (Figure
3.9B). However, synaptophysin was not detected in protein extracts from some cultures in
one differentiation round (day 50 CTRL1, N279K1, V337M; day 100 N279K2), so ratios
could not be calculated between the day 50 and day 80-100 values for cultures. Therefore,
two (instead of three) points are displayed for cultures derived from these iPSC lines in
Figure 3.9B.
I analysed the data in Figure 3.9A with a two-way ANOVA, which found a significant
main effect of time, meaning that the amount of synaptophysin increased significantly
between day 50 and day 80-100 (F(1,10)=6.447, p=0.0294). There was no significant main
effect of iPSC line (the amount of synaptophysin did not vary significantly between the
cultures derived from the five iPSC lines: F(4,10)=0.2538, p=0.9008), and there was no
significant interaction effect (time has the same effect on the amount of synaptophysin in
cultures derived from all five iPSC lines: F(4,10)=0.09714, p=0.9810).
I stained day 50 and day 80-100 neural cultures for synaptophysin and β III-tubulin to
see the distribution of synaptophysin staining in these cultures. Representative images are
shown in Figure 3.10, in which cultures derived from all five iPSC lines at both day 50 and
day 80-100 have synaptophysin positive puncta, overlapping with β III-tubulin positive cell
bodies and processes.
In summary, these results suggest that synapse number increases over time in cultures
from all five iPSC lines. Since neuronal maturation should lead to an increase in synapse
formation, the synapse number increase shown here is as expected.
3.4.6 Expression of tau isoforms
To assess the maturity of my cultures in terms of tau isoform expression, and to confirm the
action of the N279K mutation on exon 10 splicing in my cultures, I detected tau isoforms by
Western blotting. To do this, I dephosphorylated protein extracts with alkaline phosphatase
from E.coli, since tau is phosphorylated in cells and runs as a smear on Western blots, whereas
dephosphorylated tau isoforms can be seen as distinct bands. I used recombinant human
tau isoforms to determine the identity of the various isoforms, and human brain extract as a
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Fig. 3.11 Western blots for tau show expression of 0N3R tau and some 0N4R tau at day 50.
A representative blot performed with protein extract from 50 day-old CTRL1, CTRL2, N279K1,
N279K2 and V337M neural cultures. Lanes in which alkaline phosphatase (AP) has been used to
dephosphorylate tau and produce distinct isoform bands are marked "+" and highlighted in yellow.
Lanes in which the protein extract was not treated with alkaline phosphatase, in which phosphorylated
tau runs as a smear, are marked "-". The identity of recombinant tau isoforms and tau isoforms from
dephosphorylated human brain are indicated, as is the size and position of molecular weight markers.
A) is a low exposure image of the membrane probed with an antibody against all tau isoforms (tau
DAKO). Arrows indicate the position of tau isoform bands, visible after dephosphorylation in the
lanes marked with a "+" on a yellow background. 0N3R tau bands (blue arrows) of varying intensity
are visible in each of the dephosphorylated lanes ("+"). In addition, a 0N4R band (red arrow) is visible
in the N279K1 dephosphorylated lane ("+"). B) is a high exposure image of the membrane shown
in A). Arrows mark the position of tau isoform bands. 0N3R tau bands (blue arrows) are visible
at higher intensities in each of the dephosphorylated lanes ("+"). 0N4R tau bands (red arrows) are
visible at low intensity in the CTRL1 and V337M dephosphorylated lanes ("+"), and at high intensity
in the N279K1 dephosphorylated lane ("+"). A shadow which may be a low intensity 0N4R tau band
(orange arrow) is visible in the N279K2 dephosphorylated lane ("+"). C) shows the same blot stripped
and re-probed for β III-tubulin and β -actin as loading controls. Although equal amounts of protein
were loaded (according to a BCA assay), unequal amounts of β III-tubulin and β -actin were detected.
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Fig. 3.12 Western blots for tau show expression of 0N3R tau, some 0N4R tau, and occasional
1N3R tau at day 80-100. A representative blot performed with protein extract from 80-100 day-old
CTRL1, CTRL2, N279K1, N279K2 and V337M neural cultures. Lanes in which alkaline phosphatase
(AP) has been used to dephosphorylate tau and produce distinct isoform bands are marked "+" and
highlighted in yellow. Lanes in which the protein extract was not treated with alkaline phosphatase,
in which phosphorylated tau runs as a smear, are marked "-". The identity of recombinant tau
isoforms and tau isoforms from dephosphorylated human brain are indicated, as is the size and
position of molecular weight markers. A) is a low exposure image of the membrane probed with
an antibody against all tau isoforms (tau DAKO). Arrows indicate tau isoform bands, visible after
dephosphorylation in the lanes marked with a "+" on a yellow background. 0N3R tau bands (blue
arrows) of varying intensity are visible in the dephosphorylated lanes ("+") for CTRL2, N279K1,
N279K2 and V337M. B) is a high exposure image of the membrane shown in A). Arrows mark tau
isoform bands. The box around the two CTRL1 lanes shows an even higher exposure of the same
membrane, in which the 0N3R tau isoform is visible (blue arrow). 0N3R tau bands (blue arrows) are
visible at higher intensities in the CTRL2, N279K1, N279K2 and V337M dephosphorylated lanes
("+"). 0N4R tau bands (red arrows) are visible at low intensity in the CTRL1, N279K1, N279K2
and V337M dephosphorylated lanes ("+"). There is an additional 1N3R band visible at low intensity
(green arrow) in the V337M dephosphorylated lane ("+"). C) shows the same blot stripped and
re-probed for β III-tubulin and βactin as loading controls. Although equal amounts of protein were
loaded (according to a BCA assay), unequal amounts of β III-tubulin and β -actin were detected.
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Table 3.2 Tau isoforms in day 50 and day 80-100 iPSC-derived neurons detected by
Western blotting
CTRL1 CTRL2 N279K1 N279K2 V337M
50 100 50 100 50 100 50 100 50 100
0N3R 2 3 3 3 3 3 3 3 3 3
0N4R 1 1 - 1 2 2 1 2 2 1
1N3R - - - - - - - - - 1
The summarised results of Western blotting experiments to detect the tau isoforms present in day
50 and day 80-100 cultures. Blots were performed individually for day 50 and day 80-100 cultures,
and either once or twice for each of the three independent differentiation rounds. The table indicates
which tau isoforms were observed in each iPSC line and each time point over the three differentiations,
although the isoform bands in the blots were not always clear. For example, 2 means the isoform was
seen in two differentiations, 3 means the isoform was seen in all three differentiations, - means the
isoform was not seen in any differentiations.
positive control. Tau isoforms were detected with a total tau antibody, then the membrane
was stripped and probed for β III-tubulin and βactin as loading controls (Figures 3.11 and
3.12). Western blots were run for day 50 and day 80-100 of each differentiation round, and
the results of these blots are summarised in Table 3.2. Western blots were performed for each
of three differentiation rounds at day 50, and at day 80-100. Each blot was performed once
or twice.
Tau isoform expression at day 50
A representative blot using day 50 cultures is shown in Figure 3.11. At low exposure (3.11A),
0N3R tau bands are visible, although the relative intensity of the bands is highly variable.
At high exposure (3.11B) some of the 0N3R tau bands are saturated, but higher molecular
weight bands (corresponding to 0N4R tau) are visible, indicating that 0N4R tau is present
in lower amounts than 0N3R tau in these cultures. Further over-exposure of the membrane
caused more areas to be saturated and did not clearly reveal more tau isoform bands.
The tau isoforms detected at day 50 in cultures from all three differentiation rounds are
summarised in Table 3.2. Although I attempted to identify the tau bands, their identity was
not always clear due to high background after long exposure.
The 0N3R tau isoform was detected in cultures from all five lines in the three differentia-
tion rounds, with one exception: in the day 50 CTRL1 culture from the third differentiation
round, no tau bands were visible and the amount of β III-tubulin detected was low, although
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the amount of β -actin was comparable to that in other lanes (not shown). This suggests that
the culture contained mostly non-neuronal cells, or that the proteins did not transfer from
the gel to the membrane correctly. Unfortunately, this blot could not be repeated because
there was not enough protein extract remaining. The 0N4R tau isoform was detected in one
of the control cultures in one differentiation round, as well as in N279K cultures in two
differentiation rounds, and in V337M cultures in two differentiation rounds.
Tau isoform expression at day 80-100
A representative blot using day 80-100 cultures is shown in Figure 3.12. At low exposure
(3.12A), 0N3R tau bands are visible, and the relative intensity of the bands is variable. At
high exposure (3.12B) some of the 0N3R tau bands are saturated, but higher molecular
weight bands (corresponding to 0N4R and 1N3R tau) are visible. The box around the CTRL1
lanes indicates an even higher exposure, to visualise the low amount of 0N3R tau in this lane.
The tau isoforms detected at day 80-100 in cultures from all three differentiation rounds
are summarised in Table 3.2. The 0N3R tau isoform was detected in cultures from all
five lines in the three differentiation rounds, and predominated, even when other isoforms
were also expressed. The 0N4R tau isoform was detected in the control cultures in one
differentiation, and 0N4R tau, with occassional 1N3R tau, was detected in cultures with the
N279K or V337M MAPT mutations.
As can be seen in Table 3.2, the proportion of cultures in which 0N4R or 1N3R tau
isoforms were detected increases between day 50 and day 80-100 overall, suggesting that the
cultures were maturing over time. In the N279K1 cultures, the 0N4R isoform was detected
in two of the three differentiation rounds at day 50 and day 80-100, which is in agreement
with the effects of the N279K mutation - an increase in exon 10 splicing and therefore an
increase in 4R relative to 3R tau (Hong, 1998; Iovino et al., 2015). In the N279K2 cultures,
0N4R tau was detected at day 50 in one differentiation, and 0N4R tau was detected in two
differentiation rounds at day 80-100. In V337M cultures, 0N4R bands were detected in two
of the three differentiation rounds at day 50, and 0N4R and 1N3R tau were detected in one
of the three differentiation rounds at day 80-100.
However, the results in Table 3.2 must be interpreted with caution, since it is difficult
to establish the identity of tau isoforms visible in the Western blots due to over-exposure
increasing the background. To help corroborate the findings from Western blots, I stained my
iPSC-derived neural cultures for 3R and 4R tau using the exon-junction specific antibodies
RD3 and RD4. RD4 signal was amplified with fluorescent streptavidin, as done by Iovino
et al. (2015).
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Fig. 3.13 3R tau is expressed in iPSC-derived neurons at day 50 and 80-100. Representative
immunofluorescence images showing CTRL1, CTRL2, N279K1, N279K2 and V337M neural cultures
stained for the RD3 antibody, which detects 3R tau. 3R tau is visible in the cell bodies and processes
of neurons in all five cultures at day 50 and day 80-100. This is an expected result and staining pattern.
Most of the 3R tau protein detected is likely to be 0N3R tau (which is expressed in fetal human
neurons, as well as in the post-natal human neurons alongside the other five isoforms), since 0N3R
tau was the main isoform detected by Western blot. Scale bar = 10µm.
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Fig. 3.14 4R tau is expressed in iPSC-derived neurons at day 50 and 80-100. Representative
immunofluorescence images showing CTRL1, CTRL2, N279K1, N279K2 and V337M neural cultures
stained for the RD4 antibody, which detects 4R tau. Faint 4R tau staining is visible in the cell bodies
and in some processes in all five cultures at day 50 and day 80-100. Faint 4R tau staining is expected,
since 0N4R tau is not expressed until later in development (post-natally in human neurons). The
4R tau protein detected is likely to be mostly 0N4R, since low amounts of 0N4R tau were detected
by Western blotting. 4R tau staining was brighter in some cultures, particularly in N279K1 cultures
at day 80-100. This may reflect a larger amount of 4R tau protein, or it may reflect variability
in immunostaining. Two images at the bottom of the figure show the background introduced by
streptavidin 586, in a staining performed without biotin. The lack of green fluorescence indicates that
streptavidin 586 contributes little non-specific staining. Scale bar = 10µm.
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Figure 3.13 shows that 3R tau was detected in neuronal processes and cell bodies in
cultures from all five iPSC lines at day 50 and 80-100, with no noticeable differences in
staining intensity. This supports the prominent 0N3R tau detected by Western blotting in all
of the cultures at both day 50 and day 80-100. Four repeat tau was detected at a much lower
level than 3R tau in day 50 and 80-100 cultures (Figure 3.14). At day 50, some staining is
visible in cell bodies and to a lesser extent in processes in cultures from all five lines. At
day 80-100 4R tau staining is visible in cell bodies and some processes in all cultures, but
more brightly stained individual neurons are visible in the N279K1 and N279K2 cultures,
suggesting a higher level of 4R tau expression.
Overall, my results indicate that 3R tau is strongly expressed in neurons from all iPSC
lines at day 50 and day 80-100, whilst 4R tau expression is lower than 3R tau expression, and
increases over time. In the N279K cultures, particularly N279K1, 0N4R tau is more abundant
than in control cultures, possibly due to the action of the N279K mutation. Unexpectedly,
tau isoforms expression in V337M cultures is more similar to that in N279K1 cultures than
to that in control cultures. Since the V337M mutation does not affect tau splicing, this result
may be due to variability in Western blots, or the different genetic background of the control
and V337M iPSC lines.
3.4.7 Appearance of astrocytes in aged cultures
To assess the maturity of my iPSC-derived cultures in another way, and to investigate possible
astrocyte overgrowth in MAPT-mutant cultures, I stained for the astrocyte marker S100β .
S100β is a calcium binding protein expressed by a subset of mature astrocytes. I chose
S100β rather than GFAP as an astrocyte marker because S100β is expressed only in mature
astrocytes, whereas GFAP is expressed in both mature astrocytes and radial glia cells: the
precursors in the developing brain which divide to produce neurons and glia (Raponi et al.,
2007). In COs, radial glia are identifiable from their arrangement in culture (Chapter 6), but
the monolayer iPSC-derived neural cultures used in this Chapter contained a disorganised
arrangement of cells, making it impossible to exclude radial glia by eye.
At day 50, a small number of S100β positive cells are visible in each of the lines (Figure
3.15A). By day 100, more S100β positive cells are visible, and the cells are larger, with
longer processes. To quantify this, I counted the number of S100β positive astrocytes and
the number of DAPI positive nuclei, then compared the proportion of S100β positive cells
between iPSC lines using a two-way ANOVA (Figure 3.15B). There was a significant main
effect of time: the proportion of S100β positive astrocytes in all cultures at day 80-100 was
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Fig. 3.15 The proportion of S100β positive astrocytes in neuronal cultures increases from day
50 to day 80-100. A) CTRL1, CTRL2, N279K1, N279K2 and V337M neural cultures stained
for S100β . The proportion of astrocytes increased over time, indicating maturation of the culture.
This was an expected result, since astrocytes are produced by the last division of neural precursors.
Scale bar = 10µm. B) The proportion of S100β positive astrocytes in the cultures, counted in
immunofluorescence images. For every iPSC line, each point represents the mean of one of three
independent differentiations. Each mean was calculated from at least six fields of view (three from
each of two or three coverslips). Bars show mean±SD; ** is p≤0.01 . C) The percentage area covered
by S100β positive astrocytes. For every iPSC line, each point represents the mean of one of three
independent differentiations. Each mean was calculated from at least eight fields of view. Bars show
mean±SD; ** is p≤0.01 .
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significantly higher than the proportion of S100β positive astrocytes in all cultures at day 50
(F(1,10)=17.9, p=0.0017, Figure 3.15A and B). There was no significant main effect of iPSC
line (the proportion of S100β positive cells did not vary significantly between the cultures
derived from the five iPSC lines: F(4,10)=1.712, p=0.2234), and there was no significant
interaction effect (time has the same effect on the proportion of S100β positive cells in
cultures derived from all five iPSC lines: F(4,10)=1.939, p=0.1804). After a visual inspection
of the difference in the proportion of S100β positive cells between day 50 and day 80-100 in
each of the iPSC lines, I performed further statistical analysis using t-tests to compare the
proportion of astrocytes in day 50 and day 80-100 cultures from the same iPSC line. No
statistically significant differences were observed when comparing day 50 and day 80-100
cultures from each of the iPSC lines.
In addition, I measured the area of each field of view covered by S100β positive cells,
and compared between iPSC lines using a two-way ANOVA (Figure 3.15C). This too showed
a significant main effect of time: the area covered by S100β positive astrocytes in all cultures
at day 80-100 was significantly higher than the area covered by S100β positive astrocytes
in all cultures at day 50 (F(1,10)=10.08, p=0.0099, 3.15A and C). There was no significant
main effect of iPSC line (the area covered by S100β positive cells did not vary significantly
between the cultures derived from the five iPSC lines: F(4,10)=1.11, p=0.4042), and there
was no significant interaction effect (time has the same effect on the area covered by S100β
positive cells in cultures derived from all five iPSC lines: F(4,10)=1.314, p=0.3293). In
addition, I used t-tests to compare the area covered by astrocytes at day 50 and day 80-100 in
cultures from each iPSC line. No statistically significant differences were observed when
comparing day 50 and day 80-100 cultures from each of the iPSC lines.
These results show that the proportion of S100β positive astrocytes increases over time
in iPSC-derived neural cultures, with no detectable effect of the MAPT mutations N279K
and V337M. This suggests that the astrocytes are appearing in culture due to the division of
late precursors.
3.5 Discussion
The results described in this Chapter indicate that my iPSC-derived neural cultures have
a forebrain fate, and are maturing over time. The cultures express the neuronal marker
β III-tubulin and the pre-synaptic marker synaptophysin with no significant differences in
expression level between the control and MAPT-mutant iPSC lines. The neural cultures also
contain an increasing number of astrocytes over time, with no difference in astrocyte prolifer-
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ation between cultures derived from the control and MAPT-mutant iPSC lines. Examination
of tau isoforms present in these cultures suggests maturation of the cultures over time, with
the action of the N279K mutation inducing an increase of 4R tau, as previously described
using a different differentiation method (Iovino et al., 2015).
The results also show variability between the three differentiation rounds, which is
particularly clear in the quantification of Western blots for synaptophysin at day 80-100, and
in Western blots for tau isoforms at day 50 and day 80-100. A contributor to this variability
could be that I derived NPCs from iPSCs three times, and differentiated the NPCs to neurons.
This means that small stochastic differences arising during NPC differentiation, or differences
in my tissue culture skills over time, for example, could cause variability between cultures
obtained from the three differentiation rounds. One way to decrease variability would be to
produce a large number of NPCs, freeze some, and differentiate them to neurons in three
independent differentiations. However, this method would not control for the process of
neuralising the iPSCs.
3.5.1 Differentiation of iPSCs to NPCs
In day 16 NPCs, I observed clear staining with the Otx2, Pax6 and Nestin antibodies.
However, FoxG1 expression was mostly cytoplasmic, despite FoxG1 being a transcription
factor expected to be present in the nucleus. This may be because FoxG1 can be present in the
cytoplasm of differentiating NPCs (Regad et al., 2007), indicating that I should have stained
for FoxG1 at an earlier timepoint. Indeed, (Watanabe et al., 2005) observed nuclear FoxG1
staining on day 10 when differentiating ESCs to NPCs using a similar method. However, the
cytoplasmic FoxG1 staining could observed could have been due to non-specific antibody
staining. Whether or not the FoxG1 staining was specific could have been confirmed using a
positive control, such as embryonic mouse brain (provided that the antibody detected both
mouse and human FoxG1).
Alternatively, I could have stained for cortical layer markers, which would confirm the
cerebral cortex specificity of the neurons produced. Since the differentiation method I used
did not employ caudalising or ventralising factors, the default model (in which PSCs cultured
in minimal media differentiate towards a rostral forebrain fate) predicts predominantly
glutamatergic neurons (Chambers et al., 2009; Elkabetz et al., 2008). No papers have been
published on the identity and proportion of cell types produced using the Kirkeby et al.
(2012)/Santiváñez Pérez (2017), but Jessica Santiváñez Pérez, who adapted the method for
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iPSCs, found that the resulting iPSC-derived neurons were predominantly glutamatergic,
with a small numbers of tyrosine hydroxylase positive and GAD65/67 positive cells.
Not all cells in the day 16 NPC cultures were Otx2, Pax6 and Nestin positive, indicating
that not all of them were neuronal precursors. By day 16, a small number of NPCs had
spontaneously differentiated to neurons, as can be seen in Figure 3.6. Therefore, other cell
types intermediate between NPCs and neurons may have contributed to the number of Otx2,
Pax6 and Nestin negative cells in NPC cultures. For example, intermediate progenitor cells
(Tbr2 positive, Pax6 negative) are produced from the asymmetric division of (Pax6 positive)
radial glial cells (Englund, 2005; Hansen et al., 2010; Kriegstein and Alvarez-Buylla, 2009).
It is also possible that cells from other germ layers may have been present in the cultures.
These could have been detected by immunostaining for ectoderm, mesoderm and endoderm
markers, to determine the proportion of the cells not differentiating towards the ectoderm
lineage, which could not contribute to the neuroectoderm.
Proliferation of NPCs
I observed no significant difference in the proliferative capacity of my control and MAPT-
mutant NPC cultures at day 16, indicating that there was not a significant difference in
spontaneous differentiation at this stage. To confirm this, I could have performed the
same staining and quantification during a time course, allowing the NPCs to spontaneously
differentiate over an extended time in culture, as opposed to re-plating the NPCs on day 21
and adding DAPT to induce neuronal differentiation. Since I added DAPT to my cultures at
day 21, NPCs were forced out of the cell cycle at this time point, preventing the detection of
differences in spontaneous NPC differentiation to neurons between the control and MAPT-
mutant cultures, if they were present.
Future work could include further examination of spontaneous differentiation in control
and MAPT-mutant NPCs, since there is some evidence that MAPT-mutant iPSC-derived
NPCs do not behave in the same way as controls.
For example, Wren et al. (2015) reported that N279K iPSCs were less able to differentiate
into ectoderm, and produced fewer Nestin and β III tubulin positive neurons as compared to
controls. Similar features have not been reported by groups making iPSC-derived neurons
and NPCs from different N279K mutant iPSC lines (Ehrlich et al., 2015; Iovino et al., 2015),
suggesting a problem with the N279K iPSC clone or differentiation methods used by Wren
et al..
In addition, a study of iPSC-derived NPCs with three MAPT mutations (N279K, P301L
and intron 10+16) showed a (non-significant) trend for a lower proportion of proliferative
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NPCs than in controls (García-León et al., 2018). However, it is unclear if this is a cumulative
effect of three MAPT mutations (which may not be detectable in NPCs with only one MAPT
mutation), or the effect is caused by a single one of the three MAPT mutations.
3.5.2 Differentiation of NPCs to neurons
The amount of β III-tubulin in my iPSC-derived neural cultures decreased from day 50 to
day 80-100, as determined by Western blot. This may be due to an increase in the number
of non-neural cells, which would decrease the proportion of total protein which was β III-
tubulin. Since the proportion of astrocytes in the cultures increased over time, this is a
possible explanation. To prevent non-neural cells from proliferating in culture, I could
have used DAPT to force NPCs out of the cell cycle, and then added an anti-mitotic agent
such as mitomycin C to prevent proliferative cells from dividing further, as was done by
Schwartzentruber et al. (2018).
The decrease in the amount of β III-tubulin may also have been caused by cell death,
which is explored further in Chapter 4. I observed more condensed pyknotic nuclei in day
80-100 cultures as compared to day 50 cultures regardless of the parent iPSC line, although
this does not necessarily mean that more cells died at later timepoints.
As mentioned above, some day 80-100 cultures derived from each of the five iPSC
lines had discontinuous, blobby-looking β III-tubulin staining, as compared to the relatively
smooth and continuous staining in day 50 cultures (Figure 3.10). This may be an artefact of
how the cultures changed over time, since processes in some areas of day 80-100 cultures
formed dense mat-like surfaces where it was difficult to see individual processes. In areas of
the same culture, processes formed thick bundles, where it was again difficult to distinguish
individual processes. These areas both had a higher density of blobby-looking β III-tubulin
staining despite repeated washing during staining, suggesting that primary and secondary
antibody might have become trapped in these densely packed areas. A dense neuropil-like
mesh has also been observed in 112 and 300 day-old neuronal cultures by Odawara et al.
(2016), suggesting that the changes described above can commonly occur in iPSC-derived
monolayer cultures over time. This did not occur in 3D culture, and is discussed in Chapter
6.
The amount of β III-tubulin in the cultures was assessed by Western blot. Although
the concentration of protein extracts was measured by BCA, and although protein extract
volumes were calculated such that the same amount of protein was run in each lane, this was
not reflected in the results. This can be seen in Figure 3.8, where the amount of β -actin is
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lower in the control lanes than the MAPT-mutant lanes, bringing into question the reliability
of this result. The results of this blot could have been confirmed using a more quantitative
method, such as qPCR, although this method, like Western blotting, would not distinguish
an absolute change in neuron number from a decrease in the proportion of neurons in the
culture.
Synaptophysin expression
The levels of synaptophysin, detected by Western blotting, increased in my iPSC-derived
neural cultures over time. This may indicate ongoing synaptogenesis, as it has previously
been reported that the number of synapses formed by iPSC-derived neurons increases with
age, even after 100 days in culture (Bergström et al., 2016; Odawara et al., 2016). The amount
of synaptophysin staining was highly variable between cultures at day 80-100. This may
reflect unintended variation between the differentiation rounds, or even between different
individual cultures generated in the same differentiation round.
There was no effect of parent iPSC line on the amount of synaptophysin detected,
suggesting that there was no MAPT mutation dependent synapse loss in the MAPT-mutant
cultures. This is similar to the findings of Silva et al. (2016), who found no difference in
expression of PSD-95, synapsin-I and synaptophysin proteins in 35 day-old iPSC-derived
control and A152T mutant neurons. However, the neurons examined were relatively young at
35 days old, and A152T has not yet been confirmed as an FTDP-17T-linked mutation (Kara
et al., 2012).
In addition, studies of neurons derived from iPSCs from AD patients, with either sporadic
AD or with mutations in amyloid precursor protein, also found no change in synaptic protein
levels relative to control cultures (Birnbaum et al., 2018; Israel et al., 2012; Nieweg et al.,
2015). Together, these data suggest that synapse loss is not observed in iPSC-derived cultures
without the addition of exogenous stressors.
If synapse loss had been detected at such an early timepoint relative to human brain devel-
opment, it may have represented synaptic pruning, or a failure to make synaptic connections
rather than a neurodegenerative phenotype. Studies using iPSC-derived neurons to examine
the effects of diseases with a developmental component suggest that this may be the case,
since synapse formation deficits have been detected in iPSC-derived neuron models of autism
spectrum disorders and schizophrenia (reviewed by Habela et al., 2015).
Synaptophysin levels were measured by Western blot, but the amount of protein detected
in each Western blot lane was not equal (Figure 3.8) despite calculating and loading the same
protein concentration. The variability in the amount of protein detected means that results
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from these Western blots may not be reliable. To confirm the increase in synaptophysin levels
over time, I could have used additional techniques. For example, I could have measured
synaptophysin mRNA levels by qPCR.
Another alternative would be quantification of immunostaining images. To ensure that
synaptophysin puncta were specific to synapses, I could have used an antibody against a
post-synaptic protein such as PSD-95 alongside the synaptophysin antibody. Counting the
number of puncta that were both synaptophysin and PSD-95 positive would confirm that
synapses with both pre- and post-synaptic membranes were identified, and would give an
estimate of synapse number.
Alternatively, I could have confirmed my Western blotting results by measuring synapse
function using electrophysiological techniques. For example whole cell patch-clamping, in
which the voltage or current can be held constant, can be used to classify neuronal maturity
and to identify neuronal subtypes (Belinsky et al., 2014). One drawback of this method is
that it is time consuming, and each measurement is performed on a single cell for period of
seconds to minutes. An alternative to this is multi-electrode arrays, which can be used to
measure the electrophysiological activity of an entire culture over a period of days to weeks
(Odawara et al., 2016).
However, electrophysiological activity has already been measured in neurons derived
from the same control and N279K iPSC lines I used, albeit using a different method for iPSC
differentiation. Iovino et al. (2015) observed faster electrophysiological maturation in iPSC-
derived neurons with the N279K or P301L mutation relative to in the control neurons: neurons
with N279K or P301L mutations fired regenerative, sodium channel blocker-sensitive action
potentials (APs) at day 50-79, whereas control neurons did not fire comparable regenerative,
sodium channel blocker-sensitive APs until day 100.
The appearance of astrocytes
The number of astrocytes in my iPSC-derived neural cultures increased over time, and the
lack of difference between control and MAPT-mutant cultures suggests that there was no
MAPT mutation related astrocyte overgrowth. The appearance of astrocytes in my neural
cultures at 50 days (small, rounded and with few processes) and at later time points (larger,
with many processes) is similar to that described in ESC-derived neural cultures (Johnson
et al., 2007), suggesting that my cultures developed normally in this respect. However,
astrocytic growth may have been enhanced by the use of BDNF in the maintenance media,
since BDNF is thought to be pro-neural when it signals via the full length trkB receptor
(which is expressed by NPCs early in development), but pro-glial when it signals via the
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truncated trkB receptor (expressed later in brain development) (Cheng et al., 2007). However,
BDNF probably had a small effect, since the proportion of astrocytes in my cultures remained
less than 20%.
I chose S100β as an astrocyte marker since it is expressed in a subset of mature astrocytes,
but not by radial glia (Raponi et al., 2007). However, it is not a perfect marker for excluding
other cell types, since it is also expressed in oligodendrocyte precursors (Deloulme et al.,
2004), and myelinating oligodendrocytes during development (Hachem et al., 2005). There-
fore, some S100β negative astrocytes may have been undetected by my analysis, and some
S100β positive oligodendrocyte precursors may have been included. Full characterisation of
the astrocytes present in my neural cultures was beyond the scope of my project, and would
have required an in-depth study considering the variety of astrocytes which exist (reviewed by
Krencik and Ullian, 2013). Although the analysis I performed is superficial relative to what
could have been done in a comprehensive characterisation, it is informative, since it shows a
maturation-related increase in astrocyte number over time, and no differences between the
control and MAPT-mutant cultures.
I did not examine the presence of cell types other than neurons and astrocytes in the
day 50 and day 80-100 cultures, but other cell types may have been present. For example,
the radial glia that generate astrocytes after neurogenesis also produce oligodendrocyte
precursors (Kriegstein and Alvarez-Buylla, 2009; Rakic, 2003), suggesting that these too
may have been present in my cultures. Further characterisation of these cultures could have
included immunostaining for these cells.
3.5.3 Tau isoforms detected
I assessed the maturity of my iPSC-derived neural cultures and the action of the N279K
mutation in these cultures by Western blotting to examine tau isoforms. In the control cultures
0N3R isoforms and occasionally 0N4R isoforms were visible at day 50, whereas 0N3R tau,
some 0N4R tau, and occassional 1N3R tau were visible in one of the three differentiation
rounds at day 80-100, suggesting a degree of maturation over time. Likewise, other studies
have found 0N4R tau isoforms in control neural cultures after 50 days (Iovino et al., 2015;
Sposito et al., 2015). Since some 4R tau immunoreactivity is visible in control neural cultures
at day 50 and day 80-100, it is possible that insufficient 0N4R tau protein was present for
detection by Western blot in all of the differentiation rounds, or that the quality of the blots
did not allow detection.
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The N279K1 neural cultures demonstrate the action of the N279K mutation, since 0N4R
tau is visible in cultures from two differentiation rounds at day 50 and day 80-100. In
addition, 1N3R tau is visible at both day 50 and day 80-100, and a faint band which may
correspond to 1N4R tau is visible at day 50. The early appearance of 0N4R tau in this line
has also been observed by Iovino et al., and the bright appearance of N279K1 neurons stained
for 0N4R tau at day 80-100 corroborates the results observed by Western blot.
The 0N4R tau isoform was detected in N279K2 cultures at day 50 (one differentiation
round) and day 80-100 (two differentiation rounds). In addition, brighter 4R tau immunoreac-
tivity can be seen in N279K2 cultures relative to control cultures. Not detecting 0N4R tau as
frequently in the N279K2 cultures as in the N279K1 culture led me to check that the N279K
mutation was present in both lines, which was confirmed by Sanger sequencing (Figure 3.3).
The relative lack of 0N4R tau isoforms in the N279K2 cultures may therefore be due to less
neuronal content in the N279K2 cultures, which can be seen as less β III-tubulin and 0N3R
tau in the Western blots for tau isoforms. Lower levels of tau isoforms would make them
more difficult to detect by Western blot.
Notably, 0N3R tau predominated in cultures from all iPSC lines at both timepoints, even
when other isoforms were visible. This has also been reported by other groups (Iovino
et al., 2015; Sposito et al., 2015), and suggests a high proportion of immature neurons in
the cultures. However, Iovino et al. (2015) found that 0N3R tau protein levels were reduced
relative to control in the presence of the N279K mutation, and groups studying iPSC-derived
neurons from intron 10+14 and intron 10+16 mutant iPSCs (which also alter tau splicing)
have found a similar effect (Imamura et al., 2016; Sposito et al., 2015).
In the V337M cultures, 0N4R tau was visible in Western blots from at day 50 (two differ-
entiation rounds) and day 80-100 (one differentiation round). In addition, faint bands which
may correspond to 1N3R and 1N4R tau were visible at day 80-100 (in one differentiation
round). This could suggest that the V337M cultures either matured more quickly with respect
to tau isoform expression than the control cultures. Published studies of V337M-mutant
iPSC-derived neurons have shown that 3R and 4R tau mRNA expression is comparable to
that in control cultures at day 40 (Ehrlich et al., 2015). This is expected, since the V337M
mutation does not alter exon 10 inclusion in splicing assays (Hong, 1998), and tau inclu-
sions in the brains of individuals with the V337M mutation consist of both 3R and 4R tau
(Spillantini et al., 1996a), indicating that the V337M mutation does not alter exon 10 splicing.
Previous published examinations of tau isoforms from the Spillantini lab have used
perchloric acid to selectively solubilise and extract tau from iPSC-derived neural cultures
(Iovino et al., 2015; Lindwall and Cole, 1984). This method may make the tau present more
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visible, since the selective solubility of tau in perchloric acid means that other proteins which
contribute to background signal are removed. However, protein extract in perchloric acid
cannot be used to measure the quantities of other proteins, so further cultures would be
needed from each differentiation to obtain this information. To avoid these problems, I made
protein extracts in RIPA buffer, to examine both tau isoforms and other proteins using the
same extract. Although some tau isoforms can be detected in my Western blots, a better
approach might have been to use a method for generating NPCs which allowed extensive
NPC expansion, in order to make large enough neural cultures to perform perchloric acid
extraction.
The amounts of protein detected in Western blots varied between cultures derived from
different cell lines. This is apparent in Figures 3.8, 3.11 and 3.12 when looking at the amount
of β -actin present, and could account for differences in the number of tau isoforms detected
in each cell line. This discrepancy was despite measuring the concentration of protein extracts
by BCA before Western blotting, and loading the same amount of protein extract in each
lane. To avoid this, tau isoform expression could have been confirmed at the mRNA level by
qPCR, as was done by Iovino et al. (2015), since this method would provide a quantitative
result.
Although I observed brighter 4R tau staining in some day 80-100 N279K cultures as
compared to controls, differences in staining intensity may have been caused by factors
other than the amount of protein. For example, factors during staining, such as the degree
of antibody penetration which could be affected by the density of neurons and other cells
in the culture, could affect staining intensity. Factors after staining, such as photobleaching
caused by exposure to light whilst imaging, could decrease the brightness of the last image
taken relative to that of the first image taken. Careful quantification, rather than judging by
eye, would have been required to determine whether there was a difference in tau staining
intensity between the N279K and control neurons. In addition, positive and negative controls
for 3R and 4R tau should have been used, to determine whether 3R and particularly 4R tau
staining was specific.
Another factor which likely prevented me from detecting more tau isoforms is the amount
of time I maintained the iPSC-derived neural cultures for. Initially, I intended to maintain
my cultures for over 100 days, to observe more adult tau isoforms as seen after 150 days by
Iovino et al. (2015). However, cultures in 12- 24- and 96-well plates began to detach from the
plate surface at around day 100, despite the measures I took to prevent this. These included
adding laminin every 10 days to aid adherence to the culture surface, using tissue-culture
treated plastic coverslips (instead of glass) additionally treated with poly-L-ornithine and
100 Characterisation of iPSC-derived neurons with MAPT mutations
laminin, and changing the culture media as gently as possible (Chapter 2). I fixed cultures for
staining and collected others for protein extraction as soon as the first signs of detachment
were visible in any of the iPSC lines, and for this reason my late timepoint is a range:
80 to 100 days. A possible solution to this problem could be using an anti-mitotic agent
such as mitomycin C to prevent the continued proliferation of non-neural cells in culture
Schwartzentruber et al. (2018). Other groups have overcome this problem using a matrigel
layer on top of the cultures (Choi et al., 2014), and by culturing iPSC-derived neurons in
suspension as cerebral organoids (Lancaster et al., 2013), which is explored in Chapter 6.
The above points could explain the variability in tau isoform expression that I observed.
3.5.4 Advancing the maturity of iPSC-derived neurons
One of the biggest challenges in using iPSC-derived neurons to model neurodegenerative
conditions is culturing neurons which resemble those in a mature, rather than developing
brain. There are several methods which I could have used to advance the appearance of
adult-like tau isoforms.
For example, making induced neurons (iNs) may provide a more mature neuron more
quickly. According to one study, iNs produced from iPSCs with the intron 10+16 mutation
express 0N4R tau after 7 days, and the mature MAP isoforms MAP2A/B after 14 days
(Imamura et al., 2016). In addition, another study showed that iNs produced from fibroblasts
with the K298E mutation and iNs from control fibroblasts both expressed 3R and 4R tau
after 30 days in culture (Iovino et al., 2014). However, tau isoform expression in iNs has not
yet been extensively characterised.
Tau exon 10 splicing can also be controlled by trans-splicing, in which a pre-trans-splicing
cassette is introduced into the cells, then transcribed to make RNA. To control tau exon
10 splicing, an RNA strand coding for exons 10, 11, 12 and 13 would bind to intron 9 of
endogenous tau pre-mRNA, replacing the endogenous exons 10 (if present), 11, 12 and
13. The inclusion of exon 10 in the trans-splicing RNA would cause expression of 4R tau.
This has been demonstrated in both ESC-derived neurons (Lacovich et al., 2017) and mice
expressing human tau (Avale et al., 2013), although it does not recapitulate the splicing of
all six tau isoforms as seen in the adult human brain. This strategy would be useful to study
mutations which do not alter tau splicing, and occur only in exon 10.
The 3D culture of neurons has also been shown to enhance neuronal maturity, in terms
of β III-tubulin expression, synaptic protein expression and synaptic function (Choi et al.,
2014; Liedmann et al., 2012; Ortinau et al., 2010; Seidel et al., 2012; Zhang et al., 2016).
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Most importantly for studying MAPT mutations, 3D culture may also enhance maturity with
respect to tau isoform expression (Agholme et al., 2010; Choi et al., 2014). A 3D culture
system is explored further in Chapter 6.
3.5.5 Summary
In this Chapter, I:
1. Differentiated iPSCs to NPCs. The NPCs’ forebrain fate was confirmed by seeing the
expected staining pattern using Pax6, Otx2 and Nestin antibodies. Staining with the
FoxG1 antibody did not show the expected pattern (cytoplasmic instead of nuclear).
This may be due to the antibody itself, or the differentiation of NPCs towards a
neuronal fate. NPCs from all five iPSC lines were similarly proliferative, as confirmed
by counting Ki67 positive proliferative cells at day 16.
2. Differentiated NPCs to neurons, and maintained them in culture until day 50 or day
80-100. The proportion of neurons in the cultures was measured by Western blotting,
which found a decrease in the amount of β III-tubulin from day 50 to day 80-100.
This was not an expected result, and may have been caused by neuron death, or by an
increase in the number of non-neural cells in the cultures over time. In support of the
latter, the number of astrocytes in the cultures increased from day 50 to day 80-100.
This was expected, since astrocytes emerge in maturing cultures from the last divisions
of neural precursor cells.
3. Examined synaptic protein expression by Western blotting and immunostaining. There
was an increase in the amount of synaptophysin (relative to the amount of β III-tubulin)
from day 50 to day 80-100. This was an expected result, since synaptogenesis has been
observed to increase over time in iPSC-derived neuronal cultures.
4. Assessed tau isoform expression by Western blotting and immunostaining. The 0N3R
tau isoform predominated in all cultures at day 50 and day 80-100, which was result
given the age of the cultures, since 0N3R tau is the only isoform expressed in the fetal
brain. 0N4R and 1N4R tau isoforms were observed, with higher frequency at day
80-100 as compared to day 50, suggesting that the cultures matured with respect to tau
splicing over time. 0N4R tau was observed at higher abundances in day 50 N279K
cultures as compared to day 50 control cultures, indicating the action of the N279K
mutation.
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In this Chapter, I found no significant difference between the control and MAPT mutant
cells when measuring the proportion of proliferating NPCs, the amount of β III-tubulin, the
proportion of astrocytes, or the amount of synaptophysin. In the next Chapter, I will explore
potential FTDP-17T-relevant differences between the control and MAPT mutant cultures.
Chapter 4
Pilot search for morphological and
phenotypic changes in MAPT-mutant
iPSC-derived neurons
4.1 Introduction
4.2 Aims
In Chapter 3, I established that the control and MAPT-mutant iPSC-derived cultures matured
over time with respect to synapse formation, the growth of β III-tubulin positive neurons, and
astrocyte proliferation.
In the brains of individuals with FTDP-17T, and in the brains of some animal tauopathy
models, tau is abnormally phosphorylated and forms insoluble aggregates. There is also
neuronal loss, and, in the case of human FTDP-17T sufferers, αB-crystallin positive bal-
loon neurons can be found. These changes do not occur in the brains of people without
neurodegenerative diseases.
The aim of the work described in this Chapter is to investigate the presence of phenotypic
and morphological FTDP-17T-relevant changes in iPSC-derived neurons with the MAPT
mutations N279K and V337M, as compared to controls. This aim will be fulfilled by:
1. Examining the degree of tau phosphorylation at the AT8 epitope (Ser202 and Thr205).
Iovino et al. previously detected increased AT8 staining in N279K neurons made from
the same iPSCs but using a different method. I will establish whether this result can be
repeated using neurons produced from a different differentiation method.
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2. Looking for changes in tau’s conformation using the antibody MC-1 (against hairpin-
like conformation of tau) and the dye pFTAA (which detects AT100 positive, MC-1
positive tau). MC-1 positive, misfolded tau has not previously been detected in iPSC-
derived neural cultures without the addition of exogenous tau.
3. Assessing the appearance of αB-crystallin positive balloon neuron-like cells. Swollen
cells, which may be balloon neurons, were visible in some cultures at day 80-100.
Immunostaining with αB-crystallin will help to determine the identity of these cells.
4. Comparing the appearance of sodium channels between MAPT mutant and control
cultures. Iovino et al. found an increase in sodium currents in N279K neurons
as compared to controls. Examining sodium channel expression may provide an
explanation for this result.
5. Measuring differences in spontaneous cell death. A decrease in the amount of β III-
tubulin over time was observed in Chapter 3. This decrease may have been caused by
neuronal death in the cultures, or increased numbers of non-neuronal cells. Measuring
cell death will help to determine the relative contributions of these two explanations.
4.2.1 Tau phosphorylation and misfolding
Tau phosphorylation at the AT8 epitope
Tau is a phosphoprotein, with 85 potential phosphorylation sites, although not all of these are
phosphorylated in vivo (reviewed by Hanger and Noble, 2011). Whilst tau in the normal adult
human brain is phosphorylated, aberrant phosphorylation occurs in FTDP-17T and other
tauopathies (Goedert et al., 1992; Spillantini et al., 1996b). Several antibodies have been
produced which detect tau phosphorylated to a greater extent in tauopathies than in normal
brains (Chapter 1). These include the AT8 antibody, whose epitope is the phosphorylated
Ser202 and Thr205 residues. AT8 positive tau is found in the brains of people with tauopathies
such as FTDP-17T, including those with the N279K or V337M mutations (Han et al., 2009;
Miklossy et al., 2007; Spillantini et al., 1996b).
Tau phosphorylation is also developmentally regulated: phosphorylated 0N3R tau from
fetal brains is normally hyperphosphorylated compared to tau in adult brains, and is stained
by several phosphorylation-dependent antibodies including AT8 (Goedert et al., 1993),
AT270, AT180, PHF-1 and 12E8 (Table 1.1 in Chapter 1). Some development-like tau
phosphorylation might be expected in iPSC-derived neurons, since iPSC-derived neurons
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more closely resemble those from a fetal than an adult brain according to gene expression
studies, even after 59-180 days in culture (Handel et al., 2016; Patani et al., 2012).
Phosphorylation at the AT8 epitope has been investigated by several groups in MAPT-
mutant iPSC-derived neural cultures. Increased phosphorylation at the AT8 epitope relative
to control neurons has been reported in N279K (Ehrlich et al., 2015; Iovino et al., 2015),
P301L (Iovino et al., 2015), V337M (Ehrlich et al., 2015) and A152T (Fong et al., 2013;
Silva et al., 2016) MAPT-mutant iPSC-derived neurons, indicating that AT8 phosphorylation
of MAPT-mutant neurons can be recapitulated in culture. The proportion of AT8 positive
control neurons was variable between these studies: Iovino et al. (2015) and Ehrlich et al.
(2015) found that 10-20% of control neurons were AT8-positive at day 55 and 40 respectively,
whereas Fong et al. (2013) found that less than 1% of control neurons were AT8 positive
at approximately day 60, and Silva et al. (2016) detected significantly lower AT8 levels in
control neurons by Western blot after approximately 40 days, suggesting a variable degree of
developmental-like AT8 phosphorylation.
Tau protein misfolding
A change of tau conformation can be detected by various antibodies including MC-1. The
MC-1 epitope is tau amino acids 7–9 and 312–342, and immunoreactivity with this antibody
is thought to represent the folding of a single tau molecule (Jicha et al., 1996). MC-1
immunoreactivity has been observed in several animal models of FTDP-17T (Decker et al.,
2015; Maeda et al., 2016; Xu et al., 2014), and in the brains of people with tauopathies
including AD (Bouras et al., 2003), where it is thought to represent a pathological form of
tau prior to aggregation (Jeganathan et al., 2008).
In iPSC-derived neurons, MC-1 positive misfolded tau has not been reported to appear
spontaneously in aging neurons, but it has been shown in neurons exposed to cues such as
tau fibrils, tau overexpression, or a neurodegenerative environment. For example, Espuny-
Camacho et al. (2017) observed MC-1 positive control and intron 10+16 iPSC-derived
neurons after the neurons had been grafted into an AD mouse brain, and left for 180 days.
Espuny-Camacho et al. did not observe MC-1 positive tau in control or intron 10+16
iPSC-derived neurons grafted into control mouse brains, indicating the importance of the
environment for the conformation and phosphorylation state of both mutant and wild-type
tau. MC-1 positive neurons have also been observed in control iPSC-derived neurons seven
days after exposure to 2N4R wild-type tau oligomers (Usenovic et al., 2015), and in control
iPSC-derived neurons overexpressing 2N4R P301L tau 14 days after exposure to fibrils made
from a tau repeat domain (RD) fragment containing the P301L mutation (Medda et al., 2016).
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Tau aggregation
Tau forms insoluble aggregates in FTDP-17T, AD and other tauopathies. However, this has
only been recapitulated in iPSC-derived neuronal models to a limited extent.
Experiments in which iPSCs derived from FTDP-17T patients’ tissues have been made
into neurons rely on the endogenous mutation to produce a disease-relevant phenotype. So
far, the spontaneous emergence of tau aggregates over time has been reported in a limited
number of studies. For example, Imamura et al. (2016) detected punctate staining with anti-
oligomeric TOC antibody in iNs with the intron 10+16 MAPT mutation, which increases the
amount of 4R relative to 3R tau. TOC binds to mis-folded tau dimers, oligomers, or polymers
(Ward et al., 2013), suggesting that tau dimers or larger oligomers form spontaneously
in the presence of the intron 10+16 mutation. In addition, Iovino et al. (2015) detected
AT100 positive tau in 150 day-old iPSC-derived neurons with the N279K MAPT mutation.
The AT100 epitope requires a filament-like conformation (Zheng-Fischhofer et al., 1998),
suggesting the spontaneous formation of tau filaments in the presence of the N279K mutation.
However, other studies have found no indication of tau aggregation. For example, Silva
et al. (2016) found that A152T iPSC-derived neurons were thioflavin-S negative after 55 days
in culture, and Verheyen et al. (2018) found that 100 day-old P301S iPSC-derived neurons
did not have a detectable increase in alpha-LISA signal (alpha-LISA measures the distance
between tau monomers and is used to quantify tau aggregation).
Tau aggregation has been induced in iPSC-derived models using non-physiological
mutations, tau overexpression or tau fibrils. For example, Reilly et al. (2017) detected
SDS-insoluble tau, as well as thioflavin-T and Gallyas silver positivity in control iPSC-
derived neurons following overexpression of tau RD with the P301L and V337M mutations.
Similarly, Usenovic et al. (2015) observed thioflavin-S positive cells, detected an increase in
sarkosyl-insoluble tau, and saw an increase in alpha-LISA signal in control iPSC-derived
neurons seven days after exposure to 2N4R wild-type tau oligomers. García-León et al.
(2018) observed an increase in alpha-LISA signal in 70 day-old iPSC-derived neurons with
the three tau mutations P301L, N279K and intron 10+16, after exposure to tau RD fibrils.
Verheyen et al. (2018) found an increase in alpha-LISA signal in iPSC-derived neurons
homozygous for the intron 10+16 and P301S mutations exposed to tau RD fibrils with
the P301L mutation, but these aggregates are likely to be small, since they detected no
sarkosyl-insoluble tau.
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4.2.2 Sodium channels
Iovino et al. (2015) observed faster electrophysiological maturation in neurons made from
iPSCs derived from patients with the MAPT mutations N279K and P301L. They also found an
increase in peak sodium channel current in N279K and P301L neurons compared to controls,
which coincided with regenerative, sodium channel blocker-sensitive action potential (AP)
firing by MAPT-mutant neurons, but not by control neurons, which did not fire regenerative,
sodium channel blocker-sensitive APs until a later timepoint. When control neurons did fire
these APs, the peak sodium channel current reached similar levels to that initially observed
in N279K and P301L neurons.
Earlier electrophysiological maturity has also been observed in iPSC-derived neurons
with the all three of the N279K, P301L and intron 10+16 mutations (García-León et al.,
2018), although sodium channel currents were not measured. In addition, neuronal hyper-
excitability has been detected in hippocampal slice cultures from mice expressing human
P301L mutant tau (Crimins et al., 2012).
Furthermore, increased electrophysiological activity may also be relevant to human
tauopathies. People with Alzheimers disease have a 6- to 10-fold higher risk of seizures
than age matched controls, and dementia severity correlates with seizure risk (reviewed
by Pandis and Scarmeas, 2012). Likewise, people with FTD have a 6-fold higher risk
of seizures (Beagle et al., 2017), and seizures have been reported in individuals with the
FTDP-17T-relevant mutation P301S (Sperfeld et al., 1999).
Since I was using the same control and N279K iPSC lines as Iovino et al., I wanted to
investigate differences in sodium channel expression between the iPSC-derived neurons,
which might contribute to their early excitability.
Sodium channels are expressed in neurons throughout the cell soma, dendrites and axon
at low levels, and are most densely clustered in the axon initial segment (AIS): a length
of axon with a high density of sodium and potassium channels where APs are initiated
(reviewed by Kole and Stuart,2012). AIS assembly is cell autonomous and dependent on
Ankyrin G, which also anchors the AIS proteins in place (reviewed by Rasband, 2010). Four
sodium channel subunits are expressed in the brain (Nav1.1, 1.2, 1.3, and 1.6) and three of
these (Nav1.1, 1.2, and 1.6) are found in the AIS, with variations depending on cell type and
region (Kole and Stuart, 2012; Lorincz and Nusser, 2008). The AIS in developing neurons
and in adult unmyelinated neurons contains sodium channels made of Nav1.2 subunits. In
developing myelinated neurons levels of the Nav1.6 subunit (the predominant subunit in the
adult AIS) increases over time (Boiko et al., 2003).
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The AIS has been detected using a pan-sodium channel antibody in iPSC-derived neurons.
For example, Higurashi et al. (2013) observed AIS-like sodium channel clustering by 36 days
after NPCs (analogous to approximately day 56 in my cultures) in a population of mostly
GABAergic neurons. With this in mind, I set out to investigate sodium channel distribution
in my iPSC-derived neurons.
4.2.3 Balloon neurons
Balloon neurons are enlarged neurons with eccentrically positioned nuclei which are found
in the brains of people with various neurodegenerative diseases including the tauopathies
PiD, CBD, PSP and FTDP-17T (López-González et al., 2014). Although balloon neurons are
sparsely distributed in the brains of control subjects over 90 years old, they are not present
in younger control brains (Iwaki et al., 1990) and their role in neurodegeneration is unclear.
As well as being morphologically distinct from normal neurons, balloon neurons stain for a
number of antibodies (summarised in Table 4.1) including αB-crystallin.
Table 4.1 Proteins detected in balloon neurons found in the brains of people with neu-
rodegenerative diseases.
Protein detected in balloon neurons Disease
αB-crystallin AD [1,2], AGD [1], CBD [3,4,5], CJD [5,6,7]
Diffuse Lewy body disease [6], FTDP-17T [4]
MSA [6], PD [1], PSP [4,6,8,9], old age >90 years [6]
Total tau Variable in PSP [9]
Phosphorylated tau: AT8 AGD, PD, AD [1]
Phosphorylated tau: PHF-1 AGD, PD, AD [1], variable in AD [2]
Phosphorylated neurofilament AGD, PD, AD [1], CBD [3,5], PSP [9], CJD [5,7]
Non-phosphorylated neurofilament AGD, PD, AD [1]
Ubiquitin Variable in AGD, PD, AD [1], variable in PSP [9]
Synaptophysin Weak in AGD, PD, AD [1], strong in CBD [3]
Nestin CJD [7]
References: [1]: Tolnay and Probst (1998); [2]: Fujino et al. (2004); [3]: Matsumoto et al. (1996); [4]:
Dabir et al. (2004); [5]: Sakurai et al. (2000); [6]: Iwaki et al. (1990); [7]: Mizuno et al. (2003); [8]:
Togo and Dickson (2002); [9]: Mori et al. (1996).
4.2 Aims 109
Balloon neurons have been identified in at least four FTDP-17T cases with the N279K
mutation (Arvanitakis et al., 2007; Delisle et al., 1999; Slowinski et al., 2007; Wren et al.,
2015), and in at least four cases with the P301L mutation (Forrest et al., 2018; Reed, 2001).
Of balloon neurons identified in brains of people with the N279K mutation, two cases were
stained for αB-crystallin (Delisle et al., 1999; Wren et al., 2015); other balloon neurons
were detected by their distinct appearance. In addition to balloon neurons, some astrocytes
and oligodendrocytes in PSP, CBD and FTDP-17T (with the K317M, N279K or intron
10+16 MAPT mutation) have been found to be αB-crystallin positive (Dabir et al., 2004;
López-González et al., 2014).
αB-crystallin is part of the small heat shock protein (HSP20) family: a group of proteins
whose expression can be induced by heat shock or cell stress (Klemenz et al., 1991; Leak,
2014). αB-crystallin is expressed in the heart, muscle and brain of rats (Bhat and Nagineni,
1989), and in normal human subject brain tissue it is expressed in oligodendrocytes, a subset
of astrocytes (approximately 5%), and at low levels in neurons (López-González et al., 2014).
αB-crystallin can act as a chaperone and prevent unfolded proteins aggregating (Jakob
et al., 1993; also reviewed by Bloemendal et al., 2004). However, αB-crystallin does not
renature denatured, misfolded or aggregation-prone proteins itself, instead it holds them until
they are renatured by another chaperone, or broken down by proteolysis (Bloemendal et al.,
2004; Horwitz, 2003).
The expression of αB-crystallin in so many neurodegenerative diseases and its role as a
chaperone suggests αB-crystallin may be part of a protective mechanism. This is supported
by findings in the brains of PD sufferers, in which most neurons expressing αB-crystallin do
not contain Lewy bodies, and most neurons with Lewy bodies do not contain αB-crystallin
(Braak et al., 2001), suggesting that neurons in which αB-crystallin expression is high are
able to prevent α-synuclein aggregation. In addition, there is a positive correlation between
tris-buffered saline soluble tau and αB-crystallin expression, and negative correlation between
small insoluble tau species and αB-crystallin expression in the frontal and temporal lobes
from brains of people with tauopathies, suggesting that αB-crystallin (and other small heat
shock proteins) help prevent tau aggregation (Sahara et al., 2007). However, this evidence is
only circumstantial.
Balloon neurons have been observed in an ex-vivo model of AD. Shahani et al. (2006)
expressed wild-type human tau or pseudo-phosphorylated human tau (in which ten serine
and threonine residues were replaced with glutamate to mimic phosphorylation) in cultured
mouse hippocampal slices, and found some neurons with swollen balloon-like cell bodies
in the presence of pseudo-phosphorylated tau. However, Shahani et al. did not further
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characterise the balloon neurons, so it is unknown if they would stain for the same antibodies
as balloon neurons in human tauopathy brains.
To my knowledge, balloon neurons have not been studied in iPSC-derived neural cultures
to date, but αB-crystallin has been studied in iPSC-derived neurons used as a model of
Alexander’s disease, which is caused by GFAP mutations. Kondo et al. (2016) found small
αB-crystallin puncta in some cell bodies, near areas of abnormal GFAP.
4.2.4 Cell death
The brains of people with FTDP-17T atrophy over time, and there is neuron loss (reviewed
by Ghetti et al., 2015). Neuronal loss is also observed in the brains of several animal models
of FTDP-17T. For example, mice expressing P301S mutant human tau show cortical neuron
loss after 3 months of age (Hampton et al., 2010; Yang et al., 2016), and mice expressing
N279K mutant human tau show substantia nigra neuron loss after 12 months of age (Dawson
et al., 2007).
Cell death has also been observed in iPSC-derived neuronal cultures with MAPT muta-
tions, and is often detected by an LDH (lactate dehydrogenase) assay. LDH is an enzyme
present in the cytoplasm of most cells, which is released into the media when a cell dies.
LDH is relatively stable in the media, and is a commonly used method for detecting cell
death in culture (Chan et al., 2013).
Wren et al. (2015) found that N279K iPSC-derived NPCs spontaneously released more
LDH into the media than control NPCs. However, since Wren et al. were unable to
differentiate N279K NPCs into neurons, the high rate of cell death may have been due to a
problem with the NPCs unrelated to the N279K mutation.
Other groups have observed cell death in iPSC-derived neuronal cultures following the
addition of exogenous tau or toxic substances. For example, Ehrlich et al. (2015) found that
N279K and V337M midbrain-like iPSC-derived neurons were more vulnerable to cell death
following rotenone-induced complex I inhibition leading to oxidative stress, as measured by
an increase in LDH release. In addition, Usenovic et al. (2015) observed increased cell death
following the addition of recombinant 4R2N tau oligomers to control iPSC-derived neurons,
using both a live cell dye and an LDH assay.
As mentioned in Chapter 3, I observed more condensed pyknotic nuclei in day 80-100
neural cultures relative to day 50 cultures, with no clear differences between MAPT-mutant
and control cultures, as determined by a superficial observation. However, since I observed
pyknotic nuclei after several washing steps during staining, these nuclei must have remained
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adhered to the coverslips despite washing, so it is likely that pyknotic nuclei were not washed
away during media changes, and instead accumulated over time. To get some information on
spontaneous cell death in culture, I examined cell death at several points during differentiation,
using an LDH assay.
4.3 Materials and Methods
4.3.1 iPSC culture and differentiation
iPSCs were thawed, cultured, prepared for karyotyping and differentiated to neurons as
described in Chapter 2, and cultured as described in Section 2.3.
4.3.2 Immunostaining, Western blotting and statistical analysis
Immunostaining and imaging was performed as described in Section 2.5.1, Western blotting
was performed as described in Section 2.6, and statistical analysis was performed as described
in Section 2.7. AT8, MC-1, and αB-crystallin staining was quantified using ImageJ.
AT8
Cultures were co-stained with the AT8 and β III-tubulin antibodies. I counted the number
of neurons which were AT8 positive by hand, and recorded this as a proportion of the total
number of β III-tubulin positive neurons. To facilitate counting of AT8 positive cells, images
were converted to binary images (Image→Adjust→Threshold in ImageJ) with the Threshold
value adjusted such that background staining was eliminated. Cells were counted manually
with the Plugins→Analyse→Cell Counter tool in ImageJ. Neurons were counted in two,
or more commonly three, different wells from the same differentiation round (as technical
replicates). The total number of neurons counted in two or three technical replicates was at
least 100, and frequently 200-300. Neurons were counted in a total of three independent
differentiation rounds.
To account for the presence of AT8 positive processes as well as AT8 positive cell bodies,
I measured the area of each image that was AT8 positive using ImageJ, and normalised to the
number of β III-tubulin positive neurons in the same image.
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MC-1
Cultures were co-stained with the MC-1 antibody and an antibody (tau DAKO) which detects
all six tau isoforms independent of their phosphorylation state.
αB-crystallin
Cultures were co-stained with the αB-crystallin and β III-tubulin antibodies. I counted the
number of neurons which were αB-crystallin positive, and recorded this as a proportion of
the total number of β III-tubulin positive neurons.
4.3.3 LDH assay
To assess spontaneous cell death at days 30, 50, 70 and 100, NPCs were plated at the same
density in a 96-well plate, as described in Section 2.3. Cells were maintained with 300µl per
well of NDM (Section 2.2.1), which was replaced every other day. On day 28, 48, 68 or 98,
media was removed from all wells and replaced with 300µl per well of NDM, which was
collected after 2 days (on day 30, 50, 70, and 100) and stored immediately at -80◦C.
LDH in the collected media was measured using a Bioluminescent LDH assay (Promega).
Three media dilutions were tested (1:10, 1:20, 1:100), of which 1:20 gave the highest signal
to background ratio. Media samples were diluted 1:20 with DPBS, and 20µl of each sample
was added to a white 96-well plate (Costar), along with media alone (negative control)
and media from cells lysed with 0.5% Triton X-100 in NDM (positive control). Reductase
substrate was diluted 1:200 in LDH assay buffer and 20µl of this mixture was added to
each sample. Samples were incubated at room temperature and protected from light for 30
minutes, then luminescence was read on an Infinite M200 Pro Tecan plate reader (integration
time: 1 second, settle time: 150ms). One experiment was performed, using media from
three differentiations of each cell line at four time points each. Two technical replicates were
performed and averaged.
4.4 Results
4.4.1 Tau phosphorylation at Ser202 and Thr205; the AT8 epitope
I determined the proportion of AT8 positive neurons in N279K and V337M mutant cultures
as compared to the controls. Although AT8 phosphorylation in N279K neurons derived
from the same iPSCs has been investigated by Iovino et al. (2015), I used a different method
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Fig. 4.2 The proportion of AT8 positive neurons is significantly higher at day 80-100 than at day
50, and there is a significantly higher proportion of AT8 positive N279K neurons as compared
to control neurons at day 50. A) The proportion of AT8 positive neurons was counted in CTRL1,
CTRL2, N279K1, N279K2 and V337M cultures at day 50 and 80-100. Cultures produced from three
independent differentiations were assessed. Each point represents the mean measurement from one
independent differentiation with at least two, and usually three technical replicates. At least 100 cells
from each cell line were counted per differentiation. Bars show mean±SD. Significance bars show the
results of a two-way ANOVA: there was an increase in the proportion of AT8 positive neurons over
time (* indicates p<0.05). B) The data presented in A) re-organised by iPSC line. Significance bars in
black show the results of a post-hoc test following a two-way ANOVA: there was a higher proportion
of AT8 positive neurons in N279K1 cultures than in CTRL2 or V337M cultures (* indicates p<0.05).
Significance bars in grey show the results of paired t-tests comparing the difference in the proportion
of AT8 positive cells in cultures derived from each iPSC line at day 50 and day 80-100. There was a
significantly higher proportion of AT8 positive neurons in day 80-100 CTRL1 cultures as compared to
day 50 CTRL1 cultures (** indicates p<0.01). Comparisons between day 50 and day 80-100 cultures
were not significant for other iPSC lines. C) The proportion of AT8 positive neurons in cultures from
both CTRL1 and CTRL2 iPSC lines (control) and in both N279K1 and N279K2 cultures (N279K) at
day 50. Significance bars show the results of Student’s t-test. There was a higher proportion of AT8
positive N279K neurons than control neurons at day 50 (* indicates p<0.05). D) The area covered by
AT8 positive cell bodies and processes was quantified in cultures derived from each iPSC line at day
50 and day 80-100. Significance bars show the results of a two-way ANOVA. There was an increase in
the AT8 positive area over time (* indicates p<0.05). E) The area covered by AT8 positive cell bodies
and processes in cultures from both CTRL1 and CTRL2 iPSC lines (control) and in both N279K1 and
N279K2 cultures (N279K) at day 50. Significance bars show the results of Student’s t-test. There was
no significant difference in the AT8 positive area between N279K and control cultures at day 50.
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for neuronal differentiation (summarised in Table 3.1, Chapter 3) and wanted to see if
comparable results were obtained. AT8 phosphorylation in iPSC-derived neurons with the
V337M and N279K mutations has also been previously investigated by Ehrlich et al. (2015),
who differentiated N279K and V337M iPSCs to GABAergic and dopaminergic neurons
to make midbrain-like cultures. However, my iPSC-derived neurons have a forebrain fate
(Chambers et al., 2009; Kirkeby et al., 2012), since neurons in the frontal and temporal lobes
are most affected by FTDP-17T (reviewed by Ghetti et al., 2015).
To determine the proportion of AT8 positive neurons, I stained for AT8 at day 50 and day
80-100 (Figure 4.1). At day 50, AT8 positive cell bodies and some processes were visible in
both control and MAPT-mutant cultures; at day 80-100, more extensive AT8 staining was
visible in both cell bodies and processes in all cultures.
I quantified this data in two ways: by counting the proportion of AT8 positive neuronal
cell bodies, presuming that this would also account for the AT8 positive processes (Figure
4.2A), and by quantifying the AT8 positive area, to account for both AT8 positive cell bodies
and AT8 positive processes (Figure 4.2D).
When counting the number of AT8 positive neuronal cell bodies, a two-way ANOVA
found a significant main effect of iPSC line (F(4,10)=7.662, p=0.0043) meaning that the
number of AT8 positive neurons was significantly different between cultures derived from
different iPSC lines. This difference was assessed with a post-hoc multiple comparisons test,
with a Bonferroni correction, in which the proportion of AT8 positive neurons in cultures
derived from each iPSC line was compared. The post-hoc test found significant differences
in the proportion of AT8 positive neurons between CTRL2 and N279K1 (p=0.0106), and
between N279K1 and V337M (p=0.0110); in Figure 4.2, it is clear that the significant
difference is an increase in AT8 positive neurons in N279K1 neurons as compared to CTRL2
and V337M neurons. This is shown in Figure 4.2B with black bars.
The two-way ANOVA also found a significant main effect of time F(1,10)=8.283,
p=0.0164), meaning that the proportion of AT8 positive neurons was significantly increased
between day 50 and day 80-100 (Figure 4.2A and Figure 4.1). The two-way ANOVA found
no significant interaction effect between time and iPSC line (F(4,10)=0.6965, p=0.6114),
meaning that time had the same effect on the number of AT8 positive cells derived from all
five iPSC lines.
To compare my results directly to those of Iovino et al. (2015), I grouped day 50 CTRL1
and CTRL2 results as control, and day 50 N279K1 and N279K2 results as N279K, then
performed the same analysis: Student’s t-test. This revealed a significant difference in the
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proportion of AT8 positive neurons between N279K and control cultures at day 50 (p=0.0120,
Figure 4.2C).
In addition, I used t-tests to compare the change in the proportion of AT8 positive neurons
in cultures from each iPSC line at day 50 and day 80-100. The t-tests showed no significant
difference between the proportion of AT8 positive neurons at day 50 and day 80-100 in
neurons from the CTRL2, N279K1, N279K2 and V337M iPSC lines. There was a significant
difference (paired t(2)=12.96, p=0.0059) in the proportion of AT8 positive neurons derived
from the CTRL1 iPSC line between day 50 and day 80-100. These results are shown in
Figure 4.2B with orange bars.
AT8 staining was present in both cell bodies and processes (Figure 4.1). Since counting
the number of AT8 positive cell bodies may not have captured differences in the number of
AT8 positive processes, I quantified the AT8 positive area of each image, and normalised
to the number of neurons (Figure 4.2D). A two-way ANOVA found a main effect of time
(F(1,10)=5.459, p=0.0416), meaning that the AT8 positive area per neuronal cell body was
significantly increased between day 50 and day 80-100. The two-way ANOVA also found
no main effect of iPSC line (F(4,10)=0.4735, p=0.7546; the AT8 positive area per neuronal
cell body was not significantly different between cultures derived from different iPSC lines),
and no interaction effect (F(4,10)=0.9025, p=0.4982; time had the same effect on the AT8
positive area per neuronal cell body in cultures derived from all five iPSC lines).
I also represented these results in the same was as those in Figure 4.2C), by grouping
day 50 CTRL1 and CTRL2 results as control, and day 50 N279K1 and N279K2 results as
N279K, then performing Student’s t-test. There was no significant difference in the area
covered by AT8 positive neurons and processes between N279K and control cultures at day
50 (p=0.4219, Figure 4.2E).
In conclusion, there was an increase in the proportion of AT8 positive neurons over time,
when AT8 phosphorylation in all cultures at day 50 was compared to AT8 phosphorylation
in all cultures at day 80-100. There was also an increase in the proportion of AT8 positive
neurons in both N279K cultures at day 50, as compared to both control cultures at day 50.
When comparing cultures derived from different iPSC lines at day 50, there was an increase
in the proportion of AT8 positive neurons in N279K1 cultures, as compared to CTRL2 and
V337M cultures.
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4.4.2 Conformational changes in tau
To see if misfolded tau was detectable in day 80-100 cultures, I used the MC-1 antibody,
whose epitope (tau amino acids 7–9 and 312–342; Jicha et al. (1996)) detects misfolded tau
prior to aggregation. To ensure that MC-1 immunoreactivity identified was not background
staining, I co-stained with an antibody that detects all six tau isoforms (Tau DAKO) and used
secondary antibodies fluorescent at 488nm (Tau DAKO) and 647nm (MC-1). Images were
then taken in at 488, 568, and 647nm, and the absence of fluorescence at 568nm confirmed
that there was no bleed-through between the two stainings.
MC1 staining was bright in the positive control (adult P301S mouse dRG, Figure 4.3B),
indicating that the staining was sufficient to detect misfolded tau. However, very little MC-1
immunoreactivity was visible in cultures derived from both control and MAPT-mutant iPSC
lines (Figure 4.3A), suggesting that tau was not misfolded in day 80-100 iPSC-derived
neurons.
This result was expected, since there was little difference in the proportion of AT8 positive
cells between controls and N279K or V337M cultures, indicating that FTDP-17T-relevant
abnormal phosphorylation was not present in the N279K or V337M cultures. Abnormal phos-
phorylation is thought to precede tau misfolding and aggregation (Goedert and Spillantini,
2001), so MC-1 positive, misfolded tau would only be expected after abnormal phosphoryla-
tion had been observed.
4.4.3 Preliminary results: probing for filamentous tau
To see if filamentous tau was present in the oldest neuronal cultures (at day 100), I used the
dye pentameric formyl thiophene acetic acid (pFTAA). pFTAA has been shown by Brelstaff
et al. (2015) to co-label AT8 positive neurons in AD patient’s brains, and as well as AT100-
or MC1-positive dorsal root ganglion neurons from mice expressing P301S mutant tau.
I co-stained day 100 cultures with an antibody that detects all tau isoforms (tau DAKO,
referred to as total tau), to ensure that pFTAA staining detected was also tau positive. As
a positive control, I used a cryosectioned dorsal root ganglion from a 5 month-old P301S
mouse.
Visualising pFTAA staining required strong illumination, and this induced a high level of
background fluorescence, which can be seen in the negative control of Figure 4.4. The high
background fluorescence makes it difficult to attribute fluorescence in the samples to pFTAA
staining, although some areas of higher fluorescence are visible in the V337M and CTRL2
cultures. The areas of higher intensity staining do not overlap with total tau staining in the
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Fig. 4.4 Filamentous tau was not detected in day 100 neural cultures using the dye pFTAA.
Day 100 neural cultures derived from the CTRL2, N279K1 and V337M iPSC lines were stained with
the dye pFTAA (which detects filamentous tau) and the tau DAKO antibody (which detects all six
tau isoforms). The expected staining pattern was observed with the tau DAKO antibody, but pFTAA
staining in CTRL2, N279K and V337M cultures did not overlap with tau staining, suggesting that the
pFTAA staining visible was not specific for tau. Dorsal root ganglion cells from a 5 month old P301S
mouse were used as a positive control, and the expected staining pattern with pFTAA (brightly stained
cell bodies) was seen under an epifluorescent microscope. However, this bright staining was not well
detected in the confocal microscope images shown, even when exposure was high. High exposure led
to autofluorescence in the green channel, as shown in the no-pFTAA control. Scale bar = 10 µm.
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merged images, indicating that pFTAA is not bound to tau. In the areas that are total tau
positive in the merged images, the high level of background fluorescence makes it difficult to
distinguish between negative and potentially positive staining.
This staining was only performed on cultures from one differentiation round, and cultures
derived from the CTRL1 and N279K2 iPSC lines were washed off the coverslips during
staining. This result is therefore preliminary, and suggests that pFTAA-positive tau was not
present in cultures at day 100. Given that only small differences in the proportion of neurons
containing AT8 positive tau were detected between control and MAPT mutant cultures, and
given that no MC-1 positive tau was detected, the lack of fibrillar tau detected with pFTAA
was an expected result.
4.4.4 Balloon neurons
Some swollen cells were visible in day 80-100 cultures from all cell lines, so I stained
for αB-crystallin to see if these neurons were balloon neuron-like. αB-crystallin positive
neurons (which also stained for the neuronal markers β III-tubulin or tau) were observed
mostly in N279K1, N279K2 and V337M cultures (Figure 4.5). αB-crystallin was visible
in cell bodies and occasionally in processes. Morphologically, αB-crystallin positive cells
resembled αB-crystallin positive balloon neurons in human brains from FTDP-17T patients
with the N279K mutation, as shown in Figure 4.8.
αB-crystallin-positive neurons were also positive for 4R tau (Figure 4.7A, n=1). Co-
staining for αB-crystallin and AT8 showed that the majority of αB-crystallin positive neurons
were AT8 negative, with a few being AT8 positive (Figure 4.7B, n=1). However, these two
stainings were only performed on neurons from one differentiation round.
The proportion of αB-crystallin positive neurons in cultures from each of three indepen-
dent differentiations is quantified in Figure 4.6. A relatively low proportion of αB-crystallin
positive neurons were detected in the second differentiation round so, Figure 4.6B shows
the data in Figure 4.6A normalised to the values for N279K2, which were set to one. A low
proportion of αB-crystallin positive neurons detected in the second differentiation round in
part because the cultures detached from their cover slips during staining, and were rescued
on glass slides. This lead to lower-quality staining, and low numbers of neurons stained.
The staining could not be repeated due to a lack of remaining cultures. A one-way ANOVA
revealed no significant difference between the mean proportion of αB-crystallin positive
neurons derived from the different iPSC lines.
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Fig. 4.6 The number of αB-crystallin positive balloon neuron-like neurons was not significantly
different between control and MAPT mutant cultures at day 80-100. A) The proportion of αB-
crystallin positive neurons in CTRL1, CTRL2, N279K1, N279K2 and V337M cultures at day 80-100
was counted by hand in cultures from three independent differentiations. There was no sigificant
difference in the proportion of αB-crystallin positive neurons between the cell lines, as determined
by a one-way ANOVA. B) The same data as shown in A) is normalised to the values for N279K2
cultures, which were set to one. In both A) and B), bars show mean±SD and points show the mean
proportion of αB-crystallin positive neurons in cultures from each of three differentiations.
In conclusion, some αB-crystallin positive neurons were present in day 80-100 neural
cultures, although there was no significant difference in the number of αB-crystallin positive
neurons between cultures derived from control and MAPT-mutant iPSC lines.
4.4.5 Markers of the AIS
To investigate differences in sodium channel expression between iPSC-derived MAPT mutant
and control neurons, I immunostained day 50 and 80-100 neurons using a pan-sodium channel
antibody (PanNa), raised against an epitope in the intracellular III-IV loop which is conserved
between sodium channels. Staining in differentiation rounds one and two, at day 50 and
day 80-100 gave diffuse, faint staining of the cell soma and processes. This staining may be
specific for sodium channels even though an AIS was not detected, since sodium channels
are expressed throughout the cell body, dendrites and axon (Kole and Stuart, 2012).
Potential AIS-like staining was visible in day 50 N279K1 neurons from the third dif-
ferentiation round (Figure 4.9A), although neurons from the same differentiation round at
day 80-100 and day 16 did not show the same pattern of staining. The average length of
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Fig. 4.7 αB-crystallin positive balloon neuron-like neurons in cultures at day 80-100 were 4R
tau positive, but most were not AT8 positive. Representative images of αB-crystallin positive
neurons from one differentiation of CTRL2, N279K1, N279K2, and V337M cultures at day 80-100,
co-stained for A) 4R tau, and B) tau phosphorylated at Ser202 and Thr205 (detected with AT8). Scale
bar = 10µm.
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A
N279K2B
αB-crystallin N279K frontal cortex 
Wren et al (2015)
αB-crystallin N279K temporal cortex 
Wren et al (2015)
N279K2 N279K1N279K1 N279K1
Fig. 4.8 αB-crystallin positive balloon-neuron-like neurons at day 80-100 compared to αB-
crystallin positive balloon neurons in human FTDP-17T brain. A) shows αB-crystallin positive
balloon neurons in the frontal and temporal cortex of two human FTDP-17T patients with the N279K
mutation, taken from Wren et al. (2015) and Delisle et al. (1999). Scale bars = 10µm. No scale bars
were provided in the Delisle et al. paper. B) shows representative αB-crystallin positive balloon-
neuron-like neurons from N279K1 and N279K2 cultures at day 80-100. Scale bar = 10µm, and all
images are resized such that the scale bars in the images are the same length.
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Fig. 4.9 Sodium channel staining in day 50 cultures was not specific for the AIS. A) Diffuse
sodium channel staining (Pan Na) was visible throughout the cell soma and processes in cultures from
the CTRL1, CTRL2, N279K1, N279K2, and V337M iPSC lines from three independent differentiation
rounds at day 50. Potential AIS-like staining was visible in an N279K1 culture at day 50 (marked
with white arrowheads in the enlarged merge). To confirm the presence of an AIS, the same N279K1
cultures were immunostained with B) ankyrin G or C) neurofascin. Ankyrin G and neurofascin
antibodies gave diffuse staining, indicating that an AIS was not present. Scale bar = 10µm.
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the AIS-like staining was 16.1±2.2µm, which is within the range of reported AIS lengths:
10-60µm (Kole and Stuart, 2012; Rasband, 2010).
To confirm the sodium channel staining was AIS staining, I stained the same cultures
for ankyrin G, which detects a scaffold protein restricted to the AIS that is vital for AIS
integrity (Rasband, 2010), and for β III-tubulin, but no AIS-like staining was detected (Figure
4.9B). I also stained the same cultures for neurofascin, which detects the cell adhesion
molecule neurofascin that binds to Ankyrin G at the AIS (Rasband, 2010), and co-stained
for β III-tubulin and MAP2, which is present in dendrites but not axons (Kosik and Finch,
1987). However, no AIS-like staining was detected: all neurofascin staining overlapped with
dendritic MAP2 staining. Both of these stainings were done once.
Together, the results of staining with pan-sodium channel, ankyrin G and neurofascin
antibodies suggests that no AIS was detected.
4.4.6 Cell death
To measure spontaneous cell death in iPSC-derived neural cultures, I collected media at day
30, 50, 70, and 100 from each of three differentiations. Since media were changed every two
days, the data represents spontaneous LDH release occurring over two days in culture. In
order to maintain the neurons in culture until day 100, NPCs were plated at the same low
density in 96-well plates and the same amount of media was added prior to every media
collection. Media was frozen at -20oC following collection and analysed together (in two
technical replicates) when all the media had been collected using a chemiluminescent LDH
kit.
The data are presented in Figure 4.10. LDH release was normalised to the value at
day 70 in CTRL2 cultures, which was set to one for each differentiation. This approach to
normalising LDH release has also been used by Ehrlich et al. (2015) and Usenovic et al.
(2015) in their experiments with iPSC-derived neurons. A positive control was made by
lysing a culture with 0.5% Triton X-100 in NDM, and used alongside the other samples to
show maximal LDH release.
In Figure 4.10A, the change in LDH release over time is shown for each iPSC line, and
a positive control indicates maximum LDH release. In one day 100 culture derived from
the N279K1 line there is a high level of LDH in the media which is very similar to that of
the positive control. High values were recorded in two technical replicates, indicating that
the values are not measurement errors, and suggesting that they were specific to high LDH
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Fig. 4.10 There was no significant change in cell death over time as measured by spontaneous
LDH release into the media. Spontaneous LDH release at day 30, 50, 70, and 100, measured in
the media of CTRL1, CTRL2, N279K1, N279K2, and V337M cultures from three independent
differentiations. Measurements are normalised to the reading at day 70 in CTRL1 cultures for each
differentiation. Each point represents the normalised LDH release measured at one time point in
one of the three differentiation rounds, and as an average of two technical replicates. The positive
control indicates maximal LDH release from one culture, following lysis. Bars indicate the mean±SD.
The same data are presented in A) and B). A) shows data organised by parental iPSC line to show
the change in LDH release in each culture over time. Significance bars in black show the results
of a two-way ANOVA: there was no significant difference in cell death when comparing between
the parental iPSC lines. Significance bars in grey show the results of paired t-tests comparing LDH
release at day 30 and day 100 in each iPSC line: there was no significant change in LDH release
comparing day 30 and day 100 for cultures from each iPSC line, although there may be a trend. B)
shows data organised by timepoint. Significance bars in black show the results of a two-way ANOVA:
there was no significant change in LDH release over time. Overall, no significant differences in cell
death were detected.
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release. This high level in a single culture could have been related to detachment of the cells
from the plate surface.
The data were analysed by a two-way ANOVA. This found no significant main effect of
time, meaning that the amount of LDH released is not significantly different between day 30,
50, 70, and 100 (F(3,30)=1.723, p=0.1833), although there is a trend towards a difference.
This is shown by a black bar in Figure 4.10B. There was no significant main effect of iPSC
line, meaning that the amount of LDH release did not vary significantly between the cultures
derived from the five iPSC lines (F(4,10)=0.3391, p=0.8435), which is shown by a black bar
in Figure 4.10A. Finally, there was no significant interaction effect (time has the same effect
on LDH release in cultures derived from all five iPSC lines: F(12,30)=0.8427, p=0.6087).
To see if there was a significant change in LDH release over time in each culture, I
performed paired t-tests comparing LDH release at day 30 and day 100 in each iPSC line.
The results of these tests are shown by orange bars in Figure 4.10A: all the t-tests showed no
significant change.
Together, these results indicate that there was no significant change in cell death in culture
over time or between cultures from each of the iPSC lines. As can be seen in Figure 4.10,
there is little variation in LDH level release between the cultures, with the exception of
one near-maximal point at day 100 in N279K1, and one slightly higher point at day 50 in
N279K2.
4.5 Discussion
4.5.1 Tau phosphorylation at the AT8 epitope
There was an increase in the number of AT8 positive neuronal cell bodies over time when I
compared the cultures at day 50 to the cultures at day 80-100 (two-way ANOVA, p=0.0164).
To investigate this further, I used t-tests to compare the difference in the proportion of AT8
positive neurons derived from each iPSC line at day 50 and day 80-100. No significant
differences were detected, except for in the CTRL1 line, in which there was a significant
increase in the proportion of AT8 positive neurons between day 50 and day 80-100.
These results are not easy to interpret, since the time-course of AT8 phosphorylation in
embryonic human brains has not been determined, although it is higher in fetal brains than in
the adult human brain (Brion et al., 1993; Goedert and Jakes, 1990). In chick optic lobes,
the amount of AT8 positive tau increases between embryonic days 8 and 14 (Rösner et al.,
1995), suggesting that an increase in AT8 positive neurons could be expected in iPSC-derived
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cultures, representing a development-like process. Since iPSC-derived neurons are similar
to human fetal neurons in terms of their gene expression (Handel et al., 2016; Patani et al.,
2012), a development-like process may explain the significant increase in the proportion of
AT8 positive CTRL1 neurons over time.
However, Verheyen et al. (2018) found no change in the amount of AT8 positive tau by
Western blot between day 51 and day 80 in control or intron 10+16 MAPT-mutant neural
cultures. This is in agreement with my findings of no significant change in the proportion of
AT8 positive neurons between day 50 and day 80-100 in CTRL2, N279K1, N279K2, and
V337M cultures.
With only two control iPSC lines and no data about how tau phosphorylation at the AT8
epitope proceeds over time in the human fetal brain, the meaning of this result is unclear.
Comparing the proportion of AT8 positive cells derived from the various iPSC lines, I
found a significant difference in the proportion of AT8 positive neurons between CTRL2 and
N279K1 cultures (two-way ANOVA, p=0.0106), and a trend towards a difference between
CTRL2 and N279K2 cultures (two-way ANOVA, p=0.2838). There was no significant
difference between N279K1 or N279K2 and CTRL1, or between V337M and CTRL1 or
CTRL2 according to the two-way ANOVA. The reason for the variability between neurons
derived from the two control and two N279K lines is unclear. It may be due to genetic
background differences, which highlights a weakness of many iPSC-derived neuron studies:
a small number of subjects and a lack of appropriate controls. This variability could have
been controlled for using isogenic iPSC lines.
When the control and N279K line data from day 50 was grouped, there was a significant
difference in the proportion of AT8 positive cells (according to Student’s t-test): more AT8
positive neurons were found in the N279K cultures, which is in agreement with the findings
of Iovino et al. (2015). However, the proportion of AT8 positive neurons observed was
lower in my cultures than in those of Iovino et al. This may be because my neural cultures
were differentiated from iPSCs using a different method, with different steps and media, and
the resulting cells were maintained in media containing cAMP and BDNF (amongst other
factors), both of which support neuronal survival in culture (Dugan et al., 1999; Yoshii and
Constantine-Paton, 2010), whereas Iovino et al.’s cultures were not.
This increase in the proportion of N279K-mutant AT8 positive neurons at day 50 is also
in agreement with the findings of Ehrlich et al. (2015), who found significantly more AT8
positive midbrain-like N279K-mutant neurons at day 40 as compared to control. However,
Ehrlich et al. also found an increase in the proportion of AT8 positive V337M-mutant neurons
as compared to control, whereas I did not detect a difference between V337M and CTRL1 or
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CTRL2. This discrepancy may be due to the difference in neuronal types generated, since
I generated neurons with a forebrain, glutamatergic fate, where Ehrlich et al. generated
GABAergic and catecholaminergic neurons.
To determine the proportion of AT8 positive neurons present in each culture, I counted
the number of AT8 positive cell bodies. This was difficult when cells were closely packed
(since antibodies sometimes failed to penetrate the centre of a large clump of cell bodies),
or when one of the z-stack images contained a large number of AT8 positive processes
which obscured cell bodies (in this case a higher or lower image in the z-stack was used, in
which cell bodies were clearly visible). To overcome these problems, I did not include these
non-representative fields of view, and I re-counted fields of view at least twice. In addition,
the age of the neural cultures hampered this process, as discussed below.
I could have validated the results obtained with AT8 by immunostaining using antibodies
against other phosphorylated tau epitopes, such as PHF-1. In addition, I could have confirmed
this result with Western blotting, ideally using fluorescent secondary antibodies, so that AT8
and total tau could be detected simultaneously. However, epitopes of antibodies such as
AT8 and PHF-1, which are commonly used to detect tau phosphorylation in iPSC-derived
neuronal cultures, are present in both FTDP-17T and during fetal development (Matsuo et al.,
1994; Rizzini et al., 2000; Spillantini et al., 1996a). Therefore, a better alternative would be
to use antibodies against epitopes which are present in FTDP-17T but not fetal brain, such as
AP422 (Morishima-Kawashima et al., 1995), or AT100 (Ksiezak-reding et al., 2000).
4.5.2 Conformational changes in tau
I did not detect MC-1 positive tau in neurons from control or MAPT mutant cultures at day
80-100. This is in agreement with the findings of other groups using iPSC-derived neurons,
since MC-1 positive tau has only been reported in neurons transplanted into the brain of
a AD mouse model after 180 days (Espuny-Camacho et al., 2017), after exposure to tau
oligomers (Usenovic et al., 2015), or after tau overexpression and exposure to tau fibrils
(Medda et al., 2016). MC-1 positive tau has also been found in non-iPSC-derived neuronal
models, including in control hESC-derived neurons over-expressing pseudo-phosphorylated
2N4R tau (Mertens et al., 2013), and in 3D-cultured neurons derived from SHSH-5Y cells
expressing the P301L tau mutation, following exposure to okadaic acid (Seidel et al., 2012).
The tau conformation detected by MC-1 may be preceded by phosphorylation at the
AT8 and PHF1 epitopes, since pseudo-phosphorylation at these epitopes has been shown
to bring the repeat domain and N-terminus of tau closer together, and to increase MC-1
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immunoreactivity (Jeganathan et al., 2008). Since phosphorylation at the AT8 epitope was
detected, it is possible that longer time in culture would have produced MC-1 positive tau.
MC-1 positive tau has been observed relatively early in another model: in 2.5 month-old
mice expressing human P301S-mutant tau (Brelstaff et al., 2015; Xu et al., 2014). However,
as already discussed, neurons detached from their coverslips at around day 100, making
extended timepoints impossible.
Similarly, pFTAA-positive neurons were not detected at day 100. Since pFTAA binds to
AT100 and MC-1 positive neurons in the dorsal root ganglia of mice expressing P301S tau,
and recognises a β -sheet structure, pFTAA detects filamentous tau (Brelstaff et al., 2015).
The lack of misfolded or filamentous tau detected in day 100 cultures is in agreement with
the lack of MC-1 positive misfolded tau detected, and with low levels of phosphorylation at
the AT8 epitope. Since abnormal phosphorylation is thought to occur before misfolding and
aggregation (Goedert and Spillantini, 2001), and may contribute to these processes (Despres
et al., 2017; Haase et al., 2004), a lack of misfolded or fibrillar tau in my cultures is not
surprising. It also echoes the results from other groups using FTDP-17T MAPT-mutant iPSC
derived neurons: other groups have used thioflavin-S and alpha-LISA (which measures the
distance between tau monomers) to detect tau aggregation in iPSC-derived MAPT-mutant
neurons, and found none (Silva et al., 2016; Verheyen et al., 2018). However, some groups
have found evidence for spontaneously occurring tau aggregation in iPSC-derived neurons.
For example, in neurons with the intron 10+16 MAPT mutation, Imamura et al. (2016)
observed staining using the anti-oligomeric TOC antibody which detects mis-folded tau
dimers, oligomers, or polymers (Ward et al., 2013). In addition, Iovino et al. (2015) have
observed AT100 positive tau in cultures of iPSC-derived neurons with the N279K MAPT
mutation.
3D culture may be one way to observe tau aggregation in iPSC-derived neurons. Choi
et al. (2014) cultured hESC-derived neurons overexpressing amyloidβ and/or presenilin 1
with familial AD mutations in either monolayers or a thick, 3D matrigel layer. They observed
amyloidβ deposits and Gallyas-silver positive material in the 3D cultures. 3D culture of
iPSC-derived neurons is explored further in Chapter 6.
4.5.3 αB-crystallin-positive balloon-type neurons
Staining with αB-crystallin revealed some αB-crystallin positive neurons in day 80-100
cultures. There was no significant difference in the proportion of αB-crystallin positive
neurons between the control and MAPT-mutant cultures, but there was a slight trend towards
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an increase. The detection of αB-crystallin positive neurons in iPSC-derived neurons with
the N279K MAPT mutation is in agreement with findings in human brain, where αB-
crystallin positive balloon neurons have been identified (Delisle et al., 1999; Wren et al.,
2015). However, the detection of a low number of αB-crystallin positive control iPSC-
derived neurons contrasts with findings in human brain, since control brains do not contain
αB-crystallin positive balloon neurons, with the exception of brains from people over 90
years old (Iwaki et al., 1990). This suggests that cell culture conditions may have contributed
to the appearance of αB-crystallin positive neurons in control cultures, since these are not
expected to be present in the brain of the donor from whom the iPSCs originated. This could
be confirmed using post-mortem brain tissue from the control fibroblast donors.
The αB-crystallin positive neurons in my cultures were morphologically similar to those
in the brains of people with the N279K MAPT mutation: some had eccentrically positioned
nuclei, some had a strongly αB-crystallin positive process, and others were enlarged. In
addition, αB-crystallin positive thread-like processes were detected in some cultures, which
have also been observed in tauopathy brains (Dabir et al., 2004).
Since αB-crystallin positive balloon neurons in human brains often co-stain with other
antibodies, a possible extension to this work would be to look for immunoreactivity with
antibodies such as synaptophysin (strongly expressed in αB-crystallin positive neurons
in CBD Matsumoto et al., 1996), or phosphorylated neurofilament, which is expressed in
αB-crystallin positive neurons in several diseases, including AD, CDB and PSP (Matsumoto
et al., 1996; Mori et al., 1996; Tolnay and Probst, 1998).
The αB-crystallin expressing neurons were positively identified as neurons by co-staining
with a total tau antibody (HT7) or with an antibody against 4R tau. However, αB-crystallin
positive astrocytes and oligodendrocytes have also been reported in the brains of people
with PSP, CBD and FTDP-17T (with the K317M, N279K or intron 10+16 MAPT mutation)
(Dabir et al., 2004; López-González et al., 2014). I observed a small number of αB-crystallin
positive cells which were not stained with neuronal markers, which may have been αB-
crystallin positive astrocytes. Further studies would be needed to identify the nature of these
αB-crystallin positive structures, but they were outside the scope of my thesis.
Co-staining with αB-crystallin and AT8 antibodies showed that few αB-crystallin positive
neurons were also AT8 positive. It has previously been suggested that high levels of αB-
crystallin expression are part of a protective mechanism which prevents the pathological
accumulation of proteins in neurons: in PD sufferers, high expression of αB-crystallin
and Lewy bodies are almost mutually exclusive in neurons (Braak et al., 2001). This may
explain why few AT8 positive αB-crystallin positive neurons were identified in my cultures.
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However, this staining was only performed on neurons from one differentiation round, so
these findings are preliminary and need to be validated. In addition, the co-staining of cells
for AT8 and αB-crystallin has only been performed in glia from PSP brains (López-González
et al., 2014), making the relevance of AT8 and αB-crystallin co-staining in neurons with
MAPT mutations unclear.
Counting the number of αB-crystallin positive neurons is a superficial way to assess a
potential balloon neuron phenotype, and there is scope to investigate this phenotype further.
For example, there is a decrease in αB-crystallin solubility in CBD in PSP brains as compared
to control, which correlates with an increase in insoluble tau (Dabir et al., 2004). Both of
these phenomena could be investigated simultaneously in aged iPSC-derived MAPT mutant
neurons. In addition, αB-crystallin is subject to post-translational modifications following
stressful stimuli, which make it a less effective chaperone (López-González et al., 2014).
These modifications include phosphorylation at Ser19, 45 and 59, which could be investigated
in future experiments; time constraints did not allow me to pursue this further.
4.5.4 Sodium channel expression and the lack of an AIS
Potential AIS-like sodium channel staining was detected in N279K1 neurons at day 50 from
one differentiation round, but no AIS-like sodium channel staining was detected in any other
cultures at day 16, 50 or 80-100, and no AIS-like staining was detected using the Ankyrin G
or neurofascin antibodies.
It is possible that my iPSC-derived neurons were too immature for these proteins to be
expressed and localised to the AIS. Galiano et al. (2012) found that ankyrin G is not present
at the AIS in axons migrating through the cortical plate at embryonic time points in mice.
Instead, ankyrin G is first detected at postnatal day 1, when most neurons had reached their
destinations within the cortex. However, this explanation is unlikely, since Higurashi et al.
(2013) detected AIS-like sodium channel staining in iPSC-derived neurons at day 56, and I
detected AIS-like sodium channel staining at day 50 in one differentiation round, but not at
day 80-100.
Alternatively, the AIS may not be detectable in the majority of my iPSC-derived neural
cultures because the neurons are not healthy. Schafer et al. (2009) found that neuronal injury
(90 minutes of middle cerebral artery occlusion leading to ischaemia in mice, or optic nerve
crush in mice, or oxygen and glucose deprivation in culture) results in AIS loss, with the AIS
was no longer being detectable with ankyrin G, β IV spectrin, or sodium channel antibodies.
Schafer et al. (2009) demonstrated that AIS loss was due to the specific, calcium-dependent
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proteolysis of ankyrin G and β IV spectrin by the protease calpain, which occurred rapidly
after injury and before cell death, and which was not reversible in neurons kept for eight days
in culture.
Although Schafer et al. cultured cells in media containing no glucose, causing damage,
it is possible that my iPSC-derived neural cultures suffered a lesser degree of glucose
deprivation. To determine if this was the case, I could have measured glucose levels in the
fresh and spent media, using a glucose oxidase/peroxidase assay, for example. It is less likely
that my cultures suffered oxygen deprivation, since they were stored in a normoxic incubator.
A stressor not mentioned by Schafer et al. (2009) which may have contributed to non-
optimal culture conditions is pH. I changed the culture media every other day, but the cells
were densely packed and the media was often orange, indicating a decrease in pH measured
by phenol red. Kwolek and Kepski (2015) have shown that rat primary cortical neurons
are vulnerable to low pH induced cell death, which increases with increasing acidity and
increasing time in an acidic environment. Kwolek and Kepski also found that primary
neurons were unable to maintain their normal pH when the extracellular pH was 6.8 of lower.
It is possible that a chronically lower than optimal pH was a sufficient injury to cause AIS
loss, although this has not been investigated in published work. To determine whether the
pH of cell culture media could have had a deleterious effect, I could have measured the pH
of spent media, although a more practical alternative would have been to plate neurons at
a lower density in larger wells, in order to give them a larger volume of medium. Due to
time constraints and the non-promising nature of these results, I did not investigate sodium
channel expression or the presence of an AIS further.
4.5.5 Spontaneous cell death measured by LDH release
I found no significant increase in cell death over time. When measuring cell death in my
cultures, I normalised LDH release to that at day 70 in CTRL2 cultures for each of the
three differentiation rounds. Day 70 was chosen for normalisation because the range of
luminescence values at day 70 was the smallest, and because at earlier time points some
values were close to zero. A similar approach (normalising to control LDH release) has also
been taken by Ehrlich et al. (2015) and Usenovic et al. (2015) in their investigations of cell
death in iPSC-derived MAPT-mutant neurons, but it does not take into account a potential
increase in cell number over time. Since I plated the same number of NPCs, which were then
exposed to DAPT to cause differentiation to neurons, the increase in cell number over time
is likely to have been similar between cultures. However, to take this into account I could
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have normalised LDH release to the protein concentration in the cell lysate, as was done by
Wren et al. (2015). This method requires separate wells of cells for each timepoint, whereas
I collected media from the same well over time.
In addition, the method I used to detect dying cells provided only a short snapshot of
the number of cells dying in the 48 hours between media changes. This may not have been
sufficient time to find differences in cell death between control and MAPT-mutant cultures.
As an alternative, I could have used a live-cell neuron marker such as NeuO (Er et al., 2015)
to mark neurons, and a live/dead dye. Live imaging over several timepoints would then allow
me to quantify the proportion of living neurons, the proportion of living cells (neurons and
non neurons) and the proportion of dead cells over time. This would have required a large
number of live cultures, and time constraints prevented me from producing these.
No change in cell death over time has also been observed by Medda et al. (2016), who
measured by ATP levels (as a proxy for cell viability) in control iPSC-derived cultures from
day 22-39, and found a non-significant trend towards decreased viability. Since iPSC-derived
neural cultures are more like neurons in the developing brain than those in the adult brain
(Handel et al., 2016; Patani et al., 2012), some cell death over time is to be expected, since
cell death takes place during brain development (Kuan et al., 2000). Alternatively, the low
levels of cell death may be due to the artificial cell culture environment: I maintained my
cultures with media containing cAMP and BDNF, both of which support neuronal survival
(Dugan et al., 1999; Yoshii and Constantine-Paton, 2010).
I found no change in LDH release between cultures derived from control or MAPT-
mutant iPSC lines. This suggests that longer culture periods may be needed to observe
spontaneous cell death in MAPT-mutant cultures, if present. Neuron loss in FTDP-17T
is only documented post-mortem, in brains at an advanced disease stage which contain
aberrantly phosphorylated and filamentous tau (Spina et al. 2017; Slowinski et al. 2007),
and it is difficult to determine the progression of neuron loss from the onset of pathological
changes in the brain. In mice expressing mutant human P301S tau, cortical neuron loss is
detectable as early as 3 months of age (Hampton et al., 2010; Yang et al., 2016), and mice
expressing N279K mutant human tau show substantia nigra neuron loss after 12 months
of age (Dawson et al., 2007). Longer culture might therefore be required for tau aggregate
toxicity to cause cell death. However, longer culture times were not possible, since the
neurons began to detach from their coverslips around day 100.
Since little cell death was detectable in my cultures, it is likely that the decrease in the
amount of β III-tubulin observed between day 50 and day 80-100 by Western blot (Chapter 3)
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was not caused by neuronal death. A more likely explanation is an increase in the proportion
of non-neuronal cells in culture, such as astrocytes, as explored in Chapter 3.
It is possible that FTDP-17T-relevant cell death was occurring in my cultures, but that the
experimental set up could not detect it. The neural cultures contained neurons from NPCs
with a forebrain fate, but I did not determine which layer markers the neurons expressed.
Layer identity may be important to detect a disease-relevant difference in cell death between
control and MAPT-mutant neurons, since layer II neurons may be particularly vulnerable
to cell death in FTDP-17T (Brandt et al., 2005). To explore this further I could have
differentiated iPSCs to layer II neurons, for example by Ngn2 over-expression, which has
been shown to give a pure population of layer 2/3 excitatory induced neurons (Zhang et al.,
2013), and then measured LDH release in control and MAPT-mutant neurons over time.
However, time constraints did not allow cell death to be investigated in more depth.
4.5.6 Experiments on iPSC-derived neural cultures at day 80-100
In conclusion, the N279K and V337M MAPT-mutant iPSC-derived neural cultures showed
limited pathological changes. An increase in tau phosphorylation at the AT8 epitope was
detected at day 50 in N279K relative to control cultures, but tau misfolding was not detected
and nor was tau aggregation. No detectable synapse loss was observed (Chapter 3), and there
was no MAPT-mutant specific increase in cell death under the conditions used. Some of
these phenotypes are further explored in Chapter 6, in which 3D cultures (cerebral organoids)
are made from control, N279K and P301L iPSCs.
Culturing iPSC-derived neurons until day 100 was challenging, as previously discussed
in Chapter 3. Stainings had to be repeated several times due to detachment of cells from the
coverslips, and in some cases β III-tubulin staining had a broken appearance, suggesting the
breakdown of neuronal processes, or non-specific binding of antibodies to the thick layer of
processes. The amount of cell death in the cultures was low and constant over time, indicating
that cultures were viable until they were either fixed or collected for analysis, or detached
from the culture surface. However, the lack of detectable AIS in all but one differentiation
round suggests that the cultures were not in optimal conditions.
4.5.7 Summary
In this Chapter I:
1. Examined the degree of tau phosphorylation at the AT8 epitope (Ser202 and Thr205).
There was an increase in the proportion of AT8 positive neurons over time, which may
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reflect normal maturation of young neurons, since AT8 is detected in the fetal human
brain, as well as in FTDP-17T. There was a higher proportion of AT8 positive N279K
neurons as compared to control neurons at day 50, when both N279K1 and N279K2
cultures were compared to both CTRL1 and CTRL2 cultures, although the proportion
of AT8 positive neurons was small. This was similar to the results of Iovino et al. and
may reflect FTDP-17T-relevant abnormal phosphorylation.
2. Looked for changes in tau’s conformation using the antibody MC-1 (against hairpin-
like conformation of tau) and the dye pFTAA (which detects AT100 positive, MC-1
positive tau). No MC-1 positive or pFTAA positive tau was detected, indicating that
misfolded or fibrillar tau were not present. This fits with the finding that AT8 levels
were low and similar between control and MAPT mutant cultures, since abnormal
phosphorylation is thought to precede tau misfolding and aggregation.
3. Assessed the appearance of αB-crystallin positive balloon neuron-like cells. Some
αB-crystallin positive cells were detected, and the majority of these were neurons,
since they co-stained for tau. However, there was no significant difference in the
proportion of αB-crystallin positive cells between the cultures.
4. Compared the appearance of sodium channels between MAPT mutant and control
cultures. Diffuse sodium channel staining was detected, but no AIS-specific staining
was detected with a pan-sodium channel antibody, a neurofascin antibody, or an ankyrin
G antibody. The lack of AIS detected suggests that the neurons may have been in
sub-optimal conditions.
5. Measured differences in spontaneous cell death. There were no significant differences
in cell death over time, or between cultures from different iPSC lines, although there
was a slight trend towards an increase in cell death over time. This result, and the
finding that the proportion of astrocytes increased over time (Chapter 3) suggests that
the decrease in β III-tubulin over time was due to an increase in the proportion of
non-neuronal cells, rather than neuron death.
I found minimal phenotypic changes in MAPT mutant iPSC-derived neurons as com-
pared to control iPSC-derived neurons. This may be due in part to the genetic background
differences between the five iPSC lines. Therefore, in Chapter 5, I will use the gene editing
technology CRISPR to make two isogenic iPSC lines which differ only at the N279K muta-
tion locus. In Chapter 6, I will use these isogenic iPSCs to make 3D cerebral organoids, since
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3D culture may increase neuronal maturity, and may enable the detection of disease-relevant
phenotypes (Choi et al., 2014).
Chapter 5
Gene editing by CRISPR to make
isogenic iPSC lines
5.1 Aims
One barrier to studying the effects of the N279K mutation in iPSC-derived neurons is the
genetic variability between iPSC lines derived from an FTDP-17T patient with the N279K
mutation and a control subject with no MAPT mutations. This barrier can be avoided by
making isogenic iPSC lines, share the same genetic background, differing only at the N279K
mutation. Isogenic iPSC lines are also more suitable than non-isogenic iPSC lines for making
3D cultures such as cerebral organoids, in which variability between cultures derived from
different iPSC lines can be high (see Chapter 6).
This Chapter describes the attempt to use CRISPR to produce isogenic iPSC lines by
correcting the N279K mutation in FTDP-17T patient-derived iPSCs and to induce the N279K
mutation in control subject-derived iPSCs.
5.2 Introduction
5.2.1 The origins of CRISPR
"CRISPR" stands for clustered regularly-interspaced short palindromic repeats and refers to
short DNA sequences in prokaryotes which were first found by Ishino et al. (1987) in E. coli.
The significance of these sequences was confirmed when Barrangou et al. (2007) showed
that bacteria exposed to bacteriophages incorporated bacteriophage DNA fragments (named
"spacers") into their genomes, between CRISPR sequences. When the spacers were removed
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from bacteria resistant to a particular bacteriophage, the bacteria became vulnerable to the
bacteriophage again, indicating that inclusion of foreign DNA into the CRISPR array plays
an active role in prokaryote adaptive immune systems.
CRISPR systems have since been discovered in a range of archea and prokaryotes and
can be divided into two classes (Makarova et al., 2015). Class 1 (types I, III and IV) CRISPR
systems are defined by their multi-protein complexes which bind to and cleave the target
DNA, whereas Class 2 systems (types II and V) have a lone effector protein. The type II
CRISPR system is most commonly used in gene editing and is discussed here.
The CRISPR defence mechanism has three stages: adaptation, expression and interference
(reviewed by Sternberg and Doudna, 2015). In prokaryotes with type II CRISPR systems, a
library of protospacer sequences, interspaced with CRISPR sequences, is acquired during
the adaptation phase. On transcription (the expression phase), CRISPR RNA (crRNA)
is produced and base-pairs with transactivating CRISPR RNA (tracrRNA) (Figure 5.1).
The crRNA-tracrRNA hybrid complexes with the effector CRISPR-associated protein 9
(Cas9) nuclease, targeting Cas9 to DNA sequences complementary to the protospacer. If
these sequences directly precede a protospacer-adjacent motif (PAM), Cas9 cuts both DNA
strands, completing the interference phase. Thus, exogenous DNA sequences are specifically
disrupted, conferring resistance against invading viruses and plasmids.
5.2.2 CRISPR for gene editing
CRISPR has been adapted for gene editing because it can make predictable DNA breaks at
specifically targeted sequences. CRISPR-Cas9 technology for gene editing is derived from
the Streptococcus pyogenes adaptive immune system (reviewed by Ran et al., 2013). To
edit DNA, guide RNA (gRNA) is designed complementary to a target DNA sequence, with
minimal homology between the gRNA and the rest of the genome, to avoid off-target DNA
editing. gRNA is then inserted into an RNA backbone which combines aspects of tracrRNA
and crRNA. The gRNA complexes with Cas9 protein and directs Cas9 to cut the DNA at
the target site (Figure 5.1), provided that the DNA target directly precedes a PAM (bases
NGG in the S. pyogenes system, where N is any base). Wild-type Cas9 (Cas9wt) makes a
double-stranded DNA break (DSB) but a modified version, Cas9 nickase (Cas9n), which has
a D10A mutation in the RuvC catalytic region, can be used to make a single-stranded cut
on the strand complementary to the gRNA (Jinek et al., 2012). A Cas9n pair targeted to the
sense and anti-sense strands makes an offset DSB, which reduces the chance of off-target
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Fig. 5.1 The S. pyogenes CRISPR system in immunity and in gene editing. A) The type II
CRISPR system in S. pyogenes. Fragments of exogenous DNA are incorporated as protospacers
between CRISPR repeats. tracrRNA and crRNA are transcribed, then hybridise with each other and
Cas9 nuclease. The crRNA targets the Cas9-crRNA-tracrRNA complex to its complementary DNA
and Cas9 makes a double-strand break (DSB). B) The type II S. pyogenes CRISPR system adapted
for gene editing. gRNA, a fusion of crRNA (designed complementary to a target DNA sequence) and
tracrRNA, is transcribed and hybridises with Cas9. gRNA targets Cas9 to its complementary DNA
sequence and Cas9 makes a DSB. C) A DSB can be made by wild-type Cas9 (right) or Cas9 nickase
(left) which makes two neighbouring single-stranded breaks, constituting an off-set DSB. The DSB is
repaired by homology-directed repair with a single- or double-stranded DNA template containing
the desired mutation. The mutation is precisely inserted into the endogenous DNA. Diagram adapted
from Sander and Joung (2014).
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DNA cutting since the homologous region required for a DSB is twice as long as that of
Cas9wt.
DSBs are then repaired by non-homologous end joining (NHEJ) or homologous recom-
bination (HR). NHEJ makes insertion and deletion mutations (indels) of varying lengths,
which can result in a premature stop codon and gene knockout (reviewed by Chang et al.,
2017). In HR, homologous DNA acts as template for precise reconstruction (reviewed by
Ranjha et al., 2018). Providing a double- or single-stranded DNA template with the desired
insertion, deletion or point mutation can hijack the HR pathway for gene editing to make
precise mutations, in a process known as homology-directed repair (HDR) (Figure 5.1).
5.2.3 Mechanisms of DNA repair by homologous recombination
HR can occur via one of several mechanisms (Figure 5.2): double-strand break repair
(DSBR), synthesis-dependent strand-annealing (SDSA), or single-strand DNA incorporation
(ssDI). Kan et al. (2014) showed that HR with a double-stranded DNA repair template takes
place via DSBR in human cells: 5’ cut DNA ends are resected to leave 3’ single-stranded
DNA, which invades the double-stranded template. New DNA is synthesised, forming double
Holliday junctions. These are resolved, then the endogenous DNA and repair template
separate, producing either cross-over or non-cross-cover products.
HR with a single-stranded DNA oligomer (ssODN) template occurs preferentially via
SDSA in human cells, although ssDI is also possible (Kan et al., 2017). In SDSA, 5’ cut
DNA ends are resected, then the 3’ single-stranded DNA end extends along the homologous
complementary sequence of the ssODN. The newly synthesised strand disengages from the
ssODN and anneals to the complementary DNA strand. After the resolution of remaining
gaps, the result is a non-cross over product: the break is repaired by newly synthesised DNA
(Nassif et al., 1994). This contrasts with ssDI, in which the ssODN itself is incorporated into
the DNA at the break site (Radecke et al., 2006).
5.2.4 Off-target editing with CRISPR
Cas9 is guided to its target locus by gRNA binding to complementary DNA but off-target
editing can still occur despite the specificity of nucleotide binding. The extent of reported
off-target editing with CRISPR varies considerably (reviewed by O’Geen et al., 2015).
For example, Fu et al. (2013) used CRISPR to edit DNA at four loci in HEK293 (human
embryonic kidney), U2OS (human osteosarcoma) and K562 (human leukaemia) cells, then
sequenced these loci and the most similar off-target loci. Fu et al. found high on- and
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Fig. 5.2 Mechanisms of DNA repair by homologous recombination. Mechanisms of DSBR,
SDSA and ssDI are shown. Red lines indicate endogenous DNA which has a double stranded break,
blue lines indicate double- or single-stranded repair template DNA. Repair of the double-stranded
break with a single-stranded template can lead to the incorporation of the template (in ssDI) or the
synthesis of new DNA, without the incorporation of the template (in SDSA). The figure was adapted
from https://blog.addgene.org/crispr-101-homology-directed-repair (DSBR and SDSA), Liang et al.,
2017 and Kan et al., 2017 (ssDI).
144 Gene editing by CRISPR to make isogenic iPSC lines
off-target editing rates: the off-target loci examined had between one and four mismatches
with the target locus but off-target and on-target editing rates were comparable.
Other groups report low levels of off-target modification. Hsu et al. (2013) found off-
target modifications after CRISPR in HEK293 cells at a rate two orders of magnitude below
that of on-target editing and Cho et al. (2014) found off-target editing at a frequency of
0.01% in K562 cells, compared to an on-target frequency of 60-75%. The differing extent
of reported off-target editing might be explained by targeting different loci, or by varying
dosages of Cas9 since on- and off-target editing increases as the concentration of transfected
Cas9 increases (Hsu et al., 2013).
Gene editing efficiency is lower in iPSCs than in other cell types, such as HEK293 or
K562 cells (Mali et al., 2013). If off-target effects occur approximately 100 times less often
than on-target editing (as suggested by Hsu et al., 2013 and Cho et al., 2014), off-target
editing may be near undetectable in iPSCs. Indeed, whole-genome sequencing of two
CRISPR-edited iPSC lines and their parental line gave an estimate of 7-12 indels and 217-281
point mutations in each iPSC genome after editing (Smith et al., 2014). However, these
mutations did not overlap with off-target sites predicted by sequence homology and were
unique to each edited iPSC line, suggesting that they may have occurred spontaneously during
iPSC clone expansion, not because of off-target Cas9 cutting. Veres et al. (2014) performed
a similar experiment with six CRISPR-edited human embryonic stem cell (ESC) lines, and
found indels, structural variants and point mutations but the modification locations could
not be predicted by off-target gRNA binding, again suggesting that they may have emerged
during clonal expansion. These results indicate that gene editing by CRISPR appears to be
highly specific in iPSCs, but the isogenic iPSC lines generated can contain mutations arising
during clonal expansion which may remain undetected unless whole-genome sequencing is
performed.
5.2.5 Minimising unwanted CRISPR activity
CRISPR is reported to be highly specific in iPSCs (Smith et al., 2014; Veres et al., 2014)
but off-target editing is possible (Cho et al., 2014; Fu et al., 2013; Hsu et al., 2013) and the
magnitude of off-target effects may depend on the gRNA used (Fu et al., 2013; Tsai et al.,
2015). In addition to off-target editing, unwanted CRISPR modifications can also occur at
the target site, for example when the repaired DNA is re-cut by Cas9. The CRISPR design
strategies discussed in this section decrease the chances of unwanted CRISPR activity.
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Cas9 nickase (Cas9n)
Cas9n makes a single-stranded DNA break and a Cas9n pair can be used to make an offset
DSB. Compared to Cas9wt, Cas9n decreases the probability of off-target mutations since
the homologous sequence required for two adjacent single-stranded DNA breaks (Cas9n) is
twice that required for one DSB (Cas9wt). The requirement for a longer homology region
decreases the chance of similar off-target sequences in the genome and paired Cas9n sites
without meaningful off-target homology are easy to find (Sections 5.4.1 and 5.4.2).
Furthermore, unpaired (off-target) single-stranded breaks created by Cas9n are repaired
seamlessly, unlike DSBs, which are repaired by error-prone NHEJ (Cong et al., 2013;
reviewed by Dianov and Hübscher, 2013). This results in fewer off-target indels. Cho et al.
(2014) measured off-target cleavage induced by Cas9wt and Cas9n pairs at six off-target sites,
which differed from the target site by one or two nucleotides. Cas9wt produced off-target
indels at a frequency of 0.5-10%, as compared to no indels above the detection limit of
0.01% for Cas9n. Similarly, Ran et al. (2013b) used deep sequencing to compare off-target
cleavage at five loci after editing by either Cas9wt or Cas9n. Both Cas9wt and Cas9n had
similar on-target activity but the specificity (the ratio of on- to off-target indel formation) was
100-fold higher for Cas9n than for Cas9wt.
Another advantage of Cas9n is that it may favour HDR over NHEJ, increasing the
probability of making precise mutations with a repair template. Mali et al. (2013) compared
the effects of transfecting HEK293 cells with a repair template and either Cas9wt or a Cas9n
pair and observed decreased NHEJ with Cas9n but similar levels of HR. Later, Gopalappa et al.
(2018) reported that paired Cas9n are at least as efficient for making on-target modifications
as Cas9wt and are sometimes more efficient.
Altered gRNA length
Truncating gRNAs from the usual 20 nucleotides reduces off-target modifications. Fu et al.
(2014) used gRNAs between 15 and 20 nucleotides long to target Cas9 to four sequences
in one gene and found that 17 or 18 nucleotide-long gRNAs had similar on-target activity
to 20 nucleotide gRNAs but made fewer off-target cuts. gRNAs with 15 or 16 nucleotides
produced either undetectable or significantly reduced on-target activity. Fu et al. suggest
that the counter-intuitive increase in activity with shorter gRNAs occurs because the last two
nucleotides are not essential for on-target gRNA binding but they could compensate for other
mismatches between the DNA and gRNA at off-target sites.
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Counterintuitively, adding two guanine nucleotides (GG) to the 5’ end of gRNA can also
increase specificity. The standard format for gRNA is GX19, where X is any nucleotide and
G is guanine, which is required for RNA transcription (Ran et al., 2013b). Cho et al. (2014)
compared four GGGX19 gRNAs with four corresponding GX19 gRNAs and found that all
four GGGX19 gRNAs caused fewer off-target indels in K562 cells. One GGGX19 gRNA
resulted in fewer on-target indels than the corresponding GX19 gRNA, suggesting that the
additional GG decreases off-target indels by decreasing gRNA-DNA binding at all loci.
Single-stranded repair templates
Single-stranded ssODN repair templates may lead to fewer off-target effects than double-
stranded plasmid repair templates. Chen et al. (2011) measured random integration of single-
and double-stranded repair templates into cell line DNA after CRISPR and detected randomly
integrated plasmid DNA but ssODNs were randomly integrated at a low enough frequency to
be undetectable.
Studies comparing the efficiency of single- and double-stranded DNA templates for
inducing precise mutations have given varied results. ssODNs are reported to be more
efficient for small insertions in K562 cells (Chen et al., 2011), or for point mutations in
HEK293 cells (Liang et al., 2017). However, plasmids are reported to be more efficient for
point mutations in iPSCs (Flynn et al., 2015) and HEK293 cells (He et al., 2016). These
results indicate that both ssODNs and plasmids can be used for HDR and suggest that their
relative efficiency is context dependent. The discrepancy in editing efficiency could be caused
by different target loci, transfection methods, ssODN or plasmid production methods or the
effective template concentration at the repair site in each of the studies. Since both ssODNs
and plasmids can induce precise mutations, eschewing plasmids for ssODNs to reduce the
possibility of random integration will not necessarily decrease on-target editing efficiency.
Minimising homology between on- and off-target loci
DNA cleavage by Cas9 relies on homology between the gRNA and target DNA. Therefore,
off-target cleavage can be reduced by using gRNA design programs to maximise the number
of mismatches between the target locus and the rest of the genome. Single nucleotide
mismatches are most effective when they are in the gRNA seed sequence: the 8-13 nucleotides
closest to the PAM (Jinek et al., 2012). Mutations outside this region are better tolerated by
Cas9, which can still cut the DNA (Hsu et al., 2013).
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Single nucleotide mismatches are not always sufficient to prevent off-target cleavage.
Cho et al. (2014) measured indels at loci which differed from the target site by one nucleotide
and detected off-target activity at a frequency of 1.6-43% across three gRNA. When the
mismatch was increased to two nucleotides, off-target editing was reduced to 0.1-1.8%.
Although only three gRNAs were compared, this study shows that the number of mismatches
needed to significantly reduce off-target editing varies between gRNAs, even at the same
gene locus.
The positioning of mismatches relative to the PAM and to each other can also alter the
rate of off-target cleavage. Hsu et al. (2013) quantified indels at three loci, using multiple
gRNAs which had two, three or five mismatches with the target locus. Hsu et al. found
that DNA cleavage occurred at lower rates when mismatches were: consecutive or less than
four base pairs (bp) apart; at least two mismatches were in the seed region; and there were
at least three mismatches. Two mismatches between the gRNA and DNA decreased indel
formation but three mismatches reduced indel formation to near undetectable levels unless
the mismatches were all distal to the PAM. Five mismatches provided little advantage over
three mismatches, suggesting that three mismatches should be the minimum acceptable
difference between on- and off-target loci.
Cas9-mediated DNA cleavage also depends on the presence of an NGG PAM sequence
3’ of the gRNA binding site. A single nucleotide mismatch in a potential (off-target) PAM
sequence can reduce off-target DSBs almost 500-fold (Cho et al., 2014), underlining the
importance of the PAM sequence. However, Cas9 can cleave DNA with an NAG PAM
sequence, as well as the NGG sequence, increasing the number of off-target sites with a
potential PAM (Hsu et al., 2013).
Off-target gRNA-DNA binding is possible even with mismatches: gRNA can bind DNA
with up to three (Mali et al., 2013) or up to five (Li et al., 2014b) non-matching bases.
However, gRNA binding does not necessarily result in DNA cleavage. Wu et al. (2014)
mapped DNA binding to four different catalytically inactive gRNA-dead Cas9 complexes
in mouse ESCs and found binding at 26-6000 loci, depending on the gRNA. Repeating
the experiment with catalytically active gRNA-Cas9 complexes resulted in an off-target
mutation at only one locus, indicating that requirements for Cas9 cutting are more stringent
than for Cas9 binding. Programs such as the CRISPR Design Tool (http://crispr.mit.edu/),
which predict off-target cleavage sites by homology with the target sequence, may therefore
over-estimate the number of potential off-target cutting sites.
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Blocking mutations
Silent blocking mutations, in the PAM or gRNA target sequence, can be introduced in the
repair template to prevent Cas9 re-cutting DNA after HDR. The introduction of blocking
mutations follows the same principle as minimising homology between on- and off-target
sites: a blocking mutation in the PAM sequence (Cho et al., 2014), or between one and
three blocking mutations in the gRNA binding sequence (Cho et al., 2014; Hsu et al., 2013),
preferably in the seed region (Jinek et al., 2012), reduce re-cutting most efficiently. However,
blocking mutations must be silent, to avoid altering the target protein.
Blocking mutations increase the number of correctly edited clones. Using a repair
template with a mutant PAM sequence increases editing efficiency in iPSCs 10-fold (Flynn
et al., 2015), or between two- and 10-fold, depending on the locus (Paquet et al., 2016).
Similar results have been found in HEK293 cells (He et al., 2016; Paquet et al., 2016).
Blocking mutations can also reduce unwanted on-target modifications. Merkle et al.
(2015) found that 18% of sequencing reads from iPSC clones with an insertion had on-target
indels but when the insertion site was altered to destroy the gRNA binding site, on-target
indels fell to 0.08% of sequencing reads in edited clones.
5.2.6 Maximising on-target editing
Mutation locus proximity to the double-stranded break (DSB)
The distance between the DNA break and the desired mutation locus is a major factor in
causing a point mutation. Elliott et al. (1998) measured point mutation induction in mouse
ESCs after DSBs were made by I-SceI endonuclease and found higher mutation induction
closer to the DSB: 83% of clones which underwent HDR resulting in a correction at the
cut site also had a point mutation 7bp away and 40% of clones corrected at the cut site had
a point mutation 45bp away. In iPSCs, Paquet et al. (2016) had similar findings: 50% of
clones which underwent HDR incorporated a point mutation 10bp from the DSB, 25% of
edited clones incorporated a point mutation 20bp from the DSB and 10% of edited clones
incorporated a point mutation 30bp away. Paquet et al. (2016) observed similar results in
HEK293 cells.
These high percentages (the proportion of edited clones which also contain point mu-
tations) can be misleading since the proportion of edited clones out of all clones screened
can be very low. For example, after CRISPR to cause a point mutation less than 10bp from
the DSB, Yang et al. (2013) found that 1% of all iPSC clones sequenced incorporated the
mutation. When the mutation was 20bp from the DSB, only 0.2% of all clones screened had
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the mutation. Together, these results indicate that point mutation induction is more likely
when the distance between the DSB and the mutation locus is lower.
5.2.7 Advantages of CRISPR for gene editing
CRISPR has several advantages over the gene editing systems zinc-finger nucleases (ZFNs)
and transcription activator-like effector nucleases (TALENs).
Firstly, CRISPR components are relatively quickly designed and synthesised compared
to ZFNs or TALENs. CRISPR relies on DNA-RNA base pairing, so Cas9 can be targeted to
a particular locus by finding a sequence with a neighbouring PAM, then inserting the gRNA
sequence into a Cas9 and gRNA expression plasmid (Ran et al., 2013b).
In contrast, ZFNs and TALENs rely on DNA-amino acid pairing, making their design and
synthesis more complex and time consuming. ZFNs are based on zinc fingers: eukaryotic
DNA binding domains in which groups of amino acids recognise different nucleotide triplets.
Zinc fingers recognising every possible nucleotide triplet are available, so ZFN dimers can be
targeted to a locus by combining the appropriate zinc fingers with a Fok1 cleavage domain.
At the target site, the Fok1 nuclease domains dimerise and cleave the DNA (Vanamee et al.,
2001). However, ZFNs cannot be targeted to every locus. TALENs are based on TALE
DNA-binding domains, which are repeat sequences that recognise one nucleotide. Like ZFNs,
TALENs are also designed as dimers, by combining appropriate DNA binding domains which
are fused to FokI nuclease (reviewed by Gaj et al., 2013).
Secondly, Cas9 makes a blunt-ended DSB 3bp upstream of the PAM Jinek et al. (2012),
whereas TALENs cut DNA non-specifically in the 12 to 24bp space between the TALEN
binding sites (Miller et al., 2011). Predicting the cut position matters for small mutation
induction by HDR since mutations closer to the DSB are more likely to be included (Elliott
et al., 1998; Yang et al., 2013).
Perhaps most importantly, CRISPR is reported to have higher, or at least equal, gene
editing efficiency compared to TALENs in iPSCs. Yang et al. (2013) targeted seven sequences
at one gene locus in iPSCs with Cas9 or TALENs, and found that Cas9 resulted in more
edited clones. Similarly, Ding et al. (2013) compared Cas9- and TALEN-mediated gene
knock-down at seven loci and mutation knock-in at one locus in iPSCs: Cas9 gave more
edited clones for both knock-out and knock-in. Ding et al. suggest that Cas9 is better
tolerated by iPSCs than TALENs since the GFP marker in TALEN and CRISPR plasmids
was expressed earlier and in a higher proportion of iPSCs electroporated with Cas9 than with
TALENs.
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Other groups report comparable activity between TALENs and CRISPR in iPSCs: Li et al.
(2014a) used two TALEN and one CRISPR strategy to cause gene knock-out and knock-in
and found similar indel and insertion rates induced by each method.
Overall, CRISPR is easier to design than ZFNs or TALENs, makes more predictable cuts
than TALENs and is at least as efficient at gene editing in iPSCs as TALENs.
5.2.8 Using CRISPR to make isogenic iPSC lines
CRISPR, ZFNs and TALENs have increased the potential use of iPSCs to make iPSC-
derived disease models since they allow isogenic lines to be created, which differ only at a
disease-relevant mutation. Isogenic iPSC lines can be used to observe the disease-relevant
effects of a mutation without the intrusion of unpredictable changes caused by the genetic
background. Avoiding differing genetic backgrounds between control and mutant iPSC
lines is advantageous because different iPSC lines have different gene expression and DNA
methylation profiles (Bock et al., 2011) and have variable capacities to differentiate into other
cells types, such as motor neurons (Boulting et al., 2011).
The efficiency of CRISPR-mediated gene editing is lower in iPSCs than in other human
cell lines, such as HEK293 cells (Mali et al., 2013). The reported indel efficiency ranges
from 51-79% (Ding et al., 2013) to 1% (Miyaoka et al., 2014) and point mutation efficiency
ranges from 23% (Flynn et al., 2015) to 1% (Yang et al., 2013).
At least 11 isogenic iPSC lines with MAPT mutations have been produced using CRISPR
or TALENs and these are listed in Table 5.1. Other MAPT mutant iPSC lines or iPSC-derived
cells are available through repositories or commercially, but have not yet been described in
any publications.
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Table 5.1 iPSC lines and iPSC-derived cells with MAPT mutations induced by gene
editing.
Cell type Initial mutation→ edited population Editing method References
iPSCs Het A152T→ Hom A152T TALENs [1]
iPSCs Het A152T→ Isogenic control TALENs [1]
NPCs Het A152T→ tau knockdown CRISPR [2]
NPCs Het N279K→ isogenic control CRISPR [3]
iPSCs Het P301L→ isogenic control CRISPR [4]
iPSCs Het intron 10+14→ isogenic control CRISPR [5]
iPSCs R406W→ isogenic control CRISPR [5,6,7]
iPSCs Control→ Hom N279K, P301L, intron 10+16 CRISPR-FokI [8]
iPSCs Control→ Het intron 10+16 ZFNs [9]
iPSCs Control→ Hom intron 10+16 ZFNs [9]
iPSCs Control→ Hom P301L, intron 10+16 ZFNs [9]
Abbreviations: het: heterozygous mutation; hom: homozygous mutation; iPSC: induced pluripotent
stem cell; NPC: neural precursor cell. References: [1]: Fong et al. (2013); [2]: Silva et al. (2016); [3]:
Hallmann et al. (2017); [4]: Nimsanor et al. (2016a); [5]: Imamura et al. (2016); [6]: Nimsanor et al.
(2016b); [7]: Nimsanor et al. (2016c); [8]: (García-León et al., 2018); [9]: (Verheyen et al., 2018).
Gene editing in proliferative versus non-proliferative iPSCs and iPSC-derived cells
Gene-editing is usually performed on proliferative cells, which can be amplified by passaging.
In the case of iPSC-derived neurons, iPSCs or neural precursor cells (NPCs) are usually
edited, then differentiated to neurons. This is because relying on HDR to induce a precise
mutation after a DSB requires efficient DNA repair machinery. Saleh-Gohari (2004) found
that HDR of DSBs in a human cell line was 24 times higher in cells arrested in S (synthesis)
phase as compared to those arrested in G0 (resting) or G1 phases, suggesting that actively
dividing cells are more likely to use the HR pathway for DNA repair than cells in a resting
state.
Furthermore, the dominant repair mechanism for DSBs switches from HDR in prolifera-
tive NPCs to NHEJ in post-mitotic neurons. Orii et al. (2006) showed that, in embryonic
day 14.5 mice with defective NHEJ machinery and normal HR machinery, differentiated
neurons were more vulnerable to DNA damage-induced apoptosis as compared to the control
mice. This suggests that DNA damage in neurons is repaired mainly by NHEJ but not HR.
Orii et al. also noted that mouse embryos with inactive HR machinery and normal NHEJ
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capability had widespread DNA damaged-induced apoptosis in proliferative NPC regions
throughout the brain and did not survive beyond embryonic day 10, indicating that DNA
repair takes place mainly by HR, not NHEJ, in NPCs. For gene-editing by CRISPR, these
findings suggest that precise mutations by HDR are most likely to occur in proliferative cells,
whereas indels are more likely in post-mitotic cells.
5.3 Materials and Methods
5.3.1 Design and assembly of Cas9 nickase and Cas9 wild-type plas-
mids
Three CRISPR strategies, two using Cas9 nickase (Cas9n) and one using Cas9 wild-type
(Cas9wt), were designed to target the N279K mutation locus in tau exon 10, following the
protocol of Ran et al. (2013b). For both the Cas9n strategies, two gRNA sequences ("left"
and "right") were chosen using a CRISPR design tool (http://crispr.mit.edu/). The input
sequence was 242bp centred on tau exon 10: 80bp of intron 9, exon 10 (93bp) and 45bp
of intron 10. The Cas9wt gRNA location was chosen by inspection of the DNA sequence
of tau exon 10 and checked with the CRISPR design tool to check for off-target matches.
The choice of gRNA sequences was limited by the need for: a PAM sequence (bases NGG,
where N is any base) immediately downstream of the gRNA sequence; DSB proximity to the
N279K mutation locus; and a 0-20bp offset between the gRNA sequences for Cas9n (Ran
et al., 2013b).
For both Cas9n strategies, four single-stranded DNA oligomers (left and right, sense and
anti-sense) were obtained (Sigma). The anti-sense strand of the left pair and the sense strand
of the right pair would act as gRNA in the left and right Cas9n plasmids. For the Cas9wt
strategy, two single-stranded DNA oligomers were required, in which the sense strand would
act as the gRNA (Table 5.2).
The oligomers were diluted to 100µM with ddH2O. One µl sense and anti-sense oligomers
were mixed with 8µl of ddH2O and annealed (95ºC for five minutes, cooling down to
25ºC at 5ºC/minute). This formed left and right gRNA oligomers with overhanging se-
quences for ligation into Cas9 plasmids. One µl of 1µg/µl Cas9n plasmid (#48141, Addgene,
pSpCas9n(BB)-2A-Puro from Ran et al., 2013) or Cas9wt plasmid (#62988, Addgene,
pSpCas9(BB)-2A-Puro from Ran et al., 2013) was digested with 1µl Bbs1, 2µl 10x Buffer
2.1 (both New England Biolabs) and 16µl ddH2O for three hours at 37°C. 1 µl of either left
or right annealed oligomers (for Cas9n) or the annealed oligomers (for Cas9wt), 1.5µl T4
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Table 5.2 Oligomer sequences for incorporation into Cas9 plasmids.
CRISPR strategy gRNA Strand Sequence
Sense AAACGTCCAAGTGTGGCTCAAAGGC
Left
Anti-sense CACCGCCTTTGAGCCACACTTGGAC
Sense CACCGAATATCAAACACGTCCCGGG
1 (nickase)
Right
Anti-sense AAACCCCGGGACGTGTTTGATATTC
Sense AAACTGCGAGCAAGCAGGCGGGTCC
Left
Anti-sense CACCGGACCCGCCTGCTTGCTCGCA
Sense CACCGGTGTCACTCATCCTTTTTTC
2 (nickase)
Right
Anti-sense AAACGAAAAAAGGATGAGTGACACC
Sense CACCGGCAGATAATTAATAAGAAGC
3 (wild-type) -
Anti-sense AAACGCTTCTTATTAATTATCTGCC
Sequences are written 5’ to 3’. Underlined bases are sequences for ligation, which were digested with
the restriction enzyme Bbs1. Each gRNA sequence contains 19 nucleotides homologous to the DNA
target, the 1st base in each gRNA is G, which is part of the U6 promotor.
DNA ligase and 1 x T4 ligase buffer (both New England Biolabs) were added to the digestion
mixture for three hours at 37°C.
One Shot Stbl3 Chemically Competent E.coli (Invitrogen) were transformed with 1µl left-
Cas9n, right-Cas9n or Cas9wt plasmids by heat shock at 42°C for 45 seconds as described in
the manufacturer’s instructions. Transformed bacteria were streaked on agar plates containing
ampicillin (100µg/ml, Sigma) and incubated overnight at 37°C. Cas9n plasmids contained
ampicillin-resistance genes for selection of plasmid-containing bacteria. Single colonies
were picked and incubated in 5ml LB medium (Invitrogen) with ampicillin at 37°C, shaking
at 225rpm overnight. Plasmid DNA was extracted using a Qiagen miniprep kit: a bacterial
cell pellet was collected by centrifugation at 13000g for three minutes and re-suspended
in 250µL re-suspension buffer. The cells were lysed and their DNA denatured with 250µL
lysis buffer, containing sodium hydroxide and sodium dodecyl sulfate (SDS). Cell debris
were precipitated with 350µL high-salt buffer and pelleted by centrifugation at 17000g for
10 minutes. The supernatant, containing plasmid DNA, was centrifuged at 17000g for 60
seconds in a spin column. DNA bound to the spin column was washed with 750µL PB
buffer, then with 750µL PE buffer and centrifuged at 17000g for 60 seconds to remove
remaining high salt buffer. Bound DNA was eluted with 30µL water and stored at -20°C.
gRNA incorporation into the Cas9n plasmids was confirmed by Sanger sequencing (Source
Bioscience) with the primer U6-Fwd (Table 5.3).
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Table 5.3 Primers used for PCR and sequencing.
Primer name Sequence F/R Reference
U6-Fwd GAGGGCCTATTTCCCATGATTCC F [1]
073 GGGGTACCAATCCCAGCTTCGTAAAGCCCGCT F [2]
074 CGGGATCCTCATCTGCCCTATTCTGTCCACACA R [2]
E75 TCGAAAGTGGAGGCGTCCTT F -
REV83 GCATGGGACGTGTGAAGGTA R -
Sequences are written 5’ to 3’. All primers were ordered from Sigma. References: [1]: Source
Bioscience (www.sourcebioscience.com); [2]: Anfossi et al. (2011).
For transfection, DNA was amplified from 50ml overnight cultures of transformed
bacteria. Plasmid DNA was purified using an endonuclease-free maxiprep kit (Qiagen):
a bacterial cell pellet was collected by centrifugation at 6000g for 15 minutes at 4°C and
re-suspended in 10ml re-suspension buffer. The cells were lysed and their DNA denatured
with 10ml lysis buffer, then cell debris were precipitated with 10ml high-salt buffer and
removed by filtration. The lysate was incubated on ice for 30 minutes with 2.5ml endotoxin
removal buffer to prevent bacterial lipopolysaccharides binding to the DNA-binding column.
The lysate was filtered through a Qiagen column by gravity to bind plasmid DNA. Bound
DNA was washed and subsequently eluted with 15ml high-salt buffer. Plasmid DNA was
precipitated with isopropanol and collected by centrifugation at 15000g for 10 minutes. The
DNA pellet was washed with endotoxin-free ethanol, centrifuged at 15000g for 10 minutes
and then air-dried. Plasmid DNA was re-suspended in 50µL ddH2O and stored at -20°C.
5.3.2 Homology directed repair templates
Single-stranded repair template for CRISPR 2
A 153bp sense ssODN (sequence below), centred on the right nick site, with the N279K
mutation (red nucleotide) and the left PAM mutation (green nucleotide), was ordered from
Integrated DNA Technologies as a 4nM, desalted, non-PAGE purified ultramer and diluted
under sterile conditions with ddH2O to 10µM for transfection. The position of the N279K
mutation locus relative to both PAM sites is shown in Figure 5.6.
ssODN sequence:
5’-TCCAGGGTGGCGCATGTCACTCATCGAAAGTGGAGGCGTGCTTGCGAGCAAGCAGG
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CGGGTCCAGGGTGGCGTGTCACTCATCCTTTTTTCTGGCTACCAAAGGTGCAGATAATT
AAGAAGAAGCTGGATCTTAGCAACGTCCAGTCCAAGTG-3’
Single-stranded repair template for CRISPR 3
Two 100bp sense ssODNs (sequences below), centred on the N279K mutation, were ordered
from Integrated DNA Technologies as 4nM, desalted, non-PAGE purified ultramers. One
ssODN had the N279K mutation (red nucleotide):
5’-TGGCGTGTCACTCATCCTTTTTTCTGGCTACCAAAGGTGCAGATAATTAAGAAGA
AGCTGGATCTTAGCAACGTCCAGTCCAAGTGTGGCTCAAAGGATAA-3’
The other ssODN had the control sequence (blue nucleotide):
5’-TGGCGTGTCACTCATCCTTTTTTCTGGCTACCAAAGGTGCAGATAATTAATAAGA
AGCTGGATCTTAGCAACGTCCAGTCCAAGTGTGGCTCAAAGGATAA-3’
ssODNs were diluted under sterile conditions with ddH2O to 10µM for transfection.
5.3.3 iPSC transfection by electroporation
iPSCs were transfected by electroporation, using the Amaxa electroporation system as
described by Petersen et al. (2017). Petersen et al. used program CA137, whereas Byrne et al.
(2014b) and Yang et al. (2014) used program CB150 for iPSCs. To optimise electroporation
conditions, programs were compared by electroporating CTRL2 iPSCs with either the
CRISPR 2 plasmids and ssODN, or without CRISPR components and allowing the iPSCs to
recover without puromycin selection. Twenty-four hours after electroporation, the number of
attached iPSCs was compared: there were more attached iPSCs in the CA137 wells than the
CB150 wells, so program CA137 was chosen for electroporation.
ssODN concentration was optimised by comparing the number of attached iPSCs 24 and
48 hours after electroporation with 50pmol or 100pmol ssODN. There was no difference in
the number of surviving cells between these ssODN concentrations, as judged by eye.
Puromycin selection was optimised by electroporating CTRL2 iPSCs with CRISPR
plasmids (+) or without plasmids (-), then dividing each batch of electroporated iPSCs into
four wells. After recovery for 24 hours, + and - iPSCs were exposed to 0.5, 0.25 or 0.125
µg/ml puromycin for 48 hours. The fourth wells of + and - iPSCs were left without selection
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as controls. Four days after puromycin selection ended, some iPSC colonies were present
in all + wells and in the 0.25 and 0.125µg/ml - wells. No iPSC colonies were present in the
- 0.5µg/ml puromycin well, indicating that 0.5µg/ml puromycin is sufficient to kill iPSCs
electroporated without plasmids but does not kill iPSCs expressing the plasmids.
Twenty-four hours before transfection, iPSC medium was changed to KSR without pen-
strep and with 10µM ROCK inhibitor to improve iPSC survival. On the day of transfection,
iPSCs were lifted from the MEF layer with collagenase-dispase, as described in Section 2.2.2
and dissociated to 2-3 cell clumps with Accutase. For each transfection 2x106 iPSCs,
100µl P3 solution plus Nucleofector supplement (Lonza Transfection Kit) and 8µg of 1µg/µl
DNA were mixed in a plastic cuvette. The DNA mixture contained 100pmol (1µl 10µM)
ssODN, with either 8µg of 1µg/µl Cas9wt or 4µg of 1µg/µl or each of left and right Cas9n.
Electroporation was performed with an Amaxa Nucleofector, program CA 137. After
electroporation, cells were left to recover for 5 minutes at room temperature and then plated
onto neomycin- and puromycin-resistant irradiated MEFs (DR4, Applied StemCell) in pen-
strep-free KSR with 10µM ROCK inhibitor (Figure 5.3). Twenty-four hours later, the medium
was changed to KSR with FGF2 (4ng/ml). Forty-eight hours after transfection, puromycin
(0.5µg/ml, Life Technologies) was added to the media for 48 hours, to select for iPSCs
transfected with Cas9 plasmids, which contain puromycin-resistance cassettes. Puromycin
also killed the MEFs, so new MEFs were added after puromycin selection to support iPSC
colony growth. When colonies became visible, they were picked and transferred to 48-well
plates for expansion, then picked again and transferred to 48-well plates to create duplicates.
After picking, transfected iPSCs were detached from the MEF layer with collagenase-dispase,
as described in Section 2.2.2 and cell pellets were collected by centrifugation. DNA was
extracted with 10µl QuickExtract solution (Epicentre) by incubation at 65°C for 30 minutes,
then at 90°C for 15 minutes. DNA in QuickExtract was diluted 1:10 in ddH2O as a PCR
template.
5.3.4 PCR for mutation screening
The primers 073 and 074 (Table 5.3) were used to amplify a 642bp region including tau exon
10 from genomic DNA extracted from edited iPSC colonies. Five µl 10x Pfu buffer with
Mg2+, 1µl Pfu DNA polymerase (both Thermo Scientific), 1µl 10mM dNTPs (Invitrogen),
2.5µl each of 10µM forward and reverse primers, 1µl DNA template (DNA in QuickExtract,
diluted 1:10 in ddH2O) and 37µl ddH2O were mixed in a PCR tube. The PCR cycle was
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Resistant colonies (2-3 wks)Puromycin selection (48 hrs)
Electroporation of 2x106 N279K2 or CTRL2 iPSCs as 2-3 cell clumps (not single cells)
CRISPR 2
100bp
Recovery (48 hrs)
48 hrs after electroporation Cell death 24 hrs after puromycin Surviving clone 2 weeks after 
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Fig. 5.3 Workflow for gene editing in iPSCs using CRISPR. The left and right Cas9n plasmids
(CRISPR 2) or the Cas9wt plasmid (CRISPR 3) and the ssODN repair template, were electroporated
into a suspension of iPSCs consisting of 2-3 cell clumps. Cas9n and Cas9wt plasmids contained a
puromycin resistance cassette for antibiotic selection. iPSCs were then plated onto MEFs and allowed
to recover for 48 hours before selection with puromycin. Images (left to right) show iPSCs on MEFs
after electroporation; high levels of cell death following puromycin selection, after which new MEFs
were added to support iPSC colony growth; the emergence of a surviving CTRL2 iPSC colony after
selection. The surviving colonies were then screened by sequencing DNA with Sanger sequencing
or restriction digest. Edited colonies would be checked for a normal karyotype and off-target edits.
Scale bar = 20µm.
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4 minutes at 95°C, then 35 cycles of 1 minute at 95°C, 1 minute at 60°C and 3 minutes at
72°C, followed by 10 minutes at 72°C.
5.3.5 Mutation screening by restriction digest
After PCR, DNA was purified using a Qiagen Gel Extraction kit. The PCR product was
mixed with three 150µl of high-salt buffer QG and 50µl of isopropanol. The sample was
centrifuged in a QIAquick column at 17000g for one minute to bind the DNA to the column.
The DNA was washed with 500µL buffer QG and centrifuged at 17000g for one minute to
remove excess agarose, then washed with 750µL buffer PE and centrifuged at 17000g for
one minute to remove remaining salts. DNA was eluted by incubation with 10µL ddH2O and
centrifugation at 17000g for one minute, then the DNA concentration was measured with a
Nanodrop spectrophotometer (Thermo Fisher).
One µg purified DNA was added to 1µl BsaH1 (for CRISPR 2) or 1µl AseI (for CRISPR
3) in 5µl 10x CutSmart buffer (all New England Biosciences) and ddH2O up to 50µl. The
mixtures were incubated for 3 hours at 37°C, then 16 hours at 18°C for digestion. 15µl
digestion mixture was mixed with 6x DNA Loading Dye (Fermentas) and loaded into
the wells of a 0.8% agarose gel in 1x Tris-Borate-EDTA buffer for gel electrophoresis at
120mV for one hour. Digested products were run next to their undigested counterparts. For
CRISPR 3, a positive control (N279K2 iPSCs) and negative control (CTRL2 iPSCs) were
also included. After electrophoresis, colony genotype was established by comparing the
digested and non-digested lanes. For CRISPR 3, 642bp band intensity was compared to
358bp and 284bp band intensity using ImageJ, as described for Western Blot quantification
in Section 2.6.5.
5.3.6 Mutation screening by Sanger Sequencing
PCR products were mixed with 6x DNA Loading Dye and loaded into the wells of a 0.8%
agarose gel in 1x Tris-Borate-EDTA buffer (Merck) for gel electrophoresis at 120mV for one
hour. The 642bp band was excised and DNA was extracted using a Qiagen Gel Extraction
kit. The gel was dissolved in high-salt buffer QG and isopropanol. The amount of high-salt
buffer QG buffer was calculated by weighing the excised gel, then adding 3µl of buffer for
every mg of gel. The amount of isopropanol used was 1µl for every mg of gel. For example,
a gel weighing 100mg required 300µl of high-salt buffer QG and 100µl of isopropanol. Gel
extraction was then performed as described in Section 5.3.5.
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For CRISPR 3, Mariagrazia Paonessa performed approximately 25% of the PCR reactions
and gel electrophoreses.
The DNA concentration was measured with a Nanodrop spectrophotometer and adjusted
to 10ng/µl with ddH2O. DNA was sequenced with primers E75 and Rev83 (Table 5.3) by
Source Bioscience (www.sourcebioscience.com).
5.4 Results
5.4.1 CRISPR nickase strategy 1
The first CRISPR strategy I designed (CRISPR 1 in Table 5.2) targeted tau exon 10 with
Cas9 nickases, to increase the chance of HDR (Mali et al., 2013) and to reduce the chance
of off-target mutations (Cho et al., 2014; Ran et al., 2013b). The gRNA sequences were
chosen with the MIT CRISPR design tool (http://crispr.mit.edu/), which constrains and ranks
possible gRNA sequences: 1) the target sequence has minimal similarity to other sequences
in the genome; and 2) off-target sequence cleavage is unlikely because similar sequences are
either not next to an NGG or NAG PAM, or contain PAM-proximal mismatches (Hsu et al.,
2013).
I chose the gRNA pair with the fewest off-target matches that was closest to the N279K
mutation locus since proximity to the (offset) DSB is an important factor in point mutation
correction (Elliott et al., 1998; Liang et al., 2017; Paquet et al., 2016; Yang et al., 2013).
Each gRNA had predicted off-target sequences which could result in single-stranded off-
target DNA nicks but together, the gRNA pair had no predicted off-target sites (Figure 5.4).
Counting the first nucleotide of exon 10 as nucleotide 1, the gRNA targeted nucleotides
42-61 (left) and 64-83 (right). This gives a 5’ overhang required for efficient nicking and
a 2bp offset between the sequences, which is within the optimal 0-20bp (Ran et al., 2013;
Figure 5.4). The nickases would make cuts between nucleotides 80 and 81 on the anti-sense
DNA strand (right nick) and between nucleotides 44 and 45 on the sense strand (left nick),
29 base pairs from the N279K mutation locus.
To precisely induce the N279K mutation, I designed a repair template consisting of tau
exon 10 DNA in a pcDNA3 plasmid. The repair template contained sequences complementary
to the gRNA and therefore could be cut by the left and right nickases. To prevent this, I
added blocking mutations which block Cas9n from recognising the gRNA sequence after
it has been corrected. I added a silent mutation at the left PAM, because PAM mutations
decrease Cas9 cleavage approximately 500-fold (Cho et al., 2014). The mutation (39C→G,
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GTGCAGATAATTAATAAGAAGCTGGATCTTAGCAACGTCCAGTCCAAGTGTGGCTCAAAGGATAATATCAAACACGTCCCGGGAGGCGGCAGT
CACGTCTATTAATTATTCTTCGACCTAGAATCGTTGCAGGTCAGGTTCACACCGAGTTTCCTATTATAGTTTGTGCAGGGCCCTCCGCCGTCA
E10
I10
I9 cgcatgtcactcatcgaaagtggaggcgtccttgcgagcaagcaggcgggtccagggtggcgtgtcactcatccttttttctggctaccaaag
gcgtacagtgagtagctttcacctccgcaggaacgctcgttcgtccgcccaggtcccaccgcacagtgagtaggaaaaaagaccgatggtttc
gtgagtaccttcacacgtcccatgcgccgtgctgtggcttgaattattaggaagtggtgtgagtgcgtacacttgcgagacactgcatagaat
cactcatggaagtgtgcagggtacgcggcacgacaccgaacttaataatccttcaccacactcacgcatgtgaacgctctgtgacgtatctta
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Fig. 5.4 gRNA sequences for CRISPR 1. A) Schematic diagram of two gRNA sequences for
CRISPR 1 on the antisense (left gRNA) and sense (right gRNA) DNA strands. Red arrows indicate
DNA cut sites. Green boxes show gRNA sequences, the number of off-target sites with sequence
homology to each gRNA and the number of off-target sites for the gRNA pair. Diagram from the
MIT CRISPR design tool. B) and C) Detailed representation of CRISPR 1. Double-stranded DNA of
exon 10 (E10, upper case) and flanking regions of introns 9 and 10 (I9 and I10, lower case) are shown.
Nucleotides in exon 10 are numbered, counting the first nucleotide as 1. B) Control DNA with the
N279K mutation locus at nucleotide 15 in exon 10 (yellow box). The 20bp gRNA target sites (red
nucleotides) match the gRNA: the left gRNA matches the anti-sense strand and is complementary
to the sense strand, whilst the right gRNA matches the sense strand and is complementary to the
anti-sense strand. Nickase cut sites (red dotted lines) are 3bp upstream of the PAM (bold font) on the
complementary DNA strand. A red arrow indicates the distance (29bp) between the Cas9n cut site
and the N279K mutation locus. C) Control DNA after editing. The induced N279K mutation is at
nucleotide 15 (yellow box), the left PAM mutation is at nucleotide 39 (dark red box) and prevents
repaired DNA being recut by the nickase. The right gRNA mutations are at nucleotides 72, 75 and 78
(dark red box) where they prevent the right gRNA binding.
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Fig. 5.5 Cis regulatory sequences in tau exon 10. Introns 9 and 10 are lower case, exon 10 is upper
case. Nucleotides are numbered, counting the first nucleotide of exon 10 as 1, the first nucleotide
upstream of exon 10 in intron 9 as -1 and the first nucleotide downstream of exon 10 in intron 10 as +1.
Exon 10 amino acids are shown above the corresponding codons. Labelled bars represent nucleotide
sequences that influence exon 10 splicing. Intron 9 contains two tandem repeat sequences (TRS, blue
bars), two possible branch point sequence sites (BPS, teal bars) with critical “a” nucleotides indicated
by black arrowheads, and a polypurine tract (PPT, thick teal bar). Exon 10 contains four splicing
enhancers (green bars): a SC35-like binding sequence (SC35), a polypurine enhancer (PPE), an A/C
rich element (ACE), two exon splicing enhancers (ESEs), a potential inhibitory sequence (maroon
bar), and an exon splicing silencer (ESS, maroon bar). Exon 10 also a microtubule binding repeat
(grey-purple bar). The stem loop region (purple bar) spans the exon 10/intron 10 boundary. Intron 10
contains a potential intron splicing silencer (ISS, maroon bar) and an intron splicing modulator (ISM,
green bar). The N279K mutation locus (nucleotide 15) is marked with a yellow arrowhead. gRNA
target sites are shown by red (CRISPR 1), green (CRISPR 2) or blue (CRISPR 3) lines. Arrows on
these lines indicate Cas9 nicking sites: downwards arrows show a nick site on the sense DNA strand,
upwards arrows show a nick on the anti-sense strand.
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Figure 5.4) would be a non-coding mutation in valine 287 (using numbering for the longest
4R tau isoform).
The right PAM site could not be silently mutated, so I added three silent blocking
mutations in the right gRNA recognition sequence since having three non-consecutive
mismatches between the DNA and gRNA is reported to reduce Cas9 cleavage (Hsu et al.,
2013). The three mutations (72A→G, 75C→T, and 78C→T, Figure 5.4), would be non-
coding mutations in lysine 298, histidine 299, and valine 300 (using numbering for the
longest 4R tau isoform).
Although the planned silent mutations were not known MAPT mutations, they were in
sequences which regulate exon 10 splicing (Figure 5.5). The left PAM 39C→G mutation
was in the A/C rich splice enhancer (ACE), in which the conserved sequence is two or three
repeat motifs: either CAA, CCA, or CA (D’Souza and Schellenberg, 2000). A left PAM
mutation would decrease the C content of the ACE and disrupt a potential CCA repeat motif,
which could decrease exon 10 inclusion in tau mRNA transcripts. However, the effect of
mutating this nucleotide on exon 10 inclusion has not been tested.
The right gRNA recognition sequence mutation 72A→G was in an exon splicing silencer
(ESS), which was detected in deletion experiments by D’Souza and Schellenberg (2000),
between 55T and 72A. Simultaneous mutation of 70A→G, 71A→C and 72A→T significantly
increased exon 10 inclusion in a splicing assay, indicating that the ESS purine content is
important for exon silencing (D’Souza and Schellenberg, 2000). This result suggests that the
72A→G mutation could also increase exon 10 inclusion, although this mutation has not been
tested.
The right gRNA recognition sequence mutations 75C→T and 78C→T were in two
adjacent exon splicing enhancers (ESEs), which were detected when their deletion decreased
exon 10 inclusion in a splicing assay (D’Souza and Schellenberg, 2000, 2002). However,
the 75C→T and 78C→T mutations have not been specifically tested for their effects on tau
splicing.
I checked these potential mutation sites against the single nucleotide polymorphism (SNP)
database (dbSNP, https://www.ncbi.nlm.nih.gov/snp/), to determine if any were common
SNPs not linked to FTDP-17T, even if they occurred in exon 10 splicing regulatory sequences.
The 72A→G and 78C→T mutations are not SNPs but 75C→T and 39C→G are. 75C→T is
SNP rs147401702, which occurs in 0.00051230% of genomes in dbSNP and it is not reported
as clinically significant, although this does not mean it has no effects on exon 10 splicing.
39C→G is SNP rs1275756209, which has no associated frequency information in dbSNP
and is also not reported as clinically significant.
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All the silent blocking mutations I planned had the potential to alter tau exon 10 splicing,
which would alter the 3R to 4R tau ratio in CRISPR-edited iPSC-derived neurons. To avoid
this, I designed a second CRISPR strategy.
5.4.2 CRISPR nickase strategy 2
I re-designed the CRISPR nickase strategy by using the MIT CRISPR design tool to choose
a gRNA pair which did not overlap with exon 10 (CRISPR 2 in Table 5.2) and chose the pair
with the fewest off-target matches, which made nicks closest to the N279K mutation locus
(Figure 5.6). CRISPR 2 targeted nucleotides -61 to -43 (left gRNA) and -32 to -13 (right
gRNA) in intron 9, counting nucleotides backwards from the start of exon 10, which gave a
5’ overhang required for efficient nicking and an 11bp offset between the gRNAs, which is
within the optimal 0-20bp (Ran et al., 2013b). The nickases would cut between nucleotides
-58 and -59 (left nickase) and between nucleotides -16 and -15 (right nickase), 30bp from the
N279K mutation locus. Although each gRNA had off-target sequence matches (Figure 5.6),
the gRNA pair had no off-target matches.
The right gRNA sequence overlapped with two intron 9 regulatory elements: the poly-
purine tract (PPT) and branch point sequence (BPS), which are present in mammalian
intron 3’ splice sites (D’Souza and Schellenberg, 2002). Right PAM mutations in the
repair template were therefore not possible without potentially altering exon 10 splicing
(Figure 5.5). Furthermore, the right PAM sequence (nucleotides -10, -11 and -12) includes
two loci associated with exon 10 splicing: a G→T mutation at nucleotide -10 has been found
in three individuals with FTDP-17T (Malkani et al., 2006) and a G→T mutation at -11, in
combination with mutations of G→T at -10 and A→T at -7 causes constitutive exon 10
inclusion in a splicing assay (D’Souza and Schellenberg, 2002). In addition, there are no
SNPs reported at position -11 in dbSNP.
The left gRNA sequence overlapped with part of an intron 9 tandem-repeat sequence
which spans nucleotides -21 to -55 and -69 to -116 (D’Souza and Schellenberg, 2002; Poorkaj
et al., 2001; Figure 5.5). The significance of this sequence is unclear but its exclusion does
not alter exon 10 splicing in a splicing assay: D’Souza and Schellenberg (2002) transfected
COS-7 cells, PC12 cells and rat neurons with constructs encoding either 1) 567bp of intron
9, plus exon 10 and 190bp of intron 10; or 2) 33bp of intron 9, plus exon 10 and 51bp of
intron 10; and found that exon 10 expression was the same with both constructs. The left
PAM (on the anti-sense strand) contains two C nucleotides (G on the anti-sense strand) at
positions -63 and -64, neither of which have associated SNPs, according to dbSNP. A left
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Fig. 5.6 gRNA sequences for CRISPR 2. A) Schematic diagram of two gRNA sequences for
CRISPR 2 on the antisense (left gRNA) and sense (right gRNA) DNA strands. Red arrows indicate
DNA cut sites. Green and yellow boxes show gRNA sequences, the number of off-target sites with
sequence homology to each gRNA, and the number of off-target sites for the gRNA pair. Diagram
from the MIT CRISPR design tool. B) and C) Detailed representation of CRISPR 2. Double-stranded
DNA of exon 10 (E10, upper case) and flanking regions of introns 9 and 10 (I9 and I10, lower case)
are shown. Nucleotides in exon 10 are numbered, counting the first nucleotide as 1. B) shows control
DNA with the N279K mutation locus at nucleotide 15 in exon 10 (yellow box), the gRNA target sites
(green nucleotides) and nickase cut sites (green dotted lines) 3bp upstream of the PAM (bold font)
on the complementary DNA strand. The green arrow shows the distance (30bp) between the cut site
and the N279K mutation locus. C) shows control DNA after editing. The induced N279K mutation
is at nucleotide 15 (yellow box) and the left PAM mutation is at nucleotide -64 (dark green box), to
prevent Cas9n re-cutting the repaired DNA.
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Fig. 5.7 Potential changes in tau exon 10 splicing which may be caused by a PAM mutation in
intron 9. Results from Human Splicing Finder (HSF) comparing wild-type tau intron 9 with intron 9
plus the left PAM mutation. The sequences input were 103bp of intron 9, exon 10 and 87bp of intron
10. A) shows the disruption of a splice acceptor site; B) shows the destruction of an ESE and two
pESEs.
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PAM mutation (C→G at nucleotide -64) would fall between the tandem-repeat sequences and
since the smaller construct tested by D’Souza and Schellenberg excluded intron 9 nucleotides
upstream of nucleotide -33 without altering exon 10 splicing, the left PAM mutation seems
unlikely to alter exon 10 splicing.
To further investigate the potential effects of the left PAM mutation, I used Human
Splicing Finder (HSF, http://www.umd.be/HSF/) to predict changes it could cause in splice
sites, BPSs, ESEs and ESSs. HSF’s predictive ability has been validated with mutations
which have been shown to alter splicing in vivo: it correctly predicted all 84 mutations tested
which disrupt splice sites, 13 out of 14 mutations which inactivated BPSs, 20 out of 20
mutations which altered ESEs or ESSs, and could discriminate between a different set of 36
experimentally validated ESE or ESS altering mutations and 220 SNPs which do not alter
ESEs or ESSs (Desmet et al., 2009). HSF is therefore a reasonable tool to predict the splicing
effects of a mutation.
HSF detected no significant splicing motif alterations, indicating that the left PAM
mutation is unlikely to alter splicing. The four potential changes HSF found are show in
Figure 5.7. A potential splice acceptor site was altered, giving a variation of -2.59% between
the wild-type and mutant sequences. According to HSF’s validation with experimentally
determined splice sites, variation of less than 10% is not enough to significantly alter splicing
Desmet et al. (2009).
A potential ESE which binds the splicing factors serine/arginine-rich protein 55 (SRp55)
and 9G8 was destroyed by the mutation. The reported effects of SRp55 on exon 10 splicing
are mixed. Yin et al. (2012) transfected four cell lines with a tau minigene and found that
SRp55 expression increased exon 10 inclusion but did not identify SRp55’s binding site
beyond indicating several possible sites in exon 10. Contrary to this, Wang et al. (2005)
expressed SRp55 and a smaller tau minigene in COS cells and reported a decrease in exon
10 inclusion. When Wang et al. deleted nucleotides 8-15 (counting from the first nucleotide
of exon 10), SRp55 expression did not decrease exon 10 inclusion, suggesting that SRp55’s
binding site is in the potential inhibitory sequence identified by D’Souza and Schellenberg
(2000), rather than in intron 9.
Finally, two putative ESEs (pESEs) were altered by the left PAM mutation. pESEs
were identified by Zhang et al. (2005) by statistical comparison of human exon and intron
sequences; out of 2000 identified, 30 have been tested experimentally and 28 were shown to
increase exon inclusion, although the pESEs altered by the left PAM mutation have not been
tested.
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Analysing the effect of the left PAM mutation did not find strong evidence for a critical
role in exon 10 splicing, which would be grounds to avoid this mutation. The analysis did
indicate potential splicing alterations, so I decided to introduce the left PAM mutation into
the HDR template alongside the N279K mutation and to test its effects in CRISPR-corrected
iPSC-derived neurons.
To induce the N279K mutation I designed a single-stranded DNA template since ssODNs
are less likely to be randomly inserted into the genome than double-stranded plasmid tem-
plates (Chen et al., 2011). Since homology between the DNA and ssODN is required for
efficient editing, I sequenced DNA from CTRL2 iPSCs to check for SNPs in the region cov-
ered by the ssODN that could act as blocking mutations. This revealed one SNP (rs41543317)
at position -176 (counting backwards from the 3’ end of intron 9 as -1) which was outside
the homology region.
ssODNs for inserting small insertions or point mutations are most efficient when centred
on the mutation, with homology arms between 40bp (Chen et al., 2011; Liang et al., 2017)
and 35bp (Yang et al., 2013) on each side. Therefore, I designed a 153bp sense ssODN, with
the left PAM mutation and the N279K mutation. The ssODN position with respect to the
mutation loci was determined by comparing the predicted homodimer and hairpin formation
of six similar ssODNs, using Oligo Analyser (https://www.idtdna.com/calc/analyzer), to
select the ssODN least likely to form secondary structures. The ssODN was longer than the
optimal 70-90 nucleotides determined by Yang et al. (2013) but the extra length allowed
homologous sequences of 39 nucleotides before the PAM mutation and 35 nucleotides after
the N279K mutation locus.
The ssODN was sense rather than anti-sense to minimise ssODN cleavage by Cas9n. The
ssODN was complimentary to the left gRNA, so the two sequences could bind but the left
PAM mutation would prevent cutting. The ssODN and the right gRNA could not bind, as
both sequences were sense.
5.4.3 Transfection of iPSCs with CRISPR 2 nickase components
I chose to transfect iPSCs rather than NPCs because HDR is more likely to occur in dividing
cells (Orii et al., 2006; Saleh-Gohari, 2004) and because isogenic iPSCs would give a large
supply of cells for differentiation to neurons. Although NPCs are also proliferative and
suitable for transfection, repeated transfections would be needed to produce neurons from
three independent differentiations, making this a less practical solution.
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Fig. 5.8 Screening for CRISPR-corrected iPSC colonies by restriction digest following CRISPR
2. A The BsaHI recognition sequence (purple box) is present in wild-type DNA, so the DNA is
digested (red line). A PAM mutation (yellow circle) disrupts both the PAM (green box) and the
BsaHI recognition sequence (purple box), so CRISPR-corrected DNA is not cut. B A 642bp segment
of DNA containing tau exon 10 and part of the flanking introns 9 and 10 was amplified from iPSC
colonies which survived antibiotic selection. The DNA was digested with BsaHI (+) or incubated in
the digestion mixture without the enzyme (-) and separated by gel electrophoresis. Representative
results are shown: DNA from all colonies was cut by BsaHI.
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Fig. 5.9 Immunostaining with the FLAG-M2 antibody was not specific enough to detect FLAG-
tagged Cas9 in transfected iPSCs. iPSC colonies two days after electroporation with either Cas9n
or no plasmid. iPSCs are immunostained with the FLAG-M2 antibody to detect the FLAG tag on
Cas9n (green) and Oct4 to detect iPSC colonies (red). In the upper panel, an Oct4 positive, FLAG-M2
positive iPSC colony is marked by an arrow. FLAG-M2 staining of iPSCs suggests that the iPSCs had
been successfully transfected with Cas9n. In both panels, FLAG-M2 positive, Oct4 negative cells are
marked by arrowheads. These cells were either MEFs (which were not transfected with Cas9n) or
differentiated iPSCs. The presence of FLAG-M2 immunostaining in the lower panel, where Cas9n
had not been introduced, indicates that FLAG-M2 immunostaining was not specific for the FLAG tag,
and was therefore not a reliable indication that iPSCs had been successfully transfected with Cas9n.
Scale = 10µm.
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I chose to transfect CTRL2 iPSCs by electroporation, using the Amaxa electroporation
system as described by Petersen et al. (2017), since electroporation gives higher efficiency
than lipofection with ssODNs (Ran et al., 2013b). The Amaxa electroporation program,
ssODN concentration, and puromycin selection concentration were determined (5.3.3) and
the iPSCs were electroporated with the ssODN repair template and the left and right Cas9n
plasmids, then transfected iPSCs were selected with puromycin since the Cas9n plasmids
contained puromycin-resistance cassettes. Surviving colonies were expanded, DNA was
extracted and a 642bp region was amplified by PCR. DNA was subjected to restriction digest
using BsaH1, which cuts the wild-type intron 9 sequence but not the introduced G→C PAM
mutation. Digested samples were run next to a non-digested control on an agarose gel to
visualise mutation insertion. Representative results are shown in Figure 5.8, in which all the
DNA samples have been digested, indicating that the PAM mutation was not introduced.
To determine why no left PAM mutations were detected in the edited iPSCs, I checked
for Cas9n expression. To do this, I electroporated iPSCs with Cas9n or with no vector,
plated them on mouse embryonic feeder cells (MEFs) and allowed colonies to grow without
puromycin selection. Two days after electroporation I immunostained for FLAG (since Cas9n
had a FLAG-tag) and the pluripotency marker Oct4 to label the iPSCs (Figure 5.9). Some
FLAG-M2 immunoreactivity was visible in transfected iPSCs positive for Oct4, although
background staining in the green (FLAG-M2) channel was high in the non-transfected
iPSCs. In addition, cells with bright fluorescence in the green channel were visible in both
transfected and non-transfected wells (arrows in Figure 5.9). These cells were not Oct4
positive, suggesting that they were MEFs or differentiated iPSCs and their presence in both
the transfected and non-transfected wells suggests that the FLAG-M2 antibody lacked the
specificity to determine whether Cas9n was expressed.
After screening at least 30 colonies by restriction digest and finding them all to be wild-
type, I discussed the method with Manousos Koutsourakis and re-designed the CRISPR
strategy to maximise DSB proximity to the N279K mutation locus.
5.4.4 Wild-type CRISPR strategy design
I designed a third CRISPR strategy, targeting wild-type Cas9 to tau exon 10 (Figure 5.10).
The gRNA sequence was chosen by searching for the closest PAM (NGG) sequence to the
N279K mutation locus since mutation efficiency increases with proximity to the DSB (Elliott
et al., 1998; Liang et al., 2017; Paquet et al., 2016; Yang et al., 2013). In this case, the DSB
would be 5bp from the N279K mutation locus which is within the 8-10bp where DNA editing
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is most efficient (Elliott et al., 1998; Liang et al., 2017; Paquet et al., 2016; Yang et al., 2013).
The gRNA was checked with the MIT CRISPR design tool for off-target sites, which found
347 potential off-targets, 25 of which were in genes. The chromosomal location, sequence
and number of mismatches from the gRNA of the 20 most similar off-target sites are shown
in Appendix 1.
The gRNA targeted nucleotides 3 to 23, including the N279K mutation locus at nucleotide
15 (counting the first nucleotide of exon 10 as 1). The PAM was nucleotides 24-26, making
the N279K mutation the 9th nucleotide from the PAM, which is at the boundary of the
8-13 nucleotide PAM-proximal seed region (Jinek et al., 2012), in which single nucleotide
mismatches between target DNA and gRNA are most effective at preventing Cas9 cleavage
Hsu et al. (2013).
I used dbSNP to look for potential blocking mutations in the gRNA seed sequence. There
are two SNPs in the PAM sequence at positions 25 (rs1284201310) and 24 (rs1449406929),
counting the first nucleotide of exon 10 as 1. Rs1284201310 is a missense mutation but
no information on its frequency or clinical significance was available, which discounts it
as suitable blocking mutation since it may be a rare, unidentified pathological mutation.
Rs1449406929 is a silent mutation at the end of the PPE (Figure 5.5), without frequency
or clinical significance listed on dbSNP. Deletion of any of the three nucleotide triplets that
make up the PPE decreases exon 10 inclusion (D’Souza and Schellenberg, 2000) and deletion
of the first triplet (nucleotides 16-18, ∆280K) causes FTDP-17T (Momeni et al., 2009).
Deletion of the second triplet (nucleotides 19-21) is reported as a potentially deleterious
SNP on dbSNP (rs1168968788)and SNPs are reported at positions 16 (rs1369606320), 17
(rs755156853), 18 (rs182024939), 22 (rs1340490783), and 24 (rs1449406929), counting
from the beginning of exon 10. Deletion of the second triplet and the mutations at positions
17 and 18 are rare, with no information on their pathogenicity. Mutations at positions 16, 22
and 24 have no available data on their frequency or pathogenicity. Given that these SNPs are
rare and overlap the PPE, I judged them unsuitable as blocking mutations.
Therefore, I designed two ssODN repair templates: one with the N279K mutation and one
wildtype. No blocking mutations were included, depending instead on the single nucleotide
difference at the N279K mutation locus to prevent ssODN cutting and re-cutting of edited
DNA. The ssODNs were 100 nucleotides long, sense, and centred on the N279K locus.
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Fig. 5.10 gRNA sequences for CRISPR 3. A) Schematic diagram of 30 potential gRNA sequences
for CRISPR 3, targeting Cas9wt to the antisense (arrows pointing right) and sense (arrows pointing
left) DNA strands. The gRNA closest to the N279K mutation locus is marked in blue. Text shows
the gRNA sequence and the number of off-target sites with sequence homology. Diagram from the
MIT CRISPR design tool. B) and C) Detailed representation of CRISPR 3. Double-stranded DNA
of exon 10 (E10, upper case) and flanking regions of introns 9 and 10 (I9 and I10, lower case) are
shown. Nucleotides in exon 10 are numbered, counting the first nucleotide as 1. B) shows control
DNA with the N279K mutation locus at nucleotide 15 in exon 10 (yellow box), the gRNA target
sites (blue nucleotides), the PAM sequence (bold font) and Cas9 cut site (blue dotted line). C) shows
control DNA after editing. The induced N279K mutation is at nucleotide 15 (yellow box).
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Fig. 5.11 Screening for CRISPR-corrected iPSC colonies by restriction digest following
CRISPR 3. A) The AseI recognition sequence is present in wild-type DNA, so the DNA is di-
gested (red line). The N279K mutation (blue box) disrupts the AseI recognition sequence, so
CRISPR-mutated DNA is not cut. The N279K mutation is heterozygous, so half of the DNA is cut
and half is not. B) CTRL2 iPSCs were electroporated with CRISPR 3 components and DNA was
extracted from colonies which survived antibiotic selection. A 642bp segment of DNA containing tau
exon 10 and part of the flanking introns 9 and 10 was amplified and the DNA was digested with AseI
(+) or incubated in the digestion mixture without the enzyme (-), then separated by gel electrophoresis.
N279K2 and CTRL2 DNA was included as positive and negative controls for the restriction digest.
Representative results (samples 10-16) are shown. The ratio between the uncut (642bp) and cut
(358bp or 284bp) bands was calculated and ratios from the transfected iPSC colonies were compared
to those calculated for wild-type and N279K DNA.
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Fig. 5.12 Screening by Sanger sequencing following CRISPR 3. A) Sanger sequencing reads from
CTRL2 (wild-type) and N279K2 (heterozygous) iPSCs. The N279K mutation locus is highlighted
with a yellow box. B) Sanger sequencing reads from one CTRL2 iPSC colony after CRISPR. The
Cas9 cut site is marked with an arrow. Mixed sequencing reads are visible, starting around the cut site.
C) Sequences reconstructed from the mixed reads: small deletions and insertions were detected but
the N279K mutation was not induced in CTRL2 iPSCs, nor corrected in N279K2 iPSCs.
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5.4.5 Transfection of iPSCs with CRISPR 3 components
iPSCs were electroporated with the Cas9wt plasmid and the appropriate ssODN repair
template: an ssODN with the N279K mutation was used to induce the N279K mutation
in CTRL2 iPSCs, and the wild-type ssODN was used to correct the N279K mutation in
N279K2 iPSCs. Following electroporation and recovery, iPSCs were selected with puromycin
treatment (5.3.3). Surviving colonies were expanded and then picked: half of each colony
was seeded into a new plate and half was kept for DNA extraction. A 642bp DNA region
including exon 10 was amplified by PCR, then DNA was purified from the PCR mixture.
DNA was subjected to restriction digest using AseI, which cuts wild-type exon 10 but not
exon 10 with the T→G N279K mutation. Fifty-two digested samples were run next to their
non-digested counterparts on an agarose gel to visualise mutation insertion or correction,
alongside non-transfected CTRL2 and N279K2 DNA: the parental iPSC line was a negative
control and the other iPSC line (either N279K2 or CTRL2) was a positive control. Most
colonies had a digestion pattern like that of the parental iPSC line but some samples had
a digestion pattern suggesting that the N279K mutation had been induced (in the CTRL2
iPSCs) or corrected (in the N279K iPSCs).
When the digestion pattern suggested editing, I calculated the ratio of the uncut (642bp)
band intensity to the cut (358bp and 284bp) band intensity using ImageJ and compared this
ratio to that of the positive and negative control. This identified four N279K2 and eleven
CTRL2 colonies with digestion patterns suggesting some editing at the N279K mutation
locus, like sample 11 in Figure 5.11. Sanger sequencing of DNA from these colonies revealed
parental sequences in all but three N279K2 and four CTRL2 colonies, which had mixed
sequencing reads, indicating that the iPSCs in the colonies were not edited in the same way.
Since electroporation was performed on 2-3 cell clumps rather than single cells, it was
possible that surviving colonies had a mixed population of cells, rather than being clonal.
Therefore, I split the duplicates of the three N279K2 and four CTRL2 colonies with mixed
DNA sequences into 2-3 cell clumps and re-plated them sparsely in an attempt to create
clonal colonies, or colonies which contained a mixture of fewer types of edited cells. This
was similar to the protocol of Miyaoka et al. (2014), who repeated this method to isolate
rare mutations from edited iPSCs. When the colonies were big enough, I picked them
and seeded half of each into new plates, then extracted DNA from the other half. All the
surviving colonies were sequenced. Twenty-nine N279K2 colonies survived and DNA could
be extracted from 19: 10 began to differentiate after picking and could not be recovered.
Sequencing showed that all the N279K2 colonies contained the N279K mutation and there
were no mixed reads. Thirty-three CTRL2 colonies survived and DNA could be extracted
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Fig. 5.13 The position of silent blocking mutations and the P301L mutation in tau exon 10
DNA from P301L heterozygous and homozygous iPSCs created using CRISPR. Nucleotides in
double-stranded DNA from tau exon 10 (E10) is shown. Nucleotides are numbered, counting the first
nucleotide of exon 10 as 1. A) Control DNA with the P301L mutation locus at nucleotide 80 in exon
10 (blue box). The loci of the three silent mutations are marked with yellow boxes. B) CRISPR-edited
DNA in P301Lhom and P301Lhet iPSCs. The induced P301L mutation is at nucleotide 80 (blue box
and text), and the three silent mutations are at nucleotides 72, 75, and 78 (yellow box and yellow
text). C) CRISPR-edited DNA in P301Lhom and P301Lhet iPSCs. Boxes show sequences which
affect splicing. Exon 10 contains five splicing enhancers (green boxes): a SC35-like binding sequence
(SC35), a polypurine enhancer (PPE), an A/C rich element (ACE), and two exon splicing enhancers
(ESEs); and two splicing silencers (red boxes): a potential inhibitory sequence (Inhib), and an exon
splicing silencer (ESS). Bars show the positions of altered sequences detected by HSF: one potential
splice acceptor was created (blue bar); four potential ESS sites were created (orange bars); nine
potential ESE sites were disrupted (purple bars).
from 28: 22 colonies were wild-type and six had mixed reads (Figure 5.12), from which I
reconstructed the DNA sequences present manually. In these colonies, the N279K locus was
not altered but small insertion and deletion mutations (indels) were present upstream and
downstream of the cut site.
In summary, I was not able to correct the N279K mutation in the N279K2 iPSC line, nor
was I able to induce the N279K mutation in the CTRL2 iPSC line, meaning that no isogenic
iPSC lines were created.
5.4.6 The effect of silent mutations in isogenic P301L iPSC lines
When I was unable to make a pair of isogenic iPSC lines with and without the N279K
mutation, I used a set of isogenic iPSCs from Axol Bioscience which consisted of an isogenic
control and knock-in P301L heterozygous and homozygous lines. The P301L iPSC lines
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were generated from control iPSCs using a DNA template containing the P301L mutation
and three silent blocking mutations to increase point mutation efficiency (Cho et al., 2014;
Hsu et al., 2013; Jinek et al., 2012). The location of the three silent mutations and induced
P301L mutation are shown in Figure 5.13B. In this section they are referred to according
to their position relative to the first nucleotide of exon 10 (designated as one). The silent
mutations are 72A→G, 75C→T, 78C→T; and the P301L mutation is 80C→T.
As discussed in this Chapter, tau exon 10 contains multiple regulatory elements (Figure
5.13C and Figure 5.5) and their disruption can alter tau splicing, as demonstrated by FTDP-
17T-related MAPT mutations including N279K (Hong, 1998; Hutton et al., 1998; Spillantini
et al., 1998b). Potential disruption of regulatory elements was one reason I did not use
blocking mutations when trying to generate isogenic N279K iPSCs using CRISPR.
To predict possible effects of the blocking mutations on tau splicing, I checked the three
silent mutation sites against the SNP database dbSNP (https://www.ncbi.nlm.nih.gov/snp/) to
determine if these mutations were linked to FTDP-17T, or were known SNPs. The nucleotide
changes 72A→G and 78C→T are not listed in dbSNP. 75C→T is SNP rs147401702, which
is of unknown significance with low representation in the cohorts investigated (less than
0.06%).
I then used Human Splicing Finder (HSF, http://umd.be/HSF3/, Desmet et al., 2009), to
predict changes caused by the three silent mutations in regions altering tau splicing. HSF
predicts possible changes to splice site acceptors and donors, BPSs, ESSs, and ESEs. HSF’s
predictive ability has been validated with mutations which have been shown to alter splicing
in vivo, as described in Section 5.4.2 (Desmet et al., 2009).
The three silent mutations caused several potential changes. One new potential splice
acceptor site was created by the 72A→G mutation (the blue bar in Figure 5.13C). Activation
of this cryptic splice site by the silent mutation could provide an alternative to the natural
splice acceptor site at the 3’ end of intron 9. If the cryptic splice site was used instead,
the resulting tau mRNA would contain truncated exon 10 (effects of cryptic splice sites
reviewed by Caminsky et al., 2014). However, the human genome contains many pseudo
splice sites which do not take part in splicing (Sun and Chasin, 2000). Since the effect of this
specific mutation on tau splicing has not been tested experimentally (to my knowledge), it is
impossible to know what effect it has.
In addition, four potential new ESSs were detected by HSF in a region overlapping one
ESS and one ESE (orange bars in Figure 5.13C). Creation of a new ESS could decrease tau
exon 10 inclusion in mRNA, decreasing the amount of 4R tau.
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HSF also predicted nine potential disruptions of existing ESE sites (purple bars in
Figure 5.13C). All these overlapped to some extent with an experimentally determined
ESE (D’Souza and Schellenberg, 2005). The nine sequences are predicted to bind the
serine/arginine rich (SR) splicing factors SRp40, Tra2-β , SF2/ASF, 9G8, SRp55, and SC35.
All but SRp40 are reported to have a role in tau exon 10 splicing (Yu et al., 2004).
Tra2β and SF2/ASF increase exon 10 inclusion through binding to the poly-purine
enhancer (PPE) towards the 5’ end of exon 10 (Figure 5.13C) (D’Souza and Schellenberg,
2006; Jiang et al., 2003; Kondo et al., 2004). The effect of Tra2β is abolished by the
delta 280K MAPT mutation, and the effect of SF2/ASF is greatly reduced (D’Souza and
Schellenberg, 2006). Delta 280K is the deletion of nucleotides AAG at positions 16-18 in
Figure 5.13C. The effect of this deletion on both Tra2β - and SF2/ASF-mediated splicing
suggests that the main binding sites of these two splicing factors are not disrupted by the
silent mutations.
SRp55 has been reported to increase (Yin et al., 2012) or decrease (Wang et al., 2005)
exon 10 inclusion in tau transcripts in two different studies. However, Wang et al. found that
deleting nucleotides 8-15 (counting from the first nucleotide of exon 10) prevented SRp55
decreasing exon 10 inclusion, suggesting that SRp55’s main binding site is not the ESE site
disrupted by the silent mutations. Disruption of the potential ESE by the silent mutations
may therefore not affect tau splicing.
Overexpression of 9G8 is reported to decrease exon 10 inclusion (Gao et al., 2007).
However, deletion of intron 10 nucleotides +11 to +22 (counting from the first nucleotide of
intron 10 as one) prevented a 9G8-induced decrease in exon 10 inclusion, suggesting that
9G8 binds in intron 10, not exon 10 (Gao et al., 2007), so alteration of the ESE site towards
the 3’ end of exon 10 may not alter tau splicing.
SC35 is implicated in exon 10 inclusion (Qian and Liu, 2014). However, SC35 primarily
interacts with the SC35-like binding sequence at the 5’ end of exon 10, since when this
sequence is deleted, SC35 no longer increases exon 10 inclusion in tau mRNA (Qian et al.,
2011). The disruption of a possible SC35 binding sequence towards the 3’ end of exon 10
may therefore not affect exon 10 splicing.
Altogether, the results from HSF suggest that the silent blocking mutations in the
P301Lhet and P301Lhom iPSC lines used in this Chapter may activate a cryptic splice
acceptor site (potentially producing truncated tau exon 10), create an ESS (potentially de-
creasing tau exon 10 inclusion), and disrupt existing ESEs (potentially decreasing tau exon
10 inclusion). Of these possible changes, the creation of an ESS and of a splice acceptor
site are the most likely to alter tau splicing, since the splicing factors predicted to bind the
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disrupted potential ESEs have been shown to influence tau splicing primarily by binding to
other sequences.
In conclusion, tau expression in neurons derived from these isogenic lines should be
investigated further. This is done in Chapter 6.
5.5 Discussion
I was not able to induce or correct the N279K mutation in iPSCs. Some loci are more
amenable to editing by CRISPR than others, due in part to closed versus open chromatin
(Daer et al., 2017) and it is possible that tau exon 10 is not amenable to gene editing. However,
this is unlikely: indels in CTRL2 colonies indicate that Cas9 cut the DNA, and the N279K
mutation has been corrected in iPSC-derived NPCs by Hallmann et al. (2017), who used
two Cas9wt nucleases to target the intron 9/exon 10 and exon 10/intron 10 boundaries,
and an ssODN as a repair template. Therefore, the lack of CRISPR-edited iPSCs suggests
methodological problems. In this section, I discuss the shortfalls of CRISPR strategies 2 and
3, and some alternative strategies.
5.5.1 Improvements to CRISPR 2
In the second strategy I designed (CRISPR 2, Section 5.4.2), I screened 30 CTRL2 iPSC
colonies for the PAM mutation by restriction digest. There are several potential explanations
for why this strategy did not work: gRNA positioning, using Cas9 nickase, and screening
insufficient colonies.
gRNA positioning
The CRISPR 2 gRNAs were upstream of the N279K locus and the closest nick site was 29bp
away. Trevino and Zhang (2013) suggest that one nick should be within 20bp of the mutation
locus for HDR, so my CRISPR 2 design may be inefficient. In addition, Ran et al. (2013a)
showed that gRNAs for Cas9n are efficient when they either flank the mutation locus, or
have one nick site within 1bp of the mutation locus. Although Ran et al. did not explore the
efficiency of Cas9n pairs further from the mutation locus, this indicates that a better design
would have the Cas9n pairs flanking the mutation site.
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Cas9 nickase
Cas9n is reported to be at least as efficient as Cas9wt for gene editing (Gopalappa et al.,
2018) and may be more efficient for HDR (Mali et al., 2013). However, my Cas9n strategy
depended on electroporating three components (left and right Cas9n plasmids and the ssODN)
into the same iPSC, which is less likely than electroporating in two components (Cas9wt and
the ssODN) required for Cas9wt. Therefore, using Cas9n in CRISPR 2 may have decreased
the probability of successful editing, which caused me to use Cas9wt for CRISPR 3.
I used Cas9n to decrease the chance of off-target effects, despite reports that these are
rare in iPSCs (Smith et al., 2014; Veres et al., 2014), because high levels of off-target editing
had been reported in cultured cells (Fu et al., 2013). Using Cas9n was more cautious than
necessary, at the expense of decreasing CRISPR efficiency and this was another factor which
led me to use Cas9wt for CRISPR 3.
Screening insufficient colonies
I screened only 30 colonies after CRISPR 2, so I would not have detected edited colonies
if the editing efficiency was less than 3.3%. I screened so few colonies because I decided
to redesign my CRISPR strategy, rather than continue with a flawed strategy. I screened
colonies for the PAM mutation, not the N279K mutation, because digestion with BsaH1
(which digests the control but not the PAM mutant sequence) gave cleaner differentiation
between digested and undigested bands than AseI (which digests the control but not the
N279K mutant sequence). This strategy produced the possibility that an undigested band
(indicating the presence of the PAM mutation) would be present due to incomplete digestion
rather than successful editing. For this reason, both positive (known to be digested) and
negative (known not to be digested) controls were included in screening by restriction digest
in Section 5.4.4.
Since the PAM mutation was closer to the nick sites, it was more likely to be induced
by HDR than the more distal N279K mutation (Elliott et al., 1998; Paquet et al., 2016).
Screening for the PAM mutation was therefore a poor proxy for the N279K mutation and
would have over-predicted the number of edited colonies.
Furthermore, I did not sequence any colonies from CRISPR 2 since I did not consider
the possibility of non-clonal colonies, like those found after CRISPR 3. To detect mutations
in non-clonal colonies, I could have run digested next to undigested DNA samples and
compared the relative ratios, as I did in Section 5.4.4.
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5.5.2 Improvements to CRISPR 3
In the third strategy I designed (CRISPR 3, Section 5.4.4), I screened 99 colonies for the
N279K mutation by restriction digest and Sanger sequencing. Although I detected indels
in some CTRL2 colonies, no indels were detected in the N279K2 colonies and the N279K
mutation locus was not edited. There are several possible reasons why this strategy did
not work: insufficient screening, no blocking mutations, and not optimising transfection
conditions for both iPSC lines.
Insufficient screening
CRISPR-induced point mutations are inefficient in iPSCs, with frequencies as low as 1%
(Yang et al., 2014). Screening only 99 colonies means I would not have detected editing at
frequencies below 2%, so the simplest improvement to this strategy would be screening more
colonies. I did not do this because picking individual colonies, expanding them, screening
them and keeping the duplicates in culture whilst interpreting the screening results was time
consuming and labour intensive. In addition, not all colonies survived picking, which limited
the number of colonies available for screening: some did not attach to the feeder layer, some
attached but then differentiated, and some attached but failed to grow.
Non-clonal colonies
Some colonies had mixed sequences after CRISPR, which made screening difficult. This
may be because I electroporated iPSCs in 2-3 cell clumps, or because Cas9 was active
during colony expansion: Merkle et al. (2015) observed heterogeneously edited colonies
after CRISPR and reduced (but did not eliminate) heterogeneity by limiting the Cas9 activity
window with a doxycycline-inducible Cas9. To produce fewer non-clonal colonies, I could
have combined Merkle et al.’s method with that of Byrne et al. (2014a), who electroporated
iPSCs with GFP-labelled Cas9, then FACs sorted single GFP-positive iPSCs into individual
wells of a 96-well plate.
Another way to increase the proportion of clonal colonies is using NPCs, which grow
more easily from single cells than iPSCs (Reinhardt et al., 2013). Hallmann et al. (2017)
used this method and although they did induce the N279K mutation, they only used NPCs
from one differentiation in their experiments. CRISPR editing of NPCs leaves two options:
differentiate and edit three sets of NPCs independently generated from iPSCs, or count three
independent differentiations of NPCs to neurons as three independent experiments. CRISPR
editing three times would be extremely time consuming and disregarding the importance of
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the iPSC to NPC transition could skew results. In addition, editing only NPCs narrows the
potential uses of the edited cell line for other researchers. For these reasons, I chose to edit
iPSCs.
I could have increased the number of clonal colonies with a different antibiotic selection
method. To increase the number of iPSCs surviving puromycin selection which were edited,
rather than just expressing the puromycin resistance gene in the Cas9 plasmid, I could have
used a repair template which inserted a puromycin-resistance cassette next to the mutation.
Imamura et al. (2016) used this method to edit iPSCs at the MAPT exon 10+14 locus and
excised the cassette using the piggyBac transposon system. I did not consider this method
because transposon insertion and excision can leave scars but Imamura et al. isolated scarless
edited iPSCs, indicating that this is a viable alternative.
Given that CRISPR 2 and 3 produced mixed colonies, I could have used the protocol of
Miyaoka et al. (2014), who adapted the yeast cloning sib-selection method for iPSCs. This
method involves dissociating iPSCs to single cells, using nucleases and repair templates to
make a desired point mutation, and then plating iPSCs into two duplicate 96-well plates
after editing. DNA is then harvested from each well of one 96-well plate, and digital droplet
PCR is performed to identify the well containing the highest proportion of edited iPSCs.
The corresponding well of iPSCs in the duplicate 96-well plate is then re-plated into two
new 96-well plates. Repeated rounds of digital droplet PCR and expansion of the most
promising wells led to isolation of scarlessly corrected iPSC clones - in Miyaoka et al.’s
paper, the corrected iPSCs isolated using this method were present as 1:2000 of the initial
population. I used a similar method: picking the most promising colonies, dissociating them
to small clumps and expanding them. However, I picked individual colonies, some of which
did not survive. Miyaoka et al.’s protocol avoids plating individual iPSCs or small iPSC
clumps, which is likely to improve iPSC survival. In addition, Miyaoka et al.’s iPSCs were
feeder-free, whereas the CTRL2 and N279K2 iPSCs are feeder-dependent and did not adapt
well to feeder-free conditions. CRISPR editing is twice as efficient with feeder-free rather
than feeder-dependent iPSCs (Byrne et al., 2014a) and this is another factor that may have
lowered the efficiency of my CRISPR strategy. If I were to edit iPSCs by CRISPR again, I
would use feeder-free iPSCs and the iPSC sib-selection method, as described above.
Blocking mutations
Indels were detected in 6 out of 58 CTRL2 colonies (10.3%), indicating that Cas9 cut the
DNA, although this does not show whether HDR took place: DSBs could have been repaired
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by HDR and re-cut by Cas9 before repair by NHEJ to make indels, or simply repaired by
NHEJ to make indels.
Re-cutting by Cas9 could be reduced by blocking mutations (Cho et al., 2014; Hsu et al.,
2013) but as discussed in Section 5.4.4, mutations in this region may alter exon 10 splicing.
Paquet et al. (2016) overcame this problem by using CRISPR to insert the desired mutation
and a blocking mutation, expanding iPSC colonies and then using CRISPR to correct the
blocking mutation, leaving only the desired mutation. However, this method is impractically
slow: Paquet et al. CRISPR-edited, expanded, screened and karyotyped the iPSCs and then
repeated the entire process. A more practical alternative would be to assess changes in exon
10 splicing caused by silent blocking mutations using exon trapping (Duyk et al., 1990):
if the blocking mutations did not change exon 10 splicing, they would be safe to use. I
designed exon trapping plasmids to test two blocking mutations which would have increased
the efficiency of gene editing at the N279K locus, but the isogenic P301L iPSC lines became
available shortly afterwards.
Repair template design
Indels may have occurred because Cas9 cut the DNA but the HDR template did not make
repairs. This could have been due to low template availability. I tested two ssODN concen-
trations declared optimal in relevant literature (Section 5.3.3) but these were similar and
since I saw no difference in cell death between the two concentrations, I chose the higher
concentration. A more thorough approach would have been to test a larger range of ssODN
concentrations and to use the highest concentration which did not cause noticeable cell death.
Additionally, my ssODN templates were not complementary to the gRNA and therefore
not optimal. Intuitively, non-complementary ssODNs are a logical choice: they cannot bind
the gRNA, so they cannot be cut by Cas9, or occupy Cas9 and reduce target DNA cutting.
However, after Cas9wt makes a DSB, the Cas9 complex releases the non-target strand
(the strand not bound to gRNA) first, before the entire complex dissociates from the DNA
(Richardson et al., 2016). Cas9 can cut DNA and then remain bound for five hours, during
which time the non-target strand is available for binding with a gRNA-complementary repair
template but the target strand is bound to Cas9 and cannot bind a gRNA-non-complementary
repair template. Since the non-target strand is more available for binding after Cas9 cleavage,
ssODNs complementary to the gRNA may be more efficient, which is supported by some
studies (Yang et al., 2013) but not others (Kan et al., 2017). Richardson et al.’s research
was not published when I was designing the ssODNs, which is why I designed them not
complementary to the gRNA.
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Optimisation of transfection conditions
There were fewer N279K2 than CTRL2 colonies after electroporation and puromycin selec-
tion, perhaps because I optimised the electroporation program, puromycin concentration and
ssODN concentration for CTRL2 iPSCs only. To get more surviving clones, I should have
optimised the parameters for both iPSC lines. I could also have tried other transfection com-
ponents, such as recombinant Cas9 protein and in vitro transcribed gRNA, which cause more
DNA cleavage in iPSCs than Cas9 and gRNA plasmids (Liang et al., 2015). Synchronising
iPSCs in M phase also increases CRISPR efficiency (Lin et al., 2014), and small molecules
including the DNA ligase inhibitor Scr7 can increase HDR up to 19-fold (Maruyama et al.,
2015).
As well as optimising the transfection conditions, I could have assessed CRISPR ef-
ficiency in easier to culture cells, such as HEK293 cells before iPSCs. Since iPSCs are
delicate relative to HEK293 cells, I decided to optimise the method once, on iPSCs, rather
than twice, on HEK293 cells and then iPSCs. However, I could have used methods such as a
T7 endonuclease assay to check the cutting ability and efficiency of my Cas9wt and Cas9n
strategies before transfecting iPSCs with the CRISPR components, to avoid using inefficient
gRNAs.
5.5.3 Summary
In this Chapter, I designed three CRISPR strategies to make isogenic iPSC lines. Two of the
CRISPR strategies were attempted, but only the third CRISPR strategy produced cells with
edited DNA. The DNA changes were indels, and no colonies containing a base change at the
N279K mutation locus were found.
The difficulties inherent in performing CRISPR on iPSCs (outlined in this section) meant
that I was unable to make isogenic iPSC lines. Since isogenic control iPSC lines for other
MAPT mutations were available, I focussed my efforts on making iPSC-derived cerebral
organoids (described in Chapter 6) rather than continuing to attempt to edit the N279K
mutation locus.
Chapter 6
Cerebral organoids
6.1 Aims
Differentiating iPSC-derived neurons in a 3D environment may provide advantages over a
2D environment, including enhanced survival and maturation. 3D culture may also provide
an advantage over 2D cultures for modelling neurodegenerative diseases: a study of iPSC-
derived neurons with AD-relevant mutations showed disease-like changes in 3D, but not in
2D (Choi et al., 2014). This suggests that 3D culture may also enhance the phenotypes of
MAPT-mutant iPSC-derived neurons.
Cerebral organoids (COs) are 3D structures which differentiate over time to produce
neurons and astrocytes (Lancaster and Knoblich, 2014a). Unlike some 3D culture systems
(which consist of neurons embedded in a thick matrigel layer), COs are generated through
directed differentiation. Beginning as embryoid bodies made of iPSCs, COs recapitulate
some features of the developing brain, including generation of neurons from all six cortical
layers, and the generation of astrocytes. The addition of patterning factors can be used to
make brain-region specific COs (Lancaster et al., 2017).
Variability between iPSC lines can contribute to variability between COs. This variability
can be decreased by using isogenic iPSCs, which share the same genetic background (Gian-
domenico and Lancaster, 2017; Lancaster et al., 2017). Although I was not able to make a
pair of isogenic iPSC lines from patient-derived iPSCs with the N279K mutation (in Chapter
5), I obtained three isogenic iPSC lines (isogenic control, P301L heterozygous, P301L ho-
mozygous). I used these three isogenic lines alongside an FTDP-17T patient-derived iPSC
line with the P301L MAPT mutation to make cerebral organoids.
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The aim of the work described in this Chapter is to make cerebral organoids from control
and MAPT-mutant iPSCs, to characterise them, and to investigate disease-relevant changes.
This aim will be fulfilled by:
1. Differentiating iPSCs into cerebral organoids, and determining the proportion of
astrocytes and neurons in the 3D cultures. The emergence of astrocytes by day 100
is expected, and indicates maturation of the culture. Determining the proportion of
astrocytes will also allow me to see whether there is FTDP-17T-relevant astrocyte
overgrowth.
2. Examining synaptic protein expression. Synapses are expected to form by day 100,
and examining synaptic protein levels will also indicate if there is FTDP-17T relevant
synapse loss.
3. Assessing tau isoform expression to determine the maturity of the neurons with respect
to tau isoform expression, since 3D culture may increase expression of 4R tau. 4R tau
expression is particularly important for neurons with the P301L mutation, since it is
only present in 4R tau.
4. Examining tau phosphorylation at the AT8 epitope and tau conformational changes
with the MC-1 antibody, to determine whether 3D culture enhances the development
of FTDP-17T-relevant changes.
6.2 Introduction
The first 3D pluripotent stem cell (PSC)-derived cultures were optic cup structures made
from mouse embryonic stem cells (mESCs) (Eiraku et al., 2011). Later, Lancaster and
Knoblich (2014a) used induced pluripotent stem cells (iPSCs) to make “minibrains” or COs
in which proliferative NPCs differentiated to produce a mixture of brain areas. At the time of
writing, COs have been produced to model brain areas including the forebrain (Kadoshima
et al., 2013), midbrain (Qian et al., 2016), cerebellum (Muguruma, 2018), hippocampus and
choroid plexus (Sakaguchi et al., 2015), and hypothalamus (Qian et al., 2016), to name a few.
COs can be made using patterning factors, which increases batch-to-batch reproducibility and
brain area specificity (Lancaster et al., 2017; Qian et al., 2016), or COs can develop through
intrinsic cues including morphogens such as Wnt and Nodal, which can be spontaneously
released in culture (Eiraku and Sasai, 2012). This gives more complex, less reproducible
COs, containing a variety of brain areas (Lancaster et al., 2013).
6.2 Introduction 187
The work described in this Chapter used forebrain-specific COs, generated from iPSCs
with the heterozygous or homozygous P301L MAPT mutation, and an isogenic control.
6.2.1 Cerebral cortex development
iPSC differentiation to COs recreates aspects of human brain development, which is briefly
described here.
During fetal development the future brain and spinal cord develop from one of three germ
layers called the ectoderm. The ectoderm forms the neural plate, which folds to make the
neural tube: a layer of neuroepithelial cells (NECs, also known as primary progenitors or
neural stem cells) radially arranged around a central cavity that becomes a ventricle. The
neural tube receives patterning cues (as described in Chapter 1) and develops rostral-caudal
and dorsal-ventral axes - the rostral part of the neural tube forms the telencephalon, which
gives rise to the future forebrain (Petros et al., 2011; Wilson and Houart, 2004).
NECs in the neural tube divide symmetrically, expanding the NEC population. When
neurogenesis begins NECs transition to radial glial cells: radially orientated, polarised cells
whose processes span from the apical side (proximal to the ventricle) to the basal side (distal
to the ventricle) of the developing tissue, forming a scaffold along which neurons migrate
(Bystron et al., 2008; Kriegstein and Alvarez-Buylla, 2009).
Radial glia are the precursors of almost all CNS cells, as demonstrated by experiments
labelling radial glia and finding almost all brain regions labelled after development (Anthony
et al., 2004). During cortical neurogenesis radial glia divide asymmetrically to produce a
radial glial cell and either a neuron, a glial cell, or an intermediate cell: an intermediate
progenitor or an outer radial glial cell (Hansen et al., 2010; Kriegstein and Alvarez-Buylla,
2009). Intermediate progenitors divide symmetrically to produce either two neurons or two
intermediate progenitors (Kriegstein and Alvarez-Buylla, 2009), whereas outer radial glial
cells can divide symmetrically to proliferate, or divide asymmetrically to produce an outer
radial glial cell and an intermediate progenitor (Hansen et al., 2010). Intermediate progenitors
are lineage-restricted: in mice they divide to produce neurons found in all six cortical layers,
but their progeny is not found in interneurons which are from a different lineage (Mihalas
et al., 2016).
The first neurons in the developing cortex are Cajal-Retzius neurons in the developing
pre-plate which originate in adjacent areas and migrate into the cortex. They help guide newly
generated neurons but disappear during development (Bystron et al., 2008). Subsequently
generated neurons form the cortical plate which splits the preplate to make the transient
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subplate and the marginal zone (the future layer I) (Mountcastle, 1997). Neurons destined
for the future layers 2-6 are made in an inside-out temporal sequence in which their birthdate
determines their future identity and cortical layer position, such that early-born neurons
populate the lower cortical layers and late-born neurons populate the upper layers (Angevine
and Sidman, 1961). These neurons can be identified by expression of specific transcription
factors (reviewed by Molyneaux et al., 2007). They are predominantly glutamatergic;
GABAergic cortical interneurons form in the caudal and medial ganglionic eminences
and migrate into the cortex later in development (Wonders and Anderson, 2006). After
neurogenesis, radial glia generate astrocytes and oligodendrocyte precursors (Kriegstein and
Alvarez-Buylla, 2009; Rakic, 2003).
6.2.2 Cerebral organoids as models of the brain
Some aspects of cerebral cortex development are recapitulated by COs (reviewed by Heide
et al., 2018). For example, COs contain proliferative NECs and radial glia which undergo
inter-kinetic nuclear migration: movement of the radial glial cell body such that cell division
happens close to the ventricle (Lancaster et al., 2013). The radial glia in COs produce
neurons, astrocytes, and oligodendrocytes in a time-dependent manner (Lancaster et al.,
2013; Monzel et al., 2017; Renner et al., 2017). Neurons in COs form synaptic connections,
are electrophysiologically active (Pas¸ca et al., 2015), and represent populations from all six
cortical layers (Lancaster et al., 2013). Although the cortical layers are not spatially separated
as they are in the fetal brain, some separation of upper and lower layers has been observed
(Kadoshima et al., 2013; Lancaster et al., 2013; Pas¸ca et al., 2015; Qian et al., 2016).
However, some aspects of the human brain are not present in COs. COs made without
patterning factors contain multiple brain areas which are not organised in terms of where
the areas develop relative to each other (Lancaster et al., 2013), perhaps because COs lack
axes across the entire tissue (Kelava and Lancaster, 2016). COs also lack other tissues found
in the developing brain, such as vasculature. This can lead to necrotic cores if COs become
too large for diffusion to adequately deliver oxygen and nutrients (Kelava and Lancaster,
2016; Raja et al., 2016) and this has been compensated for by gently agitating CO cultures
(Lancaster et al., 2013; Qian et al., 2016). Cell types such as microglia, which develop from
the yolk sac - a different lineage from the rest of the brain (reviewed by Ginhoux and Prinz,
2015), are also absent. This may have implications for synaptic pruning, which is carried
out by microglia in postnatal brains (Schafer et al., 2012), and for modelling diseases where
microglia are implicated.
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Other features of the human brain not recapitulated by COs include the extracellular
matrix which is required to support a continuous neuroepithelium rather than individual
neural rosettes (Nasu et al., 2012). In COs this is compensated for by the addition of
matrigel (Lancaster and Knoblich, 2014b; Lancaster et al., 2013). COs also lack cortical
folding into gyri and sulci. Some folding has been observed in COs with a PTEN mutation
linked to autism (Li et al., 2017) and neuroepithelial wrinkling has been reported (Karzbrun
et al., 2018) although the relevance of this to cortical folding in the human brain is unclear
(Lancaster, 2018).
As might be expected given the development-mimicking nature of COs, CO gene expres-
sion profiles are like those of the fetal brain. Gene expression studies have found comparable
expression between 75 day-old COs and 19-24 week-old fetal brain (Pas¸ca et al., 2015),
between day 40 and day 60 COs and 12-16 week-old fetal brain (Luo et al., 2016), and
between 60 day-old forebrain-specific COs and 8-9 week-old fetal brain (Lancaster et al.,
2017) .
6.2.3 Advantages of 3D neural cultures over 2D cultures
The 3D culture of COs may provide advantages over 2D cell cultures with respect to
microenvironment and maturity, which are outlined below. However, all the studies discussed
used 3D matrigel or hydrogel cell cultures, in which neurons or NPCs are disorganised, rather
than self-organising COs. To date, no studies have compared neuronal maturity (by RNA
profiling, for example) between 2D monolayer cell cultures and 3D COs.
Cell microenvironment
Neurons in 3D cultures have a more brain-like environment than those in 2D cultures. Instead
of the flat, stiff surface of a cell culture dish, cells inside a CO are in contact with other
cells or with matrigel, which more closely resembles brain stiffness (Ranjan et al., 2018).
In addition, NPCs and neurons in self-organising cultures can determine their own polarity,
whereas a 2D surface forces an apical-basal polarity which may affect cell function and
signalling (reviewed by Baker and Chen, 2012).
Culture maturity
One of the field-wide challenges in using PSC-derived neurons to examine the effects of
mutations which cause disease in adult or aged human brains is the relative immaturity of
the neurons. Therefore, the finding that 3D culture of neural cells can hasten maturity is
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particularly important. Culture in a 3D hydrogel layer (as compared to a traditional 2D
monolayer) has been shown to increase differentiation of immortalised human NPCs (ReN
cells) (Choi et al., 2014; Liedmann et al., 2012; Ortinau et al., 2010; Park et al., 2018),
SHSY-5Y cells (Seidel et al., 2012), and iPSC-derived NPCs (Muratore et al., 2014; Zhang
et al., 2016) to neurons. In the case of the ReN cell-derived NPCs (Ortinau et al., 2010) and
iPSC-derived NPCs (Zhang et al., 2016), the increased differentiation to mature neurons may
have been partly because more NPCs survived in 3D relative to 2D culture.
In addition, 3D hydrogel-cultured SHSY-5Y-derived neurons (Seidel et al., 2012) and
iPSC-derived neurons (Zhang et al., 2016) expressed more synaptic markers than those in 2D
cultures, suggesting greater maturity. Three-D iPSC-derived NPC cultures have also been
shown to enhance electrophysiological maturity as compared to 2D cultures: neurons from 3D
cultures fired more mature action potentials, and expressed higher levels of voltage-activated
sodium and potassium channels (Zhang et al., 2016).
Three-dimensional cultures of ReN cells also seem to mature faster with respect to
astrocyte production. Choi et al. (2014) reported higher levels of GFAP and S100β mRNA
in 3D as compared to 2D culture, and Park et al. (2018) detected more GFAP in 3D as
compared to 2D cultures by Western blotting. Since astrocytes are produced after neurons
in the sequence of NPC differentiation (Kriegstein and Alvarez-Buylla, 2009; Rakic, 2003),
this suggests greater maturity in the 3D cultures. However, Zhang et al. (2016) found fewer
astrocytes in differentiated 3D iPSC-derived cultures than in 2D cultures, suggesting that the
3D cultures were less mature compared to those in 2D. The finding that 3D cultured neurons
were more mature in electrophysiological and synapse development, would contradict Zhang
et al.’s conclusion, indicating that the 3D substrate may have favoured neuronal differentiation
relative to the 2D substrate.
Tau expression
Human tau isoform expression can be used as indication of an iPSC-derived neural culture’s
maturity, since the shortest 0N3R tau isoform is expressed during development, and the
remaining five isoforms (0N4R, 1N3R, 1N4R, 2N3R, 2N4R) are co-expressed with the 0N3R
isoform post-natally (Goedert and Jakes, 1990; Goedert and Spillantini, 1990). There is some
evidence that 3D culture enhances adult-like tau splicing. Choi et al. (2014) found higher
4R tau and total tau mRNA levels in 49 day-old 3D ReN cell cultures as compared to 2D
cultures, although mRNA changes were not corroborated at the protein level.
Inducing mature expression of tau isoforms is particularly important for studying some
MAPT mutations which cause FTDP-17T, such as the P301L mutation. P301L is a mutation
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in tau exon 10 (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998b), the exon
which is transcribed and translated in the three four-repeat (4R) tau isoforms (0N4R, 1N4R,
2N4R), which are only expressed post-natally.
6.2.4 Tau dysfunction in 3D PSC-derived cultures
COs are becoming an increasing popular way to model the human brain in vitro but relatively
few studies have used this system to examine the effects of FTDP-17T-relevant MAPT
mutations. Seo et al. (2017) used patient-derived iPSCs with the P301L MAPT mutation
to produce two isogenic iPSC lines using CRISPR. The iPSC lines were with and without
a delta-p35 mutation, which prevents p35 cleavage to make p25. p25 can activate cyclin-
dependent kinase 5 (Cdk5) which may have a role in tau phosphorylation in AD (Sengupta
et al., 2006; Yamaguchi et al., 1996). Eighty day-old COs derived from delta-p35 P301L
mutant iPSCs showed a trend towards a lower phosphorylated tau (pSer202 and pThr181)
over total tau ratio, and expressed more synaptophysin than COs from P301L mutant iPSCs.
This suggests a possible role for p25 in FTDP-17T, but P301L mutant COs were not compared
with control COs, making these results difficult to interpret.
Other groups have studied the effects of familial AD mutations on tau phosphorylation in
COs, reporting increases in tau phosphorylation at Ser202 and Thr205 (detected with the AT8
antibody). For example, Yan et al. (2018) found an increased proportion of AT8 positive COs
derived from iPSCs with an AD-relevant presenilin 1 mutation as compared to controls after
28 days in culture. Similarly, Gonzalez et al. (2018) found higher levels of AT8 positive and
PHF1 (detecting pSer396 and pSer404) positive tau in COs made from iPSCs with trisomy
21 (from a donor with Down’s syndrome) and from COs with an AD-relevant presenilin
1 mutation as compared to controls. Although these findings are not directly relevant to
FTDP-17T, they demonstrate that differences in tau phosphorylation can be induced by
endogenous mutations and are detectable in COs.
As well as being aberrantly phosphorylated, tau forms aggregates in FTDP-17T and
tauopathies including AD (Foster et al., 1997; Spillantini et al., 1998a). However, protein
aggregation is only recapitulated to a limited extent in iPSC-derived cultures. Gonzalez et al.
(2018) have detected Gallyas silver positive cells in 110 day-old trisomy 21 and presenilin 1
mutant COs. Gallyas silver staining is a sensitive method used to detect tau in neurofibrillary
tangles in AD, corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP),
amongst other diseases (Uchihara, 2007). Gonzalez et al. also extracted protein from COs
with PBS, and then, from the PBS-insoluble pellet, they extracted protein in formic acid. The
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results showed more tau in the formic acid soluble fraction of presenilin mutant and trisomy
21 COs than from that of control COs.
Gallyas silver positive cells have also been detected in ReN cell-derived neurons cultured
in thick matrigel layers, which over-expressed mutant β -amyloid (due to the presence of
three AD-related mutations in amyloid precursor protein) and expressed presenilin 1 with
one AD-related mutation (Choi et al., 2014). Choi et al. also found an increase in sarkosyl-
insoluble tau in the AD mutant cultures, and detected extracellular β -amyloid accumulation
in 3D but not 2D cultures. They suggested this is because the 3D matrigel layer trapped
β -amyloid released by the neurons, whereas β -amyloid released from 2D cultures diffused
into the media and was removed during media changes.
These results indicate that insoluble, abnormal tau can be detected in some COs and 3D
neural cultures, and that protein accumulation may be favoured in 3D cultures relative to
2D cultures. Again, these findings are not from cultures with MAPT mutations, but they do
demonstrate the potential for observing FTDP-17T-relevant tau changes in COs.
6.3 Materials and Methods
6.3.1 iPSC culture and differentiation
iPSCs were thawed and cultured as described in Chapter 2.
iPSCs were differentiated to COs following the method of Lancaster et al. (2017) for
forebrain-patterned COs (also known as microfilament-engineered cerebral organoids: en-
CORs). The method is described in detail in Section 2.4 and Table 6.1 in Chapter 2. I
differentiated COs from the isogenic iPSC lines IsoCon, P301Lhet, and P301Lhom, and
from the patient-derived iPSC line P301Lpat. However, not all iPSC lines differentiated
to COs with the same efficiency: IsoCon, P301Lhet, and P301Lhom COs shared the same
genetic background and differentiated more easily, although P301Lhet iPSCs could not be
maintained in culture; P301Lpat COs were more difficult to differentiate. The number of
differentiations and the characteristics of the iPSCs are shown in Table 6.1.
I made at least one batch of COs from each of the iPSC lines, aiming to culture them for
at least 100 days. However, bacterial infections meant I had to discard some batches. When
bacterial infections occurred, I kept all unaffected COs until the media needed to be changed,
checked under the microscope for the absence of infection, and cut short the differentiation.
Since some differentiations were cut short, COs were 84-100 days old.
‘
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Table 6.1 Differentiation of iPSCs to COs
iPSC line Number of differentiations iPSC culture surface
IsoCon 3 Feeder-free
P301Lhet 1 Feeder-free
P301Lhom 3 Feeder-free
P301Lpat 3 Feeder-dependent
The forebrain CO method is from Lancaster et al. (2017). The number of differentiations denotes how
many differentiations produced COs after 100 days, not how many differentiations were attempted:
one differentiation each of forebrain-patterned IsoCon, P301Lhom, CTRL1 and P301Lpat COs
became infected during culture and could not be used. I was unable to maintain the P301Lhet iPSC
line in culture after the first differentiation.
6.3.2 Immunostaining, Western blotting and statistical analysis
Immunostaining was performed as described in Section 2.5.1 and Western blots were per-
formed as described in Section 2.6. Statistical analysis was performed as described in
Section 2.7.
Quantification of immunostaining
AT8 and MC-1 staining were quantified using ImageJ. In both cases, COs were co-stained
with the total tau antibody tau DAKO. The mean AT8, MC-1, and total tau fluorescence
intensities were measured using the mean grey value function of the Measure menu in ImageJ.
Background fluorescence intensity was measured in AT8, MC-1, and total tau images by
selecting an area of the image which did not contain the CO, and using the mean grey value
function of the Measure menu. Background fluorescence intensity was subtracted from the
intensity of the whole image for each of the AT8, MC-1, and total tau images. AT8 and MC-1
values were normalised to the total tau fluorescence intensities in the corresponding images.
6.4 Results
6.4.1 Cell types present in cerebral organoids
To determine the proportion of neurons and astrocytes in COs from each iPSC line, I
quantified the amount of β III-tubulin and GFAP detected in Western blots, and normalised
these to the amount of GAPDH. Although GFAP detects radial glia as well as astrocytes
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Fig. 6.1 Western blots for GFAP, synaptophysin, β III-tubulin, and GAPDH in iPSC-derived
COs. A representative blot. Each lane contained protein from at least six COs derived from the
indicated iPSC line in one independent differentiation round. Molecular weights, in kDa, are indicated.
This blot was repeated to ensure that the results were reproducible, and to improve on the blurred
staining. The second blot confirmed the results of the first and the staining was clearer, however, there
was no protein in the third P301Lhom lane due to a loading error. Therefore, the first iteration of the
blot is shown.
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Fig. 6.2 There is no significant difference in the amount of β III-tubulin positive neurons, in the
amount of GFAP-expressing astrocytes, or in the amount of the synaptic protein synaptophysin
between IsoCon, P301Lhet, P301Lhom and P301Lpat iPSC-derived COs at day 84-100. A)
β III-tubulin normalised to GAPDH. There was no significant difference in the amount of β III-tubulin
between COs from the different iPSC lines, as determined by one-way ANOVA. B) GFAP normalised
to GAPDH. There was no significant difference in the amount of GFAP between COs from the
different iPSC lines, as determined by one-way ANOVA. C) Synaptophysin normalised to β III-
tubulin. There was no significant difference in the amount of synaptophysin between COs from the
different iPSC lines, as determined by one-way ANOVA. All results are relative to the amount of
β III-tubulin (A), GFAP (B), or synaptophysin (C) in IsoCon COs derived in the third differentiation
round, which was set to 1. Each point shows normalised chemiluminescence intensity from one of
one (P301Lhet) or three (IsoCon, P301Lhom, P301Lpat) independent differentiations; bars show the
mean±SD.
(Raponi et al., 2007), the number of radial glia (which can be identified by their radial
arrangement around a central ventricle) was low in my COs at day 84-100. Western blots
were performed using protein extracts made from at least six COs from each differentiation
of each iPSC line, meaning that each Western blot lane contained protein from at least six
COs which had all been grown together. The blot was repeated twice with the same samples,
and similar results were obtained each time. A representative blot is show in Figure 6.1, and
quantification of the Western blot is show in Figure 6.2.
I compared the amount of β III-tubulin (normalised to GAPDH) in IsoCon, P301Lhet,
P301Lhom, and P301Lpat COs using a one-way ANOVA, which showed no significant
difference between the mean values (F(3,6)=2.242, p=0.1836, Figure 6.2A). Comparing the
amount of GFAP (normalised to GAPDH) in the COs using a one-way ANOVA also showed
no significant differences (F(3,6)=1.777, p=0.2513, Figure 6.2B).
I also compared the amount of β III-tubulin and GFAP between COs by immunostaining
at least two sections from each batch of COs from each iPSC line. Most COs contained large
areas of β III-tubulin positive neurons (Figure 6.3). GFAP positive astrocytes were sometimes
packed into one area, or spread throughout β III-tubulin positive neurons (Figure 6.3).
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As an estimate of the number of synapses, I measured the amount of synaptophysin
in protein extracts from all COs. Synaptophysin is a pre-synaptic protein which has been
shown to be a good proxy for synapse number in the human brain (Bigio et al., 2001).
Synaptophysin detected in protein extracts from IsoCon, P301Lhet, P301Lhom and P301Lpat
COs is shown in Figures 6.1 and 6.2. Comparing the amount of synaptophysin (normalised
to β III-tubulin) using a one-way ANOVA showed no significant difference between the mean
values (F(3,6)=1.027, p=0.4448).
Overall, these results show no significant differences in the amount of synaptophysin,
β III-tubulin, or GFAP between COs made from different iPSC lines.
6.4.2 Layer markers
To determine whether the COs contained cortical forebrain neurons, and to establish the
relative maturity of the COs, I examined the expression of cortical layer markers by im-
munofluorescence. I used the layer markers Tbr2 (expressed by intermediate progenitors,
Bulfone et al., 1995), Tbr1 (layer 6 pre-plate neurons, Bulfone et al., 1995), and Cux1/2
(layer 2-4 neurons, Nieto et al., 2004). Initially, one section from each batch of COs from
each iPSC line was stained. If layer markers were not detected, one or two further sections
were stained. The number of differentiations in which each layer marker was detected is
summarised in Table 6.2.
A small number of Tbr2 positive intermediate progenitors were detected in IsoCon,
P301Lhom, and P301Lpat COs from one or two of three differentiations, but not in P301Lhet
COs (Figure 6.4). However, P301Lhet COs contained layer 6 Tbr1 positive neurons, and
therefore presumably contained intermediate progenitors at some point, since Tbr2 and Tbr1
are expressed sequentially (Englund, 2005). A small number of Tbr1 positive (layer 6)
Table 6.2 COs expressing the layer markers Tbr2, Tbr1, and Cux1/2
iPSC line Tbr2 Tbr1 Cux 1/2
Intermediate progenitors Layer 6 neurons Layer 2-4 neurons
IsoCon ++ +++ ++
P301Lhet - + -
P301Lhom ++ ++ ++
P301Lpat + ++ +
Symbols denote whether layer markers were detected in no differentiations (-), one differentiation (+),
two differentiations (++) or three differentiations (+++) of CO from the three iPSC lines.
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neurons were found in IsoCon COs from three of three differentiation rounds, in P301Lhom
and P301Lpat COs from two of three differentiation rounds, and in P301Lhet COs from one
of one differentiation rounds (Figure 6.5). Cux1/2 positive (layer 2-4) neurons were found in
IsoCon COs from two of three differentiation rounds, in P301Lhom COs from two of three
differentiation rounds, and in P301Lpat COs from one of three differentiation rounds, but not
in P301Lhet COs (Figure 6.6).
These results show that most COs contained at least one marker indicating the presence
of cortical neurons, although some areas within each CO did not contain any of these markers.
The timing of layer marker expression was also in line with other studies on iPSC-derived
neural cultures: Tbr1 positive layer 6 neurons have been detected in 30-110 day-old COs
(Gonzalez et al., 2018; Lancaster et al., 2013), and Cux1/2 positive layer 2-4 neurons have
been detected in 70 day-old monolayer cortical neuron cultures (Shi et al., 2012a).
6.4.3 Tau isoform expression in cerebral organoids
I assessed 3R and 4R tau isoform expression in my COs by Western blotting and immunoflu-
orescence. Representative Western blots using protein from day 84-100 IsoCon, P301Lhet,
P301Lhom, and P301Lpat COs are shown in Figure 6.7, and a summary of the tau isoforms
detected is shown in Figure 6.3. Western blots were repeated at least twice and at most three
times per independently differentiated batch of COs.
The 0N3R tau isoform was detected in protein extracts from COs derived from each iPSC
line, in each independent differentiation (blue asterisks in Figure 6.7). This was also the
predominant isoform, suggesting a high proportion of immature neurons. The 0N4R tau
isoform (red asterisks in Figure 6.7) was detected in IsoCon COs (in three differentiations),
P301Lhet COs (one differentiation), P301Lhom COs (two of three differentiations) and
P301Lpat COs (three of three differentiations). However, the prominence of the 0N3R tau
isoform band may have obstructed detection of some 0N4R isoform bands, since longer
exposure of the Western blot to detect weaker 0N4R bands increased the size of the 0N3R
band detected. The 1N3R tau isoform bands (green asterisks in Figure 6.7) were detected in
IsoCon COs (in two of three differentiations), P301Lhet COs (one differentiation), P301Lhom
COs (one of three differentiations), and P301Lpat COs (one of three differentiations).
The detection of 0N4R in most COs with the P301L mutation is particularly important
since P301L is only present in 4R tau (Hasegawa et al., 1999; Hong, 1998). Since some 4R
tau is present, effects of the P301L mutation may be present.
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Fig. 6.7 Western blots for tau isoforms show expression of 0N3R, 0N4R and some 1N3R tau in
IsoCon, P301Lhet, P301Lhom and P301Lpat iPSC-derived COs at day 84-100. Representative
blots probed for all tau isoforms using the total tau antibody tau DAKO. Each lane contained protein
from at least six COs derived from the indicated iPSC line in one independent differentiation round.
“+”, highlighted in yellow, indicates lanes containing protein which was dephosphorylated with alkaline
phosphatase (AP), to visualise the tau isoforms as distinct bands. “-” indicates lanes containing protein
not treated with alkaline phosphatase, where tau is phosphorylated, and runs as a smear. The size of
the molecular weight markers (kDa) are shown. Recombinant tau isoforms and control adult human
brain are included as positive controls, and each isoform is labelled. Low A) and high B) exposures
of the same membrane are shown. Arrows in blue (0N3R), red (0N4R), or green (1N3R) indicate tau
isoforms present in protein from COs (see Key). Black vertical lines indicate that the two parts of the
same blot are shown at different exposures.
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Fig. 6.10 Positive control for 4R tau immunostaining: dRG from a 5 month-old P301S mouse.
4R tau was detected with the RD4 antibody, then signal was amplified with biotinylated anti-mouse
IgG and a streptavidin Alexa Fluor conjugate. All tau isoforms were detected with the tau DAKO
antibody. Some cells show bright tau DAKO staining, which is expected: it indicates the presence of
tau accumulations (Mellone et al., 2013). Scale bar = 10µm.
Table 6.3 Tau isoforms in day 84-100 IsoCon, P301Lhet, P301Lhom, and P301Lpat
COs detected by Western blotting
IsoCon P301Lhet P301Lhom P301Lpat
0N3R 3/3 1/1 3/3 3/3
0N4R 3/3 1/1 2/3 3/3
1N3R 2/3 1/1 1/3 1/3
Western blots were performed using COs from each independent differentiation round. The table
indicates which tau isoforms were observed in COs from each iPSC line as a proportion of the total
number of independent differentiations. For example, 1/3 means the isoform was seen in one of three
differentiations.
I corroborated the results of Western blots by immunostaining with antibodies against
3R or 4R tau, and co-staining β III-tubulin, to identify neurons. 3R tau was detected in
cell bodies and in processes (Figure 6.8). The 4R tau signal was amplified using biotin
and streptavidin during immunostaining, and 5-month-old P301S mouse dorsal root ganglia
(dRGs) were used as a positive control (Figure 6.10) . The 4R tau isoform was detected
mostly in cell bodies (Figure 6.9).
There was no clear difference in the overall brightness of 4R tau immunofluorescence
between the COs. This is expected, since the P301L mutation does not alter 4R tau splicing
(Hasegawa et al., 1999; Hong, 1998; Hutton et al., 1998), and 0N4R tau was detected in COs
from each of the iPSC lines by Western blotting.
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Together, the Western blots and immunostaining experiments to detect tau isoforms show
that the 0N3R tau isoform was strongly expressed in COs from all iPSC lines, and that
lower amounts of 0N4R and 1N3R tau were also present. This indicates mature tau splicing
in some neurons. Since 0N4R and 1N3R tau bands were stronger in Western blots using
protein from COs than in Western blots using protein from monolayer neurons (Chapter 3)
my results suggest that 3D culture as COs increases maturation with respect to tau expression
in iPSC-derived neurons. However, to determine that this is due to 3D culture and not
differences between the iPSC lines used for monolayer culture and those used for 3D culture,
cerebral organoids and monolayer neurons would need to be grown from the same iPSCs at
the same time, and the tau isoforms present would need to be assessed on the same Western
blots.
When the P301Lhet and P301Lhom iPSC lines were generated from the IsoCon line
using CRISPR, silent mutations were introduced to increase gene editing efficiency. It is
possible that these mutations could alter exon 10 splicing, changing the amount of 4R tau
present (discussed in Chapter 5). Since the IsoCon and P301Lpat COs do not contain the
silent mutations, but the P301Lhet and P301Lhom COs do, comparing the tau isoforms
expressed is one way to determine the effects of the silent mutations on exon 10 splicing.
The detection of similar amounts of 0N4R tau in COs without the silent mutations (IsoCon
and P301Lpat) and with the silent mutations (P301Lhet and P301Lhom) suggests that the
silent mutations had a minimal effect on exon 10 splicing.
6.4.4 Tau phosphorylation at Ser202 and Thr205 (the AT8 epitope)
Tau phosphorylation at Ser202 and Thr205 (detected with the AT8 antibody) occurs in both
the fetal human brain (Goedert et al., 1993) and in disease, including in the brains of people
with FTDP-17T, but not in normal adult human brains (Han et al., 2009; Miklossy et al., 2007;
Spillantini et al., 1996b). To determine the extent of Ser202 and Thr205 phosphorylation in
my COs, I immunostained with the AT8 antibody and the tau DAKO antibody, which detects
all tau isoforms and is referred to as “total tau”.
Cryosectioned dRGs from 5-month-old P301S mice were used as positive controls for
tau staining (Figure 6.11). AT8 positive and negative cells were visible, indicating that
phosphorylated and total tau could be detected by immunofluorescence. In the COs, AT8
staining (detected at 647nm) overlapped with total tau staining (detected at 488nm), indicating
that AT8 staining was specific for tau. AT8 was visible in cell bodies and processes in the
COs (Figure 6.11).
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Fig. 6.12 Positive control for AT8 immunostaining: dRG from a 5 month-old P301S mouse.
Tau phosphorylated at Ser202 and Thr205 was detected with the AT8 antibody. All tau isoforms were
detected with the tau DAKO antibody. Some cells show bright tau DAKO staining, which is expected
and indicates the presence of tau accumulations (Mellone et al. 2013). In a subset of these cells, the
accumulated tau is phosphorylated at Ser202 and Thr205, and is therefore AT8 positive. Scale bar =
10µm.
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Fig. 6.13 There is no significant difference in AT8 immunofluorescence intensity between Iso-
Con, P301Lhet, P301Lhom, and P301Lpat iPSC-derived COs at day 84-100. Mean AT8 fluo-
rescence, minus background fluorescence (measured in areas outside the CO), normalised to total
tau fluorescence. A) Each point represents the average AT8 fluorescence (normalised to total tau
flu rescence) of COs made in three independent differentiations. Error bars show the mean± SD.
A significance bar indicates the results of a one-way ANOVA: there was no significant difference
in the amount of AT8 staining in COs made from different iPSC lines. B) shows the data which
was summarised in A). In B), each point represents the AT8 fluorescence (normalised to total tau
fluorescence) of one CO (which is an average of two representative images from each CO). Error bars
show mean±SD, considering all individual points.
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Two sections from each batch of at least six COs (at least 90µm apart) were stained and
analysed. Staining both sets of sections gave similar results, and results from the second set
of sections stained are presented here. I quantified AT8 staining by measuring fluorescence
intensity and subtracting background fluorescence (fluorescence visible outside the COs, in
empty areas), then normalising to total tau fluorescence intensity. Images for quantification
were taken at 40x (shown in Figure 6.11), from two representative areas per CO. At least six
COs from each batch were stained for AT8 and total tau, and images were taken of every CO
which had large lobes of total tau positive neurons.
Figure 6.13A shows the mean AT8 fluorescence (normalised to total tau fluorescence) for
each batch of independently differentiated COs, and 6.13B shows the mean AT8 fluorescence
intensity (normalised to total tau fluorescence) of individual COs. A one-way ANOVA
comparing the mean AT8 fluorescence intensities presented in 6.13A found no significant
difference between COs derived from IsoCon, P301Lhet, P301Lhom, and P301Lpat iPSCs
(F(3,6)=0.2568, p=0.8541).
These results show no difference in tau phosphorylation at Ser202 and Thr205 between
COs derived from the isogenic iPSC lines IsoCon, P301Lhet and P301Lhom, suggesting that
AT8 immunoreactivity in these COs is development-like, rather than related to FTDP-17T-
linked MAPT mutations.
6.4.5 Conformational changes in tau
The MC-1 antibody detects misfolded tau, with an epitope consisting of tau amino acids
7–9 and 312–342 (Jicha et al., 1996). MC-1 positive tau is detected in the brains of several
mouse models expressing mutant tau (Decker et al., 2015; Maeda et al., 2016; Xu et al.,
2014), and in the brains of people with AD and other tauopathies (Bouras et al., 2003), where
it is thought to represent a pathological conformation of tau associated with aggregation
(Jeganathan et al., 2008).
MC-1 positive tau has so far only been reported in iPSC-derived neural cultures exposed
to external cues, such as tau fibrils (Usenovic et al., 2015), tau fibrils and tau overexpression
(Medda et al., 2016), or transplantation of iPSC-derived neurons into an AD mouse brain
(Espuny-Camacho et al., 2017). For example, Medda et al. (2016) transduced control iPSC-
derived NPCs with a virus containing P301L-mutant 2N4R tau, then seeded the cultures
with a pro-aggregation tau fragment (containing the P301L mutation), and found MC-1
immunoreactivity after 32 days. However, the spontaneous appearance of MC-1 positive tau
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has not yet been reported in neural cultures derived from iPSCs whose donors carry MAPT
mutations.
To determine whether misfolded tau was present in my COs, I immunostained for MC-1
(detected at 647nm in the far-red channel) and all tau isoforms, referred to here as “total tau”
(detected with the tau DAKO antibody, at 488nm in the green channel). Very low levels of
fluorescence were detected at 568nm (in the red channel), indicating that MC-1 staining was
not bleed-through from total tau staining. A positive control for MC-1 staining (cell bodies in
dRGs from a five month-old P301S mouse) is shown in Figure 6.14, indicating that staining
technique itself was sufficient to detect misfolded tau.
Representative images from IsoCon, P301Lhet, P301Lhom, and P301Lpat COs are shown
in Figure 6.14. Some MC-1 staining was visible in COs from all iPSC lines, including in
IsoCon COs, and it was localised to cell bodies and processes. In each case, MC-1 staining
overlapped with total tau staining, suggesting that it was specific for tau. However, similar
patterns and levels of MC-1 staining were in detected control (IsoCon) as well as MAPT
mutant (P301Lhet, P301Lhom, and P301Lpat) COs. Since MC-1 staining is not detected in
control human brain (Weaver et al., 2000), and since the MC-1 staining detected in COs was
much dimmer than in the positive control (Figure 6.15) it is possible that MC-1 staining in
COs was background staining, and that mis-folded tau was not present.
Two sections from each batch of at least six COs (at least 90µm apart) were stained and
analysed. Staining both sets of sections gave similar results, and results from the second set
of sections stained are presented here. I quantified MC-1 staining by measuring fluorescence
intensity and subtracting background fluorescence (measured in empty areas outside the
COs), and normalising to total tau fluorescence intensity. Images for quantification were
taken at 40x (shown in Figure 6.14), from two representative areas per CO.
Figure 6.16A shows the mean MC-1 fluorescence (normalised to total tau fluorescence)
in COs from three independently differentiations, and Figure 6.16B shows MC-1 fluores-
cence (normalised to total tau fluorescence) from each individual CO. A one-way ANOVA
showed no significant difference between the mean MC-1 fluorescence intensity from IsoCon,
P301Lhet, P301Lhom, and P301Lpat COs (F(3,6)=0.9078, p=0.4909).
The immunofluorescence results suggest that misfolded tau was present in all COs,
including IsoCon COs. This finding was not expected, since MC-1 does not react with
control human brain (Weaver et al., 2000). Further work is needed to clarify whether the
MC-1 staining in IsoCon COs is specific.
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Fig. 6.15 Positive control for MC1 immunostaining: dRG from a 5 month-old P301S mouse.
Misfolded tau was detected with the MC1 antibody. All tau isoforms were detected with the tau
DAKO antibody. All tau isoforms were detected with the tau DAKO antibody. Some cells show bright
tau DAKO staining, which is expected and indicates the presence of tau accumulations (Mellone et al.
2013). In a subset of these cells, the accumulated tau is MC1 positive, indicating that it is misfolded.
Scale bar = 10µm.
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Fig. 6.16 There is no significant difference in MC-1 immunofluorescence intensity between
IsoCon, P301Lhet, P301Lhom, and P301Lpat iPSC-derived COs at day 84-100. Mean MC-
1 fluorescence, minus background fluorescence, was normalised to mean total tau (tau DAKO)
fluorescence. A) Each point represents the average MC-1 fluorescence (normalised to total tau
flu rescence) from at least four COs made in the same differentiation round. Bars show mean±SD. A
significance bar indicates the results of a one-way ANOVA: there was no significant difference in the
amount of MC-1 between COs made from the control and P301L mutant iPSC lines. This is likely to
be because the MC-1 staining observed is non-specific. B shows the data which was summarised in A.
In B, each point represents the mean MC-1 fluorescence value (normalised to total tau fluorescence)
for each CO imaged. Values for each CO were obtained by averaging two readings from different
areas of the same CO, where possible. Bars show mean±SD of the data, considering all individual
points.
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6.5 Discussion
6.5.1 Cell types detected
I detected β III-tubulin positive neurons, the synaptic protein synaptophysin, and GFAP
positive astrocytes in COs derived from the IsoCon, P301Lhet, P301Lhom, and P301Lpat
iPSCs, and there was no significant difference in the amount of β III-tubulin, GFAP, or
synaptophysin detected between COs from the different iPSC lines. The detection of these
proteins in 84-100 day-old COs was expected, since synapses have been detected in iPSC-
derived COs from day 28 onwards (Mariani et al., 2012; Pas¸ca et al., 2015; Yan et al., 2018),
astrocytes are expressed from approximately day 45 onwards in forebrain monolayer iPSC-
derived neural cultures (Shi et al., 2012a), and from approximately day 30 in ESC-derived
COs (Matsui et al., 2018). Using GFAP to detect astrocytes may have over-estimated the
proportion present, since radial glia also express GFAP (Raponi et al., 2007). However, I
found few neural rosette-like radially arranged areas when immunostaining. Neural rosettes
are sites of neurogenesis analogous to the neural tube, which are populated by neural
precursors including radial glia (Elkabetz et al., 2008). Finding few neural rosettes in the COs
indicates that the number of radial glia present was relatively low. By only immunostaining
for neurons and astrocytes, I did not detect other cell types that may have been present in the
COs, such as oligodendrocytes or oligodendrocyte precursors (Renner et al., 2017). Further
characterisation of these cultures could include immunostaining for these cells.
Astrocyte proliferation has been observed in cortical and sub-cortical brain areas in people
with MAPT mutations including P301L (Miyasaka et al., 2001). To see if this phenotype is
recapitulated in COs, I could have aged the COs for longer. However, control COs contain
mostly astrocytes at later timepoints (229 days) (Renner et al., 2017), so any astrocyte
proliferation in MAPT-mutant COs would probably be masked by similar overgrowth in
control COs as part of normal CO culture.
Synapse loss is a feature of human tauopathies including PSP and Pick’s disease (Bigio
et al., 2001; Callahan and Coleman, 1995; Masliah et al., 1989). It is also found in FTDP-17T
mouse models, including in three-month-old mice expressing human P301S tau (Xu et al.,
2014; Yoshiyama et al., 2007). However, significant synapse loss has not been detected
in iPSC-derived neural cultures in the presence of an endogenous MAPT mutation alone
(Silva et al., 2016). Decreased synapse density in iPSC-derived neurons has been observed
after overexpression of the tau repeat domain containing both P301L and V337M MAPT
mutations (Reilly et al., 2017), and after addition of recombinant tau fibrils (Usenovic et al.,
2015). The requirement for exogenous or abnormal tau suggests that synapse loss is unlikely
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to occur spontaneously in COs, or that it might require extended time in culture. Future
experiments could include adding tau fibrils and measuring synapse density as one parameter
which may be affected.
Early electrophysiological activity compared to controls has been observed in iPSC-
derived P301L (and N279K) MAPT mutant neurons (Iovino et al., 2015), and in hippocampal
neurons from mice expressing human P301L mutant tau (Crimins et al., 2012). Although
I did not find evidence of synaptic loss in COs with the P301L MAPT mutation, it may be
interesting to investigate electrophysiological activity in COs from the isogenic control and
P301L iPSCs, particularly since COs are amenable to acute slice electrophysiology (Pas¸ca
et al., 2015).
6.5.2 Layer markers detected
COs from most differentiations contained cortical layer markers, indicating a cortical fate.
This was expected, since the default state of NPCs differentiating without patterning cues
is rostral forebrain (Tropepe et al., 2001; Watanabe et al., 2005), and because the forebrain-
patterned COs were subjected to patterning factors to induce differentiation towards a
forebrain fate (Lancaster et al., 2017). However, most COs also contained areas in which
cortical neuron markers were not detected, and cortical neuron markers were not detected
in some COs. This suggests that neurons from non-cortical brain areas may have been
present, despite the COs having been differentiated by a protocol designed to produce mostly
forebrain tissues. It could have been interesting to investigate this further using markers for
other brain areas, such as hypothalamus, choroid plexus, retina, ventral forebrain, hindbrain,
or spinal cord, which have been detected in non-patterned COs (Lancaster et al., 2013), but
this was outside of the scope of my project. Future work on identifying the brain areas within
COs could include immunostaining for cortical lobe markers. This would allow analysis of
tau phosphorylation or misfolding focussed on frontal and temporal lobe-like tissue, which is
most affected in FTDP-17T (Foster et al., 1997).
The similarity in layer marker expression between COs from the isogenic iPSC lines
suggests that the P301L mutation does not alter layer marker expression, although a more
detailed examination of the number of cells expressing each layer marker, and the timing of
layer marker expression would be required to definitively determine this.
Exploring spontaneous NPC proliferation and the relative quantities of layer-specific
neurons produced in P301L COs may be of interest, since two studies in iPSCs have identified
effects on these parameters in the presence of MAPT mutations. García-León et al. (2018)
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found a trend towards fewer proliferative cells and higher levels of neuron markers in
spontaneously differentiating NPC cultures made from iPSCs with all three of the P301L,
N279K, and intron 10+16 MAPT mutations as compared to controls. Although the presence
of three MAPT mutations is non-physiological, it does suggest that MAPT mutations may
affect NPC differentiation, although the effects may be more subtle with only one MAPT
mutation. In addition, Verheyen et al. (2018) found that monolayer neural cultures derived
from iPSCs with either the intron 10+16 mutation or both the intron 10+16 and the P301S
mutations contained significantly fewer proliferative cells than control cultures, as well as
significantly fewer Tbr1 positive neurons than control cultures after 50 days. It may be worth
investigating this result in COs using isogenic iPSC lines.
6.5.3 Tau isoform expression in cerebral organoids
Western blotting and immunofluorescence results show that 3R tau, specifically 0N3R tau,
was strongly expressed in COs from all iPSC lines, suggesting that immature neurons
predominated. A few radially arranged rosette-like structures were visible in COs, as were
intermediate progenitors, indicating that new neurons were being generated, even at day
84-100. To minimise the proportion of immature neurons, I could have maintained the COs
for longer in culture, until neurogenesis was complete. Sloan et al. (2017) have maintained
COs for 590 days, indicating that it is possible to grow these cultures for longer, but older
COs contain predominantly astrocytes (Renner et al., 2017), so optimal aging of COs to
detect tau isoforms may involve a trade-off between CO age and neuron content.
The 0N4R tau isoform was detected in COs from each of the iPSC lines by immunoflu-
orescence and Western blotting. Since the P301L mutation is in tau exon 10 (Hong, 1998;
Spillantini et al., 1998b), it is present in 4R (but not 3R) tau. Detecting some 4R tau in the
COs indicates that P301L-mutant tau was present, and that effects of the P301L mutation
could potentially be observed. However, Western blots indicated that there was much less
0N4R tau than 0N3R tau.
Bands indicating the presence of 1N3R tau were also detected by Western blot. Expression
of 0N3R, 0N4R, and 1N3R tau in the COs indicates some adult-like tau splicing, which
has previously been observed in both control and P301L-mutation iPSC-derived monolayer
neurons (Iovino et al., 2015). To observe the tau isoforms present more clearly, I could
have made larger batches of COs, so that protein extracts could be made using RIPA and
perchloric acid independently. Tau can be selectively solubilised in perchloric acid (Goedert
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and Jakes, 1990; Lindwall and Cole, 1984), giving Western blots with lower background in
which tau isoforms can be more clearly observed.
My results suggest that 3D culture as COs (rather than 2D culture as monolayer neurons)
increases maturity with respect to tau isoform expression. This is supported by the work of
Choi et al. (2014), who found an increase in 4R tau and total tau mRNA in 3D as compared to
2D ReN cell-derived matrigel-based neuron cultures. Future work could include comparing
tau expression between day 100 monolayer neurons and COs from the same iPSC lines, to
more thoroughly examine the effect of 3D culture on tau expression in COs.
6.5.4 Tau phosphorylation
There was no significant difference in tau phosphorylation at Ser202 and Thr205 between
IsoCon, P301Lhet, and P301Lhom COs, as measured by fluorescence intensity of AT8
staining. The lack of a difference in AT8 positive tau between MAPT-mutant and control COs
was not expected, since increased AT8 staining relative to control has been detected in N279K
(Ehrlich et al., 2015; Iovino et al., 2015), P301L (Iovino et al., 2015), V337M (Ehrlich et al.,
2015) and A152T (Fong et al., 2013; Silva et al., 2016) MAPT-mutant iPSC-derived neurons.
However, the AT8 epitope is also phosphorylated during fetal development (Goedert et al.,
1993). The similarity in AT8 staining observed between the COs may have been caused by
development-like AT8 phosphorylation in control and MAPT-mutant COs
The method I used to quantify AT8 positive neurons may not have been sensitive enough
to detect small differences between COs. This was shown in Chapter 4, in which measuring
the AT8 positive area in day 50 monolayer neurons was not sufficient to detect differences in
the proportion of AT8 positive cells found when counting cells. However, measuring AT8
positive area was sensitive enough to detect an increase in the proportion of AT8 positive
neurons over time (from day 50 to day 80-100), indicating that the method is appropriate for
detecting larger differences between cultures.
Tau phosphorylation in other CO studies has been quantified using methods similar to
the one I chose. For example, Raja et al. (2016) measured tau phosphorylation at Ser396 and
Thr181 by measuring mean fluorescence intensity, and plotted it as fold increase compared
to control. Other studies have included images of phosphorylated tau immunofluorescence
without attempting quantification, demonstrating the difficulty in appropriately quantifying
apparent differences.
A more sensitive detection method might be flow cytometry, as used by Yan et al. (2018),
who detected a significant difference in the number of AT8 positive cells from COs with a
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presenilin 1 mutation as compared to control COs. However, COs must be dissociated to
single cells for this, meaning that neuronal processes (and any AT8 positive tau they contain)
may be lost. Another alternative would be detecting AT8 positive tau by Western blot. I did
detect AT8 positive tau in Western blots using IsoCon, P301Lhet, P301Lhom, and P301Lpat
COs, but the amount of total tau detected varied greatly between different samples, making
quantification impossible.
6.5.5 Tau misfolding
MC-1 positive tau in iPSC-derived neural cultures has previously been detected after addition
of tau fibrils (Usenovic et al., 2015), tau overexpression and tau fibrils (Medda et al., 2016),
or grafting into an AD mouse brain (Espuny-Camacho et al., 2017), but not in aging cultures
expressing endogenous MAPT mutations. For these reasons, I did not expect to detect MC-1
positive tau.
There was no difference in tau misfolding between IsoCon, P301Lhet, and P301Lhom
COs, as measured by the fluorescence intensity of MC-1 staining. I detected some MC-
1 staining in all COs (including IsoCon COs) and this staining overlapped with total tau
staining, suggesting that it was specific for tau. However, this would mean there was tau
misfolding in IsoCon COs, which was not expected, since MC-1 positive tau is absent from
the normal human brain (Spillantini et al., 1996b; Weaver et al., 2000). MC-1 staining in
COs was much dimmer than that in the positive control, indicating that MC-1 staining in
COs was background staining, and that mis-folded tau was not present. This result was
expected, particularly since there was no significant difference in the amount of AT8 positive
tau detected in the COs.
Future work could include further assessment of tau misfolding in COs, for example
by native blotting - since MC-1 is a conformation-dependent epitope (Jicha et al., 1996),
native blotting would need to be used, to avoid the denaturation which occurs during Western
blotting.
6.5.6 Limitations and improvements
Variability between CO cultures
Variability of CO cultures is a recognised phenomenon which may be caused in part by
incomplete neural induction (Lancaster et al., 2017): forebrain-patterned COs are more
reproducible than their non-patterned counterparts, but still show variability between batches
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(Lancaster et al., 2017). Batch variability and variability between cell lines may mask subtle
phenotypes (Giandomenico and Lancaster, 2017).
My results show some variability between COs, which may have been enhanced by
the relatively small sample sizes: a minimum of six COs from the same differentiation
round were used for each of Western blotting and immunostaining. However, given the
heterogeneity of the COs, samples for immunostaining and Western blotting may have been
dissimilar, leading to different results from immunostaining and Western blotting experiments.
Although at least six COs per batch were cryosectioned for immunofluorescence, not all
were imaged. Some COs peeled away from the slide surface during staining and were lost,
and some COs contained very few β III-tubulin positive neurons. Variability between COs
and between batches could be reduced by producing larger CO batches, perhaps in a 96-well
format (Schukking et al., 2018), or using a scaled-up version of the spinning bio-reactor
method (Qian et al., 2016).
Differences between iPSC lines may have also accounted for some variation between
COs. For example, the three isogenic iPSC lines and the patient iPSC line were derived using
different methods to make iPSCs, cultured in different iPSC culture systems (mTeSR and
vitronectin versus KSR medium and feeder cells, Chapter 2) and were at different passage
numbers when used (less than 15 for the isogenic iPSCs, unknown for the other iPSC lines).
Imaging
Immunostaining experiments were performed on at least two slices containing at least six
COs. Although the two slices were at least 90µm apart, this may not have given results
representative of the whole CO, since COs were not homogenous throughout. To quantify tau
phosphorylation with AT8 and MC-1 immunostaining, I took two images per CO, although
this still may not have been sufficient to represent all the variation of each CO. A good
alternative might be high-content imaging, to measure the fluorescence intensity in more
fields per CO. However, in COs containing non-neuronal cells or non-cortical brain areas,
this method would also have drawbacks. To counteract this, I could have immunostained
serial sections for cortical layers markers and for markers of interest (AT8, MC-1, 3R tau,
4R tau, total tau), then excluded from my analysis all non-forebrain-like tissue, and any
rosette-like structures, as done by (Renner et al., 2017).
6.5.7 Summary
In this Chapter, I
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1. Differentiated iPSCs into cerebral organoids, and determined that the proportion of
astrocytes (GFAP) and neurons (β III-tubulin) were not significantly different between
control or P301L COs. No FTDP-17T-relevant astrocyte overgrowth was detected in
the P301L COs.
2. Examined synaptic protein expression. Similar levels of synaptophysin were expressed
by control and P301L COs, and there was no FTDP-17T relevant synapse loss in
P301L COs.
3. Assessed tau isoform expression. 0N3R, 0N4R and 1N3R tau were detected by Western
blotting in COs from all iPSC lines. Although 0N3R tau predominated, indicating
a large number of immature neurons, the expression of some 0N4R and 1N3R tau
suggests that some mature neurons were present. This result suggests that 3D culture
does increase neuronal maturity with respect to tau isoform expression, and indicates
that 3D COs may be a good model method for making mature neurons.
4. Examined tau phosphorylation at the AT8 epitope. There was no significant difference
in the amount of AT8 staining between control and P301L COs, indicating that FTDP-
17T-relevant changes in phosphorylation were not occurring by day 100.
5. Examined tau conformational changes with the MC-1 antibody. There was no signifi-
cant different in the amount of MC-1 staining between control and P301L COs, and
the MC-1 staining detected across all COs is likely to have been background staining.
In conclusion, the results in this Chapter provide ample avenues for future work on COs
with MAPT mutations. In particular, examination of tau isoforms suggests that 3D COs may
be more mature in terms of tau splicing than monolayer cultures. This finding merits further
investigation, since it suggests that COs are a promising method for maturing neurons in
culture. Although limited disease-relevant changes were examined, the presence of AT8
immunoreactivity indicates that tau phosphorylation occurs in COs. Longer culture times
may be needed to detect FTDP-17T-relevant differences between control and P301L COs,
and to increase neuronal maturity.

Chapter 7
Discussion
My project aimed to study the effects of the MAPT mutations N279K and V337M in 2D
monolayer neural cultures, to generate isogenic iPSC lines with the N279K MAPT mutation,
and to investigate the P301L MAPT mutation in 3D cerebral organoids (COs). In contrast
to other studies using iPSC-derived MAPT-mutant neurons, this project made COs from
isogenic iPSC lines. There was some variability between monolayer cultures and COs
made in independent differentiations, which may have hindered my ability to detect subtle
differences between control and MAPT-mutant neurons. The monolayer neural cultures
matured over time, but I detected only one significant change in an FTDP-17T-relevant
parameter: an increase in tau phosphorylation at Ser202 and Thr205 (detected with the AT8
antibody), which has already been published (Iovino et al., 2015). In both control COs and
COs with the P301L mutation, I detected some tau phosphorylation (with the AT8 antibody)
and some tau misfolding (with the MC-1 antibody). Although this is an interesting result, I
did not corroborate or investigate it further due to time constraints.
7.1 Characterisation of control and MAPT-mutant iPSC-
derived cultures
7.1.1 Monolayer cultures
The 2D neural cultures matured between day 50 and day 80-100. At day 50 the cultures
contained mostly β III-tubulin positive neurons and few S100β positive astrocytes, but by
day 80-100, the proportion of astrocytes had significantly increased and the contribution of
neurons to total protein had fallen. The increase in astrocyte number over time indicates
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normal maturation of the cultures, since astrocytes are produced after neurons (Kriegstein and
Alvarez-Buylla, 2009; Rakic, 2003). The amount of synaptophysin (normalised to the amount
of β III-tubulin) increased over time, suggesting ongoing synapse formation in the cultures.
Tau splicing also matured over time: in the control cultures 0N3R tau and occasionally 0N4R
was visible at day 50, whereas 0N3R, some 0N4R and occasional 1N3R tau appeared by day
80-100.
7.1.2 COs
COs from each of the iPSC lines IsoCon, P301Lhet, P301Lhom and P301Lpat contained
β III-tubulin positive neurons, although the amount detected varied between CO batches.
Most COs contained some GFAP positive astrocytes, although some COs contained mostly
astrocytes and very little β III-tubulin, whereas others contained undetectable amounts of
GFAP. Most COs also expressed synaptophysin, indicating synapse formation, although
synaptophysin levels were variable. COs from all iPSC lines contained at least one marker
indicating the presence of cortical neurons.
7.2 FTDP-17T-relevant phenotypes detected
7.2.1 Comparison of my work with other findings
My results from monolayer neurons are compared with previous work using the same iPSC
lines but a different method (Iovino et al., 2015) in Table 7.1. My results from COs from
the isogenic control, P301Lhet, P301Lhom and P301Lpat iPSC lines are compared with
results from the same isogenic control and P301Lhet iPSCs grown as monolayers neurons
(Appendix 2), and with results from previous work using a different control but the same
P301Lpat iPSCs grown as monolayer neurons (Iovino et al., 2015) in Table 7.2.
7.2.2 Tau splicing
N279K
The N279K mutation increases tau exon 10 inclusion in mRNA and therefore increases 4R
tau expression (D’Souza et al., 1999; Hong, 1998), and there was evidence of this in my
cultures. The tau isoforms 0N3R, 0N4R and occasionally 1N3R and 1N4R were detected
by Western blotting in N279K cultures at day 50 and day 80-100. This is compared to the
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control cultures, which expressed 0N3R tau with occasional 0N4R tau at day 50, and 0N3R
tau with some 0N4R and 1N3R tau at day 80-100. In addition, 4R tau immunofluorescence
was brighter in N279K1 and N279K2 cultures at day 100, suggesting increased levels of 4R
tau relative to the controls.
V337M
The V337M mutation does not alter tau exon 10 splicing (Hong, 1998). In my V337M
cultures 0N3R and 0N4R tau were detected at day 50, and 0N3R, with occasional 0N4R,
1N3R and 1N4R were detected at day 80-100. However, in control cultures, 0N3R tau with
occasional 0N4R tau was detected at day 50, and 0N3R tau with some 0N4R and 1N3R
tau was found at day 80-100. This may suggest that more adult-like tau splicing was taking
place earlier in V337M cultures, although a comprehensive comparison of tau splicing would
require iPSC lines isogenic for the V337M mutation.
P301L
The P301L mutation does not alter tau exon 10 splicing (Hasegawa et al., 1999; Hong,
1998) but the P301Lhet and P301Lhom iPSCs contained silent mutations in tau exon 10
(the scars of editing by CRISPR) which may have affected tau splicing. I detected 0N3R
and 0N4R tau in control and P301L COs in all three differentiations (with the exception of
P301Lhom: 0N4R was detected in two of three differentiations). 1N3R tau was detected in
control and P301L COs from one or two differentiations. These results indicate tau splicing
in P301L-mutant COs was like that in the control, even when additional silent mutations
were present. However, the effects of the silent mutations on tau splicing may merit further
investigation.
7.2.3 Tau phosphorylation
I detected an increase in tau phosphorylation at Ser202 and Thr205 (detected with the
AT8 antibody) in 50 day-old N279K monolayer neurons (pooled results from N279K1 and
N279K2) relative to controls (pooled results from CTRL1 and CTRL2), which has already
been reported in different experiments using neurons from the same iPSC lines (Iovino et al.,
2015) but a different differentiation method. However, when each of the N279K lines were
compared to controls, the difference in the proportion of AT8 positive neurons was significant
for the N279K1 but not the N279K2 cultures. This may have been due to differences between
the two iPSC lines and variability between the differentiations.
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In addition, there was a significant difference in the proportion of AT8 positive neurons in
N279K as compared to control neurons at day 50, but not at day 80-100. Phosphorylation at
the AT8 epitope increased from day 50 to day 80-100 (comparing all cultures at day 50 to all
cultures at day 80-100), so changes in phosphorylation related to the N279K mutation visible
in the N279K1 cultures at day 50 may have been hidden by an increase AT8 phosphorylation
in control cultures, particularly in CTRL1 cultures, where the increase in the proportion of
AT8 positive cells between day 50 and day 80-100 was significant.
There was no significant difference in the proportion of AT8 positive neurons between
control and V337M monolayer cultures at day 50 or day 80-100.
In addition, there was no significant difference in AT8 fluorescence intensity between
IsoCon, P301Lhet, P301Lhom and P301Lpat COs at day 84-100.
The lack of a difference in phosphorylation at the AT8 epitope between MAPT-mutant
and control monolayer neurons and COs may have occurred because AT8 detects tau phos-
phorylated in the fetal human brain (Brion et al., 1993; Matsuo et al., 1994; Milenkovic
et al., 2018), as well as in FTDP-17T and other tauopathies (de Silva et al., 2006; Spillantini
et al., 1996a). Therefore, normal development-like AT8 phosphorylation may have hindered
my ability to detect MAPT mutation-related phosphorylation. One way to minimise this
would be to use isogenic iPSC lines which differ only at the MAPT mutation locus, or
to use antibodies which do not detect tau phosphorylated in the developing brain, such as
AT100 (Ksiezak-reding et al., 2000; Matsuo et al., 1994), or AP422 (Miyasaka et al., 2001;
Morishima-Kawashima et al., 1995).
7.2.4 Tau misfolding
No MC-1 positive tau was detected in MAPT-mutant or control monolayer cultures at day
80-100. Some pFTAA positive structures were detected in preliminary stainings of CTRL2,
N279K1 and V337M cultures, but these did not overlap with total tau staining, indicating
that they did not represent filamentous tau.
MC-1 staining, indicating mis-folded tau, was detected in COs derived from the IsoCon,
P301Lhet, P301Lhom and P301Lpat iPSC lines. However, there was no significant difference
in MC-1 fluorescence intensity between IsoCon, P301Lhet, P301Lhom and P301Lpat COs.
Since MC-1 staining is not found in the brains of control subjects (Weaver et al., 2000), this
finding merits further investigation.
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7.2.5 Other phenotypes in monolayer cultures
There was no significant difference in the number of αB-crystallin positive neurons in MAPT-
mutant as compared to control cultures at day 80-100, although there was a trend towards an
increased number in N279K1 cultures. There was no significant difference in spontaneous
cell death between control and MAPT-mutant cultures, and no significant change in cell
death between day 30 and day 100.
7.2.6 Protective factors
The detection of FTDP-17T relevant phenotypes may have been hindered by protective
culture conditions. For example, the maintenance medium for monolayer cultures contained
cAMP and BDNF which support neuronal survival in culture (Dugan et al., 1999; Yoshii
and Constantine-Paton, 2010). Maintenance media for the monolayer cultures and COs
also contained antioxidants as part of the B27 supplement, which may mask tau-related
deficits in culture: Mertens et al. (2013) found that ESC-derived neurons expressing psuedo-
phosphorylated 2N4R tau cultured without B27 formed axonal varicosities and died in culture
at higher rates than neurons expressing normal 2N4R tau. Removing protective factors may
have allowed more FTDP-17T-relevant phenotypes to be detected.
7.3 Generation of isogenic N279K iPSC lines
I was unable to make isogenic N279K iPSC lines using CRISPR. Whilst screening for the
N279K mutation, I detected small deletions in some edited iPSCs, indicating that Cas9 was
cutting DNA, and suggesting that editing with the repair template was inefficient. This may
be because I did not increase CRISPR efficiency by including silent blocking mutations
in the repair template, which would have prevented Cas9 re-cutting DNA with the desired
mutation after editing (Cho et al., 2014; Hsu et al., 2013; Jinek et al., 2012). I did not use
blocking mutations because they would have fallen within tau exon 10 or the proximal parts
of intron 9 or 10, all of which contain sequences involved in exon 10 splicing (D’Souza
and Schellenberg, 2000, 2002). Tau exon 10 contains multiple weak splice sites, splicing
silencers, modulators and enhancers which work together to control exon 10 inclusion and
exclusion (D’Souza and Schellenberg, 2002), making it difficult to determine the effects of
a silent mutation on splicing without splicing assays. The potential of silent mutations to
disrupt splicing in vivo is evidenced by the FTDP-17T-linked mutations S305I, S305N and
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S305S (in exon 10); and +3, +4, +11, +12, +13, +14, +15 and +16 (in intron 10), all of which
alter exon 10 splicing (Ghetti et al., 2015; McCarthy et al., 2015).
Making isogenic iPSCs without blocking mutations is two- to ten-fold less efficient (Flynn
et al., 2015; Paquet et al., 2016). To get around this inefficiency, I could have screened more
iPSC colonies after CRISPR, but this was a time- and labour-intensive process. Alternatively,
I could have used digital droplet PCR after CRISPR, in which edited iPSCs are screened for
the desired mutation in bulk following rounds of replating and expansion in a manner similar
to sib-selection. This method has been used to obtain isogenic iPSCs without blocking
mutations (Miyaoka et al., 2014).
Another option would have been making isogenic iPSCs with blocking mutations and
assessing exon 10 splicing in splicing assays. I designed exon trapping plasmids to do this
before being gifted the three isogenic iPSC lines (control, heterozygous and homozygous
P301L knock-in) from Axol. The two P301L lines contained blocking mutations which may
alter tau splicing (Figure 5.13 in Chapter 6). I did not see evidence of altered 4R inclusion
relative to the control in Western blots, but, having not tested the effects of the blocking
mutations on splicing, an effect on 4R tau expression cannot be discounted.
7.4 Limitations and improvements
7.4.1 Choice of control and sample size
Experiments with iPSC-derived neurons have many levels at which differences can arise
when cultures are compared. For example: people donating tissue for iPSC production
have different genetic backgrounds; tissue choice for iPSC generation may affect the iPSC
transcriptome (Hargus et al., 2014); iPSC clones from the same individual may differ due to
re-programming-induced mutations (Gore et al., 2011), or in aberrant re-programming factor
expression (Boulting et al., 2011), or in their ability to differentiate into neurons (Boulting
et al., 2011); and iPSC lines (from the same or different donors) do not differentiate into
different lineages with the same efficiency (Bock et al., 2011; Boulting et al., 2011; Hu et al.,
2010). Options for controls include multiple iPSC clones derived from the same individual
(to minimise variation associated with iPSC derivation, culture and differentiation), isogenic
iPSC lines (to minimise genetic background effects), or multiple iPSC lines from unrelated
individuals (to model variation in the population).
This problem is further compounded by the question of what a reasonable replicate
is. Most studies using iPSC-derived neurons present data from at least three temporally
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independent experiments per iPSC line, but some studies use one batch of NPCs, terminally
differentiated three times (Hallmann et al., 2017). Repeatedly differentiating neurons from
iPSCs can control for chance occurrences during differentiation, but this approach may also
increase variability between the batches of neurons produced. In contrast, differentiating
iPSCs to NPCs once and using the same NPC pool to generate multiple rounds of neurons
decreases variation due to differentiation but increases the probability that chance differences
during NPC differentiation are carried through the experiment and mistaken for results.
I performed three independent differentiations from iPSCs to neurons, so the differences
between control and MAPT cultures cannot be attributed to differences in one differentiation
from iPSCs to neurons and subsequent expansion of the NPCs.
The data in this project represents a small number of individuals. I used the statistically
significant FTDP-17T-relevant phenotype detected during this project to calculate the number
of iPSC lines necessary to get power of at least 80% and p<0.05. 80% power is generally
accepted as appropriate, and means that the probability of correctly rejecting the null hypoth-
esis is 80% (Button et al., 2013). For the monolayer neural cultures, nine control and nine
N279K iPSC lines from different donors would be required for 80% power (calculated from
the significant increase in AT8 positive neurons in N279K cultures at day 50). A total of
18 iPSC lines cultured and differentiated simultaneously would require at least two people
working on the cell cultures, but a bigger challenge might be obtaining nine iPSC lines with
the appropriate MAPT mutations from different donors.
7.4.2 Variability between iPSC lines
Genetic background differences between the iPSC lines may have contributed to variation
in my neural cultures. iPSC lines from the same or different donors differentiate into
neurons with different efficiencies (Bock et al., 2011; Boulting et al., 2011; Hu et al., 2010),
and neurons produced from different PSC lines using the same protocol exhibit different
properties (Wu et al., 2007). This may have contributed to variability in monolayer cultures
and COs (apart from those using the isogenic iPSC lines).
Genetic background has also been shown to influence tau phosphorylation in rats express-
ing truncated human tau (Stozicka et al., 2010), so it is possible that the genetic backgrounds
of the two N279K lines contributed to the difference in tau phosphorylation at day 50. Iso-
genic iPSC lines may provide a way around this, but creating isogenic lines from control
iPSCs may not be the answer, since people with the same FTDP-17T-related MAPT mutations
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do not always experience the same symptoms, leading to the suggestion that as-yet-unknown
environmental or genetic influences may be present (Foster et al., 1997).
As well as genetic background differences, differences in culture conditions could have
affected my experiments. The CTRL1, CTRL2, N279K1, N279K2, V337M and P301Lpat
iPSCs were cultured on feeder cells with KSR media, whereas IsoCon, P301Lhet and
P301Lhom COs were feeder-free, cultured on vitronectin with E8 media. This meant that the
iPSCs used to make monolayer cultures were maintained in comparable conditions, but the
iPSCs used to make COs were not, since the P301Lpat iPSCs did not adapt to feeder-free
culture. In addition, the P301Lhet iPSCs differentiated quickly in feeder-free and feeder
conditions, and I was unable to maintain the line. The loss of the P301Lhet, but not the
P301Lhom or IsoCon lines suggests that gene editing may have introduced some unwanted
changes in P301Lhet iPSCs, although these had a normal karyotype.
The contribution of differences between the iPSC lines to variability between the COs
could have been minimised by adapting the P301Lpat iPSCs to feeder-free conditions, and
culturing them on vitronectin with E8 media before making COs. However, since the
P301Lpat COs did not share a genetic background with the isogenic IsoCon, P301Lhet and
P301Lhom lines, the ideal solution would have been to make an isogenic control for the
P301Lpat line. This was not attempted, due to the time involved in gene editing experiments.
7.4.3 Variability between cultures
Variability between each differentiation to monolayer neurons or COs may have contributed
to the detection of relatively few FTDP-17T-relevant phenotypes by hiding subtle differ-
ences. Variability between monolayer cultures could have been minimised by making large
batches of NPCs from iPSCs, expanding them, and differentiating the NPCs to neurons
three independent times. However, as discussed in Section 7.4.2, any errors in the initial
differentiation to NPCs would be carried through to the neurons and may be mis-interpreted
as an FTDP-17T-relevant result.
Variation occurring due to genetic background differences was minimised by using three
isogenic iPSC lines to make COs. In addition, I differentiated the COs using a method which
produces forebrain-specific cortical tissue (Lancaster et al., 2017), rather than an earlier
method which produces a variety of brain areas in unpredictable proportions (Lancaster et al.,
2013). Nevertheless, there was some variability between the CO batches which may have
hidden subtle FTDP-17T-related phenotypes. Variability between CO batches and between
COs from different cell lines is a recognised issue (Giandomenico and Lancaster, 2017) and
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indicates that particular care needs to be taken to identify FTDP-17T-relevant changes in
COs.
7.4.4 Specificity of brain areas modelled
FTDP-17T affects primarily the frontal and temporal cortex (Foster et al., 1997). To make
my cultures as relevant as possible to these brain areas, I differentiated monolayer cultures
from NPCs with a forebrain fate which was confirmed by immunostaining for Pax6, Otx2
and FoxG1. However, FoxG1 staining was cytoplasmic rather than nuclear, suggesting that
the NPCs were differentiating towards neurons (Pancrazi et al., 2015; Regad et al., 2007).
Pax6, Otx2 and FoxG1 positive cells correspond to those in the developing telecephalon and
diencephalon (Larsen et al., 2010; Tao and Lai, 1992; Terzic´ and Saraga-Babic´, 1999), which
develop into a large number of areas in the adult brain including the thalamus, hypothalamus,
epithalamus and subthalamus (from the diencephalon), and the cerebral cortex, basal ganglia,
hippocampus, amygdala, and hypothalamus (from the telencephalon) (Augustine, 2017).
To confirm the identity of my COs, I immunostained for the cortical layer markers Tbr1
and Cux1/2, and the intermediate progenitor marker Tbr2 - the presence of other brain areas
was not investigated. At least one of these markers were detected in COs derived from
the IsoCon, P301Lhet, P301Lhom and P301Lpat iPSCs, indicating the presence of some
cortical tissue. However, the cerebral cortex contains many different areas, and methods
for making specific cortical areas from iPSCs have not yet been published. To detect the
most disease-relevant subset of neurons in my COs and monolayer cultures, I could have
used cortical lobe markers to detect neurons corresponding to the most relevant brain areas:
frontal and temporal cortex.
One way to decrease variability in my results would be to only analyse tau phosphory-
lation and misfolding in specific brain areas of the COs. To do this, I could have stained
serial sections with cortical lobe markers on the first slide of the series (to identify frontal and
temporal cortex-like areas), antibodies against phosphorylated or misfolded tau (to detect
tau pathology) on the second slide of the series, and layer markers (to further elucidate the
relevant subsets of cells) on the third slice of the series. Parts of the CO corresponding to
frontal or temporal cortex-like tissue could then be examined, and compared across COs and
across cell lines. However, this was not done due to time restrictions.
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7.5 Future directions
iPSC-derived neuron maturity
One limitation of using iPSC-derived neurons to study a neurodegenerative disease is the
relative immaturity of these cultures. Therefore, future work could include artificially aging
immature neurons using progerin, for example. This has been done by Miller et al. (2013),
who expressed progerin in iPSC-derived neurons with Parkinson’s disease-related mutations,
and found that it enhanced phenotypes including cell death and a decrease in dendrite length.
However, the physiological relevance of these findings are unclear (Ichida and Kiskinis,
2015).
Alternatively, future work could include exploring options to recreate the mature, adult-
like expression of all six tau isoforms in iPSC-derived neurons. This could include methods
such as trans-splicing, which has been used to drive the expression of 4R tau in ESC-derived
neurons and mice (Avale et al., 2013; Lacovich et al., 2017), although it has not been
used to recapitulate the splicing of all six tau isoforms as seen in the adult human brain.
Another potential avenue is making induced neurons (iNs), which may express 0N4R tau
and mature MAP isoforms earlier than traditionally differentiated neurons (Imamura et al.,
2016), although this has not yet been extensively characterised.
Another alternative would be culturing iPSC-derived COs for much longer. Since they
are in suspension, COs do not suffer from the detachment problems encountered in long
term monolayer culture, and have been cultured for as long as 590 days (Sloan et al., 2017).
This should be ample time for mature tau splicing to develop, since it has been reported
in monolayer cultures after 150 (Iovino et al., 2015), 190 (Beevers et al., 2017), and 365
(Sposito et al., 2015) days.
Yet another possible avenue would be to obtain induced neurons by transdifferentiation
of fibroblasts, which has been shown to produce neurons with retain age-dependent transcrip-
tome features (Mertens et al., 2015). Hu et al. (2015) reported that induced neurons made
from fibroblasts obtained from AD sufferers had higher Aβ40 or Aβ42 levels than those
from controls, indicating disease-relevant changes may be enhanced in induced neurons as
compared to those from directed differentiation. Since FTDP-17T emerges in adult humans,
but the iPSC-derived neurons I studied were very young compared to those in an adult brain,
retaining age-related signatures may have allowed me to see disease-relevant changes in tau.
However, not all fibroblasts are converted to neurons during transdifferentiation (Mertens
et al., 2015; Treutlein et al., 2016), and transdifferentiation efficiency decreases for fibroblasts
which have been kept in culture for longer (Sun et al., 2014), so the number of neurons which
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can be produced from one donor fibroblast sample is limited. This issue could be avoided
by using transdifferentiation to produce proliferative NPCs (Han et al., 2012; Sheng et al.,
2012), so that the number of neurons produced would no longer be limited by the number of
initial fibroblasts. NPCs from transdifferentiation could be gene edited to produce isogenic
NPCs, and cultured in 3D, in a manner similar to COs.
Work on the iPSC lines used in this project
Future work using the isogenic IsoCon, P301Lhet and P301Lhom iPSC lines could include
testing the effects of the three silent mutations on exon 10 splicing. This is necessary because
testing the silent mutations in silico suggests that they may decrease tau exon 10 splicing,
potentially decreasing the amount of 4R tau, which contains the P301L mutation.
Generation of isogenic iPSCs from the N279K iPSC lines would also be a good next
step, since this would minimise variation between monolayer cultures or COs produced
from the iPSCs, which would allow more subtle phenotypes to be investigated. Isogenic
N279K iPSC lines could be differentiated to forebrain-specific COs and cultured for at
least 150 days to allow tau splicing to mature. Serial cryosections of these COs could be
immunostained for cortical lobe markers (to detect frontal and temporal lobe-like tissue),
cortical layer markers (to determine maturity), and antibodies against abnormal tau such as
MC-1 and AT100. Analysis of only the areas corresponding to frontal and temporal lobe
cortical neurons may allow relevant and subtle phenotypes to be detected. These experiments
could also be performed with the isogenic control and P301Lhom iPSCs, although the
physiologically-relevant P301Lhet line would be absent.
Alternatively, the FTDP-17T-relevant phenotypes seen in COs could be enhanced by
seeding the COs with pre-formed tau fibrils to induce tau aggregation. I attempted this but
the COs became infected shortly after injection. If this technique is optimised, it could be
used to investigate tau aggregation and even spreading in 3D. In addition, microglia could
be added to COs to extend work done in mouse models (Brelstaff et al., 2018) to a human
brain-like system.
7.6 Conclusions
In this project, the following were achieved:
1. Forebrain-specific neurons were differentiated from patient-derived iPSCs with
the N279K and V337M MAPT mutations, and from control subject-derived iP-
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SCs. This allowed a previously reported increase in tau phosphorylation at the AT8
epitope to be observed again, using the same iPSCs but a different method of neuronal
differentiation.
2. Forebrain-patterned COs were differentiated from patient-derived iPSCs with the
P301L MAPT mutation, and from a set of three isogenic control subject-derived iPSCs,
expressing normal tau, the heterozygous P301L MAPT mutation, and the homozygous
P301L MAPT mutation. The 0N3R tau isoform was strongly expressed in COs
from all iPSC lines, and lower amounts of 0N4R and 1N3R tau were also present.
This indicates mature tau splicing in some neurons, and suggests that 3D culture
may enhance neuronal maturation with respect to tau expression. No differences in
tau phosphorylation (detected with the AT8 antibody) or tau mis-folding (detected
with the MC-1 antibody) were detected between control and P301L MAPT-mutant
iPSC-derived COs.
3. Silent mutations introduced during CRISPR which may alter tau splicing were
identified. Determining whether the affected isogenic iPSC lines express 4R tau
differently may be important in deciding whether or not to use them in future studies.
One statistically significant result relating to a FTDP-17T-relevant phenotype was detected
in this project: an increase in the proportion of AT8 positive neurons with the N279K mutation
relative to controls at day 50. This confirms previous results from the same iPSC lines using
a different differentiation method. Detection of other phenotypes may have been hindered
by the variability of the cultures created and by maintenance media containing protective
factors.
The most important finding from this project is that 3D culture may enhance neuronal
maturity with respect to tau isoform expression, as compared to monolayer cultures, making
it a potentially valuable method for studying tauopathies. Overall, this project highlights the
need for the development of methods that allow increased reproducibility in iPSC studies, as
well as appropriate numbers of iPSC lines and the use of isogenic iPSC lines.
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Appendix A
Off-target matches with CRISPR 3
282 Off-target matches with CRISPR 3
Fig. A.1 Top 20 predicted off-target sites for CRISPR 3 gRNA. The sequence and chromosomal
location of the 20 closest matches to CRISPR 3 gRNA, excluding the intended target, tau exon 10.
The number and location of mismatches between the gRNA and the endogenous DNA are indicated.
Higher scores indicate higher predicted likelyhood of off-target effects at the listed locus. Off-target
predictions are from MIT CRISPR design tool.
Appendix B
NPC-derived monolayer neurons from
IsoCon and P301Lhet iPSCs
Isogenic control (IsoCon), the corresponding knock-in P301L-heterozgyous (P301Lhet),
and unrelated non-isogenic control 6 (Con6) iPSC-derived NPCs were gifted by Axol. The
NPCs were differentiated to neurons and maintained in culture for 21 days (approximately
41 days after iPSCs, referred to here as day 41) or 40 days (approximately 60 days after
iPSCs, referred to here as day 60). The aim was to compare the knock-in P301Lhet neuron
phenotype with that of neurons carrying the same mutation obtained from an individual
suffering from FTDP-17T (Iovino et al., 2015), and to compare the effects of two types of
maturation media on the Con6 neurons (data not shown).
B.1 Confirmation of genotype in IsoCon and P301Lhet neu-
rons
To confirm the presence of the heterozygous P301L mutation in the P301Lhet neurons, and
to confirm its absence in the IsoCon and Con6 neurons, DNA was extracted from neurons
derived from the first set of NPCs received, and a 650bp fragment containing tau exon 10
was amplified by PCR. DNA was subjected to restriction digest with Sma1, which digests
wild-type, but not P301L mutant DNA. IsoCon and Con6 DNA from the first set of cells
received was completely digested to 350 and 300bp fragments by Sma1 (see Figure B.1A),
indicating the absence of the P301L mutation. P301L DNA from the first set of cells was
partially digested by Sma1, confirming the presence of the heterozygous P301L mutation
(see Figure B.1A).
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Fig. B.1 Sanger sequencing and restriction digest to assess the P301L mutation locus in IsoCon,
P301Lhet and Con6 neurons. A) 650 base pairs (bps) of DNA containing exon 10 amplified from
neurons derived from the first set of Con6, IsoCon and P301Lhet cells received, digested with Sma1.
B) Sanger sequencing results from DNA amplified from neurons derived from the second set of Con6,
IsoCon and P301Lhet cells received. C) 650bps of DNA containing exon 10 amplified from neurons
derived from the second set of Con6, IsoCon and P301Lhet cells received, digested with Sma1.
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Fig. B.2 The cytoskeletal proteins neurofilament-M and β III-tubulin in 41 day-old IsoCon and
P301Lhet NPC-derived neurons. IsoCon and P301Lhet neurons immunostained for β III-tubulin
and neurofilament-M (NF-M). Scale bar = 10µm.
This procedure was repeated using DNA extracted from neurons derived from the second
set of NPCs received. IsoCon and P301Lhet DNA was completely digested to 350 and 300bp
fragments by Sma1 (see Figure B.1C), indicating the absence of the P301L mutation. DNA
from neurons derived from the second set of NPCs was amplified again by PCR and sequenced
by Sanger sequencing. Both control and P301L sequences showed a control sequence without
the P301L mutation (see Figure B.1B). In the P301L case, base C (indicated by an arrow
in Figure B.1B) should be accompanied by base T. DNA preparation and sequencing was
repeated twice and gave the same result.
This indicates that the P301L mutation was present in neurons derived from NPCs
provided for the first set of experiments, but not the second set. Therefore, all IsoCon and
P301Lhet results presented are from the same differentiation round, and no independent
differentiation rounds can corroborate results from P301Lhet neurons.
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B.2 Cytoskeleton proteins in IsoCon and P301Lhet neu-
rons
The cytoskeletal proteins neurofilament-M and β III-tubulin were present in IsoCon and
P301Lhet neuronal processes after 21 days in culture (41 days after iPSCs), indicating the
differentiation of NPCs to neurons (see Figure B.2).
B.3 Tau isoforms in IsoCon and P301Lhet neurons
At day 41, 3R tau was detected in cell bodies and processes in both IsoCon and P301Lhet
neurons by immunofluorescence (see Figure B.3A). 4R tau was detected in cell bodies
and some processes in both IsoCon and P301Lhet neurons by immunofluorescence (see
Figure B.3B). 4R tau was present in low amounts, so signal was amplified using biotin and
fluorescently-conjugated streptavidin. There was no clear difference in fluorescence intensity
between IsoCon and P301Lhet neurons. This was expected, since the P301L mutation does
not alter exon 10 inclusion (Hasegawa et al., 1999; Hong, 1998; Hutton et al., 1998).
Immunofluorescence results were corroborated by Western blotting. Tau was extracted
from 41 day-old IsoCon and P301Lhet neurons using perchloric acid, in which tau is
selectively soluble (Lindwall and Cole, 1984), and extracts were dialysed in Tris-HCl.
Samples from each protein extract were dephosphorylated with alkaline phosphatase from
E.coli (dephos in Figure B.4) and loaded next to phosphorylated samples (phos in Figure
B.4). Faint bands corresponding to 0N3R tau were visible in the P301Lhet and IsoCon lanes
at low exposure (Figure B.4A), and at higher exposure Figure B.4B and C), but no other
tau isoforms were visible. This suggests that mostly immature neurons, expressing the fetal
0N3R tau isoform, were present at day 41, and that levels of 4R tau were too low to detect by
Western blot.
B.4 Tau phosphorylation at Ser202 and Thr205 (AT8) in
IsoCon and P301Lhet neurons
Tau phosphorylation at the AT8 epitope (at Ser202 and Thr205) occurs in both FTDP-
17T and fetal brains (Brion et al., 1993; Spillantini et al., 1996a). AT8 positive tau was
assessed by immunostaining (amplifying AT8 signal with biotin and fluorescently-conjugated
streptavidin) and counting the proportion of AT8 positive neurons. Some AT8 positive
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Fig. B.3 3R and 4R tau in day 41 IsoCon and P301Lhet neurons. A) 3R tau or B) 4R tau in day
41 IsoCon and P301Lhet neurons after 41 day-old neurons, co-stained for β III-tubulin. Scale bar =
10µm.
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Fig. B.4 Tau isoforms in 41 day-old IsoCon and P301Lhet neurons detected by Western blot.
A) Low exposure, B) higher exposure, and C) highest exposure of the same blot. Dephosphorylated
samples were loaded next to phosphorylated samples, and recombinant tau isoforms (tau ladder) and
control human brain extract were used as positive controls for tau isoforms. The membrane was
probed with an antibody against total tau.
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Fig. B.5 Tau phosphorylation at the AT8 epitope in IsoCon and P301Lhet neurons. A) 41 day-
old IsoCon and P301Lhet neurons stained for AT8 and β III-tubulin. Scale bar = 10 µm. B) The
proportion of AT8 positive, β III-tubulin positive neurons in IsoCon and P301Lhet cultures. Bars show
the average of 3 technical replicates, error bars show the standard deviation. C) The ratio of the AT8
positive area to the β III-tubulin positive area measured in IsoCon and P301Lhet cultures. Bars show
the average of 3 technical replicates, error bars show SD.
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Fig. B.6 No tau phosphorylation at the AT100 epitope in IsoCon and P301Lhet neurons. IsoCon
and P301Lhet neurons immunostained for AT100 and β III-tubulin. Scale bar = 10µm.
neurons were detected in both IsoCon and P301Lhet cultures, mostly in cell bodies (see
Figure B.5A). The proportion of AT8 positive neurons and the AT8 positive areas was not
significantly different between the IsoCon and P301Lhet neurons (see Figure B.5B and C).
This is at odds with findings using 55 day-old neurons derived from a different control
iPSC line and a different P301L iPSC line, in which there were significantly more AT8
positive P301L neurons (Iovino et al., 2015). However, results presented here were from
only one differentiation, and would require replicating to confidently reach a conclusion.
B.5 Tau phosphorylation at Thr212 and Ser214 (AT100) in
IsoCon and P301Lhet neurons
Phosphorylation and conformational changes which result in the AT100 epitope (Thr212
and Ser214) being presented occur in tauopathies, but not fetal brains (Matsuo et al., 1994;
Rizzini et al., 2000). Tau phosphorylation at the AT100 epitope was not detected in 41
day-old IsoCon or P301Lhet neurons by immunofluorescence (see Figure B.6). This was
expected, since AT100 positive tau was not observed in P301L mutant neurons from another
iPSC line, even after 150 days (Iovino et al., 2015).
B.6 α-synuclein and β III-tubulin positive puncta and loops in neuronal processes of IsoCon
and P301Lhet neurons 291
B.6 α-synuclein and β III-tubulin positive puncta and loops
in neuronal processes of IsoCon and P301Lhet neu-
rons
α-synuclein positive, β III-tubulin positive puncta and loops in neuronal processes were
detected in P301L cultures by Iovino et al. (2015). To see if this phenotype was also present
in P301Lhet cultures, I immunostained 41 day-old P301Lhet and IsoCon cultures for α-
synuclein and β III-tubulin, and counted the number of positive puncta (see Figure B.7A).
More α-synuclein positive, β III-tubulin positive puncta were found in P301Lhet neuronal
processes than in IsoCon, but the number of “loops” in neuronal processes was similar
between the two lines (see Figure B.7B).
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NPC-derived neuron genotype Average number of βIII-tubulin and syn1 positive puncta Average number of βIII-tubulin and syn1 positive loops
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Fig. B.7 α-synuclein positive, β IIItubulin positive puncta and loops in processes. A) IsoCon)
and P301Lhet neurons immunostained to show α-synuclein (Syn1) positive, β III-tubulin positive
puncta (white arrows) and loops (blue arrows) in neuronal processes. Scale bar = 10µm. B) The
number of α-synuclein and β III-tubulin positive puncta and loops were counted, blinded to genotype,
in z-stack images taken 0.2 µm apart on a confocal microscope. The table shows the average of 3
technical replicates. Graphs show the average of the 3 technical (bar) and standard deviation (error
bars).
